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Abstract
Identification of circulating endothelial progenitor cells (EPC), which share a common
precursor with haematopoietic progenitor cells (HPC), the haemangioblast, has generated
considerable interest in isolating, characterising and expanding them for clinical use. There
is no definitive phenotype of EPC but there appears to be two main types, the CD14+
monocyte derived early EPC and the CD34+ derived endothelial outgrowth cell (EOC).
These populations differ in their proliferative potential and appear quite distinct, though
their function in vasculogenesis is debated. Potential sources of such cells include peripheral
blood, bone marrow and umbilical cord blood. Peripheral blood stem cell (PBSC)
transplantation is the paradigm of adult stem cell therapy. It relies on the use of granulocyte
colony stimulating factor (G-CSF) to mobilise HPC from the bone marrow. With EPC and
HPC sharing common origins it has been suggested that G-CSF mobilised peripheral blood
would be an excellent source of EPC for clinical use. This work centres on the identification
of EPC in G-CSF mobilised peripheral blood.
G-CSF mobilised and non mobilised peripheral blood samples were obtained at a number of
time points from autologous and allogeneic donors referred for PBSC collection using G-
CSF, given alone or sequentially with chemotherapy. We consistently demonstrated marked
reductions in early EPC following the administration of G-CSF, using standard commercially
available colony assays (CFU-EPC), which is reversible within a month of G-CSF treatment.
We have also been unable to generate EOC from mobilised blood samples. Our goal has
been to resolve why, when EPC are contained within the bone marrow, that we cannot find
evidence of their mobilisation together with HPC following G-CSF.
A series of experiments were performed in order to exclude technical factors as potential
influences on CFU-EPC formation in mobilised blood. Flow cytometric analysis showed
clear changes in the proportions of leukocyte subpopulations in MNC obtained from whole
blood samples following G-CSF. We have explored the influence of cellular factors on CFU-
EPC formation and present evidence that CD66b+ granulocytes affect CFU-EPC. We have
identified phenotypic differences between CD34 positive cells mobilised with G-CSF and
CD34 positive cells present in umbilical cord blood, another potential source of CD34
positive cells for clinical use. We believe that these differences contribute to the failure of
EOC development in mobilised blood. We have yet to resolve why we are unable to generate
CFU-EPC or EOC from mobilised blood but using these results we are moving to explore
other areas including G-CSF induced alterations of cell adhesion molecules expressed by
CD14+ monocytes.
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Haematopoietic stem cell transplantation (HSCT), both from bone marrow (BM) or
more recently from peripheral blood (PB) as peripheral blood stem cells (PBSC), has
been a clinical treatment for patients with haematological disease for more than 30
years and is a paradigm for stem cell therapies. Over this period, our understanding
of stem cell biology has improved and refinements have been made in
transplantation techniques and supportive care. As the population ages, there is an
increasing demand to be able to repair damaged tissue and restore organ function.
Transplantation of tissues (blood, heart valves) or organs (liver, kidney, heart) is
limited by donor organ shortages. Transplantation is also restricted by
transplant-related issues including human leukocyte antigen incompatibility, the
requirement for immunosuppression and the inability to transplant some organs
and tissues (e.g. nervous system). This has led to increased efforts to find
alternatives such as the use of stem cells or cell-based therapies for tissue
regeneration.
Whilst HSCT has been used in the haematological setting for many years, recent
clinical and laboratory research suggests that other tissues may be amenable to
regenerative cell therapy. In particular, vascular regeneration has received much
attention. It is believed that bone marrow and/or circulating stem/progenitor cells
may contribute to vascular repair and that such cells share common precursors with
haematopoietic progenitor cells (HPC), in which case they may be obtainable from
bone marrow or by leukapheresis of cytokine mobilised peripheral blood.
Novel observations in our laboratory, employing a recently described but widely
accepted test of endothelial progenitor cell activity, have indicated reduced
endothelial progenitor cell activity in CD34-rich blood following mobilisation of
IirC from the bone marrow with granulocyte colony stimulating factor (G-CSF).
This could indicate that the preferred source of cells for vascular regeneration
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should be bone marrow rather than mobilised peripheral blood. This study aims to
further characterise this phenomenon and its implications for sourcing autologous
cells for cell therapy for vascular repair.
1.1. Cells for tissue regeneration
Stem cells are defined by their unique ability Lo self-renew, their high proliferative
potential and their capacity for multi-lineage differentiation into specialised cells. A
number of different cell types may be used as sources of stem cells for cellular
therapy (outlined below). Totipotent stem cells can generate all cells constituting the
body as well as the extra-embryonic tissue that gives rise to the placenta.
Pluripotent stem cells are capable of generating all cells found within an individual
but cannot form an embryo, as they are incapable of producing extra-embryonic
tissue. Multipotent stem cells give rise to cells of a single layer, while tissue-specific
oligopotent stem cells are capable of differentiating into lineage restricted tissue-
specific cell types.
1.1.1. Embryonic stem cells
Embryonic stem cells have the ability to proliferate indefinitely in vitro and to
differentiate into any somatic cell type (1). The blastocyst stage of embryonic
development, reached 3-5 days post fertilisation, consists of a hollow ball of 100-200
cells, the outer layer of which develops into the trophoblast/placenta, while the
inner cell mass develops into the embryo. The inner cell mass can be extracted from
the blastocyst and grown on a fibroblast (feeder) cell line to yield human embryonic
stem cells (hESC), which display long-term self-renewal potential and retain
pluripotency. Since the first reports of successful isolation of hESC in 1989, ethical
concerns have surrounded the procurement of cell lines from blastocysts derived
from in vitro fertilisation programmes. The clinical application of hESC or their
products is currently limited by a number of issues, including how to control hESC
proliferation and direct hESC differentiation to specific cell types. The
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transplantation of hESC also raises immunological concerns with the potential for
tissue incompatibility and the need for long-term immunosuppression and the
potential complications associated with this (e.g. infection) (2, 3).
1.1.2. Somatic cell nuclear transfer
Somatic cell nuclear transfer (SCNT) (or 'cloning') involves the introduction of the
nucleus of an adult donor cell into an enucleated oocyte (3). Cell stimulation gives
rise to the fusion of the donor nucleus with the oocyte, which can then be cultured
in vitro to form a blastocyst. If the blastocyst is successfully transferred into the
uterus of a female recipient, the resulting animal will be genetically identical to the
donor (reproductive cloning). Therapeutic cloning describes the process in which a
cloned blastocyst derived as above is explanted in culture to give rise to embryonic
stem cells. hESC derived in this way could, in principle, be differentiated in vitro
into a homogenous population of syngeneic immune-compatible cells to regenerate
tissue. In humans, SCNT remains limited by the availability of ova, the inefficiency
of the process with the potential for errors (1) and it remains unclear whether
epigenetic modifications affect the phenotype or functions of cloned cell lines (3).
1.1.3. Induced pluripotent stem (IPS) cells
Induced pluripotent stem (iPS) cells offer another means of reprogramming cells
that compared to SCNT is technically easier to achieve, is more reproducible and
does not require oocytes (4). Re-programming of mature lineage restricted somatic
cells to a pluripotent state was initially achieved using a set of 4 transcription
factors, Oct4, Sox2, Klf4 and c-Myc, in a murine model, shown later to be sufficient
also for iPS generation in the adult (5), but other combinations of transcription
factors have subsequently been described to achieve this (6). It is widely accepted
that mouse and human iPS cells possess morphological, molecular and
developmental features that closely resemble those of blastocyt embryonic stem
cells but it is yet to be determined whether these cells are identical to embryonic
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stem cells or how similar these cells need to be for their use in cellular therapy (7).
Murine models of disease (8, 9) have already illustrated the potential of iPS cells as a
means of generating patient-specific pluripotent stem cells for use in regenerative
medicine and therapeutic purposes. However, for clinical application, a means of
inducing the 'iPS state' other than using viruses would be preferable.
1.1.4. Adult stem cells
Adult stem cells are found within differentiated tissue and traditionally were
considered to be oligopotent stem cells. Adult stem cells may remain quiescent for
many years before being activated by inflammation or injury (10, 11), with cells then
being directed to differentiate into specific cell types to replenish damaged tissue.
Research has shown that adult stem cells are found in many organs, including the
bone marrow, skin, muscle, gut and liver, and are thought to be present in most, if
not all, tissues (10). Although constantly replenished tissues, such as blood or skin,
may exhibit a continually active system with a constant rate of turnover, other
tissues are noted for their self-renewal capacity (e.g. liver) whereas certain tissues
have been thought of as not amenable to such renewal (e.g. heart) although these
tissues are now under investigation for such mechanisms. There is evidence that
adult stem cells display the ability to differentiate into cells of other germ lines
(plasticity or transdifferentiation), rather than being restricted to tissue types
present in a specific organ (12, 13). It is not clear whether, or to what extent,
plasticity is a real phenomenon and to what extent an artefact of the experimental
conditions. This potential plasticity of adult stem cells has increased interest in
using bone marrow-derived cells as sources of material for a wide range of cellular
therapies (1, 10). Non-haematopoietic stem cells found in the bone marrow
compartment include mesenchymal stem cells (MSC) which can give rise to bone
marrow stromal cells, and endothelial progenitor cells (EPC) which give rise to
vascular structures. Differentiation of MSC into fibroblasts, bone, cartilage and fat
has been demonstrated in an experimental context.
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There is evidence that rather than being locally restricted, adult (tissue) stem cells
can contribute to tissue repair in sites remote to their origin by entering the
circulation and migrating to other sites (1). The factors that stimulate stem cells,
promote stem cell circulation or direct homing of these cells to remote sites are not
yet fully understood. Stem cells offer the hope of being useful in the treatment of
many disease processes, including neurodegenerative disease, diabetes and
myocardial ischaemia but at present the isolation and characterisation of the adult
stem cell populations remain difficult and basic questions such as stem cell
phenotype, the best source of material and optimal culture methods remain
unanswered.
1.2. Clinical use of haematopoietic stem and progenitor cells
Haematopoietic stem cells (HSC), the best characterised adult stem cell, are rare
cells, comprising one in 104-105 of bone marrow (BM) cells. Bone marrow
transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) are
established therapies for the treatment of haematological malignancies.
Recombinant human granulocyte colony stimulating factor (G-CSF) is one of many
cytokines capable of mobilising HSC and HPC from the bone marrow into the
peripheral blood and it is the agent most commonly used (14). Since the feasibility
of HPC harvesting by leukapheresis was demonstrated in 1980 (15) there has been
rapid growth in the use of G-CSF to mobilise PBSC, making it the new international
standard for HSCT (16). Since 1993, PBSC have been the preferred source of HPC
(IBMTR data) with G-CSF mobilised PBSC accounting for 74% of unrelated donor
HPC donations in 2008 (NMDP data www.marrow.ori.).
1.2.1. Mobilisation of HPC into the circulation
HPC, including HSC, are recruited into the blood (mobilised) following treatment
with G-CSF or chemotherapy; mimicking the physiological release of HPC from the
bone marrow that occurs in response to injury, inflammation or other stress signals
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(17). Originally HPC were defined and quantitated by clonogenic haematopoietic
colony assays with CFU-GM the most commonly used indicator of the
haematopoietic reconstitutive capacity of transplanted cells (18). Since the
standardisation of CD34 cell measurements, colony based assessments are no longer
routinely performed and CD34 is used as a marker for HPC. Under steady state
conditions less than 0.05% of blood leukocytes are CD34+ cells but this increases
substantially post G-CSF (19). Allogeneic PBSC donors are mobilised using 4-7 days
of G-CSF alone (5-16pg/kg/d G-CSF, as 1-2 daily doses (16, 20) and 1-3 leukapheresis
procedures are usually adequate to collect PBSC (14). Whilst the administration of
chemotherapy results in a 5-15x increase in CD34+ cells (21), administering it
together with G-CSF to autologous PBSC patients increases CD34+ numbers even
further (22, 23).
A proportion of healthy adult donors (and higher proportions of patients with
haematological disease) fail to mobilise sufficient PBSC into the peripheral blood.
HPC mobilisation is affected by donor age, gender, cytokines used, patient
diagnosis, patient treatment and radiotherapy (24-26). Various strategies to improve
PBSC mobilisation can be used including repeated mobilisation with increased
cytokine doses and use of alternative mobilisation agents (19). For autologous PBSC
patients, the potential risks of PBSC mobilisation and transplant must be balanced
against the potential benefits of PBSCT with regard to disease free survival, overall
survival and quality of life (27).
1.2.2. Safety of G-CSF and PBSC collection by leukapheresis
G-CSF-related side effects are frequently experienced. They can be divided into
expected or commonly experienced side effects which are usually of mild-moderate
severity, and into uncommon or unexpected complications that are often more
severe in nature. Common side effects include bone pain, myalgias, malaise, nausea
and headache (16, 28). Uncommon side effects include splenic enlargement or
rupture (1/5000-1/10000 donors) (29, 30). Serious adverse events and even death
-18-
have occurred as a result of G-CSF induced sickling crises (31). The rise in PB
leukocyte counts following G-CSF is associated with a thrombosis risk (16). Patients
with cardiovascular disease have an increased risk of unstable angina, acute
myocardial infarction (MI) and stroke following G-CSF (16). Mild-moderate
thrombocytopenia, as a result of G-CSF or the leukapheresis procedure, occurs in
-25% of healthy donors (28). The long-term safety of administering G-CSF to
healthy donors was questioned after two cases of leukaemia were reported in this
group (32). National Marrow Donor Program (NMDP) data following >4000 donors
at least 12 months post donation showed no cases of leukaemia or lymphoma in
donors and the incidence of cancer was the same as the age-adjusted population
average (33). Whilst it is still debated whether short term G-CSF, as administered for
HPC mobilisation, can increase the chance of haematological disease including
leukaemia, the current view is that there is no excess long term leukaemia risk for
allogeneic (normal) PBSC donors above that of aged-matched controls.
Procedure related side effects of PBSC collection for the donor include vascular
access difficulties with the need for placement of a temporary collection catheter,
anticoagulation related side effects (due to citrate sensitivity) and various other
apheresis complications (red cell loss, thrombocytopenia, vasovagal episodes, air
embolus, adverse venepuncture reactions and machine malfunctions). Donor
counselling as to the known and potentially unknown risks of G-CSF and PBSC
collection is therefore an essential part of donor assessments (33, 34).
1.2.3. Effects of G-CSF on haematopoietic elements
G-CSF receptors are found on pluripotent and myeloid-committed progenitors as
well as on differentiated myeloid cells, the numbers of G-CSF receptors increasing
with cell differentiation from myeloblast to neutrophil (35, 36). Binding of G-CSF to
myeloid cells stimulates the proliferation of myeloid precursors and accelerates the
release of neutrophils from the bone marrow resulting in markedly increased
peripheral blood neutrophil counts. G-CSF also promotes the release of contents
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from specific and azurophilic granules from neutrophils, activates secretory vesicles
and enhances neutrophil phagocytic function (27, 37, 38).
G-CSF receptors are not restricted to myeloid cells and they have been
demonstrated on other cell types including subpopulations of monocytes,
lymphocytes, platelets and endothelial cells (35, 39-41). Administration of G-CSF
increases PB monocyte counts ~3-fold, activates monocytes and alters the expression
of effector molecules such as IL-10 (42, 43). There is some evidence that G-CSF
enhances platelet aggregation (44). A prothrombotic state may develop in some
healthy donors independent of leukocytosis induced changes, as evidenced by
increased plasma markers of endothelial activation and activation of coagulation
(37, 45, 46).
1.2.4. Effects of G-CSF on progenitor cell populations
1.2.4.1. SDF1a- CXCR4 interactions
Stromal cells create bone marrow niches in which FIPC are retained for growth and
differentiation (47). Stromal derived factor (SDF-la, also known as CXCL12) is a
homeostatic chemokine that is constitutively expressed on bone marrow stromal
cells and binds to its receptor, CXCR4, located on CD34+ cells. It plays a key
regulatory role in trafficking of haematopoietic cells including CD34+ FIPC.
Interactions between SDF-la and CXCR4 are important for the bone marrow
retention of CD34+ FIPC and in regulating their release into the peripheral
circulation (48, 49). SDF-la influences other cell types within the bone marrow and
helps keep B cell precursors in close contact with bone marrow stromal cells (16).
The SDF-la-CXCR4 axis is responsive to HIF-1 (hypoxia inducible factor-1), a
central mediator of tissue hypoxia, which induces SDF-la expression in ischaemic
tissues (including within the relatively hypoxic bone marrow environment) (50).
The induction of endothelial cell SDF-la expression by HIF-1 has a role in attracting
circulating stem and progenitor cells to the area of tissue damage, providing a niche
for CXCR4-mediated tissue repair (51, 52).
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1.2.4.2. Effects of G-CSF to produce HPC mobilisation
The binding of G-CSF to G-CSF receptors on myeloid cells leads to the release of
proteolytic enzymes (elastase, cathespin G, proteinase 3, CD26) from maturing
myeloid cells as well as the release of matrix metalloproteinases (MMP2, MMP9)
from neutrophils which then inactivate and degrade bone marrow components
(adhesion molecules, trophic cytokines) (53). These elements disrupt the
SDF-la-CXCR4 axis leading to release of CD34+ HPC from the bone marrow into the
peripheral blood. Whatever the precise mechanism of G-CSF induced PBSC
mobilisation, it can be implied that agents that disrupt SDF-la-CXCR4 binding
leading to loss of the bone marrow retention signal for F4PC, result in HPC
mobilisation (49). Re-establishment of interactions between FIPC and their bone
marrow environment is required for homing and retention of HPC in the bone
marrow. Homing is a rapid process that relies on the activation of adhesion
interactions to retain HPC that have crossed the blood endothelium barrier within
the bone marrow space, a process that differs from short and long term engraftment
of bone marrow progenitors (50).
G-CSF mobilisation is also accompanied by shedding of cell adhesion molecules.
Studies have identified increased levels of sL-selectin (CD62L), sE-selectin, sCD44
but not sICAM-1 following G-CSF (43, 54) and demonstrated that G-CSF mobilised
CD34+ cells express lower levels of CXCR4, VLA-4 (CD49d) and L-selectin than BM
CD34+ or non-mobilised PB CD34+ cells (55, 56). G-CSF induces down-regulation of
SDF-la in bone marrow stromal cells and reductions in plasma levels of SDF-la
(56). In the presence of proteases there is cleavage of CXCR4 leading to mobilisation
of HSC (57, 58).
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1.2.5. Alternative agents for HPC mobilisation
1.2.5.1. AMD3100 HSC/HPC mobilisation
AMD3100, a reversible antagonist of CXCR4, was developed as a treatment for HIV
infection. Transient increases in peripheral blood leukocyte and CD34 counts
observed during treatment of patients with HIV led to testing of AMD3100 as a
mobiliser of CD34+ HPC. Drug administration to healthy volunteers produced
increases in peripheral blood leukocyLes and CD34 counts comparable to 4 days of
G-CSF (lOpg/kg/d) (59) and it was seen to act synergistically with G-CSF. AMD3100
(given on day 5) significantly increased CD34+ HPC mobilisation compared to use of
G-CSF alone (49). AMD3100 has also been used to mobilise CD34+ HPC in
haematology patients (60, 61). AMD3100 rapidly antagonises CXCR4 to inhibit the
SDF-la -CXCR4 axis, and as a result CD34+ HPC are mobilised into the peripheral
blood (49). The rapidity of action of AMD3100 compared to G-CSF reflects its direct
effect on the SDF-la-CXCR4 axis. It has been proposed that higher CXCR4
expression on AMD3100 mobilised CD34+ cells compared to G-CSF mobilised CD34+
cells indicated reversible inhibition of CXCR4 without proteolytic cleavage of the
receptor (62).
1.3. Embryonic haematopoietic and endothelial development
1.3.1. Early embryonic vascular development
The development of blood and vascular elements requires co-ordination of a
number of cell types and processes and relies on the temporal and spatial proximity
of these elements in the developing embryo (63). The embryonic vascular system
develops by vasculogenesis; the de novo formation of blood vessels from the in situ
differentiation of undifferentiated mesodermal cells into endothelial cells. Small
clusters of undifferentiated mesodermal cells appear in the extraembryonic yolk sac
and develop into blood islands. The organisation of blood islands, with
haematopoietic stem cells located centrally and endothelial progenitors towards the
periphery, illustrates the close relationship between these elements (63). With
development, multiple blood islands fuse to form the capillary network of the
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extra-embryonic yolk sac (63, 64). Once foetal liver and later bone marrow
haematopoiesis is established the intraembryonic arteriovenous vascular system
develops (65, 66).
1.3.2. Embryonic haematopoiesis
Developmental studies using different animal species have shown that cellular
regulatory factors are conserved within vertebrates (67). The development of the
blood system in vertebrates is characterised by the sequential switching of sites
where HSC undergo renewal, expansion and differentiation (68). In humans, at
approximately 6 weeks gestation, blood islands begin to regress and the foetal liver
becomes the major site of haematopoiesis. Like yolk sac haematopoiesis,
erythrocytes are the dominant blood cell but myeloid precursors can be seen. It was
previously thought that yolk sac HSC migrated to the liver but pioneering work
performed by Dieterlen-Lievre showed that this was not the case and that the
embryo body and not the yolk sac was the source of cells for the adult blood system
(69, 70). At around week 5 of human embryonic development, large populations of
CD34+ haematopoietic precursors, which are the main source of HSC in the foetal
liver, can be identified in the ventral endothelium of the dorsal aorta (71). This
region is equivalent to the para-aortic splanchnopleura demonstrated in animal
models of haematopoietic development (72, 73). It contains both endothelial and
haematopoietic progenitors, with the haematopoietic precursors migrating to the
foetal liver and then the bone marrow (74). Although haematopoietic progenitors
can be found in the bone marrow from about 8 weeks gestation the bone marrow
does not become the major site of haematopoiesis until around the 5th month
gestation (75).
1.3.3. Embryonic haemangioblast
On the basis of the close relationship observed between embryonic haematopoietic
and endothelial elements the existence of a common origin for these was proposed
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(His, 1900). Early studies of chick embryos identified synchronous development of
blood and endothelial cells (76, 77). Murray dissected out cells capable of
differentiating into both blood and endothelial cells, and he referred to this common
cell of origin as 'the haemangioblast'; a bipotential cell with the ability to
differentiate along both haematopoietic and endothelial cell lines. Work has
continued to define the cellular events and processes surrounding the
differentiation of these two elements and results from a number of lines of
investigations point towards the presence of this cell population.
A number of shared genes with important roles in haematopoietic and endothelial
development have been described and mutations of these affect the development of
both elements. Failure of blood island formation and vasculogenesis occurred in
Flk-1 (also known as KDR/ VEGFR2) deficient mice (78). Disruption of the Flk-1
gene was associated with absence of yolk sac blood islands and organised blood
vessels with much reduced numbers of haematopoietic precursors and in utero
death of homozygous mice between 8.5 and 9.5 days (78). Clonal studies on chick
embryos demonstrated that VEGFR2' mesodermal cells differentiated into
haematopoietic and endothelial elements (79). CD34 has been identified on elements
involved in embryonic murine vasculogenesis and on haematopoietic-like cells
which were thought to represent blood stem cell progenitors (80).
Scl protein is a crucial regulator of early haematopoiesis (81, 82). It has been
demonstrated in haematopoietic and endothelial elements of yolk sac, and
embryonic Scl expression parallels the haematopoietic activity of different organs
during murine development (83). Stainier identified a single cell in the ventral
marginal zone of early zebrafish blastula that gave rise to both endothelial and
haematopoietic elements. A zebrafish mutant, cloche, had absent endocardial
development and severely reduced numbers of blood cells. Overexpression of Scl
protein in this mutant rescued the defects in haematopoiesis and endocardial
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development whilst in wild type zebrafish embryos, Scl over-expression led to
expansion of haematopoietic and endothelial cells (84, 85).
Whilst supporting the concept of the haemangioblast these studies did not prove its
existence. The development of a culture system whereby embryonic stem cells were
cultured to establish the embryoid body assisted the pursuit of the haemangioblast
(86) as previously embryonic cells could not be studied prior to the stage of blood
island development (87). Embryoid bodies differentiated from embryonic stem cells
for 3-3.5 days were demonstrated to contain a unique precursor population with
definitive haematopoietic potential. When cultured in the presence of VEGF, c-kit
ligand SCF and endothelial conditioned medium, these cells, termed blast colony
forming cells (BL-CFC), expressed a number of genes common to both
haematopoietic and endothelial cells (VEGFR2, CD34, Scl/Tal-1) (87, 88). BL-CFC
were subsequently demonstrated to differentiate into haematopoietic (primitive
erythrocytes and multilineage haematopoietic cells) and endothelial cells (88) and
cultured embryonic stem cells were used to define a cell phenotype for cells at the
divergence of endothelial and haematopoietic cell line (89).
Until recently the mechanisms for the development of haematopoietic cells from the
haemangioblast were unclear. The identification of formation of a hemogenic
endothelium from haemangioblasts as an intermediate stage in embryonic
haematopoietic development provided a link between haematopoietic and
endothelial precursors (90). Lancrin et al demonstrated that upregulation of c-kit in
Tie2+ cells by SCL/Tal-1 was required for the establishment of the hemogenic
endothelium and Runxl (AML-1) was essential for formation of haematopoietic
progenitors (90).
1.4. Vascular development in the adult
It was previously held that new blood vessel formation in adulthood occurred by
the processes of angiogenesis and arteriogenesis and that vasculogenesis did not
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occur postnatally. Angiogenesis refers to the sprouting of endothelial cells from post
capillary venules and encompasses the proliferation and migration of endothelial
cells and remodelling of pre-existing vessels. Arteriogeneis is the development of
new blood vessels from the maturation of collateral vessels. The discovery of
endothelial progenitor cells (EPC) as a population of non-haematopoietic precursors
in the bone marrow that can be mobilised into the peripheral circulation and then
home to sites of neovascularisation (91) opened up many new possibilities in the
field of regenerative medicine and created great interest in extending cellular
therapy beyond the transplantation of haematopoietic progenitors.
1.4.1. Circulating endothelial cells and endothelial progenitor cells
Asahara et al proposed that peripheral blood contained a population of cells that
could differentiate into blood vessels (91). This landmark study provided evidence
that CD34+ cells could differentiate into cells with endothelial characteristics and
that CD34+ (enriched to a purity of -15%) or KDR+ cells isolated from human
peripheral blood could participate in vasculogenesis at sites of neovascularisation in
a murine hindlimb ischaemia model, challenging the understanding of adult blood
vessel development (91). These circulating cells displayed endothelial and
progenitor properties and were termed endothelial progenitor cells (EPC). EPC
display similar properties to the embryonic angioblast and have the capacity to
migrate, proliferate and differentiate in response to physiological or pathological
stimuli but have not yet acquired mature endothelial markers (92, 93). It is now
thought that the processes of angiogenesis and vasculogenesis occur simultaneously
at sites of neovascularisation and that both processes then contribute to vascular
repair.
Since the identification of EPC in adult peripheral blood (91) extensive studies have
been performed and we are now beginning to understand the complex relationships
between adult haematopoietic and endothelial elements. The bipotential
haemangioblast was thought to be a transient cell population restricted to yolk sac
and early intra-embryonic vascular development. Recent evidence supports the
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presence of a cell population that has properties similar to the embryonic
haemangioblast in the adult. Pelosi et al demonstrated that CD34+/KDR+ cells from
human bone marrow or umbilical cord blood (UCB), plated at the single cell level in
long term culture were able to generate haematopoietic and endothelial colonies
and hypothesised that haemangioblasts were contained within this cell population
(94). Assuming 1% of cells in MNC are CD34+and 1% of CD34+ cells are KDR+ the
calculated frequency of CD34+/KDR+ haemangioblasts was 5 per million MNC (94).
Circulating endothelial cells (CEC) are mature non-dividing endothelial cells that
have been sloughed from the vessel intima (95, 96). Within this cell population rare
vascular derived EPC are also found. CEC are present in low concentrations (~3
cells/mL of whole blood) and can be measured by flow cytometry using markers
such as CD146 (S-endo) (95, 97). Their enumeration might be a useful adjunct in
understanding vessel injury and disease processes (96). CEC numbers increase
following vascular stressors including infection, metabolic stress and in disease
states including sickle cell disease, vasculitis, following BMT or post solid organ
transplantation (98-101). CEC are interpreted as an indicator of vascular integrity
and their increase in the circulation is generally thought to indicate vascular
damage.
Until the demonstration of colonisation of Dacron material, wholly suspended
within an intrathoracic graft by circulating (endothelial) cells (102), the origin of
endothelial cells on implanted vascular material had been assumed to be entirely
from infiltrating vessels from the anastemoses or from microvessel penetration of
the graft material (103, 104). Evidence of circulating endothelial cells had also been
provided by reports of recipient-derived endothelial cells within the coronary
arteries of a transplanted heart (105) and of colonisation of the luminal surface of
left ventricular assist devices by endothelial cells (106). Shi et al provided evidence
for the existence of bone marrow derived endothelial cells. Dacron thoracic aorta
vascular grafts implanted six months after successful canine BMT (full donor
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engraftment) showed endothelial cells of donor origin (PCR studies) when grafts
were recovered 12 weeks later (107). Other transplantation studies, using gender
mismatched stem cells, differentiated between donor bone marrow derived and
host vessel derived endothelial cells in the circulation (108).
1.4.2. Identification of endothelial progenitor cells
EPC comprise a minor proportion of PB MNC and can also be isolated from bone
marrow (107) and UCB (109). The development of methods for EPC isolation has
been hampered by the low frequency of EPC events (96). The two main strategies to
enumerate putative EPC are flow cytometric analysis for the presence of specific
surface antigens and in vitro culture methods.
1.4.2.1. Flow cytometry analysis for the expression of surface antigens
Phenotypic analysis enables EPC to be identified prospectively using a hypothetical
definition of EPC phenotype without the need for cell culture. EPC have been
variously defined according to their expression of CD34, KDR and CD133 antigens,
with expression of these antigens alone or in combination being used to define EPC.
EPC numbers, defined using CD34+, CD34+/KDR+ or CD34+/ 133+/ KDR+ expression
or variants thereof have all been correlated with disease states (110, 111). There is
little debate about the existence of endothelial and haematopoietic progenitors
within the CD34+ fraction of bone marrow, UCB and PB MNC but it seems that KDR
(VEGFR2) and CD133, both used to define EPC, are also expressed by HSC/HPC
(93, 112, 113). Expression of surface antigens may change during progenitor
mobilisation and maturation (114). There are also difficulties associated with the
antigenic distinctions between CEC and EPC (115). The common leukocyte antigen,
CD45, can be used to exclude differentiated haematopoietic cells from endothelial
cell populations but it does not identify lineage negative HSC. Endothelial
precursors have been identified as CD45+ by some (116, 117) and CD45 by others
(118) but in many studies CD45 expression by putative endothelial progenitors has
not been assessed. The numbers of putative EPC identified within a sample are not
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only affected by the choice of phenotypic definition but also by the gating methods
used for calculation of the cell population. Van Craenenbroeck et al analysed the
whole blood and MNC EPC content, defined by CD34 and KDR expression, of
samples obtained from healthy volunteers and illustrated the huge variations in
EPC numbers introduced by the use of different gating methods (including
lymphocyte gating, CD3 negative selection, Draq 5 nuclear staining) (119).
CD133 (AC133) was found to be present on all non-committed CD34+/38" cells and
the majority of committed myeloid CD34+ cells (120). Similar to CD34, expression of
CD133 declined during differentiation and was not found on mature cells and
although EIPC expression of CD133 parallels that of CD34, the two antigens do not
share any homology (121). The actual functional role of CD133, like CD34, has not
been elucidated. It has been reported that CD133 is not expressed by mature
endothelial cells but is present on EPC in foetal liver, UCB and peripheral blood
(122). De Wynter et al studied CD34+ subsets within peripheral blood, bone marrow,
and G-CSF mobilised peripheral blood and found that significant proportions of
CD34+/133+ were present in each (36% UCB, 51% bone marrow, 75% mobilised
peripheral blood CD34+ cells) and that these cells, and not CD34+/133" cells, were
capable of repopulating NOD/SCID mice (123). A study using UCB came to similar
conclusions with CD34+/133brisht expression identifying early high proliferating/stem
and early committed progenitor cells with late committed precursors being
CD34'/133dim (124). Using culture-based colony assessments and a murine cancer
model, Gehling et al concluded that CD34+/133+ cells from bone marrow and
peripheral blood contained progenitor cells that differentiated into both
haematopoietic and endothelial cells (125).
The action of VEGF, mediated through 2 receptors, VEGFR-1 (Flt-1) or VEGFR2
(KDR/Flk-1), is one of the main inducers for vasculogenesis and angiogenesis (125,
126) and VEGF signalling is essential for haematopoietic development and
vasculogenesis. A study by Zeigler et al examining the phenotypes of primitive HSC
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in bone marrow, peripheral blood, mobilised peripheral blood and UCB reported
that pluripotent HSC were contained within the CD34+/KDR+ fraction and lineage
committed progenitor cells were restricted to CD34'/KDR cells (127). CD34+/KDR+
cells (lirr) accounted for 0.5-1.0% of CD34+ cells, findings similar to those of Pelosi et
al who hypothesised that haemangioblasts were contained within CD34+/KDR+ cells
(94, 127).
Although CD34+/133+/KDR+ (CD34+/133+/VEGFR2+) cells were proposed by some as
defining EPC (94), this population comprises an exceedingly small proportion of
MNC and in the absence of primary enrichment are very difficult to isolate. The
frequencies of CD34+/133+/KDR+ cells were determined to be 0.0084%+/-0.0052% in
whole blood, 0.021 %+/-0.0098% in UCB and 2.07%+/-0.15% in mobilised PB CD34+
cells (112). This phenotype had been used to hypothetically define EPC in a number
of studies (122, 125, 128) but the direct contribution of these cells to vasculogenesis
has not been reported (113). It now appears that the CD34+/133+/VEGFR2+ cells
identified by Piechev et al and others (122, 125, 128) represent committed
haematopoietic cells with no endothelial potential (112).
Flow cytometric detection and enumeration of EPC is subject to technical
difficulties, mainly due to the rarity of these cells. When defined phenotypically as
CD34+/KDR+ or CD34+/133+/KDR+ cells, EPC may not be identifiable by flow
cytometry, even with the collection of very large numbers of events (128). The
ability to culture these cells enables rare cells to be identified.
1.4.2.2. Culture based methods to identify EPC
Varying cell sources, cell separation methods and culture conditions have been used
by different groups examining the generation of cells with an endothelial-like
phenotype from haematopoietic sources and it is likely that different cell
populations have been studied (129). Recent opinion is that two broad types of EPC
exist. Early work by one group demonstrated the presence of two EPC populations
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within a single culture of human peripheral blood, in the gelatin adherent MNC
fraction cultured in EGM2, and coined the terms early EPC and late EPC (130, 131).
Subsequent studies have concurred with the findings of 2 distinct EPC populations
and although these share some features including lectin binding, ac-LDL uptake
and CD31 expression, the cell types differ in their proliferative capacity,
morphology and functional characteristics (93, 108, 131-134).
1.4.2.2.1. Short term culture - early EPC
A landmark study by Hill et al correlated vascular function and cardiovascular risk
with circulating EPC. In this study MNC were plated onto fibronectin coated plates
in Medium 199 supplemented with foetal calf serum (FCS) with replating of
fibronectin non-adherent cells onto fresh fibronectin plates after 48 hours (110).
Morphologically distinct colonies consisting of multiple thin flat cells emanating
from a central cluster of rounded cells appear spontaneously within the fibronectin
non-adherent cell fraction after 5-7 days of culture (110). Endothelial cell lineage was
demonstrated by immunostaining for CD31, VEGFR2, ac-LDL and Ulex lectin.
Although cell proliferation does occur within CFU-EPC, demonstrated using
radiolabeled thymidine (135) and EDU (O Tura, personal communication), cell
proliferation is limited and other processes such as cell migration are involved in
colony formation. This assay was widely adopted as a measure of circulating EPC
and a commercial CFU-EPC assay (now also referred to as CFU-Hill) was developed
(Stem Cell Technologies, UK).
It is now believed that early EPC, as presented in publications by Asahara and Hill
among others and identified using the commercially available CFU-EPC (CFU-Hill)
assay (Stem Cell Technologies, UK), plating MNC onto fibronectin coated plates, are
haematopoietic and either of myeloid lineage or derived from earlier
haematopoietic precursors (96). Our group has worked extensively using CFU-Hill
assays and identified colony forming cells in 2-hour plastic adherent MNC, shown
to be enriched to 80% purity for CD14+ monocytes, but not in plastic non-adherent
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MNC (136). Purification of CD14+ monocytes (>98% pure) by immunomagnetic
separation further increased CFU-EPC. Subsequent publications, particularly by
Rohde's group (137) but also later by van Beem et al concurred with the view that in
MNC from normal adults CD14+ monocytes are essential for CFU-EPC (135). CD14+
monocyte and CD3+ T cell interactions were proposed to be important for the
initiation of CFU-EPC (135, 137). The assay was interpreted hy one group as a
reflection of the T cell-mediated induction of monocytes towards pro-angiogenic
cells (135). CFU-EPC were influenced by alterations to CD3+/4+ T cell numbers and
whilst CD14+ monocytes were essential for CFU-EPC, interactions with CD3+/4+ T
cells, including those cytokine-mediated, were required for colony initiation (135). A
series of subtractive analyses by Rohde et al demonstrated the presence of T cells
and monocytes in CFU-EPC, and similar to van Beem et al, suggested that
interactions between these cells was essential for CFU-EPC (137)
As an alternative to the short term culture of MNC using CFU-Hill (or CFU-EPC)
assays and identification of EPC within day 1 or 2 fibronectin non-adherent MNC,
others have plated MNC on fibronectin coated plates with a variety of growth
factors and identified EPC within the fibronectin adherent fraction (129, 132, 138,
138, 139). The role of CD14+ monocytes in the development of early EPC in
fibronectin adherent MNC, as opposed to the 2 day fibronectin non adherent MNC
in the CFU-Hill assay, has also been reported by a number of groups and so it
appears that this culture method also identifies haematopoietic cells mainly of
monocytic origin (129, 132, 139). A number of studies using this method to identify
EPC in adherent MNC have specifically demonstrated the formation of EPC in
CD14-enriched fractions. During short term culture, CD45+/14+ monocytes
developed into spindle shaped adherent cells and altered their phenotype to express
endothelial-type markers (including VWF, KDR, CD105, CD144, CD146) but
without E-selectin or AC133 expression (129, 132, 140). Schmeisser et al cultured
CD34/14+ PB monocytes on fibronectin. These cells continued to be CD45+ but
expressed a range of endothelial markers at 2 weeks which were not present on day
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1, and developed cord like structures when plated into Matrigel (129). In our
laboratory, cells derived from CFU-EPC culture have not formed tubules when
plated alone in Matrigel and have not incorporated into tubules formed by
HUVECS (in Matrigel). It might be that the relatively 'late' appearance of EPC
within fibronectin adherent MNC in this early study by Schmeisser et al actually
identified late EPC.
When culturing PB MNC on fibronectin, the majority of peripheral blood derived
cultured Ulex+/ac-LDL+ cells expressed monocyte/macrophage markers and
although the cells did not proliferate significantly they did secrete pro-angiogenic
factors (132, 139). Freshly isolated CD14+ monocytes expressed higher levels of
CD31, CD144 and BS-1 lectin, slightly lower levels of CD105 and equivalent UEA-1
lectins than cultured monocytes (139) meaning that these feature fail to distinguish
between monocytes and cells of endothelial differentiation. The relevance of
monocytic features to the generation of EPC with the capacity for neovascularisation
was questioned by Urbich et al who showed that the origin of EPC isolated from
blood was not restricted to CD14+ monocytes and that other cells could display
endothelial features (141). Comparable expression of endothelial markers
(Dil-ac-LDL and lectin) was found in day 4 adherent CD14+ and CD14" MNC. Using
a murine hind limb ischaemia model, the authors showed that infusion of
uncultured CD14+ or CD14" MNC failed to improve ischaemia whilst infusion of
cultured cells (CD14+, CD14" or unselected MNC) did (141).
Similar culture methods were used to identify early EPC in the fibronectin adherent
fraction of MNC (lOxlO7 MNC cultured in growth factor supplemented EGM2
media (Clonetics, UK) for >4 days) from healthy subjects, the number of which
correlated with the number of peripheral blood 'angiogenic' T cells (142).
Angiogenic T cells, defined as the CD3+/31+/CXCR4+ T cell subpopulation, were
found predominantly within the central cores of CFU-EPC and were demonstrated
to show improved pro-angiogenic properties over CD3+/3T T cells (142).
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The cells identified in CFU-EPC assays based on short term short term MNC
adherence to fibronectin appear to form heterogeneous collections of cells. Although
CD14+ monocytes are essential for CFU-EPC it is likely there are vital contributions
made by other inflammatory cells including T cells in the initiation of colony
formation. Whilst in vitro functional studies (Matrigel assay) show reduced
incorporation of these cells into tubules, delivery of these cells to ischaemic areas in
animal models have produced clinical benefits (130). It is proposed that the
pro-angiogenic effects of these cells are due to the production and release of
angiogenic factors (VEGF, IL-8,) that act on adjacent endothelial cells to stimulate
vessel formation (130). Additionally, monocytes and macrophages have been shown
to be important in neovessel formation through their cord formation, incorporation
into structures and secretion of elastases that degrade the extracellular matrix,
providing a scaffold on which endothelial cells can grow and invade fibrotic tissue
(143, 144).
1.4.2.2.2. Endothelial outgrowth cells
Cells variously defined as late EPC, endothelial outgrowth cells (EOC), endothelial
colony-forming cells (ECFC) or outgrowth endothelial cells (OEC) are rare cells that
arise from CD45 /14" non-haematopoietic cells, display robust proliferative potential
and possess in vivo vessel forming abilities (93, 115). They are similar to the bone
marrow-derived EPC described by Shi et al (107). After 2 weeks of culture (or less if
using UCB) (133) in supplemented EGM-2 media on collagen coated plates,
adherent cells form colonies with a cobblestone appearance. Single cell studies have
confirmed a proportion of EOC displayed clonogenic expansion, stem-like
properties and could be transplanted to yield de novo vessel formation (93).
The formation of EOC and early EPC from distinct cell populations has been
demonstrated using modified culture conditions (108, 145), that support the
development of both EOC and short-term fibronectin adherent EPC (130, 146, 147).
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Independent culture of CD14+ MNC and CD14 MNC showed that early EPC were
generated by CD14+ MNC and EOC by CD14" MNC (146). The cell morphology
displayed by early and late EPC was in agreement with other studies (108). Late
EPC showed capillary formation when plated alone on Matrigel and incorporated
better with HUVEC on Matrigel than early EPC. In another study early EPC
appeared from the end of the first week of culture (and had disappeared by 8
weeks), late EPC (EOC) appeared after 2 weeks and then expanded greatly (130).
EOC but not early EPC incorporated into vascular networks in an in vitro angiogenic
assay (147).
Peripheral blood samples from patients with the myeloproliferative disorder (MPD)
polycythaemia vera (a disorder of haematopoietic progenitor cells) positive for the
Janus Kinase 2 V617F mutation were used to demonstrate the haematopoietic origin
of early EPC and to show that CFU-EPC (CFU-Hill) and EOC cells were not clonally
related (93). Whilst all genotyped CFU-EPC colonies expressed the Jak2 mutation,
only 3 of 89 EOC colonies contained mutant alleles (all from same patient,
possibility of germline mutation; sample contamination or haematopoietic
derivation of colonies possible explanations). Similar to other studies (133), EOC
colonies expressed markers of endothelial differentiation and were CD45" and CD14"
whilst CFU-EPC were CD45+ and CD14+. Another controlled study of patients with
MPD showed that disease-specific mutations (Janus Kinase 2 V617F mutation or
BCR-ABL rearrangement) could be identified in CFU-EPC but not in EOC,
demonstrating the haematopoietic origin of CFU-EPC but not of EOC (148).
Peripheral blood MNC from recipients of gender mismatched allogeneic BMT
recipients (100% donor bone marrow and peripheral blood genotype by RFLP)
cultured for EOC were used to demonstrate the presence of bone marrow derived
endothelial cells with stem/ progenitor properties in the peripheral blood and to
distinguish these from recipient derived circulating endothelial cells (CEC) (108).
Cell origins were determined using FISH for X and Y chromosomes. Whilst in fresh
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samples, only minor proportions of CEC were either transplanted cells or derived
from transplanted cells (95% recipient and 5% donor genotype) the proportions of
cells exhibiting donor genotype increased over the culture period and EOC colonies
were of donor karyotype. Donor derived EOC had extraordinary growth capacity,
suggesting these to be of stem or progenitor origin (108). EOC arising from different
sources (UCB MNC and peripheral blood MNC) are not identical. UCB EOC
appeared earlier in culture, contained larger colonies and in single cell cultures were
enriched in highly proliferative progenitor cells compared to peripheral blood EOC
(133). A hierarchy for EPC, along the same lines as the haematopoietic progenitor
hierarchy, has been proposed (133).
EOC are believed to arise from non-haematopoietic cells contained in the CD14"
MNC fraction (93, 115), perhaps from the CD34+ cells contained within the
heterogeneous CD14" cell population (131). There are complex relationships between
HPC, EOC and early EPC which are further confused by the overlap of CD34,
CD133 and KDR antigen expression between endothelial and haematopoietic
differentiated cells (120, 127). Conflicting data has been presented on the phenotype
of EOC and the contributions of different subsets of CD34+ cells to colony formation
(125, 149). The phenotype of cells contributing to EOC formation has been
investigated by a number of groups that concluded that EOC arose from CD45 /34+
cells that did not express CD133 and who refuted the belief that EPC can be defined
phenotypically by co-expression of CD34, CD133 and KDR (112, 134, 150).
Untegasser et al plated PB MNC or UCB MNC in collagen type 1 coated plates in
EGM2. Following MNC selection for CD133, CD34 or CD14, EOC colony formation
was observed in the 24 hour adherent cell fraction after 7-12 days exclusively in
CD34+/133- MNC and these cells were shown to express CD31, VWF, bind Ulex
lectin and take up ac-LDL. Cultured cells showed formation of capillary like
structures in Matrigel and homed to ischaemic myocardium in a murine model of
infarction (150). Using bone marrow and UCB as sources of CD34+ cells,
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Timmermans et al reliably generated EOC with typical cobblestone morphology and
endothelial antigen expression (CD31, CD146 CD105, CD34, VEGFR2) from
CD34+/45" cells but not from CD34+/45+ cells (134). Similar to others (131, 151), EOC
were found to be CD45/14/133-, with lack of CD133 antigen expression confirmed
by mRNA studies. CD34+/45+ cells failed to generate EOC but did develop CFU-EPC
like colonies (134). UCB CD34+/45" cells formed EOC but failed to generate CFU-EPC
or haematopoietic activity whilst UCB CD34+/45+ cells were enriched for
haematopoietic colony forming activity (112). CD34+/133+/KDR+ cells isolated from
UCB, normal peripheral blood or G-CSF mobilised PB CD34+ cells were
simultaneously plated into endothelial and haematopoietic clonogenic assays.
CD34+/133+/KDR+ cells from UCB and mobilised PB CD34+ cells failed to generate
CFU-EPC or EOC but produced LPP-CFC and EIPP-CFC in haematopoietic assays.
In keeping with this, >99% of CD34+/133+/KDR+ cells co-expressed CD45 (112). Case
et al recommended inclusion of CD45 as an exclusionary gate when identifying
CD34+/KDR+ precursors to reduce the numbers of false positive events.
1.4.3. Interactions between early EPC and EOC in promoting
neovascularisation
Murine hind limb ischaemia studies showed no differences in the vasculogenic
potential of early and late EPC (130). The discrepancy between in vitro and in vivo
function may be due to enhanced secretion of angiogenic cytokines (VEGF, IL-8) by
early EPC that may activate adjacent endothelial cells and promote angiogenesis
(130, 132). Heterogeneity in the cells comprising early EPC might also influence the
in vivo function of these cells. Synergy between haematopoietic derived CFU-EPC
and non-haematopoietic endothelial outgrowth cells is perhaps not surprising
considering their common origin and the close relationship between haematopoietic
and endothelial progenitor development. It may be that paracrine and autocrine
networks of cytokines between the two types of endothelial progenitors might be an
important mechanism of neovascularisation (131). With recognition that
pro-angiogenic effects of cell therapy extend beyond incorporation of transplanted
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cells into the vessel wall, the influence of cytokines and proteases, including matrix
metalloproteinases (MMP) released by EPC as well as other functions of EPC on
vessel formation is being investigated. It has been shown that unlike EOC, early
EPC secrete VEGF and IL-8 (130). The same group found that MMP-2 was secreted
by CD14- cells and EOC and that MMP-9 was secreted by CD14+ cells and early EPC
(131). MMP-9 is involved in the mobilisation of EIPC and EPC from bone marrow,
facilitates homing of EPC and has important roles in sprouting angiogenesis (152).
Synergistic effects on vascularisation in a murine hind limb ischaemia model were
produced by culturing early EPC together with EOC (131) and this was
accompanied by enhanced release of MMP-9 from early EPC and greater invasion
depth of early EPC (131). The role of MMP in neoangiogenesis may be relevant to
the use of G-CSF for progenitor mobilisation as G-CSF induced MMP release is
important for mobilisation of HPC from the bone marrow (53).
1.4.4. Difficulties with models of vasculogenesis
Regardless of the definitions used, putative EPC might only give rise to endothelial
cells depending on the exact combination of growth factors to which the cells have
been exposed to in vitro, the animal model used to assess vasculogenic activity and
the nature, extent and method of delivery of the antigenic stimulus in vivo (153).
Cultured cells may have acquired or lost properties during culture such that the
function and phenotype of in vitro propagated cells may differ significantly from
those of non-cultured cells (141,153).
The use of animal models for the functional assessment of putative EPC is flawed as
in vivo models of vasculogenesis do not identify vasculogenesis according to the
generation of EC from circulating EPC. They rely on the localisation of a donor cell
population to the site of vessel injury/neovascularisation as evidenced by the
presence of positively stained cells, ac-LDL uptake or lectin binding, rather than
demonstrating the actual incorporation of cells into neovessels. Additionally, there
are no antigenic markers unique to endothelial cells and lectin binding and ac-LDL
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uptake are both properties also shown by haematopoietic cells including monocytes
(132, 139, 153). Mature haematopoietic elements are involved in vascular repair and
given the expression of 'endothelial antigens' by haematopoietic cells,
co-localisation of endothelial and haematopoietic cells might be incorrectly
identified as evidence of vasculogenesis.
1.5. Clinical application of endothelial progenitor cells
The lack of a standardised accepted definition of EPC and lack of standardised
methods for their identification, isolation or expansion has not restricted entrance of
EPC into the clinical arena and their use in cell-based therapy. The treatment of
patients with cardiovascular and vascular disease has become an area of intense
study. The majority of cell therapy studies have used bone marrow as a source of
EPC with transplantation of whole bone marrow or BM MNC (or fractions thereof)
into animal or human subjects. Whilst there may be clinical benefits reported, such
are the inconsistencies in the definitions and methodologies used that it remains
difficult to compare study outcomes. The results of some studies, mainly in the
setting of cardiovascular disease are discussed below.
1.5.1. Local delivery of bone marrow MNC
Many investigators have reported on the outcomes of locally delivered
(intracoronary infusion, myocardial delivery) bone marrow derived or growth
factor mobilised cells (HSC and EPC). In the great majority of these studies, the
delivered cell product was evaluated by flow cytometry analysis for the cell
expression of CD34, alone or in combination with CD133 and/or VEGFR2 and
colony formation was not assessed.
Intracoronary infusion of BM MNC using an inflated balloon catheter to deliver
cells to the infarct related artery has produced clinical benefits in a number of small
trials (154-156). On the basis that several different MNC fractions, including bone
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marrow haemangioblasts, HSC and EPC may contribute to tissue regeneration,
unselected BM MNC were infused (154, 155). The study by Dimmeler's group was
notable as outcomes following intracoronary unselected bone marrow derived cells
were compared to infusion of peripheral blood-derived endothelial progenitors; day
3 fibronectin-adherent MNC cultured in VEGF, atorvastatin and serum
supplemented media, with no differences found between treatment arms (155).
Implantation of autologous BM MNC by intramyocardial injection following MI
was reported to reduce infarct size, improve wall thickening and wall motion (157)
whilst another (earlier) uncontrolled study failed to show significant benefit of
intramyocardial CD133+ BM MNC when administered following coronary artery
bypass grafting (CABG) post MI (158). Delivery of autologous BM MNC to the
ischaemic myocardium by the endocardial route in patients with chronic ischaemic
heart disease (non-randomised study) showed some benefits in left ventricular
volumes and left ventricular ejection fraction (LVEF) compared to controls (159).
A meta-analysis of the use of stem cell therapy in acute MI reviewed 14 studies
(20-187 patients in each) using BM MNC (12 studies) or G-CSF mobilised MNC (2
studies) (160). Stem/progenitor cell therapy did not appear to be associated with an
increase in adverse events. It concluded that although there were some general short
term improvements in cardiac function in the treated group there was insufficient
data to assess the long term clinical effects of stem/progenitor cell therapy (160).
1.5.2. Peripheral blood stem cells for cellular therapy
Collection of bone marrow requires the patient to undergo a collection procedure
whereby bone marrow is aspirated from bilateral iliac crests under anaesthetic. In
haematology, collection of bone marrow for HSCT has largely been replaced by
PBSC collected from the circulation by leukapheresis, therefore avoiding the risks of
general anaesthetic, the risks of bone marrow harvest and the unpleasantness of this
procedure. The possibility of using mobilised peripheral blood progenitor cells for
cellular therapy is an attractive option. Bussolino et al demonstrated dose
-40-
dependent increases in human endothelial (umbilical vein) cell migration in
response to G-CSF and GM-CSF and identified high affinity binding sites for both
these cytokines on human endothelial cells suggesting that cytokines could mobilise
EPC into the circulation (161).
Although there have been no direct comparisons between the therapeutic benefits of
bone marrow and cytokine mobilised EPC, studies have reported the effects of
G-CSF (and GM-CSF) administration on putative EPC using phenotypic analysis or
culture-based colony assays, with a number also reporting its clinical effects on
myocardial regeneration and function. G-CSF may contribute to the
revascularization of the infarcted area and could also facilitate the differentiation of
HSC into cardiac myocytes or supportive cells.
1.5.2.1. Effects of G-CSF on putative EPC - phenotypic analysis
There is no doubt that G-CSF mobilises HPC into the peripheral blood, identified by
their surface expression of CD45 together with CD34 and/or CD133, it remains
unclear whether EPC are mobilised together with or independently of HSC/HPC
and whether EPC can be quantified prospectively by flow cytometry.
Studies reporting on the effects of G-CSF mobilised progenitor cells on
vascularisation have used varied phenotypic combinations to prospectively identify
putative EPC within mobilised blood; CD34+ cells (162-164), CD34+/45+ cells (165,
166), CD34+/133+ (164, 167, 168), CD133+/VEGFR2 (167), CD34+/VEGFR2+ (163),
CD34+/133+/VEGFR2' (162, 163, 166). Additional antigens have also been used to
identify cells with an endothelial phenotype; CD34+/3T, CD34+/117+ (168) for
example, making it more difficult to compare study outcomes. Despite the range of
phenotypic definitions used these studies all reported that G-CSF increases
peripheral blood EPC. However, in many, if not all cases the definitions used can be
applied to HPC and may not define EPC at all, especially if, for example EPC are
CD133" and/or CD45".
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1.5.2.2. Effects of G-CSF on putative EPC - culture based colony assays
A number of other studies have been published whereby the effects of G-CSF on
putative EPC contained in peripheral blood samples obtained prior to and following
G-CSF were assessed by short term colony assays. These studies differed
substantially in the doses of G-CSF administered and the culture methods used for
in vitro assessment of EPC, with no two studies using identical methods.
A number of studies of G-CSF and peripheral blood EPC have used modified
CFU-FIill assays to identify EPC within day 1 or 2 fibronectin non-adherent MNC
(110). In 2005 it was noted within our laboratory that CFU-EPC were depressed in
samples obtained from G-CSF mobilised peripheral blood. On account of the raised
CD34-content of mobilised peripheral blood we had expected to see an increase in
CFU-EPC in these samples and we began to examine this further. Initial findings
were published (136, 169) and we have continued our study of this area principally
using the CFU-EPC assay. Powell et al used a method similar to that described by
Hill (110) to assess the effects of G-CSF on CFU-EPC formation in patients with
coronary artery disease. In a modification from previous publications by the group,
EPC colonies were enumerated at 9 days, 7 days after re-plating day 2 non-adherent
MNC (167). Powell et al reported an increase in CFU-EPC following administration
of G-CSF to healthy controls and to patients with coronary artery disease, although
patients exhibited lower CFU-EPC than healthy controls. Mauro et al assessed EPC
during HPC mobilisation by G-CSF+chemotherapy using MNC suspended in
Medium 199 supplemented with FCS (changed every 3 days) in fibronectin coated
plates. EPC were identified in the 2-day fibronectin non-adherent MNC fraction
after a total of 7 days of culture (CFU-end) (162). Mauro et al reported an increase in
CD34+/133+/VEGFR2+ cells in peripheral blood and leukapheresis collections
following G-CSF and identified so called CFU-end in leukapheresis collections. No
evaluations of PB CFU-End were made and the effect of G-CSF on colony formation
could therefore not be assessed (162). Another study similarly assessed EPC colonies
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using Medium 199 supplemented with FCS and fibronectin coated plates and
reported increases in CFU EPC following G-CSF (163). Korbling et al shortened the
primary plating period and EPC were defined in the 24 hour fibronectin
non-adherent MNC fraction after 7 days of culture. A study of autologous and
allogeneic PBSC donors reported increased CFU-EPC (vascular progenitor cells or
VPC in this publication) following G-CSF, as assessed using MNC plated into
fibronectin coated wells suspended in RPMI, supplemented with FCS and
endothelial growth factor. VPC (EPC) were identified in the 2 day fibronectin
non-adherent cells after 9 days in culture (170).
Honold et al defined EPC by ac-LDL uptake in the 3-day fibronectin adherent
fraction of MNC cultured in EBM2 medium supplemented with FCS and
atorvastatin (165). These adherent cells were then cultured for a further 2 weeks in
VEGF and assessed for colony formation on the basis of morphology alone. Using
these methods, CFU-EC were reported to increase following the administration of
G-CSF to a small number of patients with chronic ischaemia heart disease.
Interestingly, migratory responses of day 3 fibronectin adherent cells to SDF-1 and
VEGF were impaired in G-CSF treated MNC compared to untreated cells (165).
A single study has examined the mobilisation of vascular progenitor cells in the
course of PBSC mobilisation for allogeneic as well as autologous PBSCT (170). In
this study, G-CSF was administered to donors and patients according to standard
regimens for HSC/HPC mobilisation with leukapheresis commenced when PB CD34
counts exceeded 10/pL. EPC were identified as vascular progenitor cells (VPC) by
colony assay, discussed above. Peripheral blood and leukapheresis samples
obtained from autologous PBSC patients had lower pre G-CSF VPC than allogeneic
PBSC donors. Despite this, VPC increased in both patient groups following PBSC
mobilisation with G-CSF (and chemotherapy). VPC numbers failed to correlate with
CD34 counts or haematopoietic colony assays (total CFU and GM-CFU) leading the
authors to conclude that VPC were differentially mobilised from HPC (170).
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Although it is currently believed that 'true' EPC are identified in the endothelial
outgrowth colony assay, to date there is a lack of published studies examining these
cells in the setting of G-CSF PBSC mobilisation.
1.5.2.3. G-CSF administration without cell isolation - clinical outcomes
A number of studies have reported on the effects of G-CSF on clinical outcomes
without any evaluation of the effects of G-CSF on putative EPC phenotypes or
colony formation. Use of G-CSF mobilised progenitor cells for cardiovascular
regeneration stalled once adverse findings of increased incidence of instent stenosis
following intracoronary implantation of autologous G-CSF mobilised MNC in the
MAGIC trial were reported (171). Subsequent to this, an uncontrolled study
reported improved LVFF and LV volumes following intracoronary infusion of
autologous G-CSF mobilised MNC (172) but this study failed to include a G-CSF
only arm, preventing comparisons being made between outcomes following
systemic mobilisation of progenitors by G-CSF and the local implantation of
mobilised cells.
As an alternative to local (intra-coronary or intramyocardial) implantation of
autologous BM MNC or G-CSF mobilised progenitors, and on the premise that
G-CSF mobilises EPC, a number of trials have reported on the use of subcutaneous
G-CSF in the post infarct period as an adjunct to standard medical care.
Administration of G-CSF (10pg/kg/d for 5 days), commencing 5 days after acute MI
and percutaneous intervention failed to show any improvements in FVEF or infarct
size at assessment 4-6 months post randomisation (173). In this randomised double
blind trial placebo controlled trial (REVIVAF-2) both treatment groups (each
containing >50 patients) showed improvement during follow-up. A significant
proportion of patients (27%) reported G-CSF related side effects (173). Similarly,
there were no differences in LVEF and systolic wall thickness at 6 months follow-up
between treatment groups randomised to receive lOpg/kg/d G-CSF or placebo for 6
days following acute MI with successful percutaneous coronary intervention (PCI)
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(174). In addition, no differences in global or regional myocardial function were
observed between randomised treatment groups following subacute MI with
percutaneous coronary reperfusion (168). A small randomised blinded study using
lower dose G-CSF (5pg/kg/d for 4 days) or placebo in the same clinical setting failed
to show any difference in infarct size and LVEF at 3 and 6 months of follow-up
(166). Ellis et al reported no benefit of 5 or lOpg/kg/d G-CSF over standard treatment
with regard to LVEF at 3 months (175). A small open label study of patient post MI
with PCI reported improvements in regional wall motion and perfusion of G-CSF
treated ((1 Opg/kg/d for 7 days) patients compared to controls (176). One randomised
study, that reported a clinical benefit of G-CSF (lOpg/kg/d x 6 days) following acute
MI and PCI at 6 months (177) was criticised for the poor performance of the control
group. Failure to detect an expected clinical improvement in the control group
contributed to the positive outcome of this study (177).
A meta-analysis on the use of G-CSF in patients with acute MI (178) identified 10
studies, including the ones discussed above, that reported on the effects of G-CSF
on myocardial regeneration post MI, all in the context of reperfusion with PCI.
G-CSF administered in doses of 2.5-1 Opg/kg/d for 4-10 days produced an increase in
PB CD34 counts. Compared with conventional treatment, G-CSF failed to improve
LVEF or infarct size and no overall benefits of G-CSF administration were
demonstrated (178).
Early termination of the MAGIC trial, which studied the effects of intra-coronary
infusion of G-CSF mobilised MNC on patients who underwent coronary stenting
following MI, due to excessive rates of instent restenosis cast doubts over the safety
of G-CSF in this setting (171). The issue of cytokine induced instent restenosis has
been investigated by Cho et al using rabbit models of vascular injury, producing
apparently contradictory results. Increased neointimal hyperplasia following
vascular injury in G-CSF treated rabbits was largely overcome by use of a drug
(paclitaxel) eluting stent (179), whilst an earlier study, using GM-CSF, concluded
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that GM-CSF potentiated the effects of intravascular radiation in reducing
neointimal hyperplasia by accelerating re-endothelialisation (180). The authors'
commented that the specific choice of animal vascular injury models, which differed
between the studies, contributed to their findings and that the use of a paclitaxel
eluting stent resulted in delayed re-endothelialisation. G-CSF pre-treatment was
reported to accelerate re-endothelialisation and reduce neointima formation in a rat
carotid balloon injury model (181) and a canine study with G-CSF starting a week
following carotid vascular graft placement, similarly reported accelerated
endothelialisation and microvessel formation with G-CSF (182).
It may be that administration of G-CSF alone is insufficient to produce clinical
benefits and that local delivery of mobilised (and harvested) PBSC is important
(178). It may also be that the timing of G-CSF administration in relation to acute
(myocardial or other) injury is critical and there may be differences in the homing
signals expressed by damaged tissues according to the time elapsed post injury.
1.6. Cell contributions to vascular repair
The cells contributing to the repair of damaged tissue are not well defined. It may be
that bone marrow derived endothelial cells incorporate at sites of neovasculogenesis
(107). Vascular wall derived endothelial precursors may also be important (113).
However, there is likely a large contribution made by bone marrow derived cells of
haematopoietic origin. A number of recent studies suggest that the main
contribution of transplanted CD34+ or CD133+ cells may be to provide a supportive
microenvironment of tissue regeneration and vascular repair, achieved through
autocrine and paracrine actions (183).
A mouse bone marrow transplant model using green fluorescent protein
(GFP)-labelled bone marrow cells from littermates 6 weeks prior to the induction of
hindlimb ischaemia or fibrosarcoma cell implantation failed to demonstrate the
incorporation of GFP-labelled cells into the vasculature (183). GFP-labelled cells
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were found in the adventitia of collateral arteries and in perivascular spaces of leg
muscles from ischaemic limbs but no stained endothelial cells were identified.
Similarly, no stained cells were detected in the endothelium or smooth muscle of the
implanted fibrosarcoma cells (183). A functional link between monocyte
concentration and enhancement of arteriogenesis (collateral vessel growth) was
demonstrated using 5-fluorouracil to manipulate PB monocyte counts in a rabbit
model of hindlimb ischaemia whereby monocytopaenia was accompanied by
reduced limb blood flow that improved once monocyte levels rebounded (184).
Administration of G-CSF leads to an increase in the numbers of circulating CD34+
and CD133+ cells, the great majority of which are haematopoietic, as determined by
their co-expression of CD45. A number of studies, using murine transplant models,
have shown accelerated tissue regeneration and repair following infusion of human
UCB or mobilised PB CD34+ (185) or CD133+ cells (186, 187). Similar to Ziegelhoeffer
et al (183), human CD133+ or CD34+ cells were identified in the region of injury with
little/no evidence of incorporation of these cells into vessel walls or of their direct
contribution to vasculogenesis.
Recent reports from Asahara's group provide some interesting observations of the
contribution of locally implanted G-CSF mobilised CD34+ or CD133+ cells to
neovascularisation following ligament injury (mouse) (185), skeletal muscle injury
(rat) (187) and in critical limb ischaemia (human) (188). In the two murine studies
(185, 187), the clinical benefits observed following the local implantation of
(purchased) G-CSF mobilised human CD34+ or CD133+ cells compared to human
non-mobilised MNC were not delivered through incorporation of implanted cells
into sites of ncovascularisation buL by enhancing the angiogenesis of recipient cells
by creating a favourable microenvironment for tissue regeneration and producing
pro-angiogenic cytokines. In these studies far fewer numbers of localised stained
cells could be demonstrated following implantation of unselected MNC compared
to mobilised CD34+ or CD133+ cells (185, 187).
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Results of a phase I/IIa trial of locally implanted autologous G-CSF mobilised CD34+
cells for treatment of critical limb ischaemia have recently been reported (188). The
G-CSF schedule used in this dose escalation study was the same as used for PBSC
mobilisation in allogeneic PBSC donors. CD34+ cells were collected by leukapheresis
and purified by immunomagnetic (CliniMACS) separation. The outcomes of cell
therapy were measured clinically without assessments of cell fate or tissue histology
and the contralateral leg, not injected with CD34+ cells, functioned as an internal
control. Whilst a positive effect of systemic G-CSF on patient symptoms could not
be discounted, differences in measured parameters (toe brachial pressure index and
transcutaneous partial oxygen pressures) between limbs supported an additional
effect of the implanted (mobilised) cells. A non-statistically significant improvement
in clinical outcome was reported when using the author's combined 'Efficacy score'
but significant improvements were reported during the 12 weeks follow-up for a
number of variables including pain rating, walk distance, ulcer size in treated
patients (188). This study also illustrated some of the difficulties of G-CSF
progenitor cell mobilisation (188). Similar to autologous PBSC mobilisation for
PBSCT, CD34 yields were variable and failed to meet target yields over a third of
cases. Failure to reliably collect lxl06CD34/kg following G-CSF led to termination of
recruitment into the 'Hi cell dose' arm of the study. Although G-CSF and
leukapheresis side effects of mild-moderate severity were frequent they did not
affect cell collection.
1.7. Mobilisation of EPC by CXCR4 antagonists
The ability of AMD3100, a reversible CXCR4 antagonist, to mobilise EPC has been
reported by Shepherd et al (189). Culture-based colony assays were used to identify
early EPC and endothelial outgrowth cells (late EPC) in samples from healthy
volunteers mobilised sequentially with AMD3100 alone and then G-CSF alone. Both
AMD3100 and G-CSF were reported to mobilise early and late EPC. Colony
frequency was calculated per mL PB rather than per 106 MNC plated. In the setting
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of cytokine induced leukocytosis this is difficult to interpret. Early EPC were
defined as CD45+/14+ day 4 fibronectin adherent spindle shaped cells, grown in
EGM2, supplemented with VEGF and foetal calf serum. Late EPC formed after 2-4
weeks of culture in EBM2 supplemented with VEGF and foetal calf serum on
collagen type 1 plates. Flow cytometry analysis of cultured cells was used to confirm
cell phenotypes but EPC were not prospectively identified in non cultured cells. A
murine hindlimb ischaemia model also used cultured rather than freshly isolated
cells. Recovery of perfusion was assessed by Doppler ultrasound with no
assessment of location or activity of transplanted cells performed. Despite their
origin from within the CD34+ fraction of MNC, EPC could not be identified in
cryopreserved apheresis collections.
The differential mobilisation of murine HPC and EPC into the peripheral blood by
G-CSF, AMD3100 and VEGF has been reported (190). Pre-treatment with G-CSF
enhanced HPC but not EPC mobilisation. Progenitor cell numbers were assessed
using colony assays with EPC assessed in day 21 fibronectin adherent cells, plated
in supplemented EBM2, a mix of features from the more commonly used short term
CFU-EPC and EOC colony assays. EPC were not prospectively identified by FACS
analysis but were assessed as CD34'/KDR+/146+/VWI;+ day 21 adherent MNC that
also bound lectins, took up ac-LDL and formed tubules. BM EPC were identified as
CD34+/KDR+ cells but PB EPC numbers were not assessed in similar fashion. The cell
numbers plated into EOC colony assay (5 x 105 lysed peripheral blood rather than
MNC) were exceedingly low (and colony frequency high) compared to our own
work (unpublished data) and other studies enumerating EOC in human peripheral
blood (108, 133). Nevertheless, the authors showed using their colony assay that cell
cycle status is critical for G-CSF mobilisation of HPC and that VEGF, through its
influence to increase the proportion of actively cycling cells, abrogates HPC
mobilisation, features not found with EPC. Despite apparent increases in EPC
following C CSF+/-AMD3100, due to increased bone marrow egress of EPC, analysis
of BM EPC showed that EPC were significantly reduced following G-CSF, a finding
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that is contrary to their other results (190). As yet, the differential mobilisation of
HPC and EPC by G-CSF and AMD3100 has not been reported in humans. It is
difficult to extrapolate these findings to human subjects as the cytokine doses used;
2.5pg/kg/d G-CSF and 5mg/kg AMD3100, both by intraperitonal injection, differ
substantially from the intravenous delivery of 1 Opg/kg/d G-CSF and 240pg/kg
AMD3100 administered for HPC mobilisation in humans.
1.8. Thesis background and aims
This body of work is an extension of observations made by O Tura that CFU-Hill
numbers declined following administration of G-CSF to patients mobilised with
G-CSF+/-chemotherapy for PBSC collection (136, 169). At that time various trials had
been conducted using bone marrow (with only a few using PBSC) but it seemed that
PBSC were an attractive prospect for clinical use, based on the experiences with
HSCT. These findings of reduced CFU-EPC in G-CSF mobilised blood were contrary
to a number of studies examining the roles of G-CSF and G-CSF mobilised EPC, in
patients with cardiovascular disease (163,165, 167) that were published in 2005-2006
just prior to commencement of this work. Shortly after this, (2007) 2 studies reported
on G-CSF induced mobilisation of EPC in patients undergoing PBSC mobilisation
for the collection of HPC (162, 170). Our understanding of EPC and their
relationship to HPC at this point is summarised in Figure 1.1.
The short term culture of MNC on fibronectin in Medium 199 and foetal calf serum
published by Hill et al (2003) was linked with vascular function and cardiovascular
risk (110) and a commercial assay (CFU-EPC (CFU-Hill), Stem Cell Technologies,
UK) developed from this was adopted by many groups, including ours, as a
functional assessment of EPC. At that time phenotypic definitions proposed for EPC
included CD34+/133+/KDR+ cells, though almost every combination of CD34, CD133
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Figure 1.1 Illustration of relationship between haematopoetic and endothelial differentiation
as understood in 2006.
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There was strong laboratory evidence generated within our group that CFU-EPC
were derived from CD14+ monocytes (136) (oral presentation 2005 ISEH conference,
Glasgow, O Tura) and were not dependent on CD34+ or CD133+ cells. Subtractive
analysis performed to correlate the CFU-EPC assay with putative EPC phenotypes
and the contributions of CD34+ and CD133+ cells to CFU-EPC, found selective
enrichment for CD34+ or CD133+ MNC (MACS immunomagnetic separation) failed
to generate CFU-EPC. The CD34 and CD133 depleted fractions had reduced
CFU-EPC compared to unselected MNC and it was postulated that a proportion of
colony-forming cells adhered to the MACS separation columns and were 'lost' from
culture. Following on from this, 2-hour plastic-adherent cells from normal blood
(enriched to -80% purity for CD14+ monocytes) were shown to contain all CFU-EPC.
Immunomagnetic separations similarly showed that CFU-EPC formed in
CD14-enriched (-98% purity) but not CD14-depleted MNC. Papers discussing the
role of immune cells, in particular those by Rhode et al, had not been published.
Other groups were proposing that many cells could be EPC including monocytes,
especially the Dimmeler group who said there are many routes to an 'endothelial
cell' some of which might be from normal MNC, backed up by a clinical study using
peripheral blood MNC and bone marrow (155). Later the role of T cells in CFU-EPC
was proposed (135, 139, 142). CD4, CD8 and CD19 positive cells could be detected
in CFU-EPC generated from MNC but they were not detected in CFU-EPC
generated from CD14-enriched MNC, leading us to question the role for T cells to
CFU-EPC. At the time the group also took the view that CFU-EPC represented
outgrowth from a single precursor cell, some form of 'proliferative monocyte'. Work
using EDU demonstrated that cell proliferation did occur within CFU-EPC and was
necessary for CFU-EPC as blocking cell proliferation with mitomycin C abrogated
CFU-EPC formation. However, time lapse imaging also confirmed a role for cell
migration in CFU-EPC development (G Padfield, personal communication). The
work using G-CSF mobilised blood commenced in the midst of exploration of the
role of CD14+ monocytes in CFU-EPC. Although CFU-EPC were increased following
CD14-enrichment, this could not be demonstrated for G-CSF mobilised samples. It
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was found that in mobilised patient samples, 2-hour plastic adherence, performed to
enrich for CD14+ monocytes, failed to increase CFU-EPC in G-CSF mobilised
samples as it did when using non-mobilised blood samples or UCB. The effects of
G-CSF on CFU-EPC were therefore investigated. The changes that occurred in cell
content plated into CFU-EPC assays following PBSC mobilisation were examined as
it was evident that MNC recovered from density gradient centrifugation of
mobilised blood differed from MNC recovered from non-mobilised blood. The
presence of putative EPC phenotypes in mobilised samples was also assessed. In
parallel with this it was questioned as to why normal peripheral blood contained
the greatest number of CFU-EPC and that CD34-enriched mobilised blood failed to
generate CFU-EPC (169).
In 2006, the CFU-EPC (CFU-Hill) assay and other short-term culture assays plating
MNC onto fibronectin were used to functionally assess EPC. The lack of correlation
between CFU-EPC and the putative EPC phenotypes was noted by our group (136,
169) and others. Subsequently, the concepts of early and late EPC evolved in the
literature. Endothelial outgrowth cells were probably first described in experiments
using bone marrow by Lin et al (2000) (108). The concept of late outgrowth
endothelial cells and the presence of distinct populations of EPC within blood and
bone marrow were identified (130, 146). More recently, the distinction between the
haematopoietic (myelomonocytic) origin of CFU-EPC and the non-haematopoietic
CD34+ origin of endothelial outgrowth cells has been better defined (93, 115). The
research of the group then moved to plate mobilised samples into endothelial
outgrowth assays as well as CFU-EPC, to assess for the development of late
outgrowth cells. The presence of putative EPC phenotypes were re-examined in
light of this. Based on differences in 'stem cell' phenotype between UCB and
mobilised blood samples (136, 169) the phenotypes of CD34+ cells within UCB and
mobilised blood were investigated further.
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Whilst there are risks associated with G-CSF administration and leukapheresis,
cell-based therapy would be less invasive if these cells could be procured from the
peripheral blood following G-CSF administration rather than from the bone
marrow. The improvements in disease free survival and overall survival for
haematological malignancies made since the introduction of BMT and more recently
PBSCT are testaments to the benefits of stem cell therapy and the prospect of using
bone marrow-derived and blood-derived cells for applications other than 1TSCT is
exciting. However, for G-CSF mobilised blood, use of the CFU-EPC assay,
developed as an assessment of endothelial potential, failed to identify these cells,
casting doubt on the suitability of cytokine (G-CSF) mobilised blood for cell-based
(other than HSCT) or vascular therapy. This led us to pursue the evaluation of
G-CSF mobilised blood further, drawing on these initial observations to move
forward and explore the area further, possibly to shed light on the mechanism(s)
behind the depression in CFU-EPC. This forms the basis of the work presented in
this thesis.
The aims and objectives of this thesis were;
1. to extend the observations made by O Tura of the reduction in CFU-EPC
frequency following the administration of G-CSF for PBSC mobilisation;
2. to establish whether any observed reductions in CFU-EPC could be
attributed to technical factors/artefact;.
3. to establish the changes in peripheral blood and MNC leukocyte
subpopulations and erythrocytes following PBSC mobilisation and to
investigate how these might affect CFU-EPC development; and
4. to establish the frequency of putative EPC phenotypes in non-mobilised
peripheral blood, mobilised peripheral blood and UCB by extended
phenotypic definition and to observe how this changes following G-CSF
mobilisation.
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2. Materials and methods
2.1. Cell sources and sampling
2.1.1. General sample collection procedures
All cells were obtained from human sources. Appropriate ethics committee
approval was obtained and institutional procedures were followed. Informed
written consent was obtained from all patients who donated samples for this study.
2.1.1.1. Adult blood samples
The principal source of clinical samples was venous blood samples collected from
adult patients referred to the SNBTS Cell Separator Unit in Edinburgh for
autologous or allogeneic peripheral blood stem cell (PBSC) collection. Allogeneic
PBSC donors were HLA-matched adults, donating PBSC for transplantation to their
siblings who required a stem cell transplant. Autologous PBSC donors were largely
haematology patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin
lymphoma with smaller numbers of patients with other diseases including chronic
myeloid leukaemia and acute lymphoblastic leukaemia. These patients were
undergoing peripheral blood stem cell harvest (PBSCH) so that their own
haematopoietic progenitor cells (HPC) could be used to intensify their (anti-cancer)
therapy. HPC were 'mobilised' into the peripheral circulation from the bone
marrow following administration of granulocyte colony stimulating factor (G-CSF)
(Lenograstim) in a dose of 5-10pg/kg/day, given alone or sequentially following
chemotherapy. Following HPC mobilisation, PBSC were collected from the patients'
circulation by leukapheresis.
lOmF of venous blood was collected into sampling tubes containing either lithium
heparin or ethylenediaminetetraacetate (EDTA) anticoagulant. Samples were
collected at the time of donor assessment within 30 days of planned PBSC collection
(pre G-CSF sample), at the time of day 1 PBSC collection (Day 1 PBSCH) at the time
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of blood sampling prior to commencement of leukapheresis (post G-CSF or
mobilised sample) and 4-6 weeks following PBSC collection (follow-up sample).
Buffy coat leukocytes were obtained from SNBTS blood donations. Buffy coats are
the leukocyte-rich layer which sediments out at the erythrocyte/platelet interface
during the preparation of platelets from whole blood donations (buffy coat
platelets).
2.1.1.2. Umbilical cord blood samples
Umbilical cord blood samples were collected from consenting women undergoing
elective Caesarean section delivery. Umbilical cord blood was aspirated from the
umbilical veins following uncomplicated, elective Caesarean deliveries and
collected into heparinised 50mL containers.
2.1.2. Method of cell cryopreservation
Fresh MNC were suspended in PBS and counted. After the cell count was
determined, an aliquot of cells was taken into a fresh tube following discard of the
supernatant, cells were re-suspended in 500pL of complete culture media and
transferred into 1.8mL DNAse and RNAse free tubes (Greiner, UK or NUNC) at a
concentration of lxlO6 to 5 x 107/mL. Freezing medium; 400pL of foetal calf serum
and then lOOpL of DMSO; was added in drop-wise fashion to each vial. Samples
were frozen in a temperature-controlled manner. Samples were placed in a minus
20°C freezer for 1-12 hours before being transferred to a minus 80°C freezer. In the
majority of cases, samples remained in the minus 80°C freezer. A small number of
samples were transferred to liquid nitrogen (minus 140°C) after being held at minus
80°C overnight.
2.1.3. Preservation of plasma by freezing
Whole blood samples were either allowed to sediment by gravity or centrifuged at
200g for 5 minutes. The plasma layer was removed by careful pipetting and
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transferred to an Eppendorf tube. Platelet poor plasma was obtained by
centrifuging the plasma in a microfuge (Biofuge 5000rpm for 5 minutes) and then
reserving the supernatant. Plasma was frozen in aliquots in 1.8mL DNAse and
RNAse free tubes (Greiner, UK), by being placed initially at minus 20°C for at least 1
hour before being transferred to a minus 80°C freezer.
2.1.4. Thawing of cells
Cryovials of cells were removed from the minus 80°C freezer and placed on ice.
Aliquots of complete media (lOmL) were placed in clean centrifuge tubes and
warmed in water bath to reach 37°C. The cryovials were removed from the ice and
placed in fumehood. Cells were thawed initially by being placed in a waterbath
whilst being agitated. After spraying the cryovials with isopropanol, small amounts
of warmed media were pipetted into the tube. The sample was then transferred to a
clean centrifuge tube. Aliquots of warmed media were added to the cells up to a
volume of lOmL, agitating tube throughout to promote mixing to dilute DMSO. Cell
counts were determined using a Coulter counter.
2.2. Cell subpopulation isolation
2.2.1. Mononuclear cell isolation
Mononuclear cells (MNC) were isolated by buoyant density gradient centrifugation
of blood samples over Histopaque (1.077g/mL; Sigma Diagnostics, UK). Samples
were usually diluted 1:2 in sterile PBS and layered over Histopaque (5mL
Histopaque in 15mL tubes and 15mL Histopaque in 50mL tubes) before being
centrifuged at 400g for 20 minutes. Interface leukocytes were collected and washed
twice in sterile PBS before being enumerated. Unless otherwise stated, these
interface leukocytes were the basis of subsequent cell subpopulation isolations.
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2.2.2. Polymorphonuclear cell isolation
Polymorphonuclear leukocytes (PMN) were isolated from human peripheral blood
samples using Polymorphprep (PMP) (Axis-Shield PCAS, UK); a solution for the
isolation of PMN (principally neutrophils) from whole blood. 5mL of freshly
collected undiluted whole blood was layered over 5mL of PMP solution and the
tube centrifuged at 250g for 30minutes. After centrifugation, the MNC and PMN are
separated into two distinct bands of cells, with the erythrocytes sedimenting, with
MNC in the upper band and PMN in the lower band. Both the upper and lower
layers were collected by gentle pipetting. PMN (lower band of cells) were diluted by
the addition of half strength PBS to restore normal osmolality. Cells were washed
twice in sterile PBS and resuspended in Dulbecco's medium.
2.2.3. Mononuclear cell isolation using Leukosep centrifuge tubes
Leukosep centrifuge tubes contain an inert filter membrane. The tubes were
prepared for MNC separation by the addition of 15mL Histopaque (1.077g/mL;
Sigma Diagnostics, UK) to the tube (lying above membrane layer). The tubes were
then centrifuged at lOOOg for 1 minute to move the Histopaque through the
membrane. The level of the membrane within the tube was adjusted so that it was
positioned at the surface of the Histopaque solution. The diluted whole blood
sample was placed in the tube over the membrane layer and the tube centrifuged at
400g for 40 minutes. Interface leukocytes were collected and washed twice in sterile
PBS before being enumerated.
2.2.4. Purification of cells by immunomagnetic beads
2.2.4.1. Purification by antibody-conjugated microbeads
MACS® microbeads (Miltenyi Biotech) are superparamagnetic particles that are
either coupled to specific monoclonal antibodies (used to label cells directly with
microbeads) or to fluorochrome-conjugated antibodies (e.g. anti-FITC) (used for
indirect cell labelling). Microbeads are used to label the target cell population which
can then be separated from unlabelled cells by introducing them into a matrix
-58-
packed column held in a powerful magnet (magnetic cell separator). Where
antibody conjugated microbeads were available for the antigen of interest (CD14,
CD3), MACS immunomagnetic cell separation was performed using a direct
labelling method.
MNC isolates were labelled using MACS® monoclonal antibody-conjugated
microbeads (Miltenyi Biotech, UK). Up to 1 x 107 MNC isolated by buoyant density
gradient centrifugation were incubated with lOOpL of Fc-receptor blocking reagent
(Miltenyi Biotech, UK) for 10 minutes at room temperature to inhibit non-specific or
Fc-receptor mediated binding of the microbeads to non-target cells. The cells were
then labelled with lOpL of microbeads, mixed well, and incubated for 30 minutes at
4°C. The cells were washed in sterile PBS and resuspended in 500pL of medium,
ready for immunomagnetic separation. The purity of the cell populations were
assessed by flow cytometry as outlined in section 2.3.1.
Immunomagnetic separation was carried out using MACS® MS separation columns
(Miltenyi Biotech, UK). The separation column, held in the magnet, was fitted with a
MACS® pre-separation filter (Miltenyi Biotech, UK) through which microbead
labelled cells were introduced. Separation columns were prepared for use by
washing with 3 x 500pL aliquots of buffer (PBS/0.2%EDTA/10%FCS), introduced
into the pre-separation filter. The buffer was left to run down through filter and the
column before the addition of the next aliquot of wash. Aliquots of labelled cells
were then introduced into the MACS® pre-separation filter in volumes of lOOpL.
Cells were left to drip through the column before addition of the next cell aliquot.
The microbead-labelled cells were retained in the column, and therefore enriched
whilst the unlabelled cells were able to pass through the column. Both the positively
and negatively selected cells were collected. After all labelled cells had been added
to the column, at least 3 minutes was allowed to pass before washing was
commenced. Three 500pL aliquots of buffer were used to wash columns (still placed
in the separator), waiting for the buffer to clear from the column reservoir prior to
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the addition of the next wash. The wash, together with any cells contained within it,
were collected into the tube containing unlabelled cells. Positively selected cells
were recovered by removing the column from the magnetic source, placing it over a
clean collection tube and washing it with 3x 500pF aliquots of buffer (PBS/0.2%
EDTA/10% FCS). A final wash with PBS/0.2%ETDA was followed immediately with
use of the plunger supplied with the column to expel as many cells as possible from
it. The purity of the cell populations were assessed by flow cytometry as outlined in
section 2.3.1.
2.2.4.2. Purification by fluorochrome-conjuqated microbeads
When specific monoclonal antibody-conjugated microbeads were not available,
anti-fluorochrome conjugated microbeads were used and indirect cell labelling was
carried out. Cells (up to 1 x 107 MNC recovered from buoyant density gradient
centrifugation) were incubated with lOOpL of Fc-receptor blocking reagent (Miltenyi
Biotech, UK) for 10 minutes at room temperature to inhibit non-specific or Fc-
receptor mediated binding of antibody and microbeads to non-target cells. MNC
were then stained with the monoclonal antibody (e.g. anti-CD66b-FITC) and
incubated at 4°C for 30 minutes in the dark. Cells were washed twice with sterile
PBS and cells resuspended in medium. Anti-fluorochrome (e.g. anti-FITC)
conjugated microbeads (Miltenyi Biotech, UK) were added to the washed antibody
labelled cells and these were then incubated at 4°C for 30 minutes. The cells were
washed in sterile PBS and resuspended in 500pF of medium, ready for
immunomagnetic separation. The cell collection procedure was identical to that
used for directly labelled cells.
2.3. Cell identification and phenotyping
2.3.1. Flow cytometry analysis
Peripheral blood samples were investigated by flow cytometric analysis prior to
MNC isolation. Cell fractions obtained following MNC isolation using Histopaque
density gradient centrifugation or cells isolated with the use of PMP density
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gradient centrifugation were also phenotyped by flow cytometry. Four colour flow
cytometric analysis was performed using a 488nm laser; used for phycoerythrin
(PE), fluoroscein isothiocyanate (FITC) and peridin chlorophylla protein (PerCP)
fluorochrome antibody conjugates; and a 633nm laser; for allophycocyanin (APC)
fluorochrome antibody conjugates. Monoclonal antibodies used for analysis
included anti-CD45-APC, anti-CD34-PerCP, anti-CD133-PE, anti-VEGFR2-FITC,
anti-CD66b-FITC, anti-CD14-PerCP, anti-CD235-PE. See complete antibody list
(section 2.6). When the nucleic acid stain SytoRed 59 was used, this required
preparation of a working solution [5pL stock solution (supplied 5mM in DMSO)
diluted in 500pL of CellWash (Becton Dickinson, UK]. SytoRed was assessed in
channel 4 (FL4) on the same setting as used for APC.
2.3.2. Cell staining protocols
100pL aliquots of whole blood or MNC were placed in a Falcon-type 5mL tube. The
sample was stained with the optimal concentration of the appropriate antibody or
antibodies (normally 5pL of undiluted antibody) and then placed in the dark, either
at 4C or at room temperature for 30 minutes. Unbound antibody was removed by
dilution of stained cells in CellWash (Becton Dickinson, UK) and centrifugation. The
mouths of the tubes were blotted on tissue in order to remove more of the decanted
wash supernatants. Following centrifugation cells were resuspended in 500pL of
CellFix (Becton Dickinson, UK).
Where whole blood was stained, removal of erythrocytes was required. 2.5mL of
FACSLyse (Becton Dickinson, UK) was added to each tube after the initial 30 minute
incubation that followed addition of antibody (or antibodies) and the tubes were
then returned to the dark at room temperature for at least 20 minutes further
incubation. Following erythrocyte lysis, unbound antibody and cell debris was
removed by diluting cells in CellWash and washing them at least twice with
centrifugation at 200g for 5 minutes. The washing step was repeated until the
sample was free of traces of haemoglobin in the supernatant or cell pellet. Following
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the final wash the washed were resuspended in 500pL of CellFix (Becton Dickinson,
UK). Flow cytometry analysis was performed within 24 hours of antibody staining.
When flow cytometry analysis was not performed immediately the stained cells,
suspended in CellFix, were kept in the dark at 4°C. Unless specifically stated
otherwise, whole blood (PB and UCB) flow cytometry was performed on lysed
samples (using FACSLyse) and MNC flow cytometry was performed without
erythrocyte lysis.
Events were collected on a FACS Sort flow cytometer linked to an Apple Macintosh
computer equipped with CellQuestPro software (Becton Dickinson). The cytometer
was calibrated and compensated using Becton Dickinson calibration beads and
software for the fluorochromes used. Samples were all collected and analysed using
identical stored instrument settings. Collection regions were set on forward scatter
versus side scatter and for CD45 (or SytoRed59) versus side scatter to include
leukocyte populations. Overall, for whole blood data, 100,000-300,000 events were
collected in the relevant gate for 'stem cell' immunophenotyping and at least 50,000
events were collected for 'cell population' immunophenotyping. For MNC flow
cytometry, 100,000-300,000 events were collected in the relevant gate for 'stem cell'
immunophenotyping and at least 100,000 events collected for 'cell population'
immunophenotyping. However, all events, whether falling within or outside of the
collection gate, were recorded and saved for further analysis. Thus CD45~ or
SytoRed59" events (including erythrocytes and debris) could be examined. Flow
cytometry data was saved to Listmode files and moved to PC (Windows) computers
for detailed analysis. Flow cytometric analysis was performed using FCS Express
software (De Novo software, www.denovosoftware.com!.
2.3.2.1. Simple CD34+ population analysis
Cells were stained with APC conjugated anti-human CD45 and PerCP conjugated
anti-human CD34 and fixed with CellFix. CD34+ population analysis was performed
using a 'Stems CD45+R1 gate'; low forward and side scatter gated for CD45 and
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CD34 according to the ISHAGE CD34 enumeration protocol (191) (Figure 2.1) and
using a 'Stems Rl' gate whereby CD34+ events were assessed according to light
scatter characteristics and CD34 expression without consideration of CD45
expression (Figure 2.2). The co-expression of other antigens by CD34+ events was
then measured.
For Stems CD45+R1 gating, stained and fixed cells were gated according to the
ISHAGE CD34 enumeration protocol (191) using anti-CD34-PerCP and anti-CD45-
APC antibodies (Figure 2.1).The same CD34 antibody (anti-CD34-PerCP) was used
for Stems Rl gating (Figure 2.2).
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Figure 2.1 CD34 enumeration using ISHAGE guidelines in G-CSF mobilised samples.
Samples are mobilised PB from an allogeneic PBSC donor (figures 2.1a-2.1d) and mobilised
MNC from an autologous PBSC patient (figures 2.1e-2.1h) (Stems CD45+R1 gating).
Fig 2.1a and 2.1e Forward scatter versus side scatter (all events).
Fig 2.1b and 2.1 f Primary gate (R1) set on forward scatter and side scatter.
Fig 2.1c and 2.1g Expression of CD45 by R1 gated events (R2).
Fig 2.1d and 2.1h Identification of CD34+ cells in R2 gated cells (R3), displayed in red, as low
side scatter events gating within R1 and R2 that were also CD34+.
CD34+ cells have been backgated (red) in fig 2.1 b/2.1 f and fig 2.1c/2.1g.
2.3.2.2. Defining stem cells
Stem cells were defined as low forward and side scatter cells gating within the live
cell gate that expressed CD34 and/or CD133 (Stems Rl gate). CD45 was omitted
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from this definition in order to detect haematopoietic (CD45+) stem cells as well as
any non-haematopoietic (CD45) stem cells, although the vast majority of stem cells
were haematopoietic in origin.
Fig 2.2a Fig 2.2b Fig 2.2c Fig 2.2d
Figure 2.2 CD34 enumeration using Stems R1 gating in a G-CSF mobilised PB sample,
(allogeneic PBSC donor)
Fig 2.2a Forward scatter versus side scatter (all events).
Fig 2.2b Primary gate (R1) set on forward scatter and side scatter (cell size and granularity)
Fig 2.1c Expression of CD34 by low SSC events gated in R1 (R2), displayed in red.
Fig 2.1d Identification of CD34+ cells CD45+ events within R1 gate (blue).
In fig 2.2b the CD34+ cells have been backgated (in red).
CD34 gating by ISHAGE guidelines for this sample was displayed in figures 2.1a-2.1d.
2.3.2.3. Complex Immunophenotypinq
Essentially the same staining procedure was used as for CD34+ population analysis
(above) to stain whole blood samples and MNC samples with fluorochrome labelled
monoclonal antibodies. The antibody staining protocol contained a larger panel of
antibodies and tubes. The antibodies used included anti-CD34-PerCP,
anti-CD45-APC, anti-CD45-FITC, anti-VEGFR2-FITC, anti-CD133-PE, anti-
CD31-FITC, anti-CXCR4-PE, anti-CD3-PerCP, anti-CD19-PerCP, anti-CD66b-FITC,
anti-CD33-FH C, anti-CD235a-PE and anti-CD14-PerCP (see complete antibody list,
section 2.6). In most cases, lymphocytes were not identified using lymphocyte
specific monoclonal antibodies (CD3 or CD19) but were identified as a population of
low forward and side scatter CD45+ events gating in the live cell gate (Rl) that were
CD66b", CD14" and CD235a_ (Figure 5.1).
Unstained samples were used to establish negative staining boundaries.
Isotype-matched negative control (non-binding) antibodies were not used. Of note,
various isotype matched controls were used in earlier studies and compared to
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unstained samples (O Tura). There were no differences found between strategies for
setting the staining boundaries and I have continued with antibody staining
protocols using a 'fluorescence minus one' strategy for multiparameter analysis,
thus building up fluorochromes in a stepwise fashion (e.g. Tube 1 no antibody, Tube
2 CD45 only, Tube 3 CD45 and CD34, Tube 4 CD45, CD34 and CD133, Tube 5 CD45,
CD34, CD133 and VEGFR2). The previous tube becomes the control for the next
(192) (Figure 2.3).
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Figure 2.3 Fluorescence minus one gating strategy
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CD34 PerCP
10 10 10 10
CD45APC
Illustrations of KDR-FITC, CD133-PE, CD34-PerCP and CD45-APC expression in an ungated
whole blood sample from a mobilised PBSC donor using fluorescence minus one strategy
whereby antigen staining is built up in a step-wise fashion and the previous tube becomes the
control for the next.
A - no antigens, B - CD45-APC, C- CD133-PE, CD34-PerCP, D - KDR-FITD, CD133-PE, CD34-PerCP, CD45-APC.
-65-
2.4. Bioassays
2.4.1. Colony forming units - Endothelial Progenitor Cells
(CFU-EPC) — CFU-Hill
This assay is based on that described by Hill et al (110) but it has been carried out
using a commercially available kit, using the reagents supplied, in the manner
recommended by the kit suppliers (Stem Cell Technologies), after Hill's published
method.
MNC were isolated by buoyant density gradient centrifugation and washed twice
with sterile PBS. Following enumeration, MNC were resuspended at a concentration
of 2.5xl06/mL in Complete Endothelial Culture Medium (CECM) comprising
Endocult Basal medium (Stem Cell Technologies, UK) supplemented with 1/5
dilution of Endocult supplements (Stem Cell Technologies, UK). Cells were plated
at 2mL/well in fibronectin-coated 6-well plates (Becton Dickinson, UK) and
incubated for 2 days at 37°C, 5% CO2 with 95% humidity. After 2 days incubation,
when mature monocytes and endothelial cells had adhered to the well surface(llO),
the non-adherent cells (containing EPC) were recovered from the well by gentle
aspiration by pipette. These were enumerated and centrifuged before being
resuspended at 0.8-1.OxlO6 cells/mL in lmL of fresh CECM and added to a
fibronectin-coated 24-well plate (Becton Dickinson, UK). The cells were incubated
for at least a further 3 days at 37°C, 5% CO2 with 95% humidity. Depending on the
experiment being performed, the wells were inspected from day 4 (after 2 days of
culture in 24-well plates) for colony formation. Day 5 colony assessments were
always performed. The number of CFU-Hill colonies per well were divided by the
number of cells plated into the well of the fibronectin-coated 24-well plate on day 2
and expressed per 106 cells plated.
Colonies were defined according to the morphological criteria published by Hill et al
(110) and the Stem Cell Technologies' technical manual. A colony was defined as
having a central core of round cells with elongated cells 'sprouting' from the
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periphery of the core. The core was arbitrarily defined as appearing to contain
greater than 50 rounded cells. Three or more sprouting spindle-shaped cells were
also required to be present at the periphery of the core in order for the cell collection
to be scored as a CFU-EPC. CFU-EPC have now been reclassified as
early-outgrowth CFU-EPC with the colonies arising when using the method of Hill
et al (110) referred to as CFU-Hill (113). Tight collections of rounded cells (>50 cells)
without sprouting peripheral spindle cells were graded as 'clusters', not colonies. A
collection of less than 50 rounded cells, irrespective of whether spindle cells
sprouted from its periphery was graded as a cell 'clump'. Average spindle cell
number reflected the average number of spindle cells present per microscope field
of (x20 power). Spindle cells were assessed according to their length, breadth and
branching tendencies. In subsequent sections and chapters the abbreviation CFU-
Hill refers specifically to CFU-EPC enumerated in fibronectin coated wells that
contain day 2 fibronectin non-adherent MNC fraction.
Figure 2.4 Assessment of CFU-EPC and cell clusters.
Illustration of 2 cell aggregates (Fig 2.4a and Fig 2.4b) scored as CFU-EPC and 1
aggregate not scored as CFU-EPC (Fig 2.4c).
2.4.2. Modifications to CFU-Hill assay
2.4.2.1. Fibronectin-coated 12-well plates
This assay is based on that described in section 2.4.1 (above) with the only difference
from that method is in the use of fibronectin-coated 12-well plates rather than
fibronectin-coated 6-well plates in the initial 2 day culture period. MNC isolated by
buoyant density gradient centrifugation were plated at a concentration of
2.0xl06/mL in 1.5mL of CECM into fibronectin-coated 12-well plates (Becton
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Dickinson, UK) and incubated for 2 days at 37°C, 5% CO2 with 95% humidity. After
2 days incubation, the non-adherent cells were recovered and replated into a well of
a 24 well fibronectin coated plate as per the CFU-Hill assay.
2.4.2.2. Directly plated CFU-EPC (Omission of culture on fibronectin-coated
6 or 12 well plates) - CFU-Hill(direct)
This assay is based on that described in section 2.4.1 (above) with the only difference
from that method being that cell culture was performed entirely in
fibronectin-coated 24-well plates and the initial plating of cells into 6 (or 12) well
fibronectin coated plates was omitted. MNC isolated by buoyant density gradient
centrifugation were resuspended at a concentration of 1.0xl06/mL in lmL CECM
and plated into a well of a 24 well fibronectin-coated plate (Becton Dickinson, UK)
and incubated at 37°C, 5% CO2 with 95% humidity. The wells were inspected from
day 4 (after 4 days of culture in the 24-well plate) for colony formation with day 5
colony assessments always performed. In subsequent sections and chapters, the
abbreviation CFU-Hill(direct) refers to freshly isolated (day 0) MNC directly plated
for CFU-EPC assay into 24 well fibronectin coated plates.
2.4.2.3. Assessment of CFU-EPC potential of day 2 adherent MNC
500pL fresh CECM was added to the original well of a 6 or 12 well fibronectin
coated plate immediately following the aspiration of non-adherent MNC on day 2.
The plate was returned to the incubator and examined for CFU-EPC development in
the same manner that the wells containing day 2 non-adherent MNC were handled.
2.4.2.4. Refreshing CECM during culture period
Alternate daily refreshment of CECM was carried out following the transfer of lxlO6
day 2 fibronectin non-adherent MNC in lmL CECM into a well of a 24 well
fibronectin coated plate (Becton Dickinson, UK) (CFU-FIill assay). On every other
day during the culture period, 50% (500pL) of media was aspirated from the culture
well and replaced with 500pL of fresh CECM.
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2.4.2.5. Co-culture of cells using direct mixing of cells or transweli plates
Co-culture experiments were performed to assess the indirect/paracrine influence of
cells on colony formation. MNC were obtained from standard Histopaque or PMP
separation of whole blood. Granulocytes were obtained from either Polymorphprep
(PMP) separation of whole blood or CD66b MACS separations of MNC. Cells were
cultured, using a transwell set-up and/or allowing direct mixing of cells in the well.
Either a CFU-Hill assay with re-plating of non-adherent cells on day 2 or, more
commonly, a CFU-Hill(direct) assay (section 2.4.2.2) using 24-well fibronectin coated
plates (Becton Dickinson, UK), was set up to assess CFU-EPC.
Experiments were carried out using cells from the same PBSC donor (autologous
mixing experiments) or using cells from a PBSC donor together with buffy coat
MNC or volunteer samples (allogeneic mixing experiments). Between 0.25 xlO6 and
0.50xl06 'secondary cells' (MNC or granulocytes) were added to lxlO6 'primary
cells'/MNC; these figures chosen to reflect the degree of granulocytic contamination
of G-CSF mobilised MNC preparations.
For transwell mixing studies, MNC (or other cell fraction) were placed in the well
suspended in CECM as the base layer or primary cells. ThinCert™ inserts (24 well
size, 0.4pm pore diameter ThinCert™ Greiner Bio-One, UK) were placed in the well,
with care taken to ensure that the media volume rose to a level above the base of the
ThinCert™ insert. Cells suspended in CECM were added to the ThinCert™ insert as
the upper layer of the culture system. The volume of media used varied with the
relative number of cells in the upper and lower levels and was adjusted within the
recommended volumes recommended by the manufacturer (24 well ThinCert™
maximum working volumes - 0.4-1.OmL well volume and 0.1-0.35mL ThinCert™
volume) so that culture densities were very similar between the two cell
populations. In general, for co-plating experiments using 24 well fibronectin coated
plates and ThinCert™ inserts, base layer cells (primary cells) were suspended in
800pL CECM and upper layer cells (secondary cells) were suspended in lOOpL
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CECM before being added to the insert suspended in the well. When cells were
mixed together in the well, cells were suspended in 900|uL CECM. ThinCert™
inserts were removed from the wells and placed into clean wells containing sterile
PBS during well inspection and colony enumeration with the inserts returned to the
culture plate immediately following this.
2.4.3. Endothelial Outgrowth Cell (EOC) colony assays
MNC were isolated by buoyant density gradient centrifugation and washed twice
with media. The cell pellet was resuspended and cells were counted using a Coulter
counter. MNC, suspended in EBM2 media (Clonetics, UK) with EGM2 SingleQuots
supplements were plated in a well of a collagen (collagen type 1) coated 6 or 12 well
plate (Becton Dickinson, UK) up to a maximum density of 20xl06 MNC/well. Media
volumes of 2mL and 1.5mL were used for wells of 6 and 12 well collagen coated
plates respectively. Cells were cultured in 5% CO2 at 37C. After 48 hours culture
plates were removed from the incubator. The well contents were gently agitated
using a pastette prior to the aspiration (and discard) of media, together with any
collagen non-adherent MNC. The wells were washed with media (discarding the
wash) and the fresh EBM2 with supplements is then added to the well and the plate
returned to the incubator. On days 3-7 half (50%) of the media was replaced with
fresh media (EBM2 with supplements) each day. From day 8 onwards 50% of the
media was changed every 2-3 days. The wells were inspected for colony formation
from week 2 of culture.
Figure 2.5 EOC development (umbilical cord blood sample).
(Courtesy of O Tura Ceide)
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After culturing cells in EBM-2 medium for 2 weeks or more on collagen plates
clusters of spindle-shapes cells begin to appear. These cells exhibit high proliferative
capacity, can grow to confluence within the well and can be passaged at least 4-6
times (Figure 2.4).
2.4.4. Matrigel tube formation
Matrigel® Matrix (Becton Dickinson) is an endothelial cell matrix (ECM)
preparation composed primarily of laminin, collagen type IV and a number of
growth factors. Matrigel® is liquid at 4C and sets between room temperature and
37C so it needs to be handled cold using pre-cooled culture plates and equipment.
Matrigel solution was thawed slowly overnight on ice/water at 4°C. Pipettes and
plates were pre-cooled. 300jrL of Matrigel was added to 24 well plates (Greiner,
UK), with care being taken to avoid air bubbles and to ensure that the well surface
was covered. The plate was placed in a 37°C, 5% CO2, 95% humidity incubator for
45-60 minutes in order for the Matrigel to solidify. Pelleted cells (3-5x104cells/well)
were resuspended in 500pL of EBM2 medium and cultured for 5-22 hours at 37°C
with 5% CO2 and 95% humidity. Capillary-like structures and endothelial cell
networks were examined by phase contrast microscopy.
2.5. Statistical Analysis
Sets of data were compared using non-parametric statistical analysis,
Mann-Whitney test for unpaired data and Wilcoxon matched pairs tests for paired
data. The GraphPad Instat 3 statistical package was used for data analysis. All tests




2.6. Reagents, culture mediums and antibodies used
Reagents list
CellFix (Becton Dickinson, UK)
CellWash (Becton Dickinson, UK)
EDTA/PBS (0.2%) Fisher, UK and Oxoid, UK)
FACSLyse (Becton Dickinson, UK)
Foetal calf serum (FCS) (Biowhittaker, UK)
Histopaque (1.077g/mL; Sigma Diagnostics, UK)
MACS® anti-FITC microbeads (Miiltenyi Biotech, UK)
MACS® anti-CD3 microbeads (Miltenyi Biotech, UK)
MACS® anti-CD14 microbeads (Miltenyi Biotech, UK)
MACS® Fc-R blocking reagent (Miltenyi Biotech, UK)
Matrigel Basement Membrane Matrix (BD Biosciences, UK)
Penicillin/Streptomycin (lOOOOunits/mL (penicillin) and 10pg/mL (streptomycin)
(Sigma, UK)
Phosphate buffered saline (PBS) tablets (Oxoid, UK)
Polymorphprep (Axis-Shield PCAS, UK)
SytoRed59 fluorescent nuclear acid stain (Invitrogen, UK)
Culture mediums
Freezing medium - (10%dimethylsuphoxide (DMSO) (Sigma, UK) and 90% foetal
calf serum (FCS)).
Iscove's Modified Dulbecco Media (IMDM) with 10% FCS (Biowhittaker, UK), 1%




Complete Endothelial Culture Medium (CECM) comprising Endocult Basal
Medium (Stem Cell Technologies, UK) supplemented with 1/5 dilution of Endocult
supplements (Stem Cell Technologies, UK).
Endothelial Cell Basal Medium-2 (EBM®-2) (500 mL) (Clonetics, UK) with added
growth supplements (EGM2™SingleQuots® containing FBS, hydrocortisone, hFGF,
VEGF, R3-IGF-1, Ascorbic Acid, HFGF, GA-1000, heparin) (Clonetics, UK).
List of antibodies used (all anti-human specificity)
Anti-CD3-PerCP (BD Biosciences, UK)
Anti-CD14-PE (BD Biosciences, UK)
Anti-CD14-PerCP (BD Biosciences, UK))
Anti-CD66b-FITC (AbD Serotec, UK)
Anti-CD235a (Glycophorin A)-PE (Abeam, UK)
Anti-CD13-APC (BD Pharmingen, UK)
Anti-CD15-PE (BD Pharmingen, UK)
Anti-CD33-FITC (BD Pharmingen, UK)
Ant-CD64-FITC (BD Pharmingen, UK)
Anti-CD31-FITC (eBioscience, UK)
Anti-CD38-FITC (RD systems, UK)
Anti-VEGFR2 (KDR)-FITC (RD systems, UK)
Anti-CXCR4-PE (RD systems, UK)
Anti-CD133-PE (Mitenyi Biotech, UK)
Anti-CD45-FITC (BD Biosciences, UK)
Anti-CD45-APC (BD Biosciences, UK)
Anti-CD34-PerCP (BD Biosciences, UK)
Anti-CD146-PE (eBioscience, UK)
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3. Review of peripheral blood stem cell harvest
activities in Edinburgh
3.1. Introduction
The data presented in this chapter is a review of the collection of peripheral blood
stem cells (PBSC) by the Cell Separator Unit (CSU) of the Scottish National Blood
Transfusion Service (SNBTS), Edinburgh.
3.1.1. Aims of review
This review was performed in order to record the number of allogeneic and
autologous peripheral blood stem cell harvests (PBSCH) performed by the CSU. The
haematological diagnoses of patients referred for PBSCH and the PBSC mobilisation
regimens prescribed were reviewed and the influences of these factors on the
success of PBSC collection were examined. Similarities and differences between
patient and treatment groups were considered in order to determine whether
patients could be considered together in comparative studies and if there were any
differences between patient groups which could be explored. Finally, the suitability
of samples from autologous PBSC patients for inclusion in studies of the influence
of G-CSF on mobilisation of haematopoietic progenitor cells (HPC) and
non-haematopoietic progenitor cells were considered.
3.1.2. Methods
All referrals made for autologous PBSC collection between January 2004 and
October 2006 and all healthy adults referred as potential allogeneic PBSC donors
between January 2002 and October 2006 were identified. The collection period for
allogeneic PBSC donor referrals was set 2 years greater than autologous PBSC
referrals in order to increase the number of allogeneic PBSC donors reviewed. The
data considers autologous PBSC patients and allogeneic PBSC donors referred for
PBSC collection during the review periods who were assessed as fit to proceed with
PBSCH and who then received the prescribed PBSC mobilisation regimen. The
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medical records of patients referred for consideration of PBSC collection during this
period were examined and the information contained within these were correlated
with any additional written correspondence, laboratory results and clinical
information that related to the PBSC mobilisation process.
Data was analysed using Mann-Whitney tests for non-parametric data with the
probability value considered significant if it was p<0.05. In this review, the terms
'pre G-CSF' and 'pre mobilisation' refer to assessments made on donor review
within 30 days of planned PBSC mobilisation with 'post mobilisation', 'mobilised'
and 'post G-CSF' referring to assessments made on the first day of stem cell
collection (day 1 PBSCH).
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3.2. Allogeneic PBSC donors
3.2.1. Donors referred for allogeneic PBSC collection
Over the review period, 43 referrals for allogeneic PBSC mobilisation and collection
were received (21 male and 22 female donors). There was considerable variation in
the number of potential allogeneic PBSC donors referred for donor assessment and
the number of allogeneic PBSC collections performed each year by the CSU.
Thirty-five potential allogeneic PBSC donors were mobilised for PBSCH. Reasons
for failure to proceed with PBSC mobilisation (n=8) included recipient
ill-health/death (n=3), donor deferral for medical reasons (n=2), elective bone
marrow harvest rather than PBSCH (n=2), PBSCH performed by another centre
(n=2), uncertain reasons (n=2) (Table 3.1).
Year of referral** 2002 2003 2004 2005 2006$ Total
Donors referred 5 7* 8 14 9 43
PBSC Collected 5 3 7 12 8 35
Not collected 0 4* 1 2 1 8
Table 3.1 Allogeneic PBSC donor referrals and PBSC collections (2002-2006).
* Includes 2 patients referred for assessment with no intention of local PBSC collection.
** Referral year refers to date (year) patient was reviewed in CSU prior to PBSC collection.
$
January - October 2006 (10 months).
Allogeneic donors underwent PBSC mobilisation following the administration of
G-CSF alone as the mobilising regimen. Lenograstim (non-glycosylated G-CSF) was
administered in all cases. Donors generally received I Opg/kg/d G-CSF for 4 days
(days 1-4) (n=33) before commencing leukapheresis (day 1 PBSCH) on day 5 (Figure
3.1). Alternative PBSC mobilisation regimens used were lOpg/kg/d G-CSF for 3 days
(n=l) and 5pg/kg/d G-CSF for 4 days (n=l). Adequate numbers of CD34+ HPC were
mobilised into the peripheral blood (PB) to enable collection of sufficient PBSC for
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Figure 3.1 G-CSF PBSC mobilisation schedule for allogeneic donors.
3.2.2. Haematology parameters
There was no difference in donor age between female and male allogeneic PBSC
donors (mean donor age 42.2 years for female and male donors) or in pre
mobilisation PB leukocyte counts (means 6.4x109/L and 7.4xl09/L in female and male
donors respectively, p=ns). On day 1 PBSCH, following 4 days of G-CSF, there were
no gender differences in PB leukocyte counts (white cell count (WCC) 47.8xl09/L
and 49.0xl09/L respectively, p=ns) or CD34 counts (CD34 counts 58.6x106/L and
52.6xl06/L respectively, p=ns) meaning there were no differences in the relative
increases in PB leukocytes post G-CSF (7.4 and 7.1 in male and female donors
respectively, p=ns).
3.2.2.1. Days of apheresis required to reach target CD34 numbers
The average number of days of leukapheresis required to reach the CD34 targets for
allogeneic PBSCT was higher for female donors than male donors (2.1 and 1.4 days
respectively), most likely a reflection of greater differences between donor and
recipient body weights (and with recipient exceeding donor weight) when female
allogeneic PBSC donors were used.
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Ten of 17 male donors (58.8%) underwent a single leukapheresis with the remaining
7 (41.2%) requiring 2 days of PBSCH to reach the collection targets. Five of 18 female
donors (27.7%) underwent a single leukapheresis. Seven female donors (38.9%)
required 2 days of PBSCH and 6 (33.3%) required 3 collection days to reach
minimum targets for CD34 yields. In excess of 3.0xl06/kg CD34+ HPC, (based on









Patients WCC (x109/L) CD34 count (x106/L) Day 1 PBSCH CD34 yield(CD34x106/kg body weight)
Male
1 10 52.4 (32.4-90.4) 71.5 (45.2-106.8) 6.3 (4.5-9.8)
2 7 41.9 (23.7-54.2) 41.5 (22.0-75.9) 2.7 (1.42-4.8)
Female
1 5 56.0 (48.6-80.1) 90.7 (34.0-126.0) 5.5 (4.1-9.4)
2 7 53.9 (28.9-76.9) 35.8 (0.8-58.2) 1.7* (0.8-2.2)
3 6 37.4 (18.4-53.2) 28.5 (15.4-53.2) 1.3 (1.0-1.8)
Table 3.2 Post mobilisation (day 1 PBSCH) PB leukocyte and CD34 counts.
Figures are displayed according to donor gender and number of days of leukapheresis
required to attain CD34 targets (mean and range presented).
* Includes 1 donor who had insufficient CD34+ cells collected over 2 leukapheresis and
who proceeded to undergo a bone marrow harvest.
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3.3. Autologous PBSC patients
3.3.1. Patients referred for autologous PBSC collection
Over the review period, 136 referrals were received for autologous PBSC collection;
126 adult haematology patients and 10 medical oncology patients (Table 3.3). Adult
haematology patients with multiple myeloma (MM), non-Hodgkin lymphoma
(NHL) or Hodgkin lymphoma (HL) made up the bulk of referrals for autologous




PBSC Referrals Patients Mobilised
Haematology patients 126 121
Multiple Myeloma 55 53
Non Hodgkin Lymphoma 50 48
Hodgkin Lymphoma 15 14
Other Haematology patients* 6 6
Medical Oncology patients 10 10
Paediatric referrals* 5 5
Adult referral 5 5
Total donor referrals 136 131
Table 3.3 Diagnoses of all patients referred for autologous PBSC collection.
* Other Haematology patients- 3 CML, 2 AML, 1 ALL (all in remission).
$ Paediatric Oncology patients- 2 Ewings sarcoma, 1 Medulloblastoma, 1
Neuroblastoma, 1 HL.
£
Adult oncology patients- 2 Ewings sarcoma, 2 Teratoma, 1 Rhabdomyosarcoma.
3.3.1.1. Haematoloqy Patients (MM, NHL, HL)
All but 5 patients with MM, NHL or HL referred for autologous PBSCH (115 of 120
patients, 95.8%) proceeded to receive the prescribed PBSC mobilisation regimen.
Overall, the PBSC mobilisation rate was 73.9% (85 of 115 patients) for autologous
PBSC patients, meaning that these patients underwent leukapheresis to yield
sufficient CD34+ HPC for autologous PBSCT (Table 3.4).
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Patient Diagnosis MM NHL HL MM/NHL/HL
Patients mobilised 53 48 14 115
PBSC harvested 45 28 13 85
Mobilisation rate 84.9% 58.3% 92.9% 73.9%
Table 3.4 Rates of successful PBSC mobilisation according to patient diagnosis.
There were no gender differences in the proportions of autologous PBSC patients
who successfully mobilised PBSC; 49 of 64 male patients (76.6%) and 36 of 51 female
patients (70.6%). Similarly there were no differences in pre mobilisation WCC, post
mobilisation WCC and CD34 counts between male and female patients (Table 3.5).
Patients who failed to mobilise PBSC (inadequate CD34 numbers despite PB
leukocyte counts >2.0x109/L following PBSC mobilisation) had WCC comparable to
those patients who mobilised PBSC (Table 3.5).
Details Mobilised PBSC Failed PBSC Mobilisation
Patient Group All Male Female All Male Female
Number of Patients 85 49 36 30 15 15
Non-mobilised WCC (x109/L) 5.2 5.2 5.1 5.0 4.8 5.3
Mobilised WCC (x109/L) 10.1 10.2 10.0 11.3 7.4 15.3
CD34 count (x10s/L) 69.5 75.6 61.3 5.4 5.0 5.9
Table 3.5 Pre G-CSF and mobilised WCC and CD34 counts of autologous PBSC patients.
Data includes patients who mobilised and who failed to mobilise PBSC.
3.3.2. Multiple Myeloma patients
Fifty-five referrals were received for autologous PBSC collections on MM patients.
These were patients who had responded to initial chemotherapy, frequently oral
CTD (comprising cyclophosphamide, thalidomide and dexamethasone) or
intravenous combination chemotherapy (VAD (vincristine, doxorubicin,
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Figure 3.2 G-CSF PBSC mobilisation schedule for autologous MM PBSC patients.
Two patients died from disease progression prior to PBSC mobilisation. In general,
MM patients received high dose cyclophosphamide (CY) (3g/m2 body surface area
(BSA)) (on day 1) followed by at least 6 days of G-CSF (days 6-11) with PB leukocyte
and CD34 counts monitored daily from day 12 (Figure 3.2). PBSCH commenced
when PB CD34 counts exceeded 10/pL.
PBSC mobilisation
regimen










CY+5|ig/kg G-CSh 1 / 12 (/0.5%) 7 4 (57.1%) 10 8 (80%)
CY+10ng/kg G-CSF 35 30 (88.3%) 17 14 (82.4%) 18 16 (88.8%)
Table 3.G Rates of PBSC mobilisation: MM patients.
Patients mobilised with CY 3g/m2 BSA and 5-IOpg/kg/d G-CSF.
MM patients were mobilised with CY+lOpg/kg/d G-CSF (n=35) or CY+5pg/kg/d
G-CSF (n=17) with 1 patient mobilised with lOpg/kg/d G-CSF for 4 days. Greater
proportions of MM patents mobilised with sequential CY+lOpg/kg/d G-CSF
successfully mobilised PBSC and had sufficient CD34+ HPC collected for autologous
PBSCT (>3.0xl06/kg CD34+ cells) (30 of 35 patients, 88.3%) compared to those MM






PBSC mobilisation regimen and patient gender
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Total 42 30 16 14 12 8 4
Table 3.7 Days of G-CSF administered prior to commencement of PBSCH: MM patients.
The great majority of MM patients (35 of 42 patients, 83.3%) commenced
leukapheresis on day 12, after receiving 6 days of G-CSF, unaffected by G-CSF dose
or patient gender (Figure 3.2 and Table 3.7). There were no gender differences in
non-mobilised or mobilised WCC and CD34 counts between MM patients who
received the same G-CSF dose (p=ns). MM patients mobilised with CY+1 Opg/kg/d
G-CSF had higher WCC pre mobilisation and on day 1 PBSCH compared to those
who received 5pg/kg/d G-CSF (p=ns) (Table 3.8). Although MM patients mobilised
with CY+5pg/kg/d G-CSF had significantly greater proportions of PB CD34+ HPC
than CY+lOpg/kg/d G-CSF patients (1.75% and 0.72% respectively, p<0.04), the
higher post mobilisation WCC in CY+1 Opg/kg/d G-CSF MM patients meant that
numbers of CD34+ HPC did not differ between MM patient groups (p>0.8)) (Table
3.8). Use of higher dose G-CSF (lOpg/kg/d) in MM PBSC mobilisation regimens has
not improved day 1 PBSCH CD34+ HPC yields and has not reduced the number of






Successful PBSC Mobilisation Failed to mobilise




Patient numbers 30 14 16 — 3 2
Non-mobilised WCC (x109/l_) 6.7 5.7 7.5 ns 3.8 2.5
Mobilised WCC (x109/L) 14.5 11.7 17.0 ns 9.3 3.8
CD34 count (x10s/L) 76.1 61.7 88.8 ns 6.9 2.2




Patient numbers 12 4 8 — 3 2
Non-mobilised WCC (x109/L) 4.8 3.9 5.3 ns 5.0 4.0
Mobilised WCC (x109/L) 9.9 11.1 9.2 ns 15.8 9.5
CD34 count (x106/l_) 69.2 66.7 70.4 ns 6.9 2.5
CD34 (% WCC) 1.75 0.6 2.3 ns 0.07 0.03
Table 3.8 Pre and post mobilisation WCC and CD34 counts: MM patients.
Figures are displayed according to patient gender and mobilisation regimen.
Comparison between males and females receiving same G-CSF dose (Mann-Whitney test),
ns = no significant difference
Use of higher dose G-CSF has resulted in 46.4% of successfully mobilised MM
patients (13 of 28) having sufficient CD34+ HPC collected for a tandem autologous
PBSCT. More than half of MM patients mobilised with CY+lOgg/kg/d G-CSF failed
to reach this CD34 collection target as PBSCF4 was stopped after collection of
sufficient CD34+ I IPC for a single PBSCT (>3.0xl06/kg) once it was evident that even
with additional days of G-CSF and further leukapheresis, original target CD34
yields (>6.0xl06/kg) would not be achieved. The day 1 PBSCTI CD34 yields




















Female 4 66.7 3.3 1.7 5.7 1
Male 8 70.4 <CO 1.4 5.5 3
All 12 69.2 4.3 — 5.5 4 (33.3%)
10
Female 14 61.7 3.9 1.7 6.3 5
Male 16 88.8 4.4 1.9 6.7 8
All 30 76.1 4.2 — 6.5 13 (46.4%)
Table 3.9 Day 1 PBSCH CD34 counts and day 1 CD34 collection yields: MM patients.
Mean values are displayed.
A Result improved by day 1 PBSCH CD34 yield of 14x106/kg (1 patient).
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3.3.3. Non Hodgkin Lymphoma patients
Patients with a diagnosis of NHL were the second largest patient group referred for
autologous PBSC collection (n=50). All but 2 of these underwent PBSC mobilisation
with sequential chemotherapy and G-CSF (19 female and 29 male patients).
Thirty-six patients (75%) were mobilised for PBSCH 'off the back' of a cycle of
salvage chemotherapy, usually either IVE (ifosphamide, etoposide, and epirubicin)
or DHAP (cisplatin, cytosine arabinoside, and dexamethasone) (Figure 3.3). This
cycle of chemotherapy was administered in standard doses, with at least 6 days of
G-CSF (5pg/kg/d) commencing a few (usually 4) days following chemotherapy.
Three chemotherapy regimens were commonly used; IVE, DHAP or CY (44 of 48
patients) (Table 3.10). Four patients received alternate PBSC mobilisation regimens;
IVE+lOpg/kg/d G-CSF (n=l), CVP+5pg/kg/d G-CSF (n=l), lOpg/kg/d G-CSF alone
(n=2). The highest PBSC mobilisation rates were observed following IVE+5pg/kg/d
G-CSF (16 of 21 patients, 76%) with 54% of patients receiving DMAP+5pg/kg/d
G-CSF and 50% of patients receiving CY+5pg/kg/d G-CSF mobilising sufficient




















PBSC Mobilisation with Chemo + G-CSF
Figure 3.3 G-CSF PBSC mobilisation schedule for autologous lymphoma PBSC patients.
Not only did greater proportions of NHL patients mobilised 'off the back of IVE'
undergo PBSCH, these patients had higher post mobilisation CD34 counts than
NHL patients receiving alternate mobilisation regimens (p<0.0001), remaining
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statistically significant when figures were adjusted to either include or exclude
patients who failed to mobilise PBSC. The higher post mobilisation CD34 counts of
these patients were not attributable to any differences in post mobilisation PB
leukocyte counts between NHL patients mobilised with IVE+G-CSF and those who












IVE+5ng/kg/d G-CSF 21 16 (76.2%) 8 6 (75%) 13 10 (76.9%)
DHAP+5ng/kg/d G-CSF 11 6 (54.5%) 2 2 (100%) 9 4 (44.4%)
CY+5ng/kg/d G-CSF 12 6 (50.0%) 7 3 (42.9%) 5 3 (60.0%)
Table 3.10 Common PBSC mobilisation regimens used: NHL patients.
Numbers and proportions of patients are presented (n=44).
PBSC
Details
Mobilised PBSC Failed mobilisation
Mobilisation Female Male Female Male
IVE+ Patient Number 6 (75%) 10 (76.9%) 2 (25%) 3 (23.1%)
G-CSF Mobilised WCC (x109/L) 6.7 4.7 1.6 7.7
(n=21) CD34 count (x106/L) 82.3 86.4 5.2 4.6
DHAP+ Patient Number 2 (100%) 4 (44.4%) 0 (0%) 5 (55.6%)
G-CSF Mobilised WCC (x109/L) 6.2 4.9 — 5.7
(n=11) CD34 count (x106/L) 25.0 35.1 — 6.12
CY+ Patient Number 3 (42.9%) 3 (60%) 4 (57.1%) 2 (40%)
G-CSF Mobilised WCC (x109/L) 5.5 6.8 6.3 13.3
(n=12) CD34 count (x106/L) 36.7 21.0 5.0 9.4
Table 3.11 Pre and post mobilisation WCC/CD34 counts: NHL patients.
Mean values are presented for 44 NHL patients.
The majority of NHL patients who mobilised PBSC following IVE or DHAP+G-CSF,
required more than 6 days of G-CSF and did not commence PBSCH on day 12
(Table 3.12). There were no gender differences in pre G-CSF WCC or mobilised
WCC and CD34 counts for NHL patients with sequential IVE+Spg/kg/d G-CSF
(p=ns). For future comparisons, NHL patients mobilised by IVE+G-CSF were
considered as a single group. Too few NHL patients were mobilised with DHAP for







6 8 (50.0%) 2 (33.3%) 10 (45.5%)
7 6 (37.5%) 3 (50.0%) 9 (40.9%)
8 1 (6.3%) 0 1 (4.5%)
9 1 (6.3%) 1 (16.7%) 2 (9.1%)
Total 16 6 22
Table 3.12 Days of G-CSF given prior to commencement of PBSCH: NHL patients.
Figures are displayed according to PBSC mobilisation regimen (IVE or DHAP) used.
3.3.4. Hodgkin Lymphoma patients
Fifteen patients with HL (8 female and 7 male) were referred for autologous PBSC
collection during the period reviewed and all but 1 underwent PBSC mobilisation.
Two mobilisation regimens were commonly used; IVE+5pg/kg/d G-CSF (n=9) or
DHAP+5pg/kg/d G-CSF (n=3) which were identical to the IVE and DHAP regimens
administered to NHL patients (section 3.4.3 and Figure 3.3). Two patients were
mobilised using G-CSF alone (lOpg/kg/d G-CSF for 4 days). All 12 HL patients
mobilised with sequential IVE or DHAP+5pg/kg/d G-CSF had successful PBSC








Patient numbers 4 (100%) 5 (100%)
Total WCC (x109/L) (mean) 6.30 5.30
CD34 count (x106/L) (mean) 87.7 78.8
DHAP+
5pg/kg/d G-CSF
Patient numbers 1 (100%) 2 (100%)
Total WCC (x109/L) (mean) 3.1 4.9
CD34 count (x106/L) (mean) 16.7 58.5
Table 3.13 PB leukocyte and CD34 counts following PBSC mobilisation: HL patients.
No gender differences were noted in the pre G-CSF WCC, mobilised WCC or day 1
PBSCH CD34 counts for HL patients mobilised with IVE+G-CSF (p=ns). Too few HL
patients were mobilised with DHAP for gender comparisons to be made.
Similar to our experience of NHL patients, the majority of HL patients mobilised
with IVE or DHAP+G-CSF did not commence leukapheresis on day 12 as most
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patients required at least 7 days of G-CSF to achieve sufficient PB CD34 counts to






6 3 (33.3%) 0 3 (25%)
7 4 (44.4%) 3 (100.0%) 7 (58.3%)
8 2 (22.2%) 0 2 (16.7%)
Total 9 3 12
Table 3.14 Days of G-CSF administered prior to commencement of PBSCH: HL patients.
3.3.5. Lymphoma patients mobilised with IVE+5pg/kg/d G-CSF
There were no differences in pre G-CSF WCC or mobilised WCC and CD34 counts
between the 16 NHL and 9 HL patients mobilised with sequential IVE+5pg/kg/d
G-CSF ( p=ns). All lymphoma patients mobilised using IVE+5pg/kg/d G-CSF were
considered as a single patient group in subsequent comparisons. Too few patients
were mobilised with sequential DHAP+G-CSF for comparisons to be made between







Non-mobilised WCC (x109/L) 4.7 (3.3) 3.8 (3.0) ns
Mobilised WCC (x109/L) 5.4 (4.0) 5.8 (5.5) ns
CD34 count (x106/L) 84.8 (68.0) 87.3 (41.4) ns
CD34 percent (% WCC) 2.3 (1 65) 1.47 (1.16) ns
Table 3.15 Haematology parameters in lymphoma patients treated with IVE+G-CSF.
Figures are presented for 16 NHL & 9 HL patients with comparisons made between NHL and
HL patients; ns = no significant difference.
3.3.6. Differences in PBSC mobilisation between autologous
PBSC patient groups
Our data confirmed that two most frequently used regimens for autologous PBSC
mobilisation at our institution, sequential CY+lOpg/kg/d G-CSF and sequential
IVE+5pg/kg/d G-CSF, were both moderately successful in mobilising sufficient
CD34+ HPC for PBSCH and subsequent autologous PBSCT (Table 3.16).
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Mobilisation regimen CY+10(rg/kg/d G-CSF IVE+5|ug/kg/d G-CSF
Total number 36 (35 MM & 1 NHL) 30 (21 NHL & 9 HL)
PBSC Collection 30 (30 MM) 25 (16 NHL & 9 HL)
Successful mobilisation 83.3% (88.3% MM, 0% NHL) 83.3% (76.2% NHL & 100% HL)
Table 3.16 PBSC mobilisation with CY or IVE and G-CSF (autologous PBSC patients).
Figures are displayed according to mobilisation regimen used and haematological diagnosis.
There were no gender differences observed in non-mobilised or mobilised WCC and
CD34 counts (counts and proportions of leukocytes) for MM patients mobilised
with CY+lOpg/kg/d G-CSF (p=ns, n=30). Similarly there were no gender differences
in the same 4 parameters for lymphoma patients (p=ns, n=25, 16 NHL and 9 HL
patients) mobilised with IVE+5p.g/kg/d G-CSF (p=ns). Autologous PBSC patients
were therefore considered as belonging to 1 of 2 main treatment groups; MM
patients mobilised with CY+10pg/kg/d G-CSF and lymphoma patients mobilised
with rVE+5pg/kg/d G-CSF (Table 3.16).
There were differences in the mobilisation kinetics between these two treatment
groups. MM patients had significantly higher pre mobilisation WCC on donor
review than lymphoma patients (6.7xl09/L and 4.5xl09/L respectively, p<0.02). This
may reflect differences in the timing of PBSC referrals between patient groups. MM
patients have low tumour burdens prior to PBSCH as patients are referred
following completion of initial chemotherapy and confirmation of response of MM
to treatment. These patients usually have had a chemotherapy-free period (of weeks
rather than months) prior to being referred for PBSC collection. In contrast,
lymphoma patients were typically referred for PBSC mobilisation once salvage
chemotherapy (IVE) had been commenced for their relapsed lymphoma (usually
following discharge from hospital after receiving first or second cycle of IVE) and
their leukocyte counts had often not fully recovered at the time of donor review.
Patients with MM were more likely to commence leukapheresis on day 12, after 6







patients (n=25) p value
Non-mobilised WCC (x109/L) 6.7 (5.9) 4.4 (3.15) <0.02
Mobilised WCC (x109/L) 14.5 (10.9) 5.6 (4.2) <0.0001
CD34 count (x106/L) 76.1 (57.2) 85.7 (63.0) ns
CD34 percent (% WCC) 0.72 (0.49) 2.01 (1.51) 0.0002
Table 3.17 Haematology parameters taken prior to and following PBSC mobilisation.
Comparisons between MM and lymphoma patients (mean values presented).
MM patients were mobilised with CY+10pg/kg/d.
Lymphoma patients were NHL or HL patients mobilised with IVE+5pg/kg/d G-CSF.
MM patients had significantly higher post mobilisation (day 1 PBSCH) WCC
(p=0.001) but lower proportions of PB CD34+ HPC (p=0.0002) than lymphoma
patients. The higher proportions of PB CD34+ HPC in lymphoma patients might be a
reflection of the administration of more myelosuppressive chemotherapy during
PBSC mobilisation (with more rapid WCC recovery from lower nadirs) and their
later commencement of PBSCH compared to MM patients (meaning more days of
G-CSF therapy). The CD34 counts did not differ between patient groups (p=ns).
Lymphoma patients had higher yields of CD34+ HPC from day 1 PBSCH (mean
6.0xl06/kg, median 4.5xl06/kg) than MM patients (mean 4.2xl06/kg, median
3.2xl06/kg) (p=ns). Although not statistically significant, the difference in CD34+
HPC yields between patient groups meant that sufficient CD34+ HPC were collected
from a single leukapheresis for an autologous PBSCT in greater proportions of
lymphoma PBSC patients; 18 of 24 lymphoma patients (75%; 7 of 9 HL patients and
11 of 15 NHL patients) and 16 of 29 MM patients (55.2%).
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3.4. Autologous PBSC patients compared to allogeneic PBSC
donors
Autologous PBSC patients had significantly lower PB WCC than allogeneic PBSC
donors (means 5.2xl09/L and 6.9xl09/L respectively, p=0.0001) at donor review prior
to PBSC mobilisation. Following PBSC mobilisation with G-CSF, administered alone
or sequentially with chemotherapy, autologous PBSC patients continued to have
lower PB WCC than allogeneic donors (means 10.1xl09/L and 48.4xl09/L
respectively, p<0.0001) (Table 3.19). The proportions of CD34+ HPC in mobilised PB
samples were significantly greater in autologous PBSC patients than allogeneic
PBSC donors (p<0.0001). Flowever, due to the higher PB WCC counts in mobilised
samples from allogeneic PBSC donors there were no significant differences in CD34
counts between mobilised autologous and allogeneic PBSC donors (69.5xl06/L and





PBSC patients P value
n Mean n Mean
Non-mobilised WCC (x109/L) 35 6.9 82 5.2 0.0001
Mobilised WCC (x109/L) 34 48.4 85 10.1 <0.0001
CD34 count (x106/L)) 27 55.7 85 69.5 ns
CD34 (Proportion of WCC) 27 0.12% 84 1.22% <0.0001
Table 3.18 Pre and post mobilisation WCC and CD34 counts in PBSC donors.
Mean values are presented for allogeneic and autologous PBSC donors.
Comparisons were made between allogeneic donors (n=34) and the 2 main
treatment groups of autologous patients (with MM or lymphoma, n=55) (section






Chemotherapy Nil CY IVE
G-CSF 10pg/kg/d x 4 10pg/kg/d x 6 5pg/kg/d x 6
Patient numbers 34 30 25
CD34 (% leukocytes) 0.12% 0.72% 2.01%
CD34 counts (x106/L) 55.7 76.1 85.7
WCC (x109/L) 48.8 14.5 5.6
Neutrophils (%) 40.2 (82.5%) 12.1 (81.5%) 4.1 (66.6%)
Lymphocytes (%) 3.9 (8.0%) 0.7 (6.6%) 0.7 (16.2%)
Monocytes (%) 2.8 (5.8%) 1.1 (8.0%) 0.7 (16.2%)
Table 3.19 Haematology parameters following PBSC mobilisation.
Comparison between allogeneic and 2 groups of autologous PBSC donors. Figures are
expressed as mean values with proportions of leukocytes in parentheses.
3.4.1. Allogeneic donors compared to CY+IOpg/kg/d G-CSF
mobilised MM patients
For reasons relating to the timing of PBSC collection and the mobilisation regimens
used, the group of autologous PBSC patients most readily comparable to allogeneic
PBSC donors was MM patients. MM patients are referred for PBSC collection early
in the course of their disease (less than 12 months from diagnosis, often much
earlier), after maximal disease response has been achieved with initial
chemotherapy (assessed by plateau of serum paraprotein levels and reductions in
bone marrow plasma cell load). The intention is to intensify therapy (with more
myelosuppressive chemotherapy and autologous PBSCT) whilst the MM remains
quiescent. At the time of PBSC mobilisation, MM patients have completed induction
chemotherapy, have low disease bulk and a specific regimen of sequential
chemotherapy (CY) and G-CSF is administered for solely to mobilise PBSC. In
contrast, lymphoma patients referred for autologous PBSC collection may be many
years post diagnosis. They are usually receiving salvage chemotherapy for relapsed
or refractory disease and still have detectable lymphoma present when referred for
PBSC collection.
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MM patients were the only patient group referred for autologous PBSC collection
who routinely received the same daily dose of G-CSF as used for allogeneic PBSC
mobilisation, 10pg/kg/day. However, unlike allogeneic PBSC donors who received 4
days of G-CSF, MM patients received intravenous CY (3g/m2 BSA) followed by a
minimum of 6 days of G-CSF. Over the period reviewed, 30 MM patients were
successfully mobilised following CY+10gg/kg/d G-CSF. There were no gender
differences in non-mobilised and mobilised WCC and CD34 counts in MM patients
(p=ns) or allogeneic PBSC donors (p=ns) (Table 3.19).
Allogeneic PBSC donors and autologous MM PBSC differed significantly in
post-mobilisation PB leukocyte counts and proportions of PB CD34+ HPC (assessed
on day 1 PBSCH); (mean PB WCC 48.4xl09/L and 14.5xl09/L in mobilised allogeneic
PBSC donors and autologous MM PBSC patients respectively, p<0.0001, and mean
proportions of PB CD34+ HPC 0.12% and 0.72%, p<0.0001). CD34 counts did not
differ between these patient groups (55.7xl06/L and 76.1 xl06/L, p=ns) (Table 3.19).
3.4.2. Conclusions
Whilst there are obvious differences between a patient with lymphoma or MM and
a healthy adult donor, autologous PBSC patients treated at the CSU received a
narrow range of chemotherapy and were mobilised for PBSCH with a similarly
narrow range of mobilisation regimens. Mobilised PB from autologous PBSC
patients is more CD34-rich (as proportions of total leukocytes) than allogeneic PBSC
donor samples but the numbers of CD34+ cells in mobilised PB samples do not differ
between allogeneic and autologous PBSC donors. Autologous PBSC patients with
MM were the most closely comparable group of autologous PBSC patients to
healthy adult allogeneic PBSC donors.
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3.5. Rationale for use of autologous PBSC donors as sources
of G-CSF mobilised peripheral blood samples
Allogeneic PBSC donors (healthy adult subjects) remain an ideal source of
G-CSF-mobilised PB samples for study of the influence of growth factors on cell
populations. These PBSC donors are relatively young (most are 55 years old or
younger), meet blood donor criteria and are free from co-morbidities that would
preclude growth factor (G-CSF) administration or leukapheresis. However, only
about 10 healthy donors are referred to the CSU annually for allogeneic PBSC
collection and the bulk of patients treated with G-CSF are patients with
haematological malignancies undergoing autologous PBSC mobilisation.
Autologous PBSC donors are generally older than allogeneic PBSC donors (up to 70
years of age), and they may have co-morbidities including cardiopulmonary disease
or vascular disease in addition to their haematological diagnosis. Unlike allogeneic
PBSC donors who are mobilised using G-CSF alone, autologous PBSC donors are
usually mobilised using sequential chemotherapy and G-CSF.
Review of autologous PBSC harvests performed by our centre confirmed that
patients with MM and lymphoma (NHL or HL) formed the bulk of patients referred
for autologous PBSC collection and that referrals numbers have remained fairly
constant. Our data confirmed that autologous PBSC patient populations treated at
the CSU fell into distinct groups and that these patient groups could be readily
compared. Three PBSC mobilisation regimens were used for autologous PBSC
mobilisation; sequential CY, IVE or DHAP chemotherapy and G-CSF, with CY and
IVE the most commonly used. There were no gender differences within treatment
groups, facilitating data analysis and inter-group comparisons. MM patients were
the group of autologous patients undergoing PBSC mobilisation that were most
readily comparable to healthy allogeneic PBSC donors.
There are no differences between PBSC mobilisation occurring in healthy allogeneic
PBSC donors and that occurring in patients with haematological malignancies
-94-
undergoing autologous PBSC mobilisation. The disruption of the SDF-la-CXCR4
bone marrow stem cell retention signal is central to the mobilisation of HPC,
regardless of whether cytokines (G-CSF) are used alone or in combination with
chemotherapy (57, 58). Flowever, PBSC mobilisation occurs at lower PB leukocyte
counts following sequential chemotherapy and G-CSF compared to those patients
mobilised with G-CSF.
The same mechanisms operate to mobilise FIPC in allogeneic PBSC donors treated
solely with G-CSF and autologous patients undergoing PBSC mobilisation with
G-CSF and chemotherapy. It is therefore likely that similar influences are being
exerted on other bone marrow cell populations (including EPC and mesenchymal
stem cells) in allogeneic PBSC donors and autologous PBSC patients following
G-CSF administration. Clinical regenerative medicine research has largely used BM
as a source of progenitor cells for revascularisation procedures but there is
increasing interest in the use of PB-derived progenitor cells to regenerate damaged
tissues. The use of established cytokines (G-CSF or GM-CSF) to mobilise progenitor
cells into the circulation is being explored by a number of research groups including
our own.
Administration of G-CSF for the mobilisation of PBSC is standard practice in
haematology. Patients who receive G-CSF as part of routine care may be used as a
starting point in the evaluation of the G-CSF effect on cell populations and the role
of G-CSF mobilised blood for regenerative medicine purposes. Ultimately the
clinical application of regenerative medicine techniques will not be within a healthy
population but be used to benefit patients with significant organ dysfunction,
including those with cardiovascular disease or other major organ injury. For this
reason it is suggested that autologous PBSC donors, with their older age and
co-morbidities, may be a more readily comparable group to future patients
undergoing cell-based therapy than healthy adults. Blood samples obtained from
allogeneic PBSC donors and autologous PBSC patients will therefore be studied.
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Samples obtained from allogeneic PBSC donors can be used to validate observations
made using autologous PBSC patient samples.
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4. Investigation of the effect of in vivo G-CSF
administration on CFU-EPC colony development
4.1. Introduction
In this chapter the effect of in vivo administration of G-CSF, given for the routine
clinical mobilisation of HPC in haematology patients undergoing PBSC harvest
(PBSCH), on CFU-EPC frequency will be investigated. Whole blood samples were
collected from allogeneic and autologous PBSC patients on three occasions; (1) at
donor review, prior to G-CSF administration and within 30 days of PBSCH (pre
G-CSF), (2) on day 1 PBSCH following G-CSF administration (mobilised sample)
and (3) at donor follow-up, usually 4-6 weeks following PBSC collection.
In the initial sections (sections 4.2-4.5) CFU-EPC formation was assessed using the
CFU-Hill assay (as described in section 2.4.1). MNC obtained from Histopaque
density gradient centrifugation of diluted whole blood samples were resuspended
in CECM and plated into fibronectin-coated 6 or 12-well plates (Becton Dickinson,
UK). After 2 days incubation at 37°C, 5% CO2 with 95% humidity, the non-adherent
cells (containing EPC) were recovered and enumerated. Between 0.8 xlO6 cells and
l.OxlO6 cells were transferred in lmL of fresh CECM to a fibronectin-coated 24-well
plate (Becton Dickinson, UK) and then returned to the incubator. Culture wells were
inspected for colony development daily from day 4 until at least day 8, with day 5
assessments always performed. CFU-EPC (CFU-Hill) were defined as a central core
of >50 round cells with at least 3 elongated cells 'sprouting' from the periphery of
the core. The number of CFU-Hill colonies per well were divided by the number of
cells plated in the well of the fibronectin-coated 24-well plate and expressed per 106
cells plated.
In the latter half of this chapter a number of factors that might possibly influence the
results of the CFU-EPC colony assay were identified. These have been examined to
exclude whether the observed difference in CFU-EPC development following PBSC
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mobilisation with G-CSF could be attributed to an introduced artefact rather than to
real differences between patient samples.
4.2. CFU-EPC development in allogeneic PBSC donors
4.2.1. Patient samples
Anticoagulated venous blood samples were obtained from 21 individuals referred
to the CSU as potential allogeneic PBSC donors (see section 2.1.1.1). Samples were
collected from donors on the 3 occasions specified in section 4.1. PBSC were
mobilised into the peripheral circulation with G-CSF alone, administered in doses of
IOpg/kg/d for 4 days. Five potential allogeneic PBSC donors did not undergo PBSC
mobilisation meaning that only pre G-CSF samples were available from these
donors. PBSC were collected by leukapheresis following 4 days of G-CSF in the
remaining 16 cases. Paired pre G-CSF and mobilised samples were available for 16
allogeneic PBSC donors with 14 of these 16 also having donor follow-up samples
taken (matched pre G-CSF, mobilised and donor follow-up data available).
4.2.2. CFU-EPC formation
4.2.2.1. Pre G-CSF samples
CFU-EPC formation occurred in 16 of 21 (76.2%) allogeneic PBSC donor samples
with 5 samples failing to generate CFU-EPC. Overall, the mean colony development
was 8.9 CFU-EPC/106 MNC (median 6.0 CFU-EPC/106 MNC, range 0-35, n=21)
(Table 4.2).
4.2.2.2. G-CSF Mobilised samples
CFU-EPC formation occurred in 6 of 16 (37.5%) allogeneic PBSC donor samples with
10 samples failing to generate CFU-EPC. The mean colony development in G-CSF
mobilised samples was 1.6 CFU-EPC/106 MNC (median 0 CFU-EPC/106 MNC, range
0-10, n=16) (Table 4.2).
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4.2.2.3. Donor follow-up samples
CFU-EPC formation occurred in 9 of 14 (64.3%) allogeneic PBSC donor follow-up
samples with 5 samples failing to generate CFU-EPC. Overall, the mean colony
development in donor follow-up samples was 11.0 CFU-EPC/106 MNC (median 7.0
CFU-EPC/106 MNC, range 0-40, n=14) (Table 4.2).
4.2.3. Paired non-mobilised and G-CSF mobilised samples
When only the patient samples with paired non-mobilised and G-CSF mobilised
data were examined, the CFU-EPC frequencies were adjusted to be 11.0
CFU-EPC/106 MNC (n=16), 1.5 CFU-EPC/106 MNC (n=16) and 11.0 CFU-EPC/106
MNC (n=14) for pre G-CSF, mobilised and donor follow-up samples respectively
(Table 4.3).
4.2.4. Differences in CFU-EPC formation following G-CSF
administration
There were significant differences in the frequency of CFU-EPC between pre G-CSF
and mobilised donor samples (p<0.001, paired data, n=16) and between mobilised
and donor follow-up samples (p<0.005, paired data, n=14). No difference in
CFU-EPC formation was observed between the donor samples taken pre G-CSF
mobilisation and at donor follow-up (p>0.8, paired data, n=14). Sequential
CFU-EPC formation in the allogeneic PBSC donor samples is displayed in Figure
4.1.
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Figure 4.1 CFU-EPC in allogeneic PBSC donors.
Samples collected at 3 time points; pre G-CSF, day 1 PBSCH and at donor follow-up.
Pre G-CSF Post G-CSF
Timing of sample
Donor Follow-up
* p=0.0007; ** p= 0.0039; ***p>0.8, Wilcoxon matched pairs test.
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4.3. CFU-EPC development in autologous PBSC patients
4.3.1. Patient samples
Ariticoagulated venous blood samples were obtained from 55 patients referred to
the CSU as potential autologous PBSC patients. Patient samples were collected on
the same 3 occasions specified in section 4.1. Patient samples consisted of 54 pre
G-CSF samples, 43 mobilised patient samples and 9 samples collected at patient
follow-up. Patient follow-up samples were collected on admission for autologous
PBSCT, usually 4-6 weeks post G-CSF administration and PBSC collection.
Paired pre G-CSF and mobilised patient samples were available for 36 patients. Six
of these also had CFU-EPC performed on patient follow-up samples. An additional
3 patients had paired mobilised and donor follow-up samples collected (but no pre
G-CSF sample available). PBSC were mobilised into the peripheral blood with
sequential chemotherapy and G-CSF, administered in doses of 5-10pg/kg/d G-CSF
for at least 6 days.
4.3.2. CFU-EPC formation
4.3.2.1. Pre G-CSF samples
CFU-EPC formation occurred in 30 of 54 (55.6%) pre G-CSF MNC. Overall, the
mean CFU-EPC formation was 13.2 CFU-EPC/106 MNC (median 3.0 CFU-EPC/106
MNC, range 0-120, n=54) (Table 4.2).
4.3.2.2. Mobilised samples
CFU-EPC formation declined following the administration of G-CSF (and
chemotherapy). CFU-EPC formation was observed in 24 of 43 (55.8%) mobilised
patient samples with 19 failing to generate any CFU-EPC. The mean CFU-EPC
formation was 2.2 CFU-EPC/106 MNC (median 0 CFU-EPC/106 MNC, range 0-39,
n=43) (Table 4.2).
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4.3.2.3. Patient follow-up samples
CFU-EPC formation was observed in 7 of 9 (77.8%) patient follow-up samples with
2 failing to develop CFU-EPC. Overall, the mean colony formation was 10.0
CFU-EPC/106 MNC (median 3.0 CFU-EPC/106 MNC, range 0-48, n=9) (Table 4.2).
4.3.3. Paired non-mobilised and G-CSF mobilised samples
When the CFU-EPC results from patients who had paired non-mobilised (pre G-CSF
or donor follow-up) and mobilised patient samples collected were reviewed the
mean rates of CFU-EPC formation were adjusted to be 18.6 CFU-EPC/106 MNC
(n=36), 2.5 CFU-EPC/106 MNC (n=39) and 10.0 CFU-EPC/106 MNC (n=9) for pre
G-CSF, mobilised and patient follow-up samples respectively with median
CFU-EPC formation (per 106 MNC) being 5.0, 0.0 and 3.0 on the same 3 occasions
(Table 4.3).
4.3.4. Differences in CFU-EPC formation following G-CSF
administration
There were significant differences in the frequency of CFU-EPC between pre G-CSF
and mobilised patient samples (p<0.0001, paired data, n=36) and between mobilised
and patient follow-up samples (p<0.02, paired data, n=9). No difference in CFU-EPC
formation was observed between donor samples taken pre G-CSF mobilisation and
at patient follow-up (p=0.25, paired data, n=6). Sequential CFU-EPC formation in


















Figure 4.2 CFU-EPC in autologous PBSC patients.
Samples collected at 3 time points; pre G-CSF, day 1 PBSCH and at donor follow-up.
* p<0.0001; ** p<0.02; ***p=0.25, Wilcoxon matched pairs test.
4.3.5. Comparison of CFU-EPC between autologous PBSC patient
groups
CFU-EPC formation in autologous PBSC patients was considered according to their
haematological diagnoses. Of 39 patients with CFU-EPC formation assessed in
paired non-mobilised and G-CSF mobilised samples, 21 had a diagnosis of multiple
myeloma (MM) and 18 had a diagnosis of lymphoma (15 non Hodgkin lymphoma
and 3 Hodgkin lymphoma patients). Analysis of the CFU-EPC formation of pre
G-CSF and mobilised samples showed no differences between MM and lymphoma
patients (p>0.8 and >0.6 in pre G-CSF and mobilised samples respectively) (Table
4.1).
Pre G-CSF Post G-CSF Donor Follow-up
Timing of sample
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MM patients showed mean CFU-EPC formation of 19.4 CFU-EPC/106 MNC, 2.6
CFU-EPC/106 MNC and 10.0 CFU-EPC/106 MNC from pre G-CSF, mobilised and
patient follow-up samples respectively. The decline in mean CFU-EPC frequency
following G-CSF was statistically significant (p=0.0008, paired data, n=l 8) as was the
change (increase) in CFU-EPC formation between mobilised and patient follow-up
samples (p<0.02, paired data, n=9) (Table 4.1).
Lymphoma patients showed mean rates of CFU-EPC formation of 17.8 CFU-EPC/106
MNC, 2.4 CFU-EPC/106 MNC from pre G-CSF and mobilised samples respectively.
A statistically significant decline in mean CFU-EPC occurred following G-CSF
administration (p=0.005, paired data, n=18) (Table 4.1).
CFU-EPC/106 MNC n Pre G-CSF Mobilised Follow-up
Multiple Myeloma 21 19.4 (4) 2.6 (1) 10.0 (3)
Lymphoma 18 17.8 (6) 2.4 (0) No samples
Table 4.1 Comparison of CFU-EPC in autologous PBSC patient groups.
Paired non-mobilised and mobilised data displayed for MM and lymphoma (NHL+HL)
patients with samples obtained pre G-CSF, on day 1 PBSCH and at donor follow-up.
Figures are presented as mean and median (in parentheses) CFU-EPC per 10s MNC.
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4.4. Comparison of CFU-EPC formation in allogeneic and
autologous PBSC patients mobilised with G-CSF
The changes in CFU-EPC frequency following G-CSF administration observed in
samples obtained from autologous PBSC patients were identical to the changes in
CFU-EPC formation following administration of G-CSF to allogeneic PBSC donors.
There were no significant differences in the frequency of CFU-EPC in pre G-CSF,
mobilised and follow-up samples between autologous patient groups (p=0.37,
p>0.99 and p>0.99 respectively) (Table 4.2).
CFU-EPC/106 MNC Pre G-CSF Mobilised Follow-up
Allogeneic PBSC donors 8.9 (6) 1.6 (0) 11.0 (7)
Autologous PBSC patients 13.2 (3) 2.2 (0) 10.0 (3)
Table 4.2 CFU-EPC in allogeneic and autologous PBSC patients.
Pre G-CSF, mobilised and donor follow-up samples displayed.
Figures are presented as mean and median (in parentheses) CFU-EPC per 106 MNC.
Similar changes in CFU-EPC were observed when only samples from patients that
had paired non-mobilised and mobilised data available were examined. Analysis of
the mean frequencies of CFU-EPC in pre G-CSF, mobilised and donor follow-up
samples obtained from PBSC patients showed that there were no differences
between allogeneic and autologous PBSC patients (p=0.56, p>0.8 and p>0.99
respectively) (Table 4.3).
CFU-EPC/106 MNC Pre G-CSF Mobilised Follow-up
Allogeneic PBSC donors 11.1 (8) 1.5 (0) 11.0 (7)
Autologous PBSC patients 18.6 (5) 2.5 (0) 10.0 (3)
Table 4.3 CFU-EPC in allogeneic and autologous PBSC patients (paired data).
Paired non-mobilised and mobilised CFU-EPC assessments are displayed. Samples were
obtained pre G-CSF, following PBSC mobilisation and at donor follow-up.
Figures are presented as mean and median (in parentheses) CFU-EPC per 10s MNC.
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For all PBSC donors (allogeneic and autologous PBSC donors combined) CFU-EPC
activity decreased significantly following the administration of G-CSF for PBSC
mobilisation (p<0.0001, paired data, n=52) and increased between G-CSF
mobilisation and donor follow-up (p<0.0001, paired data, n=23).
4.4.1. Conclusions
The results presented in this section have established that when using a standard,
commercially available, validated colony assay (CFU-Hill), the administration of
G-CSF for PBSC mobilisation produces statistically significant reductions in
CFU-EPC concentration. There were no differences in the reduction in CFU-EPC
activity induced by G-CSF between allogeneic PBSC donors mobilised with G-CSF















Pre G-CSF Post G-CSF Donor Follow-up
Timing of Donor Sampling
Figure 4.3 CFU-EPC formation in allogeneic and autologous PBSC patients.
Samples obtained prior to G-CSF, following mobilisation and at donor follow-up.
Paired non-mobilised and mobilised CFU-EPC data presented.
p=0.37, **p>0.99, ***p>0.99, Mann-Whitney test
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4.5. CFU-EPC development in autologous PBSC patients
mobilised with G-CSF+AMD3100
Autologous PBSC patients were eligible to receive G-CSF+AMD3100 for the
mobilisation of PBSC on the basis of their failure to mobilise PBSC following G-CSF,
usually given sequentially with chemotherapy, on a previous occasion. AMD3100
(Plerixafor), a reversible CXCR4 antagonist, was administered with G-CSF
(Lenograstim) (G-CSF+AMD3100), following a strict protocol to ensure that PBSC
collections occurred during periods of peak drug activity. Patients received a total of
5 days of G-CSF (lOpg/kg/d) and a single dose of AMD3100 (240pg/kg). AMD3100
was administered on the evening of day 4 after 4 doses of G-CSF, prior to
commencing leukapheresis the next morning; 10-11 hours post AMD3100 and at
least 1 hour after the 5lh dose of G-CSF. Similar to allogeneic PBSC donors, patients
mobilised with G-CSF+AMD3100 commenced leukapheresis without confirmation
of their PB leukocyte or CD34 counts.
4.5.1. Patient samples
Anticoagulated venous blood samples were obtained from 6 patients undergoing 7
cycles of G-CSF+AMD3100 PBSC mobilisation, with 1 male patient undergoing 2
cycles of G-CSF+AMD3100 as the first cycle of PBSC collection was terminated
prematurely due to intolerable AMD3100-induced gastrointestinal side effects.
Blood samples were collected on the same 3 occasions as autologous PBSC patients
mobilised with G-CSF+chemotherapy; with non-mobilised samples collected pre
G-CSF+AMD3100 (n=5) or on donor follow-up (n=2) and mobilised samples
collected on day 1 PBSCFI following G-CSF+AMD3100 (n=6).
MNC were separated from whole blood samples by Histopaque density gradient
centrifugation, using identical methods as employed for samples from patients
receiving G-CSF+/-chemotherapy for PBSC mobilisation (see section 4.2.1). The
CFU-EPC culture methods used were identical to those used for G-CSF mobilised
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patient samples (section 2.4.1) with colonies assessed daily from day 4 until at least
day 8.
4.5.2. CFU-EPC formation
4.5.2.1. Pre G-CSF+AMD3100 samples
CFU-EPC formation was observed in all non-mobilised MNC. Pre G-CSF samples
generated greater numbers of CFU-EPC than donor follow-up samples. The mean
CFU-EPC frequency in pre G-CSF samples was 21.2 CFU-EPC/106 MNC (median 15
CFU-EPC/106 MNC, range 3-70, n=5) (Figure 4.4).
Pre AMD3100 PostAMD3100 Donor Follow-
+G-CSF +G-CSF up
Timing of Sample
Timing of patient sample
CFU-Hill formation (CFU-EPC/106MNC)
298 299 299 313 316 321
Non-mobilised 70 3 3 15 — 15
G-CSF+AMD3100 mobilised 1 0 1 0 12 2
Donor follow-up — 3 2 — — —
Figure 4.4 CFU-EPC in autologous PBSC patients mobilised with G-CSF+AMD3100.
Samples collected pre G-CSF, day 1 PBSCH and at donor follow-up.
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4.5.2.2. G-CSF+AMD3100 mobilised samples
CFU-EPC colony development declined from pre mobilisation levels following
administration of G-CSF+AMD3100, to a mean of 0.8 CFU-EPC/106 MNC (median 1
CFU-EPC/106 MNC, range 0-12, n=6). In this small group of patients, the reduction
in CFU-EPC formation post G-CSF+AMD3100 did not reach statistical significance
(p=0.0625, paired data, n=5) (Figure 4.4).
4.5.2.3. Donor follow-up samples
Donor follow-up samples, obtained 4-6 weeks after PBSC mobilisation, showed
relatively low CFU-EPC development (2.5 CFU-EPC/106 MNC, n=2). This was
similar to the rate of CFU-EPC formation observed in the corresponding pre
G-CSF+AMD3100 samples from these patients (3 CFU-EPC/106 MNC for both) and
was higher than the levels of CFU-EPC generated by the same patients' mobilised
blood samples (0 and 1 CFU-EPC/106 MNC) (Figure 4.4).
4.5.2.4. Parallels with patients mobilised with G-CSF+/-chemotherapy
This pattern of CFU-EPC activity following the administration of G-CSF+AMD3100
paralleled that seen in autologous and allogeneic PBSC donors undergoing PBSC
mobilisation with G-CSF alone or sequentially with chemotherapy.
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4.6. CFU-EPC Colony morphology
CFU-EPC were defined as collections of cells consisting of a central core estimated
to contain greater than 50 round cells with at least 3 spindle-shaped cells
sprouting/radiating from the periphery of the core. Cell clusters of round cells
without radiating spindle-shaped cells were not counted as colonies.
4.6.1. Non-mobilised samples
In non-mobilised samples that formed colonies, CFU-EPC displayed typical
morphology as described by Hill (110) with CFU-EPC having tight central cores of
round cells and spindle cells sprouting from the margins of these. Isolated cells
(background cells) were heterogeneous in appearance and included a mixture of
round and spindle cells. Although CFU-EPC all shared key characteristics there
were considerable variations in colony morphology between patients (Figure 4.5).
Whilst inter-patient variation in colony morphology was evident, there was less
variation in CFU-EPC morphology in different samples from an individual.
Consistent CFU-EPC morphology was observed in pre G-CSF and follow-up
samples obtained from the same patient and from healthy volunteers sampled on
more than one occasion.
Figure 4.5 CFU-EPC in non-mobilised PBSC donor samples.
These images demonstrate the range of CFU-EPC morphology observed.
The presence of significant numbers of erythrocytes in some non-mobilised
autologous PBSC samples made morphological assessments of CFU-EPC more
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challenging as clumps of red cells were frequently positioned at the edge of cell
cores/clusters, partially obscuring spindle cells from view. Nevertheless, CFU-EPC
could still be assessed (Figure 4.6).
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Figure 4.6 CFU-EPC in non-mobilised autologous PBSC patient samples.
The difficulty in assessment of core-associated spindle cells in the presence of erythrocytes
(individual cells and clumps) is demonstrated.
4.6.2. Mobilised samples
The majority of G-CSF+/-chemotherapy or G-CSF+AMD3100 mobilised samples
failed to develop any CFU-EPC and the formation of spindle cells was severely
curtailed compared to that seen in non-mobilised samples from the same patient. In
wells containing mobilised MNC, the great majority of cells were round in shape
and were present either as single cells in small groups (<50 cell clumps) of cells, with
larger cell clusters (>50 cells) rarely seen (Figure 4.7).
Figure 4.7 CFU-EPC/clusters in non-mobilised and mobilised samples (1).
CFU-EPC in non-mobilised sample (left) and cell cluster without core-associated spindle or
background spindle in a mobilised sample (right) obtained from an allogeneic PBSC donor.
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When CFU-EPC developed in mobilised patient samples their morphology differed
from the comparative EPC-CFU from non-mobilised sample. CFU-EPC in mobilised
samples was more ragged in appearance. Central cores of cells were less tightly
aggregated and spindle formation was reduced (quantitatively and qualitatively) in
that reduced numbers of core-associated spindles were present and these spindle
cells were shorter and wider than those seen in non-mobilised samples (Figure 4.7
and Figure 4.8). Similar stunted spindle cells were present as part of the background
cells, though most background cells were round (Figure 4.8).
Figure 4.8 CFU-EPC/clusters in non-mobilised and mobilised samples (2).
CFU EPC in pre G-CSF (left) and G-CSF mobilised (centre) samples obtained from an
allogeneic PBSC donor showing the reduction in spindle number and their stunted
appearance following G-CSF. The great majority of cell clusters in mobilised samples
consisted of round cells without colony-associated or background spindle cells (right).
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4.7. Failure of CFU-EPC formation pre G-CSF in autologous
PBSC patients may be a result of disease state or therapy
A patient's disease state or chemotherapy treatment might impact on CFU-EPC
formation in the absence of G-CSF exposure, as outlined below. Follow-up samples
were obtained from autologous PBSC patients, at the time of their hospital
admission for autologous PBSCT, 4-6 weeks following PBSCI1 (n=9, all with MM).
In contrast to pre G-CSF samples usually collected whilst patients were receiving
chemotherapy, patient follow-up samples were obtained during the chemotherapy
free period between PBSCH and induction chemotherapy for autologous PBSCT.
In most cases the frequency of CFU-EPC in donor follow-up samples approximated
that of the patient's pre G-CSF sample but on a couple of occasions the follow-up
sample generated considerably greater CFU-EPC than the comparative pre G-CSF
sample. If these follow-up samples had not been available this might have
suggested a reversal or reduction in the effect of G-CSF on CFU-EPC (Table 4.4).
Patient
ID
Timing of patient sample
Pre G-CSF Mobilised Follow-up
277 — 2 3
278 0 1 20
283 1 0 4
284 0 0 0
291 3 0 3
299 3 0 2
302 1 3 10
279 — 1 48
314 — 0 0
Table 4.4 CFU-EPC in autologous PBSC patients.
Samples obtained pre G-CSF, after G-CSF mobilisation and donor follow-up.
Similar G-CSF effects on CFU-EPC occurred in samples from autologous PBSC
patients as observed in samples from allogeneic PBSC donors. The patients'
colony-forming potential and the effects of G-CSF on CFU-EPC might be
underestimated if only the pre G-CSF and G-CSF mobilised autologous patient
samples are compared and patient follow-up testing is omitted.
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4.8. Investigation of technical factors that might influence
CFU-EPC assay
In the earlier part of this chapter data was presented that illustrated the profound
effect that in vivo G-CSF (given alone or in combination with chemotherapy or
AMD3100) administration had on CFU-EPC frequency. These results are contrary to
a number of studies that report enhanced CFU-EPC following G-CSF (162, 163, 165,
167, 170). In this section (section 4.8) a number of technical factors that were
identified as possible influences on the CFU-EPC results obtained in the previous
section are explored.
4.8.1. Reduction in CFU-EPC as a result of delayed MNC
separation
In earlier studies, performed by O Tura and other group members, geographical
separation of the laboratory from the patient review area led to significant delays
(not infrequently 24 hours) between sample collection and MNC separation. This
was solved by the laboratory's relocation to the same site as the stem cell collection
facility (CSU). An assessment of whether results of earlier investigations were
adversely affected by these delays in MNC separation was undertaken. It is
important to note that all work presented in this thesis, unless specifically stated,
refers to fresh samples that underwent MNC separation within 3 hours of collection.
4.8.1.1. Sample collection
Seven blood samples were collected from 6 patients; 2 volunteers, 1 allogeneic
peripheral blood stem cell (PBSC) donor and 3 autologous PBSC patients, consisting
of 4 non-mobilised and 3 mobilised samples. Venous blood samples collected into
anticoagulated (lithium heparin) tubes were divided into two. One half of the
sample underwent MNC separation within 3 hours of collection (TO) whilst the
remainder was stored in a specimen bag in the laboratory on the bench-top at room
temperature for 24 hours prior to MNC separation (T24). The time elapsing between
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sample collection and commencement of MNC separation was the only difference
between specimens.
4.8.1.2. Macroscopic differences between samples
TO samples had clearer separation of the MNC layer post Histopaque density
gradient centrifugation than T24 samples. Regardless of whether the samples were
non-mobilised or mobilised samples, TO samples usually had white/opaque MNC
interface cells but T24 interface cells were frequently discoloured by the many red
cells within them. Despite thorough washing of the reserved T24 interface cells,
centrifuged cell pellets remained red and the resulting cell suspension pink. It was
also noted that TO whole blood samples had more complete red cell lysis during
whole blood antibody staining for flow cytometry than T24 samples.
4.8.1.3. CFU-EPC colony formation
MNC were plated into CFU-Hill assays. Colony formation and spindle cell
development were assessed from day 4 or day 5 and up to day 15 (range day 8-15).
When the volume of media in a well of a 24-well fibronectin-coated plate declined to
less than half of the original volume, additional Compete Endothelial Culture
Medium (CECM) (200pL) was added to the well. Incubator malfunction rendered
one post G-CSF sample (patient 215) unsuitable for further review, results are





JC No 2.9 0
KS No 25.3 3.75
208 Yes 4 4
212 Yes 10 0
215 No 0 0
215 Yes — —
218 Yes 0 0
Table 4.5 CFU-EPC formation in TO and T24 samples.
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CFU-EPC colony formation was adversely affected by delays in MNC separation
and commencement of cell culture. Use of T24 rather than TO non-mobilised
samples resulted in a clear decrease in CFU-EPC. For mobilised samples the use of
TO rather than T24 samples failed to 'recover' CFU-EPC activity. The effect of G-CSF
on CFU-EPC formation cannot be solely attributed to any delays in MNC separation
and plating cells into culture.
The results of experiments suggest that use of blood samples stored overnight prior
to MNC separation (T24 samples) reduced the magnitude of difference in CFU-EPC
activity between non-mobilised and G-CSF mobilised samples, principally due to
the reduction in CFU-EPC activity in T24 compared to TO non-mobilised samples.
This would have underestimated the possible effects of G-CSF on CFU-EPC. All
analysed data, including all CFU-EPC results in section 4.2-4.5, and other results
presented in this thesis refer to freshly collected samples with MNC separation
commencing within 3 hours of blood collection (equivalent to TO samples).
4.8.2. Potential for loss of CFU-EPC forming cells in the CFU-Hill
assay
In the CIU-Hill assay, primary plating of MNC onto fibronectin with harvest of
fibronectin non-adherent cells after 48 hours incubation aims to remove mature
macrophages and endothelial cells from the specimen. The assay relies on the
non-adherent MNC fraction to contain all colony-forming cells and for mature
endothelial cells and macrophages to be retained in the fibronectin-adherent cell
fraction. We have observed a consistent reduction in CFU-EPC following G-CSF
administration (CFU-Hill assay). One concern is that the harvest and re-plating of
day 2 non-adherent MNC fails to transfer all colony-forming cells to the secondary
culture plate; i.e. the EPC forming cells may have become adherent. Omission of the
day 2 re-plating step in the CFU-Hill(direct) assay (section 2.4.2.2) overcomes the
possibility that a reduction of CFU-EPC in mobilised samples is attributable to the
loss of colony forming cells during cell culture.
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It has been found in this study that non-mobilised samples and some autologous
PBSC patients' mobilised samples contain low MNC numbers, a result of the low PB
WCC in these patients (Chapter 3). Plating cells into the CFU-Hill assay, thereby
committing 5xlO MNC to one assay, restricted the scope of experiments performed
and limited the amount of comparative data that could be generated. An additional
benefit of using CFU-Hill(direct) assays would be in enabling additional
experiments to be performed using small volume/low cellularity patient samples.
Previous studies from our group (O Tura) suggested that the initial plating step
could be omitted in the CFU-EPC assay without affecting CFU-EPC formation. This
section addresses whether CFU-EPC assessment could be simplified and if the
CFU-Hill colony assay could be replaced by the CFU-Hill(direct) assay.
4.8.2.1. Sample Characteristics
CFU-EPC formation was assessed by plating MNC into CFU-Hill(direct) assays in
parallel with the CFU-Hill assay. Forty patient samples from 28 patients were
examined; 27 PBSC patients (10 allogeneic and 17 autologous PBSC donors) and 1
healthy volunteer. This included 12 G-CSF+/-chemotherapy mobilised samples and
28 non-mobilised samples (20 pre G-CSF, 7 follow-up samples and 1 non G-CSF).
Paired pre and post (+/-follow-up) G-CSF samples were available for 6 patients (5
allogeneic and 1 autologous PBSC patient).
4.8.2.2. CFU-EPC assessment
CFU-EPC are expressed per 106 MNC plated into 24 well fibronectin coated plates.
In CFU-Hill assays, colony formation is assessed in day 2 MNC that are
non-adherent to fibronectin. Whilst a calculated number of MNC (3-5xl06 MNC) are
plated into culture on day 0, the primary plating step removes a variable proportion
of fibronectin adherent MNC. Following harvest of non-adherent MNC on day 2,
CFU-Hill formation is assessed within a defined number of MNC plated into 24 well
fibronectin coated plates. In contrast, CFU-EPC formation in CFU-Hill(direct) assays
is assessed in day 0 MNC, which represent the total population of MNC obtained
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following density gradient centrifugation of whole blood. In this section (section
4.8.2) and subsequent sections colonies forming in the standard CFU-EPC assay
(CFU-Hill) are referred to as CFU-Hill and those forming in MNC plated directly
into 24 well fibronectin coated wells are referred to as CFU-Hill(direct) colonies.
4.8.2.3. CFU-EPC in non-mobilised samples
CFU-EPC formation was assessed in 28 non-mobilised patient samples. CFU-Hill
were generated in 18 of 28 (64.3%) day 2 non-adherent non-mobilised MNC and
CFU-Hill(direct) were generated in 19/28 (67.9%) day 0 non-mobilised MNC.
Overall, comparable results were obtained between the culture methods (Table 4.6).
Non-mobilised samples that generated no/low, medium or high level of CFU-Hill
colonies generated the same level of CFU-Hill(direct) colonies. CFU-EPC
morphology of CFU-Hill and CFU-Hill(direct) colonies were comparable for the
same patient sample (Figure 4.11).
Slightly disparate results were seen on 4 occasions; development of CFU-FIill in day
2 non-adherent MNC but no CFU-Hill(direct) in day 0 MNC (n=l) and
CFU-Hill(direct) formation but not CFU-Hill formation(n=3). Samples from 2
allogeneic PBSC patients that failed to generate CFU-EPC from pre G-CSF samples
(CFU-Hill or CFU-Hill(direct)) also failed to generate CFU-EPC from mobilised
blood or at donor follow-up by either culture method, suggesting that lack of
CFU-EPC could be attributed largely to patient rather than to assay factors.
4.8.2.4. CFU-EPC in G-CSF mobilised samples
When CFU-EPC were observed in mobilised samples, colonies were reduced in
frequency compared to non-mobilised samples. Following G-CSF, CFU-Hill were
generated in 4/12 (33.3%) mobilised samples and CFU-Hill(direct) in 2/12 (16.7%).
Details of CFU-EPC are presented in Table 4.6.
Disparate results between culture methods were seen in 5 cases. Three samples
generated CFU-Hill but not CFU-Hill (direct). These showed 2 or less CFU-Hill/106
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MNC. Two samples formed CFU-Hill(direct) but not CFU-Hill colonies. No pre
G-CSF data was available for one of these patients who generated CFU-Hill(direct)
colonies from mobilised MNC whilst the other patient's pre G-CSF sample also
generated greater numbers of CFU-Hill(direct) than CFU-Hill per million MNC.
Allsamples
Time Point Pre G-CSF Mobilised Follow-up Non-mobilised
CFU-Hill 6.6 0.8 14.0 8.1
CFU-Hill(direct) 8.5 1.1 6.0 7.6
Patient number 20 12 7 28
Allogeneic PBSC donors
Time Point Pre G-CSF Mobilised Follow-up Non-mobilised
CFU-Hill 8.3 1.2 14.8 10.6
CFU-Hill(direct) 13.7 0.4 6.4 11.1
Patient number 9 5 5 14
Autologous PBSC patients
Time Point Pre G-CSF Mobilised Follow-up Non-mobilised
CFU-Hill 5.5 0.6 11.0 6.3
CFU-Hill(direct) 5.5 1.5 4.5 5.3
Patient number 11 7 2 13
Table 4.6 CFU-EPC frequencies assessed using CFU-Hill(direct) and CFU-Hill assays.
Samples obtained at assessments pre G-CSF, G-CSF mobilised and at donor follow-up.
Results (mean values) are presented for all samples, allogeneic and autologous PBSC
patients. 'All samples' includes 1 healthy volunteer sample. CFU-EPC (expressed per 106
MNC) were quantified in day 2 fibronectin non adherent MNC as CFU-Hill or in day 0 MNC
as CFU-Hill(direct).
4.8.2.5. CFU-EPC in paired non-mobilised and mobilised samples
Paired patient samples show that a marked reduction (virtual abolition) of
CFU-EPC was recorded in all (CFU-EPC forming) patient samples following G-CSF,
regardless of whether CFU-EPC were assessed using CFU-Hill (Figure 4.9) or
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Figure 4.9 CFU-EPC formation assessed using the CFU-Hill assay.













Figure 4.10 CFU-EPC formation using the CFU-Hill(direct) assay.
Paired pre G-CSF and post G-CSF ("7- donor follow-up) samples.
4.8.2.6. Conclusions
Culture results using the CFU-Hill(direct) assay were equivalent to the results
obtained using in the standard CFU-Hill assay. Although colony-forming samples
showed some minor discrepancies between the culture methods, samples with low,
medium or high CFU-EPC activity according to one method had consistent activity
with the alternate method. Re-plating of day 2 non-adherent MNC did not select out
non colony forming cells. CFU-EPC morphology was also equivalent in CFU-Hill
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out to day 15 failed to detect additional CFU-EPC (CFU-Hill or CFU-Hill(direct) that
were not already present by day 7.
By virtue of the reduced cell numbers required, the abbreviated, directly plated
CFU-EPC (CFU-Hill(direct)) assay does offer a reasonable means of expanding the
breadth of investigations performed on non-mobilised (pre or follow-up) and
mobilised patient samples. This is especially valuable when MNC numbers are
limited. Flowever, where CFU-EPC forming cells are scarce or inactive, it may be
that plating only lxl06 MNC is inferior to plating greater numbers of cells, and
perhaps in this situation CFU-EPC assays might be better performed using greater
MNC numbers.
For subsequent experiments, when MNC numbers were limited or when a large
number of separate wells were being plated using a single patient sample,
CFU-Hill(direct) assays with day 0 MNC suspended in CECM and plated into 24
well fibronectin coated plates were set up. Where possible a CFU-Hill assay was
also performed.
Figure 4.11 CFU-EPC in a non-mobilised sample (autologous PBSC patient).
Similar CFU-EPC morphology is demonstrated in CFU-EPC generated within day 2 adherent
MNC (left), day 2 non adherent MNC (CFU-Hill) (centre) and day 0 MNC (CFU-Hill(direct)
(right).
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In addition to using CFU-Hill(direct) it was decided that due to the limited numbers
of MNC available from many patient samples to reduce the well-size of the plates
used for primary plating (day 0 MNC) in the CFU-Hill assay. The assay was
modified so that 3xl06 MNC, suspended in 1,5mL of CECM, were plated in to a well
of a 12 well fibronectin coated plate (rather than 5xl06 MNC being plated in 2mL
CECM into a 6 well plate) (section 2.4.2.1). The transfer of lxlO6 day 2 non-adherent
MNC in lmL CECM into a well of a 24-well fibronectin-coated plate was carried out
unmodified.
4.8.3. CFU-EPC development within day 2 adherent MNC
It is possible that treatment with G-CSF affects the ability of target/colony-forming
cells to adhere to the fibronectin surface, and through this alter CFU-EPC formation.
If cell adhesion to fibronectin was enhanced following G-CSF exposure this might
result in failure to transfer colony forming cells within the day 2 fibronectin
non-adherent MNC fraction on day 2 to 24 well plates (CFU-Hill assay). Colony
forming cells would therefore be retained in the initial well, within the day 2
adherent MNC fraction, and not be counted within the CFU-EPC. CFU-Hill(direct)
colonies would be unaffected.
Following transfer of non-adherent MNC into 24-well fibronectin coated plates on
day 2 fresh CECM was added to the original 6 or 12 well fibronectin plate. These
'day 2 adherent' MNC were returned to the incubator and then cultured and
assessed in identical fashion as the day 2 fibronectin non-adherent MNC in the
CFU-Hill assay.
4.8.3.1. Sample population
Eighty-six patient samples (24 allogeneic and 62 autologous PBSC patient samples)
comprising 51 non-mobilised samples (35 pre G-CSF and 16 follow-up samples) and
35 mobilised samples were examined for CFU-EPC within the day 2 adherent MNC
fraction. For 80 of 86 samples the CFU- Hill assay was performed using 12 well and
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then 24 well fibronectin coated plates. The CFU-Hill assay was performed using 6
well and 24 well fibronectin coated plates in the remaining 6 cases.
4.8.3.2. CFU-EPC in non-mobilised samples
Within day 2 non-adherent MNC (CFU-Hill), CFU-EPC were generated in 13/19
(68.4%) allogeneic PBSC donor samples and 24/32 (75.0%) autologous PBSC patient
samples. CFU-EPC development in day 2 adherent MNC was observed more rarely
with 4/19 (21.1%) allogeneic and 12/32 (37.5%) autologous PBSC patient samples
generating colonies from day 2 adherent MNC. Mean CFU-EPC were 7.3
CFU-EPC/106 MNC and 2.5 colonies/well in day 2 non-adherent and adherent MNC
respectively for allogeneic PBSC donors and 10.5 CFU-EPC/106 MNC and 3.2
colonies/well for autologous PBSC patients.
With 2 exceptions, the level of CFU-EPC in day 2 adherent MNC was low. One
autologous PBSC patient who had florid CFU-EPC development in the CFU-Hill
assay (>100 CFU-EPC/106 MNC) also had prolific colonies within day 2 adherent
MNC (50 CFU-EPC/well). There was an error in cell transfer in one allogeneic PBSC
donor as minimal cells were plated into the 24 well fibronectin-coated plate on day
2; 0 CFU-EPC/106 MNC and 40 CFU-EPC/well in day 2 non-adherent and day 2
adherent MNC respectively. The frequencies of CFU-EPC in day 2 non-adherent
and day 2 adherent fractions are displayed in Table 4.7.
4.8.3.3. CFU-EPC formation in G-CSF mobilised samples
CFU-EPC development was reduced in mobilised samples. One of 5 (20%)
allogeneic and 12/30 (40%) autologous PBSC patients showed some degree of
CFU-EPC development within day 2 non-adherent MNC. CFU-EPC activity was
observed within day 2 adherent MNC in 0/5 allogeneic and 2/30 (6 7%) autologous
PBSC patients.
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No 7.6 1.7 31*
Yes 1.1 0.1 30
Allogeneic PBSC
donors
No 7.7 0.4 18**
Yes 0.6 0 5
All PBSC
donors
No 7.7 1.2 4g***
Yes 1.1 0.1 35
Table 4.7 Mean CFU-EPC development in day 2 non-adherent and day 2 adherent MNC.
* Excludes 1 outlying patient (CFU-EPC 10.5/106 and 3.2/well in D2 NA & AD MNC; n=32).
** Excludes 1 outlying patient (CFU-EPC 7.3/106and 2.5/well in D2 NA & AD MNC; n=19).
*** Excludes 2 outlying patients (CFU-EPC 9.3/106 and 2.9/well in D2 NA & AD MNC; n=51).
4.8.3.4. Changes in CFU-EPC from day 2 adherent MNC and day 2 non¬
adherent MNC are comparable in mobilised samples
Eleven of 16 non G-CSF samples (pre G-CSF or donor follow-up samples) that
generated CFU-EPC within day 2 adherent MNC had similar changes in CFU-EPC
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Figure 4.12 CFU-FPC frequencies in day 2 adherent MNC.
Pre G-CSF, G-CSF mobilised and donor follow-up samples
Figure 4.13 CFU-EPC in day 2 non-adherent MNC (CFU-Hill).
Same pre G-CSF, G-CSF mobilised and donor follow-up samples as used for figure 4.12.
When the CFU-EPC frequencies in day 2 adherent and day 2 non-adherent MNC
from paired patient samples were examined, we saw that the reduction in CFU-EPC
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following G-CSF administration observed in day 2 adherent MNC (Figure 4.12)
almost mirrored the reduction in CFU-EPC following G-CSF in day 2 non-adherent
MNC (CFU-Hill assay) (Figure 4.13).
4.8.3.5. CFU-EPC morphology
When CFU-EPC formed in day 2 adherent cells the colony morphology was very
similar to that of CFU-EPC generated in day 2 non-adherent MNC (Figure 4.11 and
4.14).
Figure 4.14 CFU-EPC in day 2 non-adherent MNC (left) and adherent MNC (right).
Non-mobilised sample obtained from an autologous PBSC patient.
4.8.3.6. Conclusions
The addition of fresh CECM to the adherent MNC remaining following recovery of
non-adherent cells on day 2 with continuation of cell culture did not reveal
CFU-EPC activity within the adherent cell fraction at the expense of CFU-EPC
formation in day 2 non-adherent MNC. On some occasions, colony forming cells
were retained within the adherent cells. This is particularly important in specimens
containing few colony forming cells. Care should be taken to ensure that all
non-adherent MNC are transferred and wells should be examined for cell content
following aspiration of the non-adherent cells to confirm that there has been no
error in collection of cells.
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The failure of CFU-EPC development post G-CSF administration cannot be
attributed to the retention of colony forming cells within adherent MNC at the time
of re-plating non-adherent MNC on day 2. When CFU-EPC were present in day 2
adherent MNC pre G-CSF, a decline in CFU-EPC formation within day 2 adherent
cells was also noted following G-CSF. This decline indicates that CFU-EPC forming
cells within day 2 adherent and non-adherent MNC are affected similarly by G-CSF.
It should be identified whether these colonies developing within day 2 adherent
MNC are identical to those developing in day 2 non-adherent MNC and if they arise
from haematopoietic elements. It should also be considered whether these colonies
should be included in colony numbers for a sample and whether CFU-EPC can be
assessed using a single continuous culture.
4.8.4. Influence of changing CECM during cell culture on CFU-EPC
Two mobilised autologous PBSC patient samples were plated into CFU-Hill assays.
1 xlO6 non-adherent MNC were transferred in duplicate into wells of a 24 well
fibronectin-coated plate on day 2. One well received no further intervention. The
other well had 50% of its media refreshed on alternate days; 500|j.L media was
aspirated and replaced with 500pL of fresh CECM. Wells were inspected daily from
day 4 for CFU-EPC.
4.8.4.1. Results
CFU-EPC activity in these mobilised patient samples was minimal (1 CFU/106 MNC
and 0 CFU-EPC/106 MNC, patients 218 and 221 respectively). Refreshing CECM
during CFU-EPC culture did not increase CFU-EPC (1 CFU/106 MNC and 0
CFU-EPC/106 MNC, patients 218 and 221 respectively). In addition, there were no
differences observed in the numbers of cell clusters, cell clumps or spindle cells
between the culture wells.
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4.8.4.2. Conclusions
Changing 50% of CECM on alternate days did not influence CFU-EPC formation or
alter the cell morphology seen in G-CSF mobilised MNC plated into CFU-EPC
assays.
4.8.5. Influence of plating increased numbers of mobilised MNC
into CFU-EPC assays
If the decline in CFU-EPC activity seen in mobilised samples is attributable solely to
reduced proportions of CFU-EPC colony forming cells within these samples then
plating increased cell numbers into CFU-EPC assays should increase CFU-EPC.
A series of mobilised patient samples (n-7) were plated into CFU-EPC assays
(CFU-Hill(direct) (n=5) or CFU-Hill (n=2)) using increasing cell doses; lxlO6, 2xl06 or
4xl06 day 0 MNC in CFU-Hill(direct) and 1 xlO6 or 2xl06 day 2 fibronectin
non-adherent MNC in CFU-Hill assays. Wells were inspected for CFU-EPC from
day 4.
4.8.5.1. CFU-EPC in CFU-Hill(direct) assay
Three of 5 patient samples plated into CFU-Hill(direct) assays failed to show any
CFU-EPC in wells containing lxlO6, 2xl06 or 4xl06 day 0 MNC. One patient sample,
with MNC plated into CFU-Hill(direct) assays, showed no (0 CFU-EPC/106 MNC)
CFU-EPC in wells containing lxl06 and 2x106 day 0 MNC but a single CFU-EPC
colony was seen in the well containing 4xl06 day 0 MNC (0.25 CFU-EPC/106 MNC).
The paired non-mobilised sample from this patient generated 7 CFU-EPC/106 MNC.
The second patient had more impressive CFU-EPC generation with plating
increased numbers of mobilised MNC into culture. G-CSF mobilised MNC plated in
CFU-Hill(direct) assays generated 0 CFU-EPC when lxlO6 MNC were plated into
culture but 9 CFU-EPC were generated from the well containing 2xl06 day MNC
(4.5 CFU-EPC/106 MNC). The corresponding non-mobilised sample from this
patient generated 19 CFU-EPC/106 MNC.
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4.8.5.2. CFU-EPC in CFU-Hill assay
Both mobilised samples plated into CFU-Hill assays at increasing concentrations
showed a dose effect. Mobilised MNC from one patient generated 0 CFU-EPC when
standard cell numbers were plated (3xl06 day 0 MNC into 12 well fibronectin plate
with replating of lxlO6 non-adherent MNC on day 2) but 10 CFU-EPC when 10x10s
cells were plated on day 0 and 2xl06 cells were transferred on day 2 (5 CFU-EPC/106
MNC). The non-mobilised sample from the second patient had high levels of colony
formation 70 CFU-EPC/106 (CFU-Hill assay). Following G-CSF, the standard
CFU-Hill assay generated 1 CFU-EPC colony (1 CFU-EPC/106 MNC) and plating
lOxlO6 MNC on day 0 with transfer of 2xl06 cells on day 2 generated 3 CFU-EPC (1.5
CFU-EPC/106 MNC).
4.8.5.3. Conclusions
There is some, albeit inconsistent, evidence to supporting a cell dose effect for
CFU-EPC formation in mobilised samples. However, CFU-EPC activity fails to
recover to levels approaching that shown by the corresponding non-mobilised
sample. If it is postulated that formation of CFU-EPC is a consequence of a single
cell and that G-CSF administration reduces the frequency of these cells then plating
increased cell numbers into CFU-EPC assay should detect CFU-EPC. However, if
G-CSF has resulted in making responsive cells inert then increasing cell numbers
will not increase CFU-EPC. Even greater cell numbers should be plated into
CFU-EPC culture to detect lower frequency events before we draw any conclusions
along those lines.
In addition to performing CFU-EPC using standard cell numbers, MNC should be
plated in CFU-EPC in higher cell doses where possible. In healthy adult allogeneic
PBSC donors, PB leukocyte counts increase ~7-fold following G-CSF administration
and MNC numbers obtained from density gradient centrifugation of whole blood
are also increased compared to non-mobilised samples, meaning that MNC are
available for this. However MNC numbers may be insufficient to support plating
higher doses of MNC from autologous PBSC patients into CFU-EPC cultures as
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MNC numbers were found to be low in many mobilised samples from these
patients.
4.8.6. Erythrocytes as a possible cause of reduction in CFU-EPC
in mobilised samples
Significant erythrocyte contamination of the MNC interface, which could then be
seen throughout the CFU-EPC assay, has been noted in many but not all specimens
obtained from mobilised PBSC patients. Erythrocyte contamination was seen as
macroscopic red or pink discolouration of the interface layer and then as redness of
MNC pellets after centrifugation. Erythrocytes were also evident on microscopic
and on later macroscopic inspection of culture wells after plating MNC into the
CFU-EPC assay. In contrast, non-mobilised samples did not usually have significant
erythrocyte contamination of MNC. No differences could be identified between
those mobilised MNC samples that displayed high or low levels of erythrocyte
contamination in how these specimens were collected and handled (including
anticoagulant used in the collection tubes, sample volume, time lapsing between
sample collection and MNC density gradient separation, centrifugation speeds, and
the presence of any clotted material in the specimens).
The presence of erythrocytes could be reducing the accuracy of day 0 and day 2
MNC enumerations and therefore be affecting the number of MNC plated into cell
culture. Erythrocytes might also be having direct negative effects on CFU-EPC
formation. As erythrocyte content of mobilised samples was higher than
non-mobilised samples (section 5.2) it might contribute to the 'G-CSF effect' on
CFU-EPC formation. A number of areas where the influence of erythrocytes on cell
culture could be assessed were identified; the use of acetic acid lysis of cell
suspensions when counting MNC and use of alternative centrifuge tubes for density
gradient centrifugation.
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4.8.6.1. Acetic acid erythrocyte lysis prior to MNC enumeration
MNC concentrations of day 0 or day 2 MNC (n=13) were counted by
haemocytometer prior to and following the addition of 3% acetic acid. Except when
there was extremely heavy erythrocyte contamination observed, a 1:1 acetic acid
dilution was performed (20ju,L 3% acetic acid added to 20pL MNC suspension).
MNC concentrations were consistently lower following acetic acid dilution of the
specimen prior to counting with mean reductions in MNC concentrations of 25%
observed. This most likely reflected better distinction of small lymphocytes (whose
diameter of 7-8gm approximated the average diameter of erythrocytes).
Additionally, use of acetic acid improved nuclear detail and allowed easier
distinction of lymphocytes and monocytes from granulocytes and myeloid
precursors. The magnitude of differences between MNC counts made prior to and
following acetic acid is displayed in Table 4.8.
The magnitude of change in MNC counts when counting using acetic acid lysis
were greater for mobilised samples. Following on from these results, dilution of
MNC 1:1 with acetic acid prior to MNC enumeration by haemocytometer was








in valuePre Dilution Post Dilution
227 Auto Post 0 3.1 2.5 17.6
227 Auto Post 2 1.8 1.3 29.2
226 Auto Post 0 RBC ++ 1.4 —
226 Auto Post 2 RBC ++ 2.6 —
228 Auto Post 0 7.9 3.9 51.0
228 Auto Post 2 4.5 3.4 24.4
225 Auto Post 0 2.1 0.7 65.4
225 Auto Post 2 1.4 1.0 26.6
229 Alio Post 0 2.9 2.7 6.2
232 Alio Pre 0 1.9 1.7 10.3
232 Alio Pre 2 2.0 1.9 5.9
234 Alio Pre 0 1.7 1.2 25.3
230 Auto Post 0 6.4 5.2 19.4
Table 4.8 Change in MNC counts following acetic acid dilution.
RBC+++ indicates that MNC sample was heavily contaminated by erythrocytes.
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4.8.6.1.1. CFU-EPC activity
CFU-EPC formation pre and post G-CSF was evaluated using 7 paired
non-mobilised and mobilised patient samples, where MNC enumeration was
performed using acetic acid dilution. A consistent reduction in CFU-EPC was noted
following G-CSF administration. This suggested that although there might have
been inaccuracies in cell plating generated from counting errors made as a result of
failure to exclude erythrocytes from MNC enumeration, the 'G-CSF effect' on









Timing of Patient Samples
Figure 4.15 CFU-EPC generated from non-mobilised and mobilised patient samples.
MNC enumeration using acetic acid erythrocyte lysis.
4.8.6.2. Use of Leucosep centrifuge tubes
Leucosep tubes (Greiner Bio-one, UK) appeared to be an option for MNC separation
as the fixed porous membrane provided a barrier between the pelleted erythrocytes
and granulocytes and the MNC layer. The Ftistopaque is forced below the porous
barrier by a brief period of centrifugation prior to the addition of the diluted whole
blood sample. This ensures that the specimen is layered adequately when it is
loaded into the centrifuge tube. Additionally, it was hoped that the barrier would
not inhibit the passage of RBC clumps through the membrane and that a cleaner
interface layer would be produced.
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Leucosep centrifuge tubes were used for MNC separation on 5 occasions (for 4
mobilised samples and 1 non-mobilised sample). For the non-mobilised sample, the
MNC interface layer was positioned close to the porous membrane and was not
clearly separated from it. Additionally the MNC interface from the Leucosep tube
contained greater numbers of erythrocytes, evident macroscopically and confirmed
by flow cytometry (25.3% versus 3.3% CD235a+ erythrocytes).
Use of Leucosep centrifuge tubes failed to improve MNC separation of mobilised
samples and in fact worsened the erythrocyte contamination. Red cell clumps were
caught above the porous membrane. These clumps extended into the interface
layers which were positioned close to the membrane. Flow cytometry showed
increased proportions of CD235a+ erythrocytes with Leucosep tubes (29.4% versus
24.6% CD235a+ erythrocytes).
4.8.6.3. Conclusions
The finding of erythrocyte contamination of MNC obtained from Histopaque
mobilised and some non-mobilised patient samples (principally those obtained from
autologous PBSC patients who were recovering from chemotherapy) suggested that
there is a population of (probably immature) erythrocytes in the peripheral blood
which have similar density properties to MNC. These therefore co-separate with
MNC during conventional buoyant density gradient centrifugation. These
erythrocytes also appear to be more robust and 'lysis resistant' than other
erythrocytes. The level of erythrocyte contamination has not been satisfactorily
reduced using the above methods. The reduction in erythrocyte levels was not
pursued further as CFU-EPC formation did not appear to be adversely affected by
their presence (Chapter 5).
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4.8.7. Influence of altered day 2 CECM volume on CFU-EPC
activity
Previous CFU-EPC colony assay experiments performed within our laboratory had
frequently been performed using 500(j.L rather than lOOOpL CECM when re-plating
day 2 MNC. This was a minor deviation from the CFU-EPC colony assay method
published by Stem Cell Technologies.
The reduced CFU-EPC formation of mobilised samples might have been influenced
by altered CECM volumes during cell culture. Use of reduced CECM volumes
results in increased cell densities within the culture well. This might have
influenced intercellular interactions and paracrine actions within the well. A
reduction in media volume will also increase the concentrations of any cytokine,
chemokine or any other soluble factor produced, with the potential of this to affect
cell activity. A reduction in media volume might also affect cell behaviour and
CFU-EPC formation due to relative nutrient deficiencies within the well.
4.8.7.1.1. Method
This experiment was performed in order to assess the influence of increasing cell
concentrations, as a result of reducing CECM volume when re-plating day 2 MNC,
on CFU-EPC development and colony morphology. Eight patient samples (4
non-mobilised and 4 mobilised samples) from 5 patients were assessed, with paired
non-mobilised and mobilised samples available for 3 patients. Patient samples were
collected into anticoagulated tubes and underwent MNC separation by buoyant
density gradient centrifugation within 3 hours of collection. MNC interface cells
were recovered, washed and counted.
CFU-EPC development was assessed using the CFU-Hill assay. 5xl06 MNC (or
maximum available MNC) were re-suspended in 2mL of CECM (2.5x106 cells/mL)
and placed in a well of a 6-well fibronectin coated plate. Non-adherent MNC were
recovered on day 2. After counting, 2 aliquots, each containing IxlO6 cells, were
transferred into clean centrifuge tubes and pelleted. MNC were resuspended in
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either 500jj.L or lOOOpL of fresh CECM and transferred to wells of a 24-well
fibronectin coated plate. Wells were inspected daily from day 4 for CFU-EPC. The
cells in all wells appeared healthy throughout the observation period.
In addition to colony enumeration, assessments were made of the numbers of cell
clusters and spindle cells present. Clusters were defined as collections of rounded
cells, estimated to contain >50 cells, distinguished from colonies by the lack of
spindle cells sprouting from their peripheries. Average spindle cell numbers were
the mean of the number of spindle cells present in 4 randomly selected x20
microscope fields not containing CFU-EPC colonies, reducing the influence of




Day 2 non-adherent cells









219 Post 2 3 1 5
220 Pre 55 35 20 72
220 Post 10 100 3 110
223 Pre 67 65 86 82
223 Post 23 63 26 58
224 Pre 7 36 4 28
224 Post 0 30 0 24
225 Pre 0 13 0 19
Table 4.9 Influence of altered day 2 media volume on CFU-EPC.
4.8.7.2. CFU-EPC in non-mobilised samples
Three of 4 non-mobilised samples generated CFU-EPC (Table 4.9). There was no
consistent change in the number of CFU-EPC according to volume of CECM used
on day 2; lower CFU-EPC formation with 500pL CECM in 2 samples and increased
in 1. Spindle cells were more common in the wells containing 500|aL CECM. Earlier
dispersal of colonies and also of clusters occurred in the 500pL wells. This may have
resulted in the appearance of a more cellular background containing more spindle
cells and rounded cells.
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4.8.7.3. CFU-EPC in G-CSF mobilised samples
Three of four mobilised samples generated CFU-EPC, but in lower frequency than
non-mobilised samples (Table 4.9). No consistent change in CFU-EPC numbers
according to the day 2 volume of CECM used was observed. See table. Use of the
lower media volume was accompanied by a reduction in CFU-EPC activity in 2
mobilised samples and a very slight increase in CFU-EPC in 1 case. Spindle
morphology was stunted in mobilised samples with shortened and thickened
spindle cells seen. Similar to non-mobilised samples, spindle cells were more
prominent in the wells containing 500pL CECM and dispersal of colonies and
clusters occurred earlier in these wells.
4.8.7.4. CFU-EPC in paired 500uL and IQOOuL CECM volumes
Pairing of CFU-EPC results when plating day 2 non-adherent MNC into 500pL or
lOOOpL CECM showed no consistent influence of media volume on CFU-EPC
(Figure 4.16). The reduced CFU-EPC in mobilised samples should not be attributed
to plating day 2 MNC into lower volumes of CECM.
219 Post G-CSF
220 Pre G-CSF
- - - 220 Post G-CSF
223 Pre G-CSF
- - - 223 Post G-CSF
224 Pre G-CSF
- - - 224 Post G-CSF
- 225 Pre G-CSF
500mcl 1000mcl
Day 2 Media Volume
Figure 4.16 Influence of day 2 CECM volume on CFU-EPC formation.
4.8.7.5. CFU-EPC in paired non-mobilised and mobilised samples
CFU-EPC formation was assessed in 3 paired non-mobilised and mobilised patient










of whether day 2 MNC were re-plated into 500pL or 1000j.iL CECM CFU-EPC
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G-CSF Administration
Figure 4.17 CFU-EPC with day 2 MNC plated into either 500|.iL or lOOOpL CECM.
Paired non-mobilised and mobilised PBSC samples.
4.8.7.5.1. Conclusions
We found no evidence that re-plating day 2 MNC into a lower volume of CECM
curtailed or enhanced CFU-EPC activity. A similar 'G-CSF effect' on CFU-EPC was
observed when day 2 MNC were plated into either 500pL or lOOOpL CECM
volumes. Increasing day 2 MNC CECM volumes did not improve CFU-EPC
formation in samples that failed to generate CFU-EPC using 500pL CECM.
Reductions in CFU-EPC formation in mobilised samples could not be attributed to
plating cells into lower CECM volumes on day 2.
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4.9. Effects of technical factors on CFU-EPC from
G-CSF+AMD3100 mobilised PBSC patients
4.9.1. CFU-EPC formation in day 2 adherent MNC
The rate of CFU-EPC formation in day 2 fibronectin adherent MNC was assessed in
4 pre mobilisation samples, 2 donor follow-up samples and 6 G-CSF+AMD3100
mobilised samples. CFU-EPC formation was observed in the day 2 adherent fraction
in 2 of 6 non-mobilised samples. In both cases the day 2 non-adherent MNC
generated moderate-high CFU-EPC (70 and 15 CFU-EPC/106 MNC). The day 2
adherent MNC contained 50 and 8 CFU-EPC/well respectively. Day 2 adherent
MNC from mobilised samples failed to generate CFU-EPC (0 CFU-EPC/well, n=6).
4.9.2. CFU-Hill(direct) assay
CFU-EPC formation was also assessed by both CFU-Hill and CFU-Hill(direct)
assays in 4 non-mobilised samples. The rates of CFU-EPC generated in the
CFU-Hill(direct) assays were comparable to that observed with the CFU-Hill assay
(mean 19.5 CFU-EPC/106 MNC and 6.3 CFU-EPC/106 MNC and median 3
CFU-EPC/106 MNC and 3.5 CFU-EPC/106 MNC for CFU-Hill and CFU-Hill(direct)
assays respectively, n=4). Mean CFU-EPC differed substantially between culture
methods for 1 patient sample; 70 CFU-EPC/106 MNC were generated in the
CFU-Hill assay and 12 CFU-EPC/106 MNC in the CFU-Hill(direct) assay.
4.9.3. Increasing cell numbers at stage 2 of CFU-Hill assay
Increased cell concentrations of G-CSF+AMD3100 mobilised MNC were plated into
CFU-Hill assays (n=2). lOxlO6 MNC were plated into 12 well fibronectin coated
plates on day 0 and 2.0xl06 day 2 non-adherent MNC were transferred into 24 well
fibronectin coated plates. Plating greater cell numbers failed to increase CFU-EPC in
1 patient sample (0 CFU-EPC/106 MNC) but plating greater cell numbers into
CFU-EPC generated 3 CFU-FPC (1.5 CFU-EPC/106 MNC) in the other sample,
marginally higher than that of standard cell concentrations (1 CFU-EPC/106 MNC).
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4.10. Endothelial outgrowth colony formation of PBSC donor
samples
4.10.1. Introduction
It is currently thought that two broad groups of EPC exist and that the cells
identified in endothelial outgrowth colony assessments represent 'true EPC' (93,
131, 133). There is evidence that EOC are derived from CD34+ cells (131)and more
recent published evidence supporting a CD34+/133~ origin of these cells (112, 134,
150). Other members of our group have cultured EOC from unselected umbilical
cord blood (UCB) MNC. We sought to establish whether EOC could be generated
from another CD34-rich blood source, G-CSF mobilised peripheral blood.
MNC were obtained following Elistopaque buoyant density gradient centrifugation
of whole blood samples. MNC were suspended in EBM2 media (with supplements)
and then plated onto plastic plates coated with type 1 collagen (Becton Dickinson,
UK)). Six or 12 well collagen type 1 plates were used. A maximum of 20xl06 MNC
were plated into each well for EOC culture. MNC were cultured according to the
method described in section 2.4. Wells were regularly inspected for EOC
development from the second week of culture.
4.10.2. Patient samples
PBSC samples from 8 PBSC donors (4 allogeneic PBSC donors and 4 autologous
PBSC patients) were plated into EOC assays. The allogeneic PBSC donor samples
consisted of 1 donor follow-up sample, 1 pre G-CSF sample and 2 G-CSF mobilised
samples. The autologous PBSC patient samples consisted of 3 pre G-CSF samples
and 1 G-CSF+chemotherapy mobilised sample. When MNC numbers permitted,
multiple wells were plated into the EOC assay, enabling multiple cell concentrations
to be plated for a single sample. This was more likely to be achievable with MNC
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from allogeneic PBSC donors than autologous PBSC patients due to their higher
peripheral blood WCC and therefore higher MNC yields.
4.10.3. EOC formation
Cells in the culture wells remained healthy throughout the culture period. No
infection was noted in any of the culture wells. Few cells remained in the culture
wells following aspiration of the non-adherent cells on day 2. This cell loss was
more pronounced in wells containing G-CSF mobilised cells.
No EOC formation was observed in any well over the review period. No other
proliferating cell populations were observed in the culture wells. However, some
differences in cell morphology between wells containing non-mobilised and G-CSF
mobilised MNC were noted. Wells containing G-CSF mobilised MNC appeared to
contain larger, bulkier-looking cells that had an ovoid shape. Non-mobilised MNC
were small and round. No cobblestone appearances were observed in the culture
wells and no significant cell proliferation was observed. No change in cell
morphology was noted when the culture period was extended beyond four weeks
and delayed colony formation did not occur.
4.10.3.1. Matriqel tubule formation
After approximately 4 weeks of culture (mean 26 days, range 16-36 days, median 30
days) no EOC formation was observed in any culture well, regardless of the density
of MNC initially plated. The morphologic differences between culture wells
containing non-mobilised and G-CSF mobilised MNC continued to be observed. It
was questioned whether the altered appearances of mobilised compared to
non-mobilised MNC might be the result of atypical EOC formation and that these
plumper mobilised cells might be a form of 'cobble-stoning', albeit with an unusual
morphology.
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Representative culture wells containing MNC from 6 patients were selected for the
Matrigel tubule formation assay; 3 non-mobilised MNC (1 allogeneic and 2
autologous PBSC patients) and 3 mobilised MNC (1 autologous and 2 allogeneic
PBSC donors). Where multiple wells had been plated for the same specimen, only
the well plated with the greatest cell density was selected for the Matrigel assay. The
method for Matrigel tubule formation was described in section 2.4. Non-adherent
cells were aspirated from the culture wells and discarded and the adherent MNC
were washed with PBS and incubated with trypsin/EDTA for a total of 10 minutes.
On examination there appeared to be a relatively high proportion of adherent cells
at this point and the cells were incubated with trypsin for a further 10 minutes.
Trypsinised cells were recovered from the culture wells and cells were counted
using a Coulter cell counter. Matrigel was thawed overnight in a 4C refrigerator. A
pre-cooled 24 well plastic plate was prepared with Matrigel and then 0.7 x 104 cells
suspended in EBM2 media (with supplements) were added to each prepared culture
well. The plate was placed in incubator overnight and the wells were inspected for
tubule formation the next morning.
No evidence of tubule formation was detected in any culture well. Cells were
sparsely placed in the wells. One limitation of this assay was the lack of a positive
control (no HUVEC were available).
4.10.4. Conclusions
No EOC development in MNC prepared from peripheral blood samples from PBSC
donors was demonstrated whether or not the samples were collected following
G-CSF administration. The lack of EOC development in CD34-rich G-CSF mobilised
samples was surprising considering the CD34-dependence of EOC. EOC have been
generated from another CD34-rich source, umbilical cord blood. The difference in
EOC development between 2 CD34-rich sources led to an investigation of the
subsets of CD34+ cells within these samples. This is presented in Chapter 6.
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4.11. Discussion
Evaluation of CFU-EPC in samples obtained from allogeneic and autologous PBSC
patients has shown that CFU-EPC frequency varies considerably, both in healthy
donors and in patients with haematological malignancies. Absence of CFU-EPC
formation in non-mobilised samples was more likely to occur in samples obtained
from autologous PBSC patients than from healthy allogeneic PBSC donors.
However, a significant proportion of healthy donors failed to develop CFU-EPC in
their pre G-CSF samples in the absence of either chemotherapy or G-CSF exposure.
The huge variations in CFU-EPC between individuals made it more difficult to
interpret the results of CFU-EPC based experiments.
G-CSF administration, either given alone, sequentially with chemotherapy or
sequentially with AMD3100, resulted in a marked reduction (and abolition in some
cases) in CFU-EPC. This was consistently demonstrated for both allogeneic and
autologous PBSC donors regardless of the mobilisation regimen used. The decline in
CFU-EPC following G-CSF was temporary, as follow-up samples taken 4-6 weeks
after PBSC mobilisation showed increased CFU-EPC towards pre mobilisation
levels. Differential effects of G-CSF and AMD3100 on CFU-EPC could not be
assessed as no patients underwent PBSC mobilisation with AMD3100 alone.
AMD3100 was available for a brief period, for PBSC mobilisation in autologous
PBSC patients when it was administered sequentially with G-CSF, but its use is not
currently being funded.
There may have been differences in CFU-EPC between allogeneic and autologous
patient groups caused by possible effects of chemotherapy on CFU-EPC. CFU-EPC
frequency was comparable in both non-mobilised samples (pre G-CSF and donor
follow-up samples). There were no significant differences in the frequency of
CFU-EPC between samples obtained from allogeneic donors and autologous PBSC
patients. However, pre G-CSF samples from autologous PBSC patients displayed
higher mean CFU-EPC than comparable samples from allogeneic PBSC donors (13.2
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and 8.9 CFU-EPC/106 MNC for autologous and allogeneic PBSC donors respectively,
increasing to 18.6 and 11.1 CFU-EPC/106 MNC when only those donors with both
non-mobilised and mobilised samples were considered), affected by 5 autologous
PBSC patient samples that showed >50 CFU-EPC/106 MNC and by a greater
proportion of patients failing to generate CFU-EPC (44.4%). Median CFU-EPC for
pre G-CSF samples was higher for allogeneic PBSC donors. There was no difference
in mean CFU-EPC between donor follow-up and mobilised samples obtained from
allogeneic or autologous PBSC donors.
The administration of myelosuppressive chemotherapy increases the numbers of
CD34+ HPC present in the circulation during the recovery phase. It might be that
CFU-EPC forming cells are similarly increased in this period. As autologous PBSC
patients were reviewed at varying times (but within a month) prior to PBSC
collection it was possible that some patients could have mobilised colony-forming
cells as a result of chemotherapy, producing a wider range of CFU-EPC frequency in
this patient group. Flowever, a disparity in CFU-EPC between pre G-CSF and
patient follow-up samples obtained from some autologous PBSC patients was
noted, with some patient follow-up samples demonstrating considerably greater
CFU-EPC than their pre G-CSF samples. No additional G-CSF or chemotherapy had
been administered between the time of PBSC mobilisation and collection of the
follow-up sample. As there was no difference in CFU-EPC frequency in follow-up
samples obtained from autologous PBSC patients and allogeneic PBSC donors this
would suggest that instead of increasing CFU-EPC, administration of chemotherapy
overall reduces CFU-EPC.
A number of technical issues that might have affected the CFU-EPC assay were
identified. It was demonstrated that none of these substantially affected the
CFU-EPC results obtained from PBSC donors, and that the effect of G-CSF of
reducing or abolishing CFU-EPC is real and not an artefact.
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Delays in MNC separation might have underestimated the differences in CFU-EPC
between non-mobilised and mobilised samples as delayed MNC separation reduced
CFU-EPC in non-mobilised samples. Prompt MNC separation of mobilised samples
however, failed to improve CFU-EPC in these samples. Colony forming cells were
not retained within the day 2 fibronectin adherent MNC in the CFU-Hill assay at the
expense of CFU-EPC formation in the day 2 non-adherent MNC. Use of
CFU-Hill(direct) assays failed to increase CFU-EPC in day 0 MNC from mobilised
patient samples. Alterations in the media volume used to culture day 2
non-adherent cells failed to increase CFU-EPC in mobilised samples. Similarly,
changing the medium during cell culture failed to increase CFU-EPC in mobilised
MNC. Many MNC contained significant proportions of CD235a+ erythrocytes and
MNC were better enumerated using a Coulter counter, but as it appeared that
CD235a+ erythrocytes were not adversely affecting CFU-EPC formation (Chapter 5),
we did not pursue reduction of erythrocyte levels in CFU-EPC.
One possible interpretation of the decline in CFU-Hill following G-CSF would be
that the reduction in CFU-Hill is caused by the expansion in MNC that occurs after
G-CSF administration, with rare colony forming cells diluted in amongst increased
PB leukocytes. We have observed very similar effects (reductions) of CFU-EPC
frequency in allogeneic PBSC donors and PBSC patients following G-CSF PBSC
mobilisation and think that it is unlikely that a dilution effect explains these
findings. In allogeneic donors, PB leukocyte counts do increase several fold
following G-CSF, from 6.9xl09/L to 48.8xl09/L, (data obtained from section 3.2) and
it is plausible that this might contribute in part to our findings. However, the
decline in CFU-EPC following G-CSF administration to autologous PBSC patients
cannot be attributed to dilution of colony forming cells as PB leukocytes counts
remained within the normal range following G-CSF; PB leukocyte counts increasing
slightly from 5.1xl09/L to 10.7xl09/L during PBSC mobilisation (data obtained from
section 3.3).
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The change in CFU-EPC following PBSC mobilisation and the administration of
G-CSF has been observed independently by a number of members of our group.
Photographs were taken of CFU-EPC cultures to record the colonies and clusters
assessed. These have been reviewed by other group members and similar
conclusions were reached as how to 'score' cell aggregates, based on descriptions by
Hill et al and the Stem Cell Technologies manual. It may be that other research
groups are relying too heavily on immunostaining and cell uptake of ac-LDL or
Ulex Lectin binding, all non specific characteristics, to score a cell cluster as
CFU-EPC rather than to first examine 'colony' morphology to ascertain whether it
meets CFU-EPC definitions. Representative images published in a paper by one
group (163) would not be scored as CFU-EPC as the colonies shown did not have
tight central cores of rounded cells with spindle cells emanating from the edges of
these, described by Hill et al as a CFU-EPC(llO). The images instead show rather
loosely aggregated central cores of rounded cells without spindle cells sprouting
from the periphery. Regardless of whether the cells in these colonies stained for
CD133, VE-Cadherin and VWF, these would not have been scored as CFU-EPC.
These results showing lack of EOC formation in non-mobilised and mobilised MNC
from autologous and allogeneic PBSC donors should be considered preliminary.
Further work is being performed in this area. The ability to generate EOC from UCB
MNC samples that contain lower proportions of CD34+ cells than mobilised MNC
led us to postulate that differences within the CD34+/progenitor cell fraction
between UCB and G-CSF mobilised MNC could be important in EOC formation.
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5. Phenotypic investigation of the alterations in cell
populations present in CFU-EPC culture following
G-CSF administration
5.1. Introduction
The CFU-Hill assay is a commercially available bioassay that has gained
widespread use for the assessment of putative CFU-EPC. Whilst the administration
of G-CSF to promote endothelial regeneration/vasculogenesis has been reported to
produce clinical benefits we have been unable to demonstrate increased (or even
adequate) CFU-EPC formation using G-CSF mobilised peripheral blood samples
and instead have consistently observed a decline in CFU-EPC following G-CSF
(+/-chemotherapy or AMD3100). No technical factors that might have influenced the
results of this study were identified.
G-CSF stimulates myeloid cells to proliferate, causing marked leukocytosis in
normal donors, and to release a variety of enzymes including elastases, proteases
and metalloproteinases, but it also effects on other cell populations including
monocytes. It was hypothesised that G-CSF, through alterations in the
subpopulations of leukocytes in mobilised blood, may have contributed to the
reduction in CFU-EPC. Previous work by our group (136) and others (129, 132, 139,
140) explored and commented on the importance of CD14+ monocytes to early EPC
formation. Based on the increase in PB monocyte counts (in the region of a 3-fold
increase (42, 43)) it would be reasonable to suppose that CD14-dependent CFU-EPC
might also increase in mobilised samples. However, in chapter 4 data was presented
that demonstrated a consistent decline in CFU-EPC following G-CSF. Earlier studies
by our group (136) found that in mobilised patient samples, 2-hour plastic
adherence, performed Lo enrich for CD14^ monocytes, tailed to increase CFU-EPC in
G-CSF mobilised samples, as it did when using non-mobilised samples or UCB.
Studies published on the effects of G-CSF on CFU-EPC (early EPC) formation have
not presented phenotypic data on MNC actually plated into cell culture (162, 163,
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165, 167, 170, 189), arid despite evidence that short term culture of MNC on
fibronectin results in colonies arising from myelomonocytic cells of haematopoietic
origin (93, 96, 130, 131) it is the CD34+ fractions the authors' have quantified and
correlated with CFU-EPC.
The influence of CD14+ monocytes and other leukocyte subpopulations on CFU-EPC
in mobilised MNC was explored by phenotypic analysis of whole blood and MNC
(section 5.2). It was found that the reduction in CFU-EPC in mobilised samples
could not be attributed to any reductions in the proportions of CD14+ monocytes in
MNC following the administration of G-CSF (alone or sequentially with either
chemotherapy or AMD3100) (section 5.2). It has been reported that CFU-EPC may
require, or be influenced by T cells (135, 137, 142) and by a subpopulation of T cells,
termed 'angiogenic' T cells, which have a phenotype CD3+/31+/CXCR4+ (142). The
numbers of angiogenic T cells in healthy subjects were reported to correlate with
early EPC frequency (142). The proportions of whole blood T cells and angiogenic T
cells were measured in PBSC donors to determine whether the decline in CFU-EPC
following G-CSF could be linked to a fall in these cells (section 5.3). The influence of
CD66b+ granulocytes, the leukocyte population most stimulated by G-CSF, on
CFU-EPC was then considered, with the effects on CFU-EPC of manipulating
CD66b+ granulocyte content of MNC examined (sections 5.4-5.6).
5.1.1. Patient samples
Peripheral blood samples were obtained from allogeneic and autologous PBSC
patients on the same 3 occasions (at donor review pre G-CSF, on day 1 PBSC
collection after G-CSF and at donor follow-up 4-6 weeks post G-CSF) as assessed in
chapter 4. The cellular contents of non-mobilised and G-CSF mobilised whole blood
and MNC samples were examined by flow cytometry. MNC were examined at two
time points. The first time point for analysis of MNC was following Histopaque
buoyant density gradient centrifugation of whole blood to obtain MNC (day 0
MNC). After enumeration, day 0 MNC were suspended in CECM and plated into
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the first stage of the CFU-Hill assay or plated into the CFU-Hill(direct) assay. The
second time point for analysis of MNC was on transfer of MNC (usually lxlO6 MNC
in lmL CECM) that were non-adherent after 2 days (48 hours) incubation on 6 or 12
well fibronectin coated plates (day 2 MNC). In this section, day 2 MNC refers
specifically to MNC that were non-adherent to fibronectin after 2 days of
incubation. These cells are identical to the cells re-plated into 24 well fibronectin
plates as part of the CFU-FIill assay. MNC in these wells were inspected for
CFU-EPC development. When plating MNC into CFU-EPC cultures, MNC were
enumerated (cell concentrations) using a haemocytometer counting chamber (early
samples) or a Coulter cell counter (virtually all data presented in this section). Both
cell counting methods excluded erythrocytes from the cell count. When cells were
counted using a haemocytometer, samples (whole blood and MNC) were mixed
with 3% acetic acid to lyse erythrocytes prior to enumeration. Coulter cell counter
settings were set to exclude erythrocytes (and smaller events) from the cell count.
5.1.2. Phenotypic definitions of ceil populations
A live cell gate was established using forward and side light scatter to include all
viable cells. Leukocytes were defined using a combination of light scatter
characteristics, the expression of the pan-leukocyte marker CD45 and expression of
lineage-specific antigens. CD66b+ granulocytes were defined as events gating within
the live cell gate co-expressing CD45 and CD66b (Figure 5.1). CD14* monocytes
were defined as events gating within the live cell gate co-expressing CD45 and
CD14 (Figure 5.1). CD235a+ erythrocytes (red blood cells) were defined as low
forward and side light scatter CD45 events expressing CD235a (Glycophorin A) but
not CD14 or CD66b (Figure 5.2). Lymphocytes were small (low forward and side
light scatter) CD45+ events gating within the live cell gate and not expressing
CD66b, CD14 or CD235a (Figure 5.1). Where events did not fall into one of these 4
defined populations (unclassified events) they were excluded from the analysis.
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Figure 5.1 Phenotyping strategy used to enumerate leukocyte proportions in whole blood.
Non-mobilised PB sample.
Fig 5.1a Forward (FSC) versus side scatter (SSC) (all events), live cell gate (R1) indicated.
Fig 5.1b FSC versus SSC (gated on R1) (indicated in red).
Fig 5.1c CD45 expression (light green) by events gating in R1 region.
Fig 5.1d FSC versus SSC of events defined by R1+CD45 (R2, teal population).
Fig 5.1c CD66b+ granulocytes (pink) (CD66b+ R2 gated events).
Fig 5.1 f CD14+ monocytes (purple) (CD14+ R2 gated events).
Fig 5.1g Lymphocytes (blue) defined by low SSC R2 gated events not expressing CD66b or
CD14.
Fig 5.1h CD45 expression of CD66b+ granulocytes (pink), CD14+ monocytes (purple) and
lymphocytes (blue).
Whole blood samples were analysed to provide information on changes actually
occurring in patients as a result of PBSC mobilisation. MNC samples were analysed
to provide information on the phenotypes of cells, isolated under a specific set of
conditions that were used to assess CFU-EPC formation of the sample. The MNC
transferred into CFU-EPC assays were enumerated using methods that excluded
erythrocytes from the cell count.
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Figure 5.2 Phenotyping strategy used to enumerate CD235a+ erythrocytes in MNC.
Non-mobilised PB sample.
Fig 5.2a Forward (FSC) versus side scatter (SSC) (all events), live cell gate (R1) indicated.
Fig 5.2b CD45 expression (marker) by events gating in R1 region.
Fig 5.2c FSC versus SSC of events defined by R1+CD45 (R2, teal population).
Fig 5.2d CD45 expression of all events (marker) not included in live cell gate (Not R1)
(R3 gated events).
Fig 5.2e CD235a+ erythrocytes within R3 gated events (pink).
Fig 5.2f FSC versus SSC (all events) showing CD235a+ erythrocytes (pink), CD14+
monocytes (purple) and lymphocytes (blue). In this figure no population of CD66b+
granulocytes is visible (accounted for <2% leukocytes).
5.1.3. Data presentation
In the following section (section 5.2) the cell contents of non-mobilised (pre G-CSF)
and mobilised (post G-CSF) samples are compared, with data presented first as
proportions of all events (Table 5.1) and then as proportions of CD45+ leukocytes
(Table 5.2). By expressing data as proportions of CD45+ leukocytes, erythrocytes are
excluded from analysis. Unless otherwise stated, the figures presented refer to cells
expressed as proportions of all events.
















5.2. Changes in leukocyte subpopulations and erythrocytes
following G-CSF+/-chemotherapy
Exposure to G-CSF, given alone or sequentially with chemotherapy, produced
predictable and reversible changes in the cell content of whole blood and MNC
samples (Table 5.1 and Figure 5.3). Overall, autologous and allogeneic PBSC donors
displayed similar changes in the composition of whole blood and MNC samples
following G-CSF but there were differences noted between patient groups.
5.2.1. CD66b+ granulocytes
5.2.1.1. CD66b+ granulocytes in whole blood samples
Analysis of the proportions of CD66b+ granulocytes contained in whole blood
samples from non-mobilised PBSC donors showed that samples obtained from
autologous PBSC patients contained significantly more CD66b+ granulocytes (65.8%)
than allogeneic PBSC donor samples (60.7%, p<0.05) (Table 5.1).
Following G-CSF treatment, the proportions of CD66b+ granulocytes increased
significantly in allogeneic PBSC donor samples (78.3%, p<0.0005) whilst no
alterations in the proportions of whole blood CD66b+ granulocytes were observed in
autologous PBSC patients (65.1%, p=ns) (Table 5.1).
5.2.1.2. CD66b+ granulocytes in MNC samples
Analysis of the proportions of CD66b+ granulocytes contained in day 0 MNC and in
day 2 MNC from non-mobilised blood samples was not significantly different for
allogeneic PBSC donors (2.86% and 2.73% respectively) or autologous PBSC patients
(5.05% and 4.22% respectively). There was no significant difference between the


















Number 13 16 12 11 13 11
CD66b+ granulocytes 60.7% 2.9% 2.7% 78.3% 31.1% 31.3%
CD14+ monocytes 5.2% 10.8% 7.7% 7.5% 20.6% 11.2%
lymphocytes 30.3% 61.9% 71.4% 15.1% 37.3% 38.8%
CD235a* erythrocytes — 11.5% 10.9% — 9.0% 6.7%
Autologous PBSC Patients














Number 38 45 33 35 36 33
CD66b+ granulocytes 65.8% 5.1% 4.2% 65.1% 27.7% 31.2%
CD14+ monocytes 8.4% 13.1% 12.8% 11.3% 11.0% 9.5%
lymphocytes 16.9% 34.4% 44.4% 14.1% 19.2% 21.1%
CD235a+ erythrocytes — 31.3% 25.8% — 34.6% 27.8%
Table 5.1 Distribution of major cell populations within pre G-CSF and mobilised blood.
Samples obtained from allogeneic PBSC donors and autologous PBSC patients undergoing
CFU-EPC culture. Figures are expressed as mean proportions of all events.
The major changes observed following G-CSF were marked increases in the
proportions of CD66b+ granulocytes contained in day 0 MNC and day 2 MNC
(5.5-fold and 6.6-fold increases respectively (all PBSC patients)). Although there was
no change in the proportions of CD66b+ granulocytes in whole blood samples from
autologous PBSC patients following PBSC mobilisation with G-CSF+chemotherapy
compared to non-mobilised samples, significant changes were observed in the
proportions of CD66b+ granulocytes in day 0 and day 2 MNC following PBSC
mobilisation.
The proportions of CD66b+ granulocytes in day 0 MNC increased significantly from
pre G-CSF levels following PBSC mobilisation with G-CSF alone in allogeneic PBSC
donors (p<0.0001) and in autologous PBSC patients mobilised with
G-CSF+chemotherapy (p<0.0001). MNC from mobilised allogeneic PBSC donors
contained 31.1% and 31.3% CD66b+ granulocytes in day 0 and day 2 MNC
respectively, marginally higher than the 27.7% and 31.2% CD66b+ granulocytes
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observed in day 0 MNC and day 2 MNC from mobilised autologous PBSC patient
samples (p=ns for comparisons between PBSC patient groups) (Table 5.1).
5.2.1.3. Changes in proportions of CD66b+ granulocytes between day 0 and
day 2 MNC
No reduction in the proportions of CD66b+ granulocytes contained in MNC from
non-mobilised samples occurred between the time points examined (p=ns for both
allogeneic PBSC donors and autologous PBSC patients). Similarly, there was no
reduction in CD66b+ granulocytes between day 0 MNC and day 2 MNC for G-CSF
mobilised samples from allogeneic PBSC donors (p=ns) or autologous PBSC patients
(p=ns).
5.2.1.4. CD66b+ granulocytes as proportions of CD45+ leukocytes
Analysis of CD66b+ granulocytes as proportions of CD45+ leukocytes in
non-mobilised and G-CSF mobilised MNC showed no statistically significant
differences in proportions of CD66b+ granulocytes between allogeneic and
autologous PBSC donors. For non-mobilised or mobilised allogeneic PBSC donor
samples, analysis of CD66b+ granulocytes as proportions of CD45+ events did not
differ significantly from the analysis as proportions of all events in day 0 and day 2
MNC (p=ns for all comparisons). Analysis showed significant differences in the
proportions of MNC CD66b+ granulocytes from autologous PBSC patient samples
when expressed as proportions of CD45+ leukocytes or proportions of all events
(p<0.03 non-mobilised day 0 MNC, p<0.001 mobilised day 0 MNC, p<0.02 mobilised
day 2 MNC) without a significant difference in the proportions of CD66b+
granulocytes in non-mobilised day 2 MNC (Table 5.2).
5.2.1.5. Comment on differences in CD66b+ granulocytes between
autologous and allogeneic PBSC samples
Non-mobilised samples from autologous PBSC patients contained higher levels of
CD66b+ granulocytes than non-mobilised samples from allogeneic donors. This
could result from patient exposure to chemotherapy/treatment during the patient
referral and review process. At PBSC assessment, most autologous PBSC patients
-152-
were receiving active treatment and patients' leukocyte counts were often
recovering following their most recent chemotherapy. These patients might have
had stimulated and left shifted bone marrows, with the appearance of immature
myeloid (and erythroid) cells in the peripheral blood. These features are similar to
the changes the observed in peripheral blood and morphology following PBSC
mobilisation with G-CSF.
Despite the higher proportions of CD66b+ granulocytes contained in autologous
PBSC patient samples, CFU-EPC were generated by non-mobilised samples from
both allogeneic PBSC donors and autologous PBSC patients. In contrast, G-CSF
mobilised samples from both allogeneic and autologous PBSC patients had severely
reduced (virtually abolished) CFU-EPC. This suggests that if CD66b+ granulocytes
do affect CFU-EPC formation in G-CSF mobilised blood samples that their influence
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Figure 5.3 Proportions of cells present in whole blood, day 0 and day 2 MNC.
Samples obtained from PBSC donors (allogeneic and autologous donors combined) pre G-
CSF, following G-CSF mobilisation and at donor follow-up. Figures are presented as mean
proportions of all events.
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5.2.2. CD14+ monocytes
5.2.2.1. CD14+ monocytes in whole blood samples
Analysis of the proportions of CD14+ monocytes in non-mobilised and G-CSF
mobilised whole blood samples showed statistically significant increases in CD14+
monocytes in mobilised samples for both patient groups compared to
non-mobilised samples (allogeneic PBSC donors p<0.02 and autologous PBSC
patients p<0.002). The proportions of CD14+ monocytes increased from 5.2% to 7.5%
post G-CSF in allogeneic donor samples and from 8.4% to 11.3% in autologous PBSC
patient samples (Table 5.1).
5.2.2.2. CD14* monocytes in MNC samples
Analysis of the proportions of CD14+ monocytes in day 0 and day 2 MNC in
non-mobilised donors showed no significant difference for allogeneic PBSC donors
(10.8% and 7.7%, p=ns) or autologous PBSC patients (13.1% and 12.8%, p=ns). There
were no significant differences in the proportions of CD14+ monocytes between
non-mobilised samples from allogeneic and autologous donor MNC (day 0 MNC
p=ns and day 2 MNC p=ns) (Table 5.1).
Following G-CSF mobilisation, day 0 MNC from allogeneic PBSC donors contained
significantly higher proportions of CD14+ monocytes (20.6%) than non-mobilised
day 0 MNC (10.8%, p<0.005) or G-CSF mobilised day 2 MNC (11.2%, p<0.02). There
were no significant differences in the proportions of CD14+ monocytes in G-CSF
mobilised autologous PBSC patient day 0 MNC (11.0%) compared to non-mobilised
day 0 MNC (13.1%, p=ns) or to mobilised day 2 MNC (9.5%, p=ns) (Table 5.1). Day 0
MNC from mobilised allogeneic PBSC donors contained significantly greater
proportions of CD14+ monocytes than autologous PBSC patient samples (20.6% and
11.0% in allogeneic and autologous PBSC patient samples respectively, p<0.0005).
This difference was not maintained in mobilised day 2 MNC (11.2% and 9.5%
respectively, p=ns).
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5.2.2.3. Changes in CD14+ monocytes between day 0 and day 2 MNC
The proportions of CD14+ monocytes in mobilised allogeneic PBSC MNC decreased
significantly between day 0 and day 2 (p<0.02). This was not noted in
non-mobilised allogeneic PBSC donor samples (p=ns). This could be a reflection of
fibronectin adherent CD14+ monocytes in mobilised allogeneic PBSC donor samples
not present in other patient groups. The reduction in proportions of MNC CD14+
monocytes between day 0 and day 2 MNC from autologous PBSC patients were not
statistically significant (non-mobilised samples p=ns and mobilised samples p=ns).
5.2.2.4. CD14+ monocytes as proportions of CD45+ leukocytes
When considered as proportions of CD45+ leukocytes rather than as proportions of
all events, the proportions of CD14+ monocytes increased significantly in
non-mobilised day 0 MNC (14.3% versus 10.7% for allogeneic day 0 MNC (p<0.05)
and 24.0% versus 13.1% for autologous day 0 MNC (p<0.002)) but not in
non-mobilised day 2 MNC (9.3% versus 7.7% for allogeneic (p=ns) and 17.6% versus
12.8% for autologous PBSC samples (p=ns)) (Table 5.2). There were no significant
changes in the proportions of CD14+ monocytes in mobilised allogeneic PBSC donor
MNC when considered as proportions of CD45+ leukocytes (23.8% versus 20.6% day
0 MNC, p=ns and 12.5% versus 11.2% day 2 MNC, p=ns). The proportions of CD14+
monocytes in mobilised autologous PBSC patient MNC increased significantly
when analysed as proportions of CD45+ leukocytes (19.7% versus 11.0% day 0 MNC
(p<0.0002) and day 2 MNC 15.2% versus 9.5% (p<0.005) (Table 5.2).
Non-mobilised samples from autologous PBSC patients contained significantly
greater proportions of CD14+ monocytes as proportions of CD45+ leukocytes than
allogeneic PBSC donor samples (day 0 MNC 24.0% and 14.3% in autologous and
allogeneic donor samples respectively, p<0.005 and day 2 MNC 17.6% and 9.3%,
p<0.02). The difference between sample groups was not maintained in mobilised
samples. There were no differences in CD14+ monocytes as proportions of CD45+
leukocytes between donor groups for mobilised PBSC in day 0 MNC (23.8% and
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19.7% in allogeneic and autologous patient samples respectively, p=ns) or day 2
MNC (12.5% and 15.2% respectively, p=ns).
Significant reductions in the proportions CD14+ monocytes between day 0 and day 2
MNC occurred in non-mobilised and mobilised allogeneic PBSC donor samples
(p<0.02 and p<0.01 respectively) and non-mobilised autologous patient samples
(p<0.02) but not in mobilised autologous PBSC patient samples (19.7% versus 15.2%
in day 0 and day 2 MNC respectively, p<0.06) (Table 5.2).
Allogeneic PBSC donors
Sample timing Pre G-CSF G-CSF mobilised
Cells examined Day 0 MNC Day 2 MNC Day 0 MNC Day 2 MNC
CD66b* Granulocytes 4.0% 3.5% 35.8% 34.7%
CD14* Monocytes 14.3% 9.3% 23.8% 12.5%
Lymphocytes 81.3% 84.1% 40.4% 44.5%
Autologous PBSC patients
Sample timing Pre G-CSF G-CSF mobilised
Cells examined Day 0 MNC Day 2 MNC Day 0 MNC Day 2 MNC
CD66b* Granulocytes 9.7% 6.4% 44.5% 45.1%
CD14* Monocytes 24.0% 17.6% 19.7% 15.2%
Lymphocytes 63.6% 68.8% 34.6% 33.1%
Table 5.2 Leukocyte subpopulations in non-mobilised and mobilised day 0 and 2 MNC.
Samples obtained from allogeneic and autologous PBSC patients undergoing CFU-EPC
culture. Figures are expressed as mean proportions of CD45+ leukocytes.
5.2.2.4.1. Paired analyses
When the proportion of CD14+ monocytes was assessed using paired analysis there
were significant reductions in CD14+ monocytes as proportions of CD45+ leukocytes
between day 0 and day 2 MNC in non-mobilised samples from autologous PBSC
patients (24.0% versus 17.6%, p<0.02) and allogeneic PBSC donor samples (14.3%
versus 9.3%, p<0.02). A statistically significant reduction in CD14+ monocytes as
proportions of CD45+ leukocytes occurred between day 0 and day 2 MNC in
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mobilised patient samples (autologous 19.7% versus 15.2%, p<0.05 and allogeneic
23.8% versus 12.5%, p<0.005).
5.2.3. CD235a+ erythrocytes
CD235a+ erythrocyte populations, defined as CD45/235a+ events not expressing
CD14 or CD66b (Figure 5.2), were always detected in MNC samples. Whilst these
populations contained some nucleated erythroid precursors, the majority of
CD235a+/45" events were mature erythrocytes that contaminated recovered MNC.
5.2.3.1. CD235a+ erythrocytes in MNC samples
Analysis of the proportions of CD235a+ erythrocytes as proportions of all events
showed that non-mobilised autologous PBSC patient samples contained
significantly greater proportions of CD235a+ erythrocytes (31.3% and 25.8% in day 0
and day 2 MNC respectively) than comparative samples from allogeneic PBSC
donors (11.5% and 10.9% respectively, p<0.0001 and p<0.01). This difference in
CD235a+ erythrocyte content between sample groups was maintained in mobilised
day 0 MNC (9.0% and 34.6% CD235a+ erythrocytes in mobilised day 0 MNC from
allogeneic and autologous PBSC patients respectively, p<0.0001) and day 2 MNC
(6.7% and 27.8% respectively, p<0.005). Within patient groups there was no
difference in the day 0 and day 2 MNC CD235a+ erythrocyte content of
non-mobilised and mobilised samples (p=ns for all comparisons).
5.2.3.2. Changes in CD235a+ erythrocytes between day 0 and day 2 MNC
Both patient groups showed little or no reduction in the proportions of CD235a+
erythrocytes between day 0 and day 2 MNC in non-mobilised and G-CSF mobilised
samples. The proportions of CD235a+ erythrocytes in day 0 and day 2 MNC
allogeneic PBSC donors decreased from 11.5% to 10.9% in non-mobilised MNC
(p=ns) and from 9.0% to 6.7% in mobilised MNC (p=ns). Similar changes were seen
in autologous PBSC patients; CD235a+ erythrocytes decreased from 31.1%, to 25.8%




When the differences between the proportions of CD235a+ erythrocytes in day 0
MNC and day 2 MNC were assessed using paired analysis, there were significant
overall reductions in CD235a+ erythrocyte content between day 0 and day 2 MNC in
non-mobilised and G-CSF mobilised autologous PBSC patient samples
(non-mobilised p<0.005 and mobilised p<0.001, n=31). There were no significant
reductions in the proportions of CD235a+ erythrocytes between day 0 and day 2
MNC in allogeneic donor samples (p=ns for non-mobilised and mobilised samples).
5.2.3.3. CD235a+ erythrocytes as proportions of CD45" events
Overall, CD235a+ erythrocytes accounted for between 48% (non-mobilised
allogeneic PBSC day 0 MNC) and 84% (G-CSF mobilised autologous PBSC day 2
MNC) of CD45" events. Significant proportions of CD45" events remained
'unidentified.' These CD457235a events might have included platelet clumps, cell
debris, necrotic cells or apoptotic cells. The largest populations of CD45/235a-
events were present in non-mobilised day 0 MNC (allogeneic PBSC donors 12.5%
and autologous PBSC patients 13.2%) (Table 5.3).







Day 0 24.0% 12.5%
Day 2 15.6% 4.7%
Autologous
Day 0 44.6% 13.3%




Day 0 13.6% 4.6%
Day 2 11.2% 4.5%
Autologous
Day 0 41.4% 6.8%
Day 2 33.2% 5.4%
Table 5.3 Mean proportions of CD45 /235a" events detected in day 0 and day 2 MNC.
Samples obtained from non-mobilised and mobilised PBSC donors. Figures are expressed
as mean proportions of all events.
5.2.3.4. Comment on differences in proportions of CD235a+ erythrocytes
between autologous and allogeneic PBSC samples
It is unclear why greater proportions of CD235a+ erythrocytes were present in
autologous PBSC patient MNC compared to allogeneic PBSC donor MNC for all
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time points examined. It might be a result of active treatment for their
haematological malignancy or may due to disease-related bone marrow changes.
On microscopic examination erythrocytic elements consisted mainly of mature
erythrocytes with rare nucleated erythrocyte precursors present.
Although autologous PBSC patient samples contained greater numbers of CD235a+
erythrocytes it is probably on balance unlikely that this contributed to the reduction
in CFU-EPC formation observed following G-CSF administration. There were no
significant differences in CD235a+ erythrocytes between non-mobilised and
mobilised samples from autologous PBSC patients (day 0 MNC 31.3% and 34.6% in
non-mobilised and mobilised samples respectively, p=ns, day 2 MNC 25.8% versus
27.8%, p=ns). Similarly, there were no differences in the MNC CD235a+ erythrocyte
content between non-mobilised and mobilised allogeneic PBSC donor samples (day
0 MNC 11.5% versus 9.0%, p=ns, and day 2 MNC 10.9% versus 6.7%, p=ns). Similar
changes (reductions) in CD235a+ erythrocyte content between day 0 and day 2 MNC
were noted for non-mobilised and mobilised samples from both patient groups.
Changes in CD235a+ erythrocyte content alone would not account for the decline in
CFU-EPC formation following G-CSF.
5.2.4. Lymphocytes
5.2.4.1. Lymphocytes in whole blood samples
Analysis of the proportions of lymphocytes in whole blood showed that
non-mobilised samples from allogeneic PBSC donors contained significantly greater
proportions of lymphocytes (30.3%) than comparative samples from autologous
PBSC patients (16.9%, p<0.0001). There was no significant difference between
patient groups in the proportions of lymphocytes contained in G-CSF mobilised
whole blood samples (15.1% and 14.1%, p=ns) (Table 5.1).
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5.2.4.2. Lymphocytes in MNC samples
The proportions of lymphocytes in non-mobilised day 0 and day 2 MNC were
significantly greater in allogeneic PBSC donor MNC (61.9% and 71.4% in day 0 and
day 2 MNC respectively) than autologous PBSC patient MNC (34.4% and 44.4%
respectively, p<0.0001 and p<0.0001). Similarly, mobilised allogeneic donor MNC
contained greater proportions of lymphocytes (37.3% and 38.8% in day 0 and day 2
MNC respectively) than autologous PBSC patient samples (19.2% and 21.1%
respectively, p<0.0001 and p<0.003).
The proportions of lymphocytes in day 0 and day 2 MNC significantly decreased in
allogeneic PBSC donor MNC following G-CSF mobilisation (p<0.0001 for days 0 and
2). Day 0 MNC lymphocytes fell from 61.9% to 37.3% and day 2 MNC lymphocytes
decreased from 71.4 to 38.8% following G-CSF (Table 5.1). The proportions of
lymphocytes in day 0 and day 2 autologous PBSC patient MNC declined
significantly following G-CSF. Compared to non-mobilised autologous patient
samples, mobilised day 0 MNC lymphocytes fell from 34.4% to 19.2% (p<0.0001)
and mobilised day 2 MNC lymphocytes fell from 44.4% to 21.1% (p<0.0001) (Table
5.1).
5.2.4.3. Changes in lymphocytes between day 0 and day 2 MNC
Analysis of the proportions of lymphocytes in non-mobilised day 0 and day 2 MNC
showed a significant increase in lymphocytes for autologous PBSC patient MNC
(p<0.005) but this failed to reach statistical significance for allogeneic PBSC donor
MNC (p<0.06). There were no changes in the proportions of lymphocytes between
day 0 and day 2 MNC in mobilised MNC from either patient group (p=ns).
5.2.4.4. Lymphocytes as proportions of CD45"1" leukocytes
There were significant increases in the proportions of lymphocytes in autologous
PBSC patient MNC (p<0.0001 for day 0 and 2 non-mobilised and mobilised MNC)
and allogeneic donor MNC (p<0.0005 for day 0 and day 2 non-mobilised and
mobilised MNC) when lymphocytes were expressed as proportions of CD45+
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leukocytes rather than of all events (Table 5.2). Non-mobilised allogeneic PBSC
donor MNC contained significantly greater proportions of lymphocytes than
non-mobilised autologous PBSC patient MNC (p<0.0005 for day 0 and day 2 MNC)
with no differences in lymphocytes expressed as proportions of CD45+ leukocytes in
mobilised samples (day 0 MNC, p=ns and day 2 MNC, p=ns) (Table 5.2). Analysis of
lymphocytes as proportions of CD45+ leukocytes showed no significant changes
between day 0 and day 2 MNC in non-mobilised and mobilised MNC from either
patient group.
5.2.5. Comparisons between pre G-CSF and donor follow-up
samples
There were differences observed in the proportions leukocytes and erythrocytes
present in pre mobilisation samples obtained from autologous PBSC patients and
allogeneic PBSC donors. These differences could be due to a number of factors
including the patients' haematological diagnoses and the effects of chemotherapy
on bone marrow haematopoietic activity. If differences in the proportions of
leukocytes and erythrocytes between sample groups became less marked when
patient follow-up samples were compared then this might indicate the influence of
treatment related factors on pre mobilisation samples.
Donor follow-up samples were available for 16 allogeneic PBSC donors and 9
autologous PBSC patients. Follow-up samples from autologous PBSC patients were
obtained after a chemotherapy-free period of 4-6 weeks immediately following
PBSC mobilisation. Analysis of the proportions of leukocyte subpopulations and
CD235a+ erythrocytes in whole blood and MNC showed little differences between
non-mobilised patient samples. There were no significant differences in the pre
mobilisation and donor follow-up samples from allogeneic PBSC donors (p=ns). The
only statistically significant difference between pre mobilisation samples and donor
follow-up samples from autologous PBSC patients was the higher proportions of
CD66b+ granulocytes in follow-up samples (11.2% and 11.0% in day 0 and day 2
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MNC respectively) than pre mobilisation samples (5.1% and 4.2% respectively,
p<0.01 and p<0.01) (Table 5.4 and Figure 5.4). It appears that the differences noted
between pre mobilisation samples from allogeneic and autologous PBSC patients
also exists in follow-up samples, suggesting that even in treatment free periods
there are some differences between these patient groups.
Allogeneic PBSC donors
Time point Whole Blood Day 0 MNC Day 2 MNC
Sample Pre G-CSF Follow-up Pre G-CSF Follow-up Pre G-CSF Follow-up
CD66b+ Granulocytes 60.7% 60.4% 2.9% 1.8% 2.7% 1.7%
CD14+ Monocytes 5.2% 4.9% 10.8% 7.3% 7.7% 5.9%
Lymphocytes 30.3% 27.7% 61.9% 53.3% 71.4% 65.7%
CD235a+ Erythrocytes - - 11.5% 23.0% 10.9% 12.7%
Autologous PBSC patients
Time point Whole Blood Day 0 MNC Day 2 MNC
Sample Pre G-CSF Follow-up Pre G-CSF Follow-up Pre G-CSF Follow-up
CD66b+ Granulocytes 65.8% 73.4% 5.1% 11.2% 4.2% 11.0%
CD14+ Monocytes 8.3% 6.7% 13.1% 10.4% 12.8% 11.6%
Lymphocytes 16.9% 17.7% 34.3% 35.4% 44.4% 39.2%
CD235a+ Erythrocytes - - 31.3% 35.2% 25.8% 32.4%
Table 5.4 Distribution of major cell populations in non-mobilised patient samples.
Pre G-CSF and donor follow-up samples obtained from allogeneic and autologous PBSC




Pre G-CSF G-CSF mobilised Donor follow-up
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.57
Figure 5.4 Changes in cell proportions between day 0 and 2 MNC during CFU-EPC.
Pre G-CSF, mobilised and donor follow-up samples. Legend
Figures are presented as mean proportions of all events. a CD66b+granu|OCytes
Fig 5.4a Allogeneic PBSC donors. m CD14+ M™0^165
Fig 5.4b Autologous PBSC patients. □ Lymphocytes
a CD235a+ Erythrocytes
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5.2.6. Changes in leukocyte subpopulations and erythrocytes
following G-CSF+AMD3100
Samples from autologous PBSC patients mobilised with G-CSF+AMD3100 were
analysed to determine whether mobilised and non-mobilised samples from these
patients contained similar proportions of CD66b+ granulocytes, CD14+ monocytes,
lymphocytes and CD235a+ erythrocytes as those obtained from
G-CSF+/-chemotherapy mobilised autologous PBSC patients (section 5.2.1-5.2.5).
The proportions of leukocyte subpopulations and erythrocytes contained in
peripheral blood and MNC were determined at the same time points, using the
methods and phenotypic definitions outlined in section 5.1.2 (Figure 5.1 and Figure
5.2).
5.2.6.1. Non-mobilised samples
Analysis of the proportions of leukocyte subsets in peripheral blood samples from
non-mobilised patients showed that on average they consisted of 70.0% CD66b+
granulocytes, 9.6% CD14+ monocytes and 16.5% lymphocytes (Table 5.4). Day 0 and
day 2 MNC from non-mobilised patients contained relatively low levels of CD66b+
granulocytes (2.3% and 3.1% in day 0 and day 2 MNC respectively) as well as
considerable CD235a+ erythrocyte contamination (30.3% and 29.5% in day 0 and day
2 MNC respectively). There were little changes in proportions of leukocyte
subpopulations and CD235a+ erythrocytes in non-mobilised samples between day 0
and day 2 MNC (Table 5.5).
The proportions of cells in non-mobilised samples from G-CSF+AMD3100 patients
were not dissimilar to the proportions of cells in non-mobilised samples from G-CSF
autologous PBSC patients and were midway between that seen in non-mobilised
samples from autologous G-CSF+chemotherapy mobilised PBSC patients and
G-CSF mobilised allogeneic PBSC donors. This might reflect the lack of recent
chemotherapy given to these G-CSF+AMD3100 PBSC patients at the time of PBSC
referral.
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5.2.6.2. G-CSF+AMD3100 mobilised samples
Analysis of the proportions of leukocytes subpopulations in G-CSF+AMD3100
mobilised samples showed that peripheral blood samples contained greater
proportions of CD66b+ granulocytes ( 78.8%) with marginally-reduced proportions
of CD14+ monocytes (8.9%) and lymphocytes (10.4%) compared to non-mobilised
samples (Table 5.5). Mobilised day 0 MNC contained significantly greater
proportions of CD66b+ granulocytes than non-mobilised day 0 MNC (20.2% and
2.3% respectively, p<0.02). There was no difference in CD235a+ erythrocyte content
of day 0 mobilised MNC (29.5%) compared to day 0 non-mobilised MNC (29.5%,
p=ns), but mobilised day 0 MNC contained slightly lower proportions of CD14+
monocytes (17.4% and 15.6%, p=ns) and especially lymphocytes than non-mobilised











Whole Blood 4.0 70.0% (72.4) 9.6% (9.8) 16.5% (17.0) —
11 Day 0 MNC 5.2 2.3% (5.1) 17.4% (23.8) 44.8% (65.0) 30.3%
C CO
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Whole Blood 1.9 78.8% (79.2) 8.9% (8.9) 10.4% (10.5) —
Day 0 MNC 6.3 20.2% (29.4) 15.6% (23.9) 28.4% (42.3) 29.5%
S <»
Day 2 MNC 19.3 9.0% (10.8) 32.1% (39.7) 26.0% (31.9) 13.6%
Table 5.5 Leukocytes and erythrocytes in G-CSF+AMD3100 PBSC patient samples.
Non-mobilised and mobilised samples obtained from autologous G-CSF+AMD3100
mobilised PBSC patients. Figures are expressed as mean proportions of all events;
proportions of CD45+ leukocytes in parentheses.
Day 0 and day 2 mobilised MNC differed in their proportions of leukocytes and
CD235a+ erythrocytes. Day 2 MNC contained substantially lower proportions of
CD66b+ granulocytes and CD235+ erythrocytes than day 0 MNC whilst the
proportions of CD14+ monocytes increased (p=ns for all comparisons). The
reduction in proportions of CD66b+ granulocytes and CD235a+ erythrocytes was
accompanied by an increase in 'unclassified events'. The proportions of cells in
G-CSF+AMD3100 mobilised samples were similar to G-CSF mobilised samples from
autologous PBSC patients mobilised with G-CSF+chemotherapy. Mobilised samples
- 166-
from G-CSF+AMD3100 patients contained cell proportions mid-way between those
of mobilised autologous and allogeneic G-CSF mobilised donors (Table 5.6).
Non-mobilised autologous PBSC Patients














CD66b' Granulocytes 65.8% 5.1% 4.2% 70.0% 2.3% 3.1%
CD14' Monocytes 8.4% 13.1% 12.8% 9.6% 17.4% 13.0%
Lymphocytes 16.9% 34.4% 44.4% 16.5% 44.8% 42.4%
CD235a' Erythrocytes — 31.3% 25.8% — 30.3% 29.5%
Mobilised autologous PBSC Patients











MNC Day 2 MNC
CD66b* Granulocytes 65.1% 27.7% 31.2% 78.8% 20.2% 9.0%
CD14+ Monocytes 11.4% 11.0% 9.5% 8.9% 15.6% 32.1%
Lymphocytes 14.1% 19.2% 21.1% 10.4% 28.4% 26.0%
CD235a+ Erythrocytes — 34.6% 27.8% ■— 29.5% 13.6%
Table 5.6 Comparison of leukocytes and erythrocytes between autologous patient groups.
Samples obtained from non-mobilised and G-CSF or G-CSF+AMD3100 mobilised
autologous PBSC patients. Figures are expressed as mean proportions of all events
5.2.6.3. 'Unclassified' events
There were relatively large populations of unclassified events (CD45/235a" or CD45+
but not identified as CD66b+ granulocytes, CD14+ monocytes or lymphocytes) in day
2 MNC, particularly mobilised samples (11.9% in non-mobilised and 19.3% in
mobilised day 2 MNC). There were substantial reductions in the proportions of
CD66b+ granulocytes and CD235a+ erythrocytes in day 2 MNC compared to day 0
MNC in mobilised samples and some of these cells lost from cell populations would
now be included in the population of 'unclassified' events.
5.2.6.4. Conclusions
The changes in proportions of leukocyte subpopulations in whole blood and MNC
samples following PBSC mobilisation with G-CSF+AMD3100 were comparable to
the changes observed following PBSC mobilisation with G-CSF+/-chemotherapy.
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5.2.7. Use of SytoRed to define leukocyte subpopulations and
CD235a+ erythrocytes
SytoRed59 fluorescent nucleic acid staining was performed in order to determine
whether a population of relevant (stem) cells was being overlooked during flow
cytometry analysis when a gating strategies using CD45 were used. SytoRed59 is
one of the members of the Syto dye family of permanent nucleic acid stains that will
stain cytoplasmic, mitochondrial and nuclear elements of eukaryotic cells as well as
most live and permeabilised bacteria. The Syto dyes differ from one another by
characteristics including cell permeability, fluorescence enhancement upon binding
nucleic acids, excitation and emission spectra, DNA/RNA selectivity and binding
affinity. SytoRed59 absorption occurs at 622nm with maximal fluorescence
emission at 645nm, detected in FL4 by the 633nm laser. A 0.05mM SytoRed working
solution, prepared from the neat solution supplied, was used for all experiments in
this section. For the remainder of this section, the term 'SytoRed' and abbreviation
'SR' refers exclusively to the SytoRed59 nucleic acid stain.
SytoRed was used to identify nucleated cells in mobilised and non-mobilised whole
blood and MNC samples obtained from allogeneic or autologous PBSC patients
referred for PBSC mobilisation with G-CSF. Results obtained using SytoRed gating
were compared to those obtained when CD45 was used. MNC were examined at
same two time points, day 0 MNC and day 2 MNC, as described in section 5.1. The 4
main cell populations were defined using the phenotypic definitions as stated in
section 5.1.1, with expression of SR replacing CD45. CD66b+ granulocytes were
defined as events gating within the live cell gate co-expressing CD45 or SR and
CD66b. CD14+ monocytes were defined as events gating within the live cell gate
co-expressing CD45 or SR and CD! 4. CD235a+ erythrocytes were defined as low
forward and side scatter CD45" or SR" (or SRiow) events expressing CD235a
(Glycophorin A) but not CD14 or CD66b. Lymphocytes were small (low forward
and side light scatter) CD45+ or SR+ events gating within the live cell gate and not
expressing CD66b, CD14 or CD235a.
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Patient samples
CD45 staining was directly compared with SR staining in 53 PBSC donor samples
(28 non-mobilised samples (10 whole blood samples, 10 day 0 MNC, 8 day 2 MNC)
and 25 mobilised samples (9 whole blood samples, 8 day 0 MNC, 8 day 2 MNC).
5.2.7.1. Proportions of CD45+ versus SR+ events
There were no significant differences in the proportions of whole blood or MNC
events that were CD45+ or SR+. Overall, the proportions of CD45+ and SR+ events
differed by <2%. Samples containing significant proportions of CD235a+
erythrocytes (poorly-lysed whole blood samples and some MNC) recorded greater
differences between the proportions of CD45+ and SR+ events identified in a sample.
Whole blood leukocytes
Flow cytometric analysis of lysed whole blood samples stained with SytoRed
produced a narrow peak of SR+ cells but when erythrocyte lysis was incomplete, a
narrow peak of SR+ events was present together with a population of erythrocytes
that produced a broader, less intense SR+ peak. Flow cytometric analysis of whole
blood samples stained with CD45 resulted in either a single peak or dual CD45+
peaks (CD45BRIGHT and CD45REG populations). CD66b+ granulocytes were the main
constituents of CD45REG cells with CD14+ monocytes and lymphocytes contained
mainly in the CD45BRIGHT fraction. A single CD45+ peak occurred when a dominant
population of CD66b+ granulocytes swamped CD45BRIGHTcells (Figure 5.5).
Day 0 MNC
SR staining of day 0 MNC was more dispersed across a wider range of fluorescence
intensities, producing a broader single peak of SR+ cells, than whole blood samples.
CD235a+ erythrocytes stained with SR and produced broader and less intense peaks
of activity. Similar to whole blood samples, the distribution of CD45 (and presence
of a single or double (consisting of CD45BR1GHT and CD45REG cells) CD45+
populations) in MNC depended on whether significant CD66b+ granulocytic
populations were present (Figure 5.5).
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Day 2 MNC
SytoRed staining of day 2 MNC was less clean and spread across a wider range of
fluorescence compared Lo day 0 MNC. A lack of distinction between SR+ and SR~
populations was frequently observed, making it more difficult to isolate positive
cells. CD45 staining was also seen to broaden and become less distinct during
CFU-EPC culture but it remained easier to isolate CD45+ from CD45" events (Figure
5.5).
5.2.7.2. Proportions of leukocyte subpopulations and CD235a+ erythrocytes
The proportions of leukocyte subpopulations and CD235a+ erythrocytes gated using
either CD45 or SR to identify nucleated cells was determined in 28 patient samples
(15 whole blood samples, 6 day 0 MNC, 7 day 2 MNC). Analysis of the proportions
of leukocyte subpopulations and CD235a+ erythrocytes contained in whole blood
and MNC samples from non-mobilised and mobilised patients showed no
significant differences between SR gated and CD45 gated events (p=ns for all
comparisons) (Table 5.7).
Non-mobilised samples displayed tighter agreements in the proportions leukocyte
subpopulations identified using SR or CD45. On review, it was apparent this was
the result of difficulties in setting a SR gate in the presence of significant numbers of




Sample Whole Blood Day 0 MNC Day 2 MNC
Antibody SR CD45 SR CD45 SR CD45
Non- mobilised
SytoRed/CD45 96.2% 94.9% 59.1% 57.9% 68.6% 66.9%
CD66b' Granulocytes 52.8% 52.3% 0.8% 0.9% 1.0% 0.8%
CD1T Monocytes 4.9% 4.8% 6.6% 7.1% 6.4% 6.4%
Lymphocytes 19.8% 19.4% 50.4% 48.0% — —-
CD235a* Erythrocytes — — 23.6% 24.9% — —
G-CSF Mobilised
SytoRed/CD45 95.4% 95.5% 65.1% 57.9% 89.8% 90.1%
CD66b* Granulocytes 73.6% 71.5% 27.0% 22.6% 68.0% 68.7%
CD14* Monocytes 11.5% 11.4% 18.1% 19.0% 4.0% 5.0%
Lymphocytes 11.6% 13.3% 25.5% 26.4% —- —
CD235a* Erythrocytes — — 36.1% 36.5% — —
Table 5.7 SytoRed versus CD45 gating of leukocyte subpopulations and erythrocytes.
Non-mobilised and mobilised whole blood and day 0 MNC samples gated using SytoRed
(SR) and CD45. Figures are expressed as mean proportions of all events.
5.2.7.3. Conclusions
The use of SR did not alter the proportions of leukocyte subpopulations detected.
Some of the minor differences in results between CD45 and SR gated cells could be
attributed to difficulties in setting the SR gate in the presence of significant
proportions of CD235a+ erythrocytes. As the morphology of day 0 and day 2 MNC
was not assessed, we do not know whether any SR+ but CD45" CD235a+ erythrocytes
represented populations of nucleated erythrocytes or immature erythrocytes
containing mitochondria and greater amounts of RNA. When SR was used in these
situations it was difficult to cleanly differentiate between SR+ and SR" events and
establish the SR gate. Technical issues overshadowed the use of SR. Difficulties were
caused by deterioration of the SR working solution over time and the intermittent
nature of PBSC donor samples. This resulted in variable intensity of fluorescence of
SR+ events. Intermittent difficulties with the FL4 laser on the flow cytometer,
resulting in failure of detection of FL4 fluorescence (including SytoRed59) occurred.
If this laser problem was not noted during flow cytometry invalid results were
produced for the sample and data was lost. For the remainder of this work the use











Figure 5.5 Changes in CD45 and SR gating during CFU-EPC culture.
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A number of published studies reporting CFU-EPC suggested that in agreement
with work within our group (136), CFU-EPC formation in normal (non-G-CSF
treated) patients is CD14+ monocyte dependent (129, 132, 137, 140). Additionally
there is some evidence that T cells might have important roles in CFU-EPC (135,
137, 142) and that their interactions with CD14+ monocytes could be important in
initiation of CFU-EPC. CFU-EPC are heterogeneous in their cell composition and it
would therefore be reasonable to suggest that changes in the proportions of these
and other leukocyte subpopulations would affect CFU-EPC. The phenotypic
analysis of the changes in cell proportions occurring in whole blood and MNC
following G-CSF administration presented in section 5.2, and summarised in the
table below (Table 5.8), indicated that that the reduction of CFU-EPC following the
G-CSF administration cannot be attributed to reductions in the proportions of CD14+
monocytes in day 0 or day 2 mobilised MNC (Figure 5.4).
Allogeneic PBSC donors
Whole Blood Day 0 MNC Day 2 MNC
CD66b' Granulocytes T* T*
CD14+ Monocytes T* T* t
Lymphocytes I* I*
CD235a* Erythrocytes <-» <-»
Autologous PBSC patients
Whole Blood Day 0 MNC Day 2 MNC
CD66b' Granulocytes <-> T*
CD14* Monocytes "T* <r+ <T+
Lymphocytes I* I*
CD235a* Erythrocytes <r+
Table 5.8 Changes in the proportions of leukocyte subpopulations and CD235a+
erythrocytes following G-CSF PBSC mobilisation.
Figures express the changes in the proportions of all events between non-mobilised and
mobilised whole blood, day 0 MNC and day 2 MNC.
Allogeneic PBSC donors (upper diagram) and autologous PBSC patients (lower diagram),
t = increased, I = decreased, <-» = no change
* = statistically significant difference between non-mobilised and mobilised samples (p<0.05)
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Whole blood samples from allogeneic and autologous PBSC donors contained
significantly greater proportions of CD14+ monocytes compared to non-mobilised
samples. When CD14+ monocytes were considered as proportions of all events, day
0 mobilised MNC from allogeneic PBSC donors contained significantly greater
proportions of CD14+ monocytes than non-mobilised MNC but this difference was
not maintained on analysis of day 2 mobilised MNC. There were no significant
differences in the proportions of CD14+ monocytes in day 0 or day 2 MNC following
G-CSF PBSC mobilisation of autologous PBSC patients. On account of the presence
of considerable proportions of CD235a+ erythrocytes in MNC from autologous
patients, particularly in mobilised samples, CD14+ monocytes as proportions of
CD45+ leukocytes were increased in mobilised autologous MNC compared to
non-mobilised samples. The lack of dependence of CFU-EPC in mobilised MNC on
CD14+ monocytes was suggested by failure of plastic adherence to enhance
CFU-EPC in mobilised MNC as it did for normal blood and UCB (136).
MNC samples from autologous PBSC patients contained significantly greater
proportions of CD235a+ erythrocytes than non-mobilised or G-CSF mobilised
samples obtained from allogeneic PBSC donors (Figure 5.4). There were no changes
in the proportions of CD235a+ erythrocytes between non-mobilised and mobilised
MNC for either allogeneic or autologous PBSC donors, the proposition that the
CD235a+ erythrocyte content alone was not responsible for the reduction in
CFU-EPC following G-CSF administration.
The lymphocyte content of whole blood samples declined following G-CSF. The
decline in whole blood lymphocyte count was minimal in autologous PBSC
patients, largely due to the presence of higher proportions of CD14+ monocytes and
CD66b+ granulocytes in non-mobilised samples from autologous PBSC patients,
possibly the result of recent chemotherapy and recovery of cell counts from their
nadir increasing the relative proportions of CD66b+ granulocytes and CD14+
monocytes. Alternatively, lymphocyte counts may have been reduced secondary to
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chemotherapy or immunotherapy administrated to these haematology patients.
There were clear reductions in MNC lymphocyte content following G-CSF
administration to allogeneic PBSC donors but less marked reductions in autologous
PBSC patient samples. Between day 0 and day 2 of CFU-EPC culture a moderate
increase in MNC lymphocyte content of pre G-CSF samples (allogeneic and
autologous PBSC donors) was observed but less change in lymphocytes occurred
between day 0 and 2 in mobilised samples (Figure 5.4), perhaps due to lack of
dilution on account of lower proportions of fibronectin adherent leukocytes.
The changes in the CD66b+ granulocyte populations were the most significant (and
consistent) change noted between pre G-CSF and mobilised samples. G-CSF
mobilised samples from allogeneic and autologous PBSC donors contained elevated
levels of CD66b+ granulocytes compared to non-mobilised samples. The magnitude
of the CD66b+ granulocyte population was not altered by replating non-adherent
MNC after 2 days of culture (Figure 5.4). Hence day 2 MNC from mobilised samples
also contained high proportions of CD66b+ granulocytes. The actions of G-CSF to
increase myeloid proliferation and stimulate the release of enzymes and other
factors from neutrophils means that it is likely that G-CSF-stimulated granulocytes
within MNC continue to be metabolically active. Through the continued release of
enzymes from granulocytes, these cells could affect cell behaviour and cell
interactions leading to a reduction in CFU-EPC.
No link between the monocyte content of MNC preparations (expressed as absolute
monocytes or expressed proportionally to lymphocytes and granulocytes) and the
potential for CFU-EPC formation in mobilised samples was identified. This means
that, although apparently essential for CFU EPC development, monocytes are
affected by the presence of other cells or soluble factors in cell culture. The wide
variation in CFU-EPC formation observed in normal donors and patients made
correlating CFU-EPC with cell numbers difficult, especially when some
non-mobilised samples failed to generate CFU-EPC. No correlation was found
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between changes in proportions of day 0 or day 2 MNC lymphocytes or CD66b+
granulocytes, for although lymphocytes decreased and CD66b+ granulocytes
increased in mobilised samples, the inter-individual variations in CFU-F.PC and lack
of CFU-EPC development in significant proportions of non mobilised samples made
comparisons difficult.
The most marked change in cell content of MNC post G-CSF was the increase in
granulocytes in MNC preparations, which led to speculation that these cells were
significant in producing the 'G-CSF effect' on CFU-EPC. It was proposed that the
increased granulocytic content of mobilised samples, rather than altered CD14+
monocyte levels, influenced CFU-EPC. This might be a result of the granulocytic
content alone, direct or indirect effects of granulocytes on other cells (monocytes)
through cellular factors or secreted factors (paracrine activity). Subsequent
experiments, selectively enriching and depleting MNC for CD66b+ granulocytes,
explored the role of granulocytes in the reduction of CFU-EPC in mobilised
samples.
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5.3. Changes in T cells and putative angiogenic T cells
following PBSC mobilisation with G-CSF or G-CSF+AMD3100
5.3.1. Introduction
A number of publications have commented on the heterogeneity of the cells
identified within CFU-EPC and have highlighted the presence of monocytes and T
cells in colonies (135, 137) with one group (142) reporting on the importance of a
subpopulation of lymphocytes, so-called 'angiogenic' T cells, to CFU-EPC. The
changes in proportions of CD3+ T cells and angiogenic T cells, defined by the
phenotype CD3+/31+/CXCR4+ (142), following PBSC mobilisation with G-CSF are
presented in section 5.4, with the decline in proportions of PB and MNC
lymphocytes following PBSC mobilisation with G-CSF+/-chemotherapy or
G-CSF+AMD3100 presented earlier (section 5.2). Whole blood samples were stained
with fluorochrome conjugated monoclonal antibodies and treated with FACS lyse
prior to flow cytometric analysis. Lymphocytes were identified as low forward and
side scatter CD45+ cells within the live cell gate not expressing CD66b, CD14 or
CD235a. Angiogenic T cells were low forward and side scatter events within the
live cell gate (i.e. displaying light scatter characteristics of lymphocytes) that
expressed CD45 together with CD3, CD31 and CXCR4. Data was presented as
proportions of all events and proportions of CD3+ T cells. For the data presented in
this section, events identified as CD66b+ granulocytes, CD14+ monocytes and
lymphocytes together accounted for greater than 98% of CD45+ events. The
proportions of angiogenic T cells were determined in whole blood samples. Based
on the relative lymphocyte content of peripheral blood and MNC samples, these
results were extrapolated to day 0 MNC.
5.3.2. Changes occurring following G-CSF+/-chemotherapy
Whole blood angiogenic T cells were evaluated in 27 samples obtained from 17
PBSC patients (2 allogeneic donors and 15 autologous patients) undergoing PBSC
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mobilisation with G-CSF, either given alone or sequentially with chemotherapy.
The results of five samples were excluded from review (22 evaluable samples); due
to spill of fluorescence from FL2 into FL1 and FL3 (an error in CXCR4 staining due
the use of an incorrect fluorochrome-conjugated antibody) (n=4) and too few cells
being present for analysis (n=l).
5.3.2.1. Non-mobilised (pre G-CSF or donor follow-up) PBSC samples
Analysis of the proportions of T cells and angiogenic T cells in non-mobilised PBSC
samples (n=12, 10 pre G-CSF and 2 donor follow-up samples) showed that 14.4% of
events (65.9% of lymphocytes) were CD3+ T cells and that 23.0% of these were
angiogenic T cells (3.2% of all events).
5.3.2.2. G-CSF mobilised PBSC samples
Analysis of the proportions of T cells and angiogenic T cells in
G-CSF+/-chemotherapy mobilised PBSC samples (n=10) showed that 8.6% of events
(62.4% of lymphocytes) CD3+ T cells and that 21.5% of these were angiogenic T cells
(1.8% of all events).
5.3.2.3. Comparison of non-mobilised and G-CSF mobilised samples
Angiogenic T cell numbers (as proportions of CD45+ events) declined significantly
following PBSC mobilisation with G-CSF+/-chemotherapy (3.2% and 1.8% in
non-mobilised and mobilised samples respectively, p<0.01) (Figure 5.6). This can be
attributed to the changes in the relative proportions of leukocyte subpopulations
following G-CSF with significant decreases in lymphocytes (20.7% and 13.1% of
whole blood leukocytes in non-mobilised and mobilised PB respectively, p<0.05)
and CD3+ T cells (14.4% and 8.6% respectively, p<0.01) observed (Table 5.9). When
angiogenic T cells were expressed as proportions of CD3+ T cells, no difference
existed between non-mobilised and G-CSF mobilised patient samples (23.0% and
21.5% respectively, p=ns) (Figure 5.7). The expression of CD45, together with the
proportions of CD3+ T cells, angiogenic T cells and the expression of CD31 and
CXC4 by CD3+ T cells are displayed in Table 5.9.
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Pre G-CSF Mobilised Donor
Follow-up
Timing of sample
Figure 5.6 Changes in angiogenic T cells (as % of leukocytes) following G-CSF.




% CD3+ T cells Angiogenic T cells
%CD31 + %CXCR4+ % all events % T cells
Non-mobilised 14.4 28.9 71.2 3.2 23.0
Mobilised 8.6 30.8 59.1 1.8 21.5
p value <0.01 ns ns <0.01 ns
Table 5.9 Changes in angiogenic T cells and CD3+ T cells post G-CSF+/-chemotherapy.
Angiogenic T cells, CD3+ T cells and T cell expression of CD31 and CXCR4 in non-mobilised
and mobilised whole blood samples obtained from patients receiving G-CSF+/-chemotherapy
for PBSC mobilisation.
p value = comparison between non-mobilised and mobilised samples, Mann-Whitney test,
ns = non significant difference between the analysed populations.
5.3.2.4. Extrapolation to day 0 MNC
The proportions of CD45+ events and lymphocytes in whole blood and day 0 MNC
were used to extrapolate the proportions of PB CD3+ T cells and PB angiogenic T
cells to day 0 MNC in a subset of patients (non-mobilised n=10, mobilised n=8).
Using these figures, non-mobilised day 0 MNC contained 31.8% CD3+ T cells and
5.9% angiogenic T cells (9.7% of CD45+ leukocytes). The proportions of day 0 MNC
CD3+ T cells and angiogenic T cells both declined in mobilised MNC (25.9% and











Figure 5.7 Changes in angiogenic T cells (as % of CD3+ T cells) following G-CSF.
Lack of difference between samples obtained from PBSC patients pre G-CSF, after G-CSF
mobilisation and at donor follow-up.
5.3.3. Changes occurring following G-CSF+AMD3100
Whole blood angiogenic T cells were measured in 12 samples obtained from 6
patients undergoing PBSC mobilisation with G-CSF+AMD3100 (5 pre G-CSF, 5
G-CSF+AMD3100 mobilised and 2 donor follow-up samples) using identical
methods and phenotypic definitions as presented in section 5.4.1.
5.3.3.1. Non-mobilised samples
Analysis of the proportions of angiogenic T cells in non-mobilised samples showed
that 21.2% of CD3+ T cells were angiogenic T cells (1.8% of all events) (Table 5.9).
The proportion of CD3+ T cells that were identified as angiogenic T cells was
comparable to the results obtained from the non-mobilised samples from patients
undergoing PBSC mobilisation with G-CSF+/-chemotherapy (section 5.4.2) (23.0%,
p=ns) but non-mobilised samples from G-CSF+AMD3100 patients contained fewer
CD3+ T cells than non-mobilised samples from G-CSF patients (3.2%, p<0.05).
5.3.3.2. G-CSF+AMD3100 mobilised samples
Analysis of the proportions of angiogenic T cells in G-CSF+AMD3100 mobilised
PBSC samples showed that 2.7% of CD3+ T cells were angiogenic T cells (0.1% of all
events) (Table 5.10). This was significantly different from angiogenic T cells as
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proportions of all events (1.8%, p<0.005) and CD3+ T cells (21.2%, p<0.01) in
non-mobilised G-CSF+AMD3100 PBSC patients. The changes in proportions of
angiogenic T cells following G-CSF+AMD3100 PBSC mobilisation (expressed as
proportions of leukocytes and proportions of CD3+ T cells) are illustrated in Figures
5.8 and 5.9 respectively. The decline in angiogenic T cells was disproportionately






% CD3+ T cells Angiogenic T cells
CD31 + CXCR4+ % all events % T cells
Non-mobilised 9.3 32.5 66.9 1.8 21.2
Mobilised 4.8 37.9 7.0 0.1 2.7
p value <0.02 ns <0.005 <0.005 <0.01
Table 5.10 Changes in angiogenic T cells and CD3+ T cells following G-CSF+AMD3100.
Angiogenic T cells, CD3+T cells and T cell expression of CD31 and CXCR4 in non-mobilised
and mobilised whole blood samples obtained from patients receiving G-CSF+AMD3100 for
PBSC mobilisation.
p valuer comparison between non-mobilised and mobilised samples, Mann-Whitney test,
ns = non significant difference between the analysed populations.
5.3.3.3. Expression of CD31 and CXCR4 on CD3+ T cells
CD31 expression
The CD3+ T cell-expression of CD31 in non-mobilised G-CSF+AMD3100 patients
was equivalent to that of non-mobilised G-CSF patient samples (p=ns). Similarly, the
expression of CD31 by CD3+ T cells in G-CSF+AMD3100 mobilised samples (37.9%)
did not differ from that of non-mobilised G-CSF+AMD3100 patient samples (32.5%,
p=ns) or non-mobilised G-CSF patient samples (28.9%) (p=ns) (Table 5.9).
CXCR4 expression
The CD3+ T cell-expression of CXC4 in non-mobilised G-CSF+AMD3100 patients
was equivalent to that of non-mobilised G-CSF patient samples (p=ns). The
expression of CXCR4 by CD3+ T cells was reduced in G-CSF+AMD3100 mobilised
PBSC samples (7.0%) compared to G-CSF mobilised PBSC samples (59.1%, p<0.001)
and to both non-mobilised G-CSF+AMD3100 (66.9%, p<0.05) and non-mobilised
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G-CSF (71.2%, p<0.005 patient samples (Table 5.9 and Table 5.10). Expression of
CXCR4 was reduced on CD3+ T cells/lymphocytes from G-CSF+AMD3100 mobilised
samples and was also reduced on granulocytes, consistent with the known














































Figure 5.9 Changes angiogenic T cells (as % CD3+ T cells) following G-CSF+AMD3100.
5.3.3.4. Angiogenic T cells in day 0 MNC
The proportions of CD45+ events and lymphocytes in whole blood and day 0 MNC
were used to extrapolate the proportions of PB CD3+ T cells and angiogenic T cells
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to day 0 MNC in a subset of patients (non-mobilised n=4, mobilised n=4). Using
these figures, non-mobilised MNC contained 27.0% CD3+ T cells and 4.7%
angiogenic T cells (7.5% of CD45+ leukocytes) with CD3+ T cells (16.8%) and
angiogenic T cells (0.6%, 1.0% of CD45+ leukocytes) declining in mobilised MNC.
5.3.4. Conclusions
PBSC mobilisation with G-CSF+/-chemotherapy was accompanied by a reduction in
the proportions of lymphocytes, CD3+ T cells and PB angiogenic T cells. However,
when angiogenic T cells were considered as proportions of CD3+ T cells, there was
no difference in the proportions of angiogenic T cells between G-CSF mobilised and
non-mobilised samples. The data presented earlier (sections 5.2.1-5.2.4) showed that
the rise in the granulocytic content of blood samples following PBSC mobilisation
with G-CSF was consistently accompanied by a reduction in the proportions of
lymphocytes in these samples. It would seem that the decrease in angiogenic T cells
in G-CSF mobilised PBSC samples paralleled these changes in leukocyte
subpopulations. Extrapolation of data to day 0 MNC showed that T cells and
angiogenic T cells both declined in mobilised samples. Analysis of PB angiogenic T
cells in G-CSF+AMD3100 mobilised PBSC patient samples showed a profound
reduction in angiogenic T cells following G-CSF+AMD3100. Extrapolation of data to
day 0 MNC showed similar reductions in CD3+ T cells and angiogenic T cells in
mobilised samples. In contrast to the reduction in angiogenic T cells following PBSC
mobilisation with G-CSF+/-chemotherapy, the fall in the proportions of angiogenic T
cells was not secondary to a fall in the proportions of CD3+ T cells alone. The
expression of CD31 by CD3+ T cells was unaltered following G-CSF+AMD3100 but
the expression of CXCR4 by CD3+ T cells was markedly reduced.
Reductions in the proportions of T cells following G-CSF may contribute to falls in
CFU-EPC. It is difficult to attribute the reduction in CFU-EPC formation following
G-CSF+/-chemotherapy or G-CSF+AMD3100 to the decline in angiogenic T cells
alone as changes also occur in lymphocytes and CD3+ T cells.
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5.4. Modification of CFU-EPC by manipulation of the cell
content of cultured cells; Polymorphprep density gradient
centrifugation
MNC recovered following Histopaque density gradient centrifugation of G-CSF
mobilised PB contained significant numbers of CD66b+ granulocytes. In the next
sections, the affects of manipulating the proportions of CD66b+ granulocytes in
MNC on CFU-EPC are presented. The affects of CD66b+ granulocytes on CFU-EPC
was investigated using 3 main techniques to alter the proportions of these cells
plated into CFU-EPC culture;
1. alteration of the cell content of interface layers (granulocyte depletion and
collection of separated granulocytes) by use of alternate density gradient cell
centrifugation techniques (Polymorphprep) (section 5.4);
2. enrichment or depletion for CD66b+ or CD14+ day 0 MNC using
immunomagnetic separation (section 5.5); and
3. depletion of MNC CD66b+ granulocytes by cryopreservation (section 5.6).
5.4.1. Introduction
Whole blood samples underwent buoyant density gradient centrifugation using
Polymorphprep (PMP) (Axis Shield, UK) using the method described in section
2.2.2. PMP separation was performed in lieu of or in addition to standard
Histopaque (1.077g/mL; Sigma Diagnostics, UK) MNC separation. Two interface
layers were obtained with PMP; an upper MNC (MNC-p) layer and a lower
granulocyte-rich (PMN-p) layer. The MNC interface layer produced following
Histopaque density gradient centrifugation of whole blood is referred to as MNC-s
in this and subsequent sections.
Cell concentrations (cell numbers) of recovered cells were determined using a
Coulter cell counter. Coulter cell counter settings were set to exclude erythrocytes
(and smaller events) from the cell count. The cell content of each interface layer
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collected (MNC-s, MNC-p, PMN-p) was determined by flow cytometry. Recovered
cells were plated into a CFU-EPC assay (CFU-Hill or CFU-Hill(direct) assays).
Where cell numbers permitted, mixing studies using different interface layers were
performed and cells were then plated into CFU-Hill(direct) assays.
Figure 5.10 Cell interface layers after Histopaque or PMP density gradient centrifugation.
MNC (and granulocyte) interface layers following density gradient centrifugation of
non-mobilised and mobilised whole blood samples shown.
Fig 5.10a Flistopaque MNC separation of a non-mobilised sample.
Fig 5.10b and 5.10c PMP separation of non-mobilised PBSC patient samples.
(allogeneic Fig 5.10b, autologous Fig 5.10c)
Fig 5.10d and 5.10e PMP separation of G-CSF mobilised samples.
5.4.1.1. Patient samples
Whole blood samples were obtained from 11 subjects (8 allogeneic PBSC donors, 3
autologous PBSC patients) on 3 occasions; pre G-CSF (n=10), after G-CSF
mobilisation (n=3) and at donor follow-up (n=3). Two buffy coat samples from blood
donors were obtained from the SNBTS were also used in these experiments.
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5.4.2. Macroscopic findings
5.4.2.1. Histopaque density gradient centrifuqation
MNC separations of whole blood samples from normal subjects in the absence of
G-CSF (healthy volunteers and non-mobilised allogeneic PBSC donors) usually
produced 'clean' cell separations with a white interface layer situated between
plasma and Histopaque (Figure 5.10a, arrow). Macroscopically apparent erythrocyte
contamination of the interface layer was frequently observed in MNC prepared
from mobilised whole blood samples (and was also sometimes observed following
recent chemotherapy without G-CSF (pre G-CSF samples from autologous PBSC
patients)).
5.4.2.2. PMP density gradient centrifuqation
Considerable erythrocyte contamination was observed when whole blood samples
from normal subjects (non-mobilised allogeneic PBSC donors) underwent PMP
separation. The degree of erythrocyte contamination of MNC-p was
macroscopically much greater than the erythrocyte content of Histopaque-separated
MNC-s (Figures 5.10b and 5.10c, arrows). Even when MNC-p appeared relatively
erythrocyte-free, flow cytometric analysis confirmed the presence of considerably
greater proportions of erythrocytes in MNC-p compared to MNC-s. Following
G-CSF administration, the erythrocyte content of MNC-p and PMN-p increased. A
red 'cell bridge', presumably with high red cell content, was frequently observed
between the layers, making collection of two separate layers of interface cells more
difficult (Figures 5.10d and 5.1 Oe, arrows).
5.4.2.3. Buffy coat preparations from normal donors
PMP separations of buffy coat preparations were unsuccessful. PMP separations
failed to produce distinct MNC-p or PMN-p layers. The bulk of erythrocytes
remained suspended between the PMP and plasma layers following centrifugation
and only a small proportion of erythrocytes passed through the gradient (Figure
5.11).
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Failure of PMP separation to
produce 2 distinct cell layers
Small pellet of red cells
Figure 5.11 Failed Polymorphprep separation of buffy coat specimen.
Failure of PMP separation may have been a result of the high density of the original
buffy coat preparations. Diluting the buffy coat (in PBS) prior to layering it on PMP
might have overcome this. The manufacturers of PMP recommend that density
gradient centrifugation is performed on samples less than four hours old. Buffy coat
preparations were available for use as 'fresh' products. However, these were
separated from whole blood donations received on the previous day and there was
no possibility of obtaining a 'fresher' product. This is probably the main reason for
the failure of PMP separation of buffy coat samples.
5.4.3. Flow cytometry analysis of MNC-s, MNC-p and PMN-p cells
Cell populations were defined phenotypically using identical definitions as used in
section 5.1.2. A live cell gate was set using forward and side light scatter.
Leukocytes were defined using a combination of their light scatter characteristics,
expression of CD45 and expression of lineage-specific antigens (CD66b+
granulocytes and CD14+ monocytes). Erythrocyte lysis was not performed during
antibody staining of MNC as the content of the cell suspension actually being plated
into cell culture was being assessed. CD235a+ erythrocytes were defined as low
forward and side scatter CD45~ events expressing CD235a but not CD66b or CD14.
Lymphocytes were small (low FSC and SSC) CD45+ events gating within the live cell
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gate not expressing CD66b, CD14 or CD235a. Events that did not fall into one of
these 4 defined populations (unclassified events) were excluded from the analysis.
The cell content of MNC-s, MNC-p and PMN-p are presented as mean proportions
of defined events (proportions of the sum of CD66b+ granulocytes, CD14+
monocytes, lymphocytes and CD235a+ erythrocytes). Pre G-CSF and donor
follow-up samples contained similar proportions of leukocyte subpopulations and
CD235a+ erythrocytes and results from these samples are frequently combined into a
single group of non-mobilised samples.
5.4.3.1. MNC (MNC-s and MNC-p) in non-mobilised samples
PMP cell separation of non-mobilised peripheral blood was inferior to Histopaque
density gradient centrifugation. MNC-p contained substantially greater proportions
of CD66b+ granulocytes and CD235a+ erythrocytes and lower levels of lymphocytes
than MNC-s. There was little difference in the CD14+ monocyte content between the
MNC preparations (Figure 5.12). The flow cytometry results of MNC-s (pre G-CSF
samples from 3 allogeneic and 4 autologous PBSC patients) were comparable to the
flow cytometry results presented in section 5.2.
5.4.3.2. PMN-p cells in non-mobilised samples
PMN-p cells were composed principally of CD66b+ granulocytes and CD235a+
erythrocytes (>90% of all events) with very low levels of CD14+ monocytes and
lymphocytes present. PMP cell separation achieved a good separation between the
interface layers in terms of CD14+ monocyte and lymphocyte content but performed
poorly with regard to CD66b+ granulocytes and CD235a+ erythrocytes. The CD235a+
erythrocyte content of MNC-p and PMN-p were considerably greater than the
degree of CD235a+ erythrocyte contamination expected with PMP according to the















CD66b+ granulocytes 37.4% 16.5% 4.3%
CD235a* erythrocytes 57.0% 37.6% 20.1%
CD14+ monocytes 1.2% 9.9% 11.8%
Lymphocytes 4.4% 36.0% 63.8%
Figure 5.12 Day 0 MNC content of non-mobilised MNC-s, MNC-p, PMN-p cells.
Pre or donor follow-up samples obtained from non-mobilised PBSC donor samples.
5.4.3.3. MNC (MNC-s and MNC-p) in mobilised samples
PMP separation of mobilised peripheral blood was inferior to Histopaque density
gradient centrifugation. Similar to the results of non-mobilised samples (section
5.4.3.1) mobilised MNC-p contained greater proportions of CD66b+ granulocytes
and CD235a+ erythrocytes but contained substantially lower levels of CD14+
monocytes and lymphocytes than mobilised MNC-s (Figure 5.13). Flow cytometry
results of MNC-s (3 mobilised allogeneic PBSC donor samples) were comparable to
the flow cytometry results presented in section 5.2.
5.4.3.4. PMN-p cells in mobilised samples
Similar to non-mobilised PMN-p, mobilised PMN-p were composed principally of
CD66b+ granulocytes and CD235a+ erythrocytes (>90% of all events) and very low
levels of CD14+ monocytes and lymphocytes were present. The increase in CD235a+
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(Figure 5.13). As seen in non-mobilised samples (section 5.4.3.2), PMP cell
separation of mobilised samples achieved good separation between the interface
layers in terms of their CD14+ monocyte and lymphocyte content but performed































Cell Type PMN-p MNC-p MNC-s
Numher 3 3 3
CD66b+ granulocytes 23.8% 60.3% 43.1%
CD235a+ erythrocytes 71.5% 27.2% 7.2%
C.D14+ monocytes 1.4% 5.1% 19.5%
Lymphocytes 3.3% 7.4% 30.2%
Figure 5.13 Day 0 MNC content of G-CSF mobilised MNC-s, MNC-p, PMN-p cells.
Samples obtained from 3 G-CGr mobilised dlluyeneio PBSC dunoi samples.
5.4.4. CFU-EPC in PMN-p and MNC-p cells compared to MNC-s
cells
MNC-s, MNC-p and PMN-p cells were enumerated and plated into either CFU-Hill
or CFU-Hill(direct) assays. Comparisons were made between CFU-EPC obtained
from each sample type.
5.4.4.1. CFU-EPC in PMN-p cells
PMN-p cells were counted and plated into CFU-EPC assays in identical fashion to
MNC. Eight non-mobilised PMN-p (7 pre G-CSF samples and 1 donor follow-up
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sample) and 4 mobilised PMN-p (all from 4 allogeneic PBSC donors) were plated
into CFU-EPC culture. No CFU-EPC activity (0 CFU-EPC/106 cells plated) was
recorded in any well containing PMN-p (mobilised or non-mobilised PMP-p).
5.4.4.2. CFU-EPC in MNC-p cells
Pre G-CSF samples from 5 allogeneic donors underwent PMP cell separation and
the resulting MNC-p were plated into CFU-EPC assays. Despite the relatively high
CD66b+ granulocyte and CD235a+ erythrocyte content of MNC-p, non-mobilised
MNC-p showed CFU-EPC activity (mean 12.8 CFU-EPC/106 MNC, n=5). Mobilised
MNC-p samples obtained from 5 allogeneic PBSC donors were plated into
CFU-EPC assays. CFU-EPC activity was virtually absent in these samples (mean 1.4
CFU-EPC/106 MNC, n=5).
5.4.4.3. Changes in CFU-EPC activity in MNC-p cells following G-CSF
When the CFU-EPC in non-mobilised and mobilised MNC-p were assessed, these
displayed the same (transient) decline in CFU-EPC formation following G-CSF
exposure as MNC-s (Figure 5.14). The CFU-EPC activity of MNC-s from 3 allogeneic
PBSC donors that had MNC separated by Histopaque and PMP are shown also in
the figure (dotted lines) to provide comparison data. However, the MNC-p were not
depleted of granulocytes (certainly not when compared to MNC-s) as had been
expected, so this did not give information on the possible effect of granulocytes on
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Figure 5.14 Changes in CFU-EPC frequency in MNC-p and MNC-s cells post G-CSF.
Samples collected pre G-CSF, following G-CSF mobilisation and at donor follow-up.
5.4.5. Co-plating of cells in CFU-EPC assays; direct mixing or
transwell experiments
5.4.5.1. Introduction
A series of co-plating experiments were carried out in order to determine whether
changes in CFU-EPC activity following G-CSF could be attributed to altered
proportions of granulocytes, the experiments were also to assess whether the
'G-CSF effect' on CFU-EPC formation was due to the presence of contaminating
cells (granulocytes) or restricted to the presence of 'mobilised granulocytes (or other
cell populations). Non-mobilised patient samples were used in most of these
co-plating experiments as non-mobilised MNC had greater chances of generating
CFU-EPC than mobilised MNC. One could therefore more readily see changes in
CFU-EPC formation.
5.4.5.2. Cell separation
Whole blood samples underwent Histopaque and/or PMP density gradient
centrifugation to obtain MNC and CD66b+ granulocyte-rich cells. The flow
cytometric analysis of PMP separated MNC-p and PMN-p was presented in section
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5.4.3. The MNC-p and PMN-p used in these co-plating experiments contained very
similar levels of CD66b+ granulocytes, CD14+ monocytes, lymphocytes and CD235a+
erythrocytes to these cells.
MNC were depleted for CD66b+ granulocytes by MACS microbead
immunomagnetic separation using an indirect labelling technique. Aliquots of
non-mobilised MNC were first stained with anti-CD66b-FITC monoclonal antibody
and then labelled with anti-FITC microbeads, as outlined in section 2.2.4.2.
CD66b-depleted MNC were used in co-plating experiments. One of the issues
concerning use of MACS microbead depleted MNC fractions is that although
enriched MNC fractions consist of relatively pure cell populations, antigen depleted
MNC contain mixtures of the remaining (antigen negative) cells as well as residual
antigen positive cells. These antigen positive cells may not have stained with the
antibody or with microbeads or were not removed by the magnetic columns.
5.4.5.3. Cell numbers used for CFU-EPC assays
When cell fractions were plated together into CFU-Hill assays, a total of 3xl06 cells
were suspended in 1.5mL of CECM in a well of a 12 well fibronectin coated plate as
day 0 MNC. 'Primary' cells were suspended in CECM and added to the well.
Secondary cells were then added without delay and the well contents were mixed
by gentle aspiration with a pipette. Following 2 days incubation, the non-adherent
day 2 cells were collected and lxlO6 cells were transferred in lmL CECM to 24 well
fibronectin coated plates (day 2 MNC).
When cell fractions were plated together into CFU-Hill(direct) assays up to 1.5x106
cells (1.0-1.5xl06 cells) were suspended in lmL of CECM and plated into a well of a
24 well fibronectin coated plate. Generally lxlO6 'primary' cells were added to the
well with CECM. The second cell fraction (0.25xl06 or 0.5x106 of secondary cells)
was added without delay and the well contents were mixed by gentle aspiration
with a pipette.
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When secondary cells were added to the primary cells in a 24 well fibronectin
coated plate in a ThinCert™ insert, lxlO6 primary cells suspended in 0 8mL CECM
were first added to the well. The ThinCert™ insert was carefully placed over the
well containing primary cells and then the chosen number (0.25xl06 or 0.5x106) of
secondary cells suspended in 0.2mL of CECM were added to the insert.
Either 0.25x106 or 0.5xl06 secondary cells were added to the primary cells. These
ratios were chosen on the basis of the analysis of the proportions of CD66b+
granulocytes in mobilised day 0 MNC, whereby mixing of lxl06MNC and 0.5xl06
PMN-p might result in CD66b+ granulocyte content close to 30%.
5.4.5.4. Co-platinq experiments using cell fractions obtained from the same
donor
5.4.5.4.1. Co-plating MNC-p cells with PMN-p cells
Non-mobilised whole blood samples from 3 allogeneic PBSC donors underwent
PMP separation to yield MNC-p and PMN-p fractions. In these experiments MNC-p
were co-plated with PMN-p (Table 5.11).
CFU-EPC formation in MNC-p and PMN-p cells
When plated alone, 3 of 3 PMN-p failed to generate CFU-EPC (0 CFU-EPC/106 cells).
Two of the 3 MNC-p generated CFU-EPC (Table 5.11).
MNC-p cells plus PMN-p cells
Addition of PMN-p to MNC-p resulted in clear reductions in CFU-EPC formation.
This occurred when PMN-p were added directly to the MNC-p in the well or were
separated from them using ThinCert™ inserts. No evidence of a dosing effect of
PMN-p could be seen in these experiments (Table 5.11).
The sample that generated no CFU-EPC from MNC-p also failed to generate any
colonies (0 CFU-EPC/106 cells) on the addition of PMN-p to the culture wells.
Subsequent samples from this patient (mobilised and donor follow-up samples) also
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failed to generate CFU-EPC from MNC-p or MNC-s. This suggested that patient
factors rather than experimental or technical factors resulted in the lack of CFU-EPC
formation in the sample obtained pre G-CSF mobilisation (Table 5.11).
5.4.5.4.2. Co-plating MNC-s cells with PMN-p cells
Non-mobilised whole blood samples from 4 PBSC donors (1 autologous and 3
allogeneic) underwent PMP separation to yield MNC-p and PMN-p fractions as
well as Histopaque separation to yield MNC-s, which were co-plated with PMN-p
(Table 5.12 and Table 5.13).
MNC-s were chosen for co-plating rather than MNC-p as MNC-s fractions
contained lower proportions of CD66b+ granulocytes and CD235a+ erythrocytes.
This meant that when co-plating MNC with PMN-p the differences in the cell
content between primary and secondary cells was maximised by using MNC-s
(Table 5.12 and Table 5.13).
CFU-EPC formation in MNC-s cells and PMN-p cells
When plated alone, all (3 of 3) PMN-p failed to generate CFU-EPC (0 CFU-EPC/106
cells). Three of the 4 MNC-s samples generated CFU-EPC (Table 5.12 and Table
5.13).
MNC-s cells plus PMN-p cells
PMN-p were added directly to the culture wells containing MNC-s and were also
added in ThinCert™ inserts so to remain separated from MNC-s. Addition of
PMN-p to MNC-s resulted in clear reductions (or abolition) of CFU-EPC formation
(assessed by either CFU-Hill or CFU-Hill(direct) assays). This change in CFU-EPC
formation occurred when PMN-p were added to wells in a ThinCert™ insert or
when PMN-p were mixed directly with MNC-s in the culture well (Table 5.12 and
Table 5.13). The patient sample that failed to generate CFU-EPC from MNC-s also
failed to generate CFU-EPC when MNC-s were co-plating with PMN-p.
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MNC-s cells plus MNC-s cells
In 3 of the 4 experiments, additional MNC-s were introduced to the culture well in
ThinCert™ inserts. The level of CFU-EPC activity generated in these wells was
virtually identical to that observed when MNC-s were plated alone (Table 5.12 and
Table 5.13). MNC-s from one patient failed to generate CFU-EPC. None of the
co-plating experiments performed using this patient sample generated CFU-EPC.
5.4.5.4.3. Co-plating of mobilised MNC-s cells with CD66b-depleted MNC
Mobilised whole blood samples from 5 PBSC donors (4 autologous and 1 allogeneic)
underwent Histopaque separation to yield MNC-s. An aliquot of each mobilised
MNC-s then underwent CD66b depletion using MACS microbead separation
(CD66b-depleted MNC) (Table 5.14) (section 2.4.2.2).
These experiments co-plated MNC-s together with CD66b-depleted MNC. Cell
fractions were plated into wells using the same ratios of MNC to
granulocyte-enriched fractions as described in section 5.5.5.3. In one case MNC-s
were also plated together with CD66b-enriched MNC.
CD66b+ granulocyte content of MNC-s and CD66b-depleted MNC
The change in CD66b+ granulocyte content of CD66b-depleted MNC from the levels
contained in MNC-s was variable and often surprisingly marginal. MNC-s
contained 22.8% (8.2-33.1% of all events). Following CD66b depletion by MACS, the
CD66b-deplete MNC contained an average 14.0% CD66b+ granulocytes (range
7.63%-25.0%), a mean reduction of 8.8% (range 0.6%-24.5% of all events) and mean
relative reduction of 38.6%. When proportions were corrected to take into account
any populations of unclassified events, slight differences are noted in the values.
The mean reduction in the proportions of CD66b+ granulocytes was then 32.6%
(Figure 5.15).
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CFU-EPC activity of mobilised MNC-s cells
Four of 5 mobilised MNC-s failed to generate any CFU-EPC (0 CFU-EPC/105 MNC).
One mobilised MNC-s showed 12 CFU-EPC/106 MNC. No non-mobilised samples
were available for that patient (Table 5.14).
CFU-EPC activity of CD66b-depleted MNC
Two of 5 CD66b-depleted MNC formed CFU-EPC when cells were plated into
CFU-EIill(direct) assays. Of note, CD66b-depleted cells that showed the greatest
reduction in CD66b+ granulocyte content from the levels contained in the mobilised
MNC-s were the cells to show some CFU-EPC activity. Matched non-mobilised (all
pre G-CSF) samples were available for 4 patients. All (4 of 4) non-mobilised MNC-s
generated CFU-EPC. There appeared to be no correlation between the numbers of
CFU-EPC from non-mobilised samples and CFU-EPC from mobilised


































CD66b+ Granulocytes 22.8% (23.3) 14.0% (15.7)
CD14+ Monocytes 14.7% (15.0) 14.5% (16.3)
Lymphocytes 31.2% (31.8) 32.1% (36.1)
CD235a+ Erythrocytes 29.3% (29.9) 28.3% (31.8)
Figure 5.15 Leukocyte subpopulations and erythrocytes in MNC-s and CD66b-depleted
mobilised MNC.
Expressed as mean proportions of all events; proportions of CD45+ cells in parentheses.
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Mobilised MNC-s cells plus CD66b-depleted MNC
Co-plating MNC-s with CD66b-depleted MNC produced CFU-EPC activity in 2
cases. This included one sample that generated CFU-EPC when CD66b-depleted
MNC were plated alone in CFU-EPC assay and one sample that did not (Table 5.14).
Mobilised MNC-s cells plus CD66b-enriched MNC
On one occasion MNC-s were also co-plated with the CD66b-enriched MNC. No
CFU-EPC formation was recorded, as was seen when the fractions were plated
alone into CFU-Hill(direct) assays (Table 5.14).
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Details CFU-EPC activity MNC- p or PMN-p CFU-EPC activity MNC-p plus PMN-p
Sample 240 240 240 240 240 240 240
Primary cells
(x106) 1.0 MNC-p
0.25 PMN-p 0.5 PMN-p 1.0 MNC-p 1.0 MNC-p 1.0 MNC-p 1.0 MNC-p
Secondary cells
(x10 )
— — — 0.25 PMN-p 0.5 PMN-p 0.25 PMN-p 0.5 PMN-p
Well set-up Standard Standard Standard Standard Standard Transwell Transwell
CFU-EPC per
106 cells 70 0 0 45 55 45 42
Details CFU-EPC activity MNC-p or PMN-p CFU-EPC activity MNC-p plus PMN-p
Sample 241 241 241 241 241 241 241
Primary cells
(x106) 1.0 MNC-p 0.25 PMN-p 0.5 PMN-p 1.0 MNC-p 1.0 MNC-p 1.0 MNC-p 1.0 MNC-p
Secondary cells
(x1 0®)
— — — 0.25 PMN-p 0.5 PMN-p 0.25 PMN-p 0.5 PMN-p
Well set-up Standard Standard Standard Standard Standard Transwell Transwell
CFU-EPC per
106 cells 0 0 0 0 0 0 0
Details CFU-EPC activity MNC-p CFU-EPC activity MNC-p plus PMN-p
Sample 242 242 242 242 242 242 242
Primary cells
(x10s) 3.0 MNC-p 3.0 MNC-p 1.0 MNC-p 1.0 MNC-p 1.0 MNC-p 1.0 MNC-p 1.0 MNC-p
Secondary cells
(x10 )
— — — 0.25 PMN-p 0.5 PMN-p 0.25 PMN-p 0.5 PMN-p
D0/D2 MNC Day 2 NA1.0 MNC-p
Day 2
Adherent Day 0 Day 0 Day 0 Day 0 Day 0
Well set-up Standard Standard Standard Standard Standard Transwell Transwell
CFU-EPC per
106 cells 6 0 0 0 0 0 0
Table 5.11 Results of co-plating non-mobilised MNC-p with PMN-p cells (section 5.4.5.4.1).
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Details CFU-EPC activity MNC-s CFU-EPC activit / MNC-s plus PMN-p or MNC-s
Sample 288 288 288 288 288 288
Primary cells
(x106) 3.0 MNC-s 3.0 MNC-s 1.0 MNC-s 1.0 MNC-s 1.0 MNC-s 1.0 MNC-s
Secondary
cells (x10 )






Adherent Day 0 Day 0 Day 0 Day 0
Well set-up Standard Standard Standard Transwell Transwell Standard
CFU-EPC
per 106 cells 5 0 3 4 0 0
Details CFU-EPC activity MNC-s CFU-EPC activit / MNC-s plus PMN-p or MNC-s
Sample 293 293 293 293 293 293
Primary cells










Adherent Day 0 Day 0 Day 0 Day 0
Well set-up Standard Standard Standard Transwell Transwell Standard
CFU-EPC
per 106 cells 0 0 0 0 0 0
Details CFU-EPC activity MNC-s CFU-EPC activity MNC-s plus PMN-p or MNC-s






































Adherent Day 0 Day 0 Day 0
Well set-up Standard Standard Standard Standard Standard Transwell Transwell Transwell
CFU-EPC per
106 cells 2 0 5 0 0 1 0 4
Table 5.12 Results of co-plating of non-mobilised MNC-s with PMN-p cells
(section 5.6.5.4.2).
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Details CFU-EPC activity MNC-s CFU-EPC activity MNC-s plus PMN-p or MNC-s
Sample 294 294 294 294 294 294
Primary cells
(x109) 3.0 MNC-s 3.0 MNC-s 2.0 MNC-s 2.0 MNC-s 1.0 MNC-s 1.0 MNC-s
Secondanr
cells (x10 )
1.0 PMN-p 1.0 MNC-s 2.0 PMN-p 2.0 PMN-p











Well set-up Standard Standard Standard Standard Standard Standard
CFU-EPC per
106 cells 2 0 0 0 3 0

















































































































29.4 1 0 0 2
Table 5.14 Results of co-plating mobilised MNC-s with mobilised CD66b-depleted MNC
(section 5.4.5.4.3).
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5.4.5.5. Co-plating experiments - cell fractions obtained from different
patients (PBSC donor and non PBSC sources)
5.4.5.5.1. Co-plating non-mobilised donor MNC-p or PMN-p cells with buffy
coat MNC-s cells
Non-mobilised (all pre G-CSF) samples from 3 allogeneic PBSC donors underwent
PMP separation of whole blood to obtain donor MNC-p and donor PMN-p. Buffy
coat cells underwent Histopaque density gradient centrifugation to yield MNC-s
(BC MNC-s). Donor MNC-p or donor PMN-p were plated together with BC MNC-s
into CFU-EPC assays. BC MNC-s were always plated into the culture wells as the
primary cells. Due to concerns about the immune compatibility of samples, MNC-p
were not mixed directly with BC MNC-s and were added to BC MNC-s in
ThinCert™ inserts. Instead, due to the low lymphocyte count of PMN-p, these cells
were either mixed directly with BC MNC-s or added in ThinCert™ inserts (Table
5.15).
CFU-EPC development in BC MNC-s cells
Of the 2 buffy coat samples used in these experiments, one failed to generate
CFU-EPC when BC MNC-s were plated alone into a CFU-Hill(direct) assay. This
was considered an aberrant result and was judged as a technical failure due to the
use of an aged fibronectin coated plate in the CFU-EPC assay. BC MNC-s from this
sample plated into other CFU-Hill(direct) assays and day 2 MNC from the second
stage of CFU-Flill assay were plated into a fresh 24 well fibronectin coated plate (the
same plate for all) and CFU-EPC formation was observed in these wells. The results
of BC MNC-s plated into the CFU-Hill have been used as the figure for BC MNC-s
CFU-EPC in experiments using this buffy coat sample (Table 5.15).
BC MNC-s from the other buffy coat sample generated CFU-EPC in the CFU-Flill
and CFU-Hill(direct) assays.
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Donor PMN-p cells plus BC MNC-s cells
The addition of donor PMN-p directly to BC MNC-s produced different effects on
CFU-EPC formation than the addition of donor PMP-p to BC MNC-s in ThinCert™
well inserts.
The addition of donor PMN-p directly to BC MNC-s appeared to negatively affect
the rate of CFU-EPC formation overall. Two of 3 experiments showed reduced
CFU-EPC formation on the addition of donor PMN-p directly to a well containing
BC MNC-s. CFU-EPC formation was reduced from BC MNC-s levels but it was not
abolished. The remaining experiment showed no negative effects of the direct
introduction of donor PMN-p on CFU-EPC formation (Table 5.15).
The rates of CFU-EPC formation increased from that observed when BC MNC-s
were plated alone into culture wells (CFU-Hill or CFU-Hill(direct) assays) when
donor PMN-p were added to BC MNC-s in ThinCert™ well inserts (3 of 3 cases)
(Table 5.15).
Donor MNC-p cells plus BC MNC-s cells
The addition of donor MNC-p to BC MNC-s in ThinCert™ well inserts produced no
demonstrable negative effect on CFU-EPC formation. In one case CFU-EPC
formation substantially exceeded (doubled) that of BC MNC-s CFU-EPC. In the
other 2 cases, the density of CFU-EPC in the wells containing donor MNC-p plus BC
MNC-s was marginally higher than seen in wells containing BC MNC-s plated alone
but lower than the CFU-EPC activity of donor PMN-p plus BC MNC-s (using
ThinCert™ inserts) wells (Table 5.15).
5.4.5.5.2. Co-plating non-mobilised patient MNC-s or PMN-p cells with
volunteer donor MNC-s cells
Two freshly collected whole blood samples were used in this co-plating experiment.
This was to overcome any effect on CFU-EPC formation produced from using buffy
coat MNC-s (which are 24 hours old when they are released for use) in experiments.
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A non-mobilised (pre G-CSF) whole blood sample from an autologous PBSC patient
underwent PMP separation to yield patient MNC-p and patient PMN-p as well as
Histopaque separation to yield patient MNC-s. The same cell separations were
performed on a whole blood sample from a volunteer (non PBSC donor) resulting in
volunteer MNC-s, volunteer MNC-p and volunteer PMN-p. These co-plating
experiments plated various combinations of patient MNC-s, volunteer MNC-s and
patient PMN-p. Patient cells were added to volunteer MNC-s using ThinCert™
inserts. Cells were not mixed together in the culture wells (Table 5.16).
CFU-EPC activity of MNC-s or PMN-p cells
Both patient MNC-s and volunteer MNC-s generated CFU-EPC when MNC-s were
plated alone into CFU-Hill(direct) assays. Volunteer MNC-s developed more
colonies than patient cells (8 CFU-EPC/106 cells versus 2 CFU-EPC/106 cells
respectively) perhaps a reflection of effects of chemotherapy or disease related
factors in CFU-EPC in this patient (Table 5.16). Only patient (and not volunteer)
PMN-p were plated into CFU-EPC assays. No CFU-EPC formation was observed in
patient PMN-p.
Patient MNC-s cells with volunteer MNC-s cells
The addition of patient MNC-s to volunteer MNC-s increased CFU-EPC formation
from that of volunteer MNC-s alone. Greater numbers of CFU-EPC were generated
in the well that contained the higher concentration (and number) MNC. The level of
CFU-EPC formation in these wells fell below that observed in a control well, where
additional volunteer MNC-s (also using ThinCert™ inserts) were added to a well
containing volunteer MNC-s (Table 5.16).
When considering the CFU-EPC formation in MNC-s, the level of CFU-EPC
formation in the co-plated wells (patient MNC-s plus BC MNC-s) was in excess of
the expected colony formation.
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Patient PMN-p cells plus volunteer MNC-s cells
Similar to the previous co-plating experiments using BC MNC-s and donor PMP-p,
CFU-EPC formation increased when patient PMN-p were added to volunteer
MNC-s. The rate of CFU-EPC formation was above that observed in the wells
containing patient MNC-s and volunteer MNC-s. No control wells, where volunteer
PMN-p were plated with volunteer MNC-s, were performed (Table 5.16).
5.4.5.5.3. Co-plating of mobilised PBSC donor MNC-s with buffy coat MNC-s
cells
A mobilised whole blood sample from an allogeneic PBSC donor underwent
Histopaque density gradient centrifugation to yield donor MNC-s. Buffy coat cells
from two different blood donors underwent Histopaque density gradient
centrifugation to yield MNC-s in addition to undergoing PMP separation. PMP
separation failed to work (section 5.4.2.3).
BC MNC-s were plated into the culture wells as the primary cells. Due to concerns
about the immune compatibility of samples, donor or buffy coat cells were not
directly mixed with BC MNC-s but were added to wells in ThinCert™ inserts (Table
5.17).
CFU-EPC formation in post G-CSF donor and BC MNC-s cells
BC MNC-s from both buffy coat specimens generated CFU-EPC from
CFU-Hill(direct) assays. Both recorded 6 CFU-EPC/106 MNC. Mobilised donor
MNC-s did not generate colonies (0 CFU-EPC/106 MNC) (Table 5.17).
Post G-CSF donor MNC-s cells plus BC MNC-s cells
Three of the four culture wells containing BC MNC-s and mobilised donor MNC-s
recorded reductions in CFU-EPC formation from that of BC MNC-s plated alone.
Mixed results were obtained for one buffy coat specimen that showed reduced
CFU-EPC formation (compared to BC MNC-s plated alone) when low dose
mobilised donor MNC-s were co-plated with BC MNC-s at and increased CFU-EPC
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when greater numbers of donor MNC-s were co-plated with BC MNC-s. This result
is not readily explainable (Table 5.17).
No control wells, where additional BC MNC-s were plated together with BC MNC-s
or additional donor MNC-s were plated together with donor MNC-s were set up in
this experiment. The use of mobilised MNC-s cells as primary cells, adding BC
MNC-s in ThinCert™ inserts as secondary cells, may have provided some
interesting additional information on the influence of non-mobilised cells on
mobilised MNC.
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D0/D2 MNC Day 2 NA Day 0 Day 0 Day 0 Day 0 Day 0 Day 0 Day 0
Well set-up Standard Standard Standard Standard Transwell Transwell Transwell Transwell
CFU-EPC per
106 cells 35 25 48 42 45 36+ 55 49


































D0/D2 MNC Day 2 NA Day 0 Day 0 Day 0 Day 0 Day 0 Day 0 Day 0
Well set-up Standard Standard Standard Standard Transwell Transwell Transwell Transwell
CFU-EPC per
106 cells 16 0* 6 3 23 20 10 15


































D0/D2 MNC Day 2 NA Day 0 Day 0 Day 0 Day 0 Day 0 Day 0 Day 0
Well set-up Standard Standard Standard Standard Transwell Transwell Transwell Transwell
CFU-EPC per
106 cells 16 0* 10 3 42 35 25 25







































Well set-up Standard Standard Standard Transwell Transwell Transwell Transwell Transwell
CFU-EPC per
106 cells 0 2 8 18 17 12 15 28
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Well set-up Standard Standard Standard Standard Transwell Transwell Transwell Transwell
CFU-EPC per










Table 5.16 Results of co-plating non-mobilised patient MNC-s with volunteer MNC-s
(section 5.4.5.5.2).
Details CFU-EPC activity MNC-s BC MNC-s plus MNC-s



























Well set-up Standard Standard Standard Transwell Transwell Transwell Transwell
CFU-EPC per

















PMN-p obtained from PMP separation of whole blood samples from non-mobilised
or G-CSF mobilised PBSC patients consistently failed to generate CFU-EPC (0
CFU-EPC/106 cells), suggesting that CD66b+ granulocytes do not participate in
CFU-EPC. However it remains unclear as to whether (non-mobilised or G-CSF
mobilised) PMN-p could influence CFU-EPC formation by other cells. Summarised
results of co-plating experiments performed using MNC and PNN-p are presented
below (Table 5.18).
Cell sources G-CSF Primarycelts
Secondary cells
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Table 5.18 Summarised results from co-plating experiments (sections 5.4.5.4, 5.4.5.5).
Legend: 0 = no CFU-EPC, t = increased, 1 = decreased, <-» = no change
Std = cells mixed together, T/well = secondary cells added in a Thinsert™ insert
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When primary and secondary cells were obtained from the same donor, the
addition of non-mobilised MNC to non-mobilised MNC in a ThinCert™ insert did
not affect CFU-EPC. In contrast, when primary and secondary cells were obtained
from different donors, the addition of non-mobilised MNC to non-mobilised MNC
in a ThinCert™ insert increased CFU-EPC whilst the addition of mobilised MNC to
non-mobilised MNC had the opposite effect on CFIJ-EPC.
The addition of PMN to culture wells affected CFU-EPC differently to MNC. When
both primary and secondary cells came from the same donor, addition of
non-mobilised PMN-p to non-mobilised MNC reduced CFU-EPC, regardless of
whether cells were directly mixed or added to MNC in ThinCert™ inserts. In
contrast, when primary and secondary cells were sourced from different donors, the
addition of non-mobilised PMN-p to non-mobilised MNC reduced CFU-EPC when
cells were directly mixed but increased CFU-EPC were observed when PMN-p were
added in ThinCert™ inserts. However, when mobilised PMN-p were added to
non-mobilised MNC from another patient in ThinCert™ inserts CFU-EPC were
reduced. Co-plating experiments that plated mobilised MNC and mobilised
CD66b-depleted mobilised MNC from the same patient had the opposite effect and
increased CFU-EPC were observed.
These results showed that CFU-EPC can be manipulated by altering the proportions
of CD66b+ granulocytes in cells plated into the CFU-EPC assay. The results
suggested that even in samples from non-mobilised patients, the degree of
'contamination' of the interface layer by CD66b+ granulocytes affected CFU-EPC;
whether this was due to the physical presence of granulocytes in the well or due to
secreted granulocytic factors that affected CFU-EPC. Further work to examine the
influence of leukocyte subpopulations on CFU-EPC formation in mobilised and
non-mobilised PBSC patient samples was performed using MACS microbead
separation methods.
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5.5. Modification of CFU-EPC by manipulation of the cell
content of cultured cells; immunomagnetic separations
5.5.1. Introduction
Co-plating experiments using MNC (MNC-s or MNC-p) and PMN-p provided some
evidence that CD66b+ granulocytes (pre G-CSF or G-CSF mobilised) can influence
CFU-EPC. FFowever, MNC-p were not sufficiently depleted in
granulocytes/myeloid content for any firm conclusions to be drawn on their affect
on CFU-EPC formation when PMP cells were plated in well together with MNC.
This series of experiments was performed in order to assess further the contribution
of CD66b+ granulocytes to CFU-EPC formation and in particular to establish
whether modification (reduction) of CD66b+ granulocytes in mobilised MNC
samples could reverse the reduction of CFU-EPC activity observed in mobilised
PBSC donor MNC.
5.5.1.1. Patient samples
Non-mobilised whole blood samples were obtained from 9 subjects; (4 pre G-CSF
autologous PBSC patients, 3 PBSC donor follow-up samples (1 allogeneic and 3
autologous) and 2 healthy volunteers). Mobilised samples were obtained from 19
PBSC donors (5 allogeneic and 14 autologous PBSC donors (G-CSF+ chemotherapy
mobilised (n=ll) and G-CSF+ AMD3100 mobilised (n=3)).
MNC-s were obtained from whole blood samples by Histopaque density gradient
centrifugation. Aliquots of the resulting MNC-s were selectively enriched or
depleted for CD66b+ granulocytes, CD14+ monocytes or CD3+ lymphocytes using
MACS microbead separation techniques (section 2.4.2).
5.5.2. Cell content of MNC prior to MACS microbead separations
The phenotype of MNC-s prior to MACS microbead separation was assessed by
flow cytometry. The proportions of CD66b+ granulocytes, CD14+ monocytes,
lymphocytes and CD235a+ erythrocytes in MNC-s (starting cell population) were
-211 -
comparable to the phenotypic analyses of non-mobilised and mobilised samples
presented in previous sections (Table 5.19).
G











(1 alio, 5 auto)
6 52.7 3.8 9.6 33.8 37.6
o




All PBSC donors 19 69.4 28.7 12.7 26.1 24.6
Allogeneic PBSC
donors
5 85.7 33.2 16.9 37.1 10.5
Autologous PBSC
patients
14 63.6 27.2 11.2 22.2 29.7
Table 5.19 Leukocyte subpopulations and erythrocytes present in MNC-s.
Mean proportions of all events presented.
(alio = allogeneic PBSC donor, auto = autologous PBSC patient).
5.5.3. MACS microbead separations for CD66b
Samples from 16 PBSC donors underwent MACS microbead separation for CD66b.
These consisted of 15 mobilised PBSC patient samples (5 allogeneic and 10
autologous PBSC patients) and 1 non-mobilised sample (allogeneic PBSC donor
follow-up sample).
CD66b MACS separation of the non-mobilised patient sample was unsuccessful.
The starting MNC contained 0.4% CD66b+ granulocytes and CD66b-enrichment or
depletion was not achieved. CD66b separation of non-mobilised samples was not
repeated.
The CD66b-enriched MNC and CD66b-depleted MNC from mobilised PBSC donors
were fairly consistent in their cell contents. The compositions of starting MNC were
comparable to previous results with the same differences between samples from
allogeneic and autologous PBSC donors being noted (section 5.2).
CD66b-enriched MNC contained high levels of CD66b+ granulocytes with very low
numbers of CD14+ monocytes, lymphocytes and 235a+ erythrocytes present.
CD66b-depleted MNC contained reduced proportions of CD66b+ granulocytes and
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higher proportions of CD14+ monocytes and lymphocytes than starting MNC (Table
5.20). Overall, CD66b-depleted MNC showed a 31.0% reduction in CD66b+
granulocyte content from starting MNC; identical in allogeneic and autologous
donor samples. In MACS separated cells an increase in the proportions of events
that were 'unclassified' using our definitions for leukocytes and erythrocytes were
noted; increasing from 3.9% to 8.1% (CD66b-depleted MNC) and 14.1%
(CD66b-enriched MNC). This might be attributed the MACS separation process
itself causing disruption and damage to these large, granular and stimulated
mobilised myeloid cells.










69.3 30.0 (43.3) 13.4 27.3 25.4
CD66b-depleted 71.2 21.3 (29.9) 18.1 27.9 24.6




85.7 33.2 (38.7) 16.9 37.1 10.5
CD66b-depleted 87.3 23.2 (26.6) 21.8 40.8 10.4




61.0 28.4 (46.6) 11.5 21.9 33.7
CD66b-depleted 63.2 20.2 (32.0) 16.1 23.9 32.5
CD66b-enriched 88.2 77.3 (87.6) 1.7 5.2 1.6
Table 5.20 Leukocyte subpopulations and erythrocytes present in CD66b-enriched and
CD66 depleted MNC.
Figures expressed as mean proportions of all events; proportions of CD45+ events in
parentheses.
5.5.3.1. Influence of CD66b depletion on CFU-EPC (allogeneic PPSC
donors)
We have evidence from CFU-EPC of PMN-p that granulocytes do not form
CFU-EPC. This was the case for both non-mobilised and mobilised PMN-p. It is
unclear whether or not the physical presence of CD66+ granulocytes alone is
sufficient to suppress CFU-EPC formation or whether cellular or secreted factors are
important influences of C.FU-EPC formation.
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5.5.3.1.1. CFU-EPC formation in non-mobilised samples
In 4 of 5 cases pre G-CSF MNC-s from allogeneic PBSC donors generated CFU-EPC
(mean 9 CFU-EPC/IO6 cells). Two of 5 donor follow-up samples generated
CFU-EPC (mean 3.8 CFU-EPC/106 cells) whilst 3 of 5 did not. In 1 of 3 samples that
failed to generate CFU-EPC from donor follow-up MNC-s, CFU-EPC failed to form
due to technical reasons (Table 5.21).
MNC-s obtained from one further allogeneic PBSC donor at follow-up failed to
show CFU-EPC activity. No CFU-EPC formation was noted in CD66b-depleted
MNC either. No pre G-CSF sample was available from this patient to provide
additional non-mobilised CFU-EPC data.
5.5.3.1.2. CFU-EPC formation in mobilised samples
Mobilised MNC-s cells
CFU-EPC formation was severely curtailed but not completely absent in MNC-s
following G-CSF administration. 1 of 5 mobilised MNC-s generated CFU-EPC, albeit
at reduced rate compared to the matched pre-CSF sample (mean 0.6 CFU-EPC/106











274 24 0 3.75 0 0*
276 15 3 5 0 14
293 0 0 0 0 0
294 2 0 0 0 0
300 4 0 15 0 1
Table 5.21 CFU-EPC in MNC-s, CD66b-enriched and CD66b-depleted MNC (1).
Samples were obtained from 5 allogeneic PBSC donors; pre G-CSF, day 1 PBSCH and at
donor follow-up.
Mobilised CD66b-enriched MNC




Plating mobilised CD66b-depleted MNC into CFU-EPC culture demonstrated
partial recovery of CFU-EPC activity (mean 4.75 CFU-EPC/106 cells). CFU-EPC
formation was restricted to those samples from allogeneic PBSC donors that
developed CFU-EPC from non-mobilised samples. Subjects with higher CFU-EPC
activity in non-mobilised samples (24/15/4 CFU/106 cells versus 2/0
CFU-EPC/106cells) demonstrated CFU-EPC recovery in mobilised CD66b-depleted
MNC (Table 5.21).
Changes in CFU-EPC colony morphology were also noted. CFU-EPC colonies from
mobilised CD66b-depleted MNC were similar in appearance to non-mobilised
CFU-EPC. Longer and more slender spindle cells were associated with tight cores of
rounded cells in wells containing CD66b-depleted MNC. This was not observed in
any CFU-EPC culture wells containing mobilised MNC-s (see Appendix).
5.5.3.2. Influence of CD66b depletion on CFU-EPC (autologous PBSC
patients)
Ten samples were obtained from 9 autologous PBSC patients (diagnoses of MM
(n=7) or NHL (n=2)) following PBSC mobilisation with G-CSF+chemotherapy (n=7)
or G-CSF+ AMD3100 (n=3). Information on the CFU-EPC generation of pre G-CSF
samples was available in 7 cases and the CFU-EPC activity of donor follow-up
samples was available in 6 cases.
5.5.3.2.1. CFU-EPC formation in non-mobiiised MNC
Five of 7 pre G-CSF patient samples showed CFU-EPC activity. In these samples,
mean colony formation was 1.9 CFU-EPC/106 MNC; a lower rate of CFU-EPC
formation compared to other pre G-CSF autologous PBSC patients samples. All 6
donor follow-up samples showed CFU-EPC formation (mean 13.3 CFU-EPC/106
MNC). Matched pre G-CSF CFU-EPC data was available for comparison in 4 of
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these 6 cases. In 2 cases, CFU-EPC formation in donor follow-up samples matched
that of the pre G-CSF sample. However, in the other 2 cases, CFU-EPC formation in
donor follow-up samples exceeded that of the pre G-CSF samples. This might
suggest a possible negative effect of chemotherapy, patient treatment or disease














277 G+C — 2 16 0 3
278 G+C 0 1.4 11.3 0 20
279 G+C — 1 1 0 48
283 G+C 1 0 0 0 4
287 G+C 1 0 0 0 —
291 G+C 5 1 0 0 —
315 G+C 0 0 0 — —
299 G+A 3 0 0 0 2
299 G+A 3 0 8 0 3
316 G+A — 12 30 0 —
Table 5.22 CFU-EPC in MNC-s, CD66b-enriched MNC and CD66b-depleted MNC (2).
Samples obtained from 10 autologous PBSC patients; 7 mobilised with
G-CSF+chemotherapy (G+C) and 3 with G-CSF+AMD3100 (G+A); samples collected pre
G-CSF, day 1 PBSCH and at donor follow-up.
5.5.3.2.2. CFU-EPC formation in mobilised cells
Mobilised MNC-s cells
Five of 10 mobilised autologous PBSC patient MNC-s generated CFU-EPC whilst 5
samples had no CFU-EPC formation (0 CFU-EPC/106 MNC). Apart from one sample
that recorded 12 CFU-EPC/106 MNC, CFU-EPC formation was at a low rate; 1.1
CFU-EPC/106 MNC in those forming colonies (overall 1.7 CFU-EPC/106 cells (n=10))
(Table 5.22).
Mobilised CD66b-enriched MNC
No CFU-EPC formation was observed in any mobilised CD66b-enriched MNC
fraction (0 CFU-EPC/106 cells) (Table 5.22).
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Mobilised CD66b-depleted MNC
Five of 10 samples showed CFU-EPC formation in mobilised CD66b-depleted MNC
(mean 6.6 CFU-EPC/106 cells). This included a sample from 1 patient that failed to
generate CFU-EPC from a pre G-CSF sample. A follow-up sample from this
particular patient subsequently generated CFU-EPC in high numbers (20
CFU-EPC/106 cells) (Table 5.22, see also section 4.7). Similar changes in colony
morphology in mobilised CD66b-depleted MNC were noted as observed in
mobilised CD66b-depleted MNC from allogeneic PBSC donors (see Appendix).
5.5.3.3. Increased CFU-EPC activity in mobilised CD66b-depleted MNC
Similar changes in CFU-EPC formation were present in MNC-s and CD66b-depleted
MNC obtained from allogeneic and autologous PBSC donors. The changes in
CFU-EPC formation using CD66b-depleted MNC in mobilised samples (in addition










- -274 66 Deplete
276 MNC STD
- - - 276 66 Deplete
300 M NC STD
- - - 300 66 Deplete
277 M NC STD
-277 66 Deplete
— 278 MNC STD
- 278 66 Deplete
—270MNC GTD
- - - -279 6b Deplete
299 M NC STD
... -29966 Deplete
■ 3« MNC STD
A 3"6 66 Deplete
Pre G-CSF Post G-CSF Donor Follow-up
Timing of patient sample
Figure 5.16 CFU-EPC in MNC-s (MNC STD) and CD66b-depleted MNC (66 Deplete).
Cells obtained from PBSC donors on 3 occasions; pre G-CSF, day 1 PBSCH and at donor
follow-up. CFU-EPC frequency is expressed per 106 cells plated.
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5.5.3.4. Correlations between CD66b+ granulocyte content, CD14+ monocyte
content. CD14+ monocyte: CD66b+ granulocyte ratio and CFU-EPC formation
There appeared to be a correlation between the magnitude of reduction of CD66b+
granulocytes in mobilised CD66b-depleted MNC from the level contained in
mobilised MNC-s and CFU-EPC formation but this failed to achieve statistical
significance (p=ns). Overall, there was a mean reduction of CD66b+ granulocyte
content from MNC-s of 41.9% in CD66b-depleted MNC that generated CFU-EPC
compared to a mean reduction of 15.7% in those CD66b-depleted MNC that did not
generate CFU-EPC.
Greater reductions in CD66b+ granulocyte content (as seen in samples generating
CFU-EPC in mobilised CD66b-deplete MNC) were accompanied by greater
increases in CD14+ monocytes and lymphocytes in the CD66b-depleted MNC
samples.
It appears that the ratios of CD14+ monocytes and CD66b+ granulocytes in a sample
might affect CFU-EPC generation in post G-CSF samples. The patient samples that
generated CFU-EPC from CD66b-depleted fractions had higher ratios of CD14+
monocytes: CD66b+granulocytes than CD66b-depleted MNC that failed to generate
CFU-EPC (p<0.02) and the magnitude of change in the CD14+ monocyte:
CD66b+granulocyte ratios from mobilised MNC-s to CD66b-depleted MNC was
significant (p<0.02).
5.5.4. MACS microbead separations for CD14
MACS microbead separations for CD14 were performed on 20 samples; 2 allogeneic
PBSC donors, 16 autologous PBSC patient and 2 healthy volunteer samples.
Mobilised samples (n=ll) were obtained from 2 allogeneic PBSC donors and 9
autologous PBSC patients (mobilised with G-CSF+chemotherapy (n=6) or
G-CSF+AMD3100 (n=3)). Non-mobilised samples (n=9) consisted of 2 healthy
volunteer, 4 pre mobilisation and 3 follow-up samples. Many of these samples
undergoing MACS separation for CD14 had additional MACS separations
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performed (for CD66b or CD3). CD14-enriched MNC and CD14-depleted MNC
were fairly consistent in their cell contents. Starting MNC (MNC-s) were
comparable to previous results and the same differences between samples from
allogeneic and autologous PBSC donors were noted (section 5.2).
Compared to CD66b-enriched MNC, CD14-enriched MNC were less 'pure'. Similar
to CD66b MACS cell separations, there were populations of 'unclassified events'.
These were most prevalent in CD14-enriched MNC. There was significant CD66b+
granulocytic content of CD14-enriched MNC, principally due to the low expression
of CD14 on a proportion of granulocytes. Non-mobilised samples, including the
samples from 2 healthy volunteers, also showed significant CD66b expression on
CD14-enriched MNC, illustrating that this problem was not limited to mobilised
samples (Table 5.23). Weak CD14 expression was displayed by a proportion of
CD66b+ granulocytes. In standard flow cytometric analysis CD14 expression on
granulocytes doesn't interfere with gating of cell populations but in MACS cell
separations there would have been sufficient CD14 expression on these cells for
some CD66b+ granulocytes to be retained in the magnetic column with CD14+
monocytes.
Cell separation by MACS will therefore not distinguish between CD14+ and
CD66b+/14 low+ events unless a second stage of bead labelling is performed, first
depleting for CD66b+ events and then enriching for CD14+ events. Due to the
presence of a significant proportion of 'unclassified' events after one labelling stage,
performing a second one was thought to be undesirable. Flow cytometry cell sorting
might overcome this issue as low and high CD14 expression could be distinguished
during the sort.
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76.7 28.8 12.7 29.8 17.8
cm 4-appieted 70.4 29.4 5.1 33.6 24.1




85.7 33.1 16.9 37.1 10.4
CD14-depleted 81.9 37.2 1.4 41.4 16.7




63.6 27.2 11.2 22.2 29.7
CD14-depleted 65.7 26.5 6.4 30.6 28.0




53.9 4.5 10.2 32.9 44.3
CD14-depleted 49.5 4.2 3.1 46.2 43.6




85.3 0.1 13.4 70.0 10.7
CD14-depleted 85.7 0.1 0.8 — —
CD14-enriched 97.2 0.6 91.5 — —
Table 5.23 Leukocyte subpopulations and erythrocytes present in MNC-s, CD14-enriched
MNC and CD14-depleted MNC.
Samples obtained from non-mobilised PBSC donors, mobilised PBSC donors and healthy
volunteers. Figures are expressed as proportions of all events.
5.5.4.1. Influence of CD14-enrichment on CFU-EPC formation
5.5.4.1.1. CFU-EPC formation in non-mobilised samples
Four of 4 pre G-CSF samples (1 allogeneic and 3 autologous PBSC patient samples)
generated CFU-EPC (mean 2.5 CFU-EPC/106 cells, n=4) and 2 of 3 donor follow-up
samples (1 allogeneic and 2 autologous PBSC patient samples) generated CFU-EPC
(mean 3.7 CFU-EPC/106 cells, n=3). Only 1 of 7 non-mobilised samples that
underwent MACS separation for CD14 showed any CFU-EPC within
CD14-enriched MNC. This was a donor follow-up sample from an autologous PBSC
patient. Neither MNC-s nor CD14-depleted MNC generated CFU-EPC but 1
CFU-EPC/106 cells developed in CD14-enriched MNC (n=l). No CFU-EPC were
observed in CD14-depleted MNC from any of the 7 samples (see Appendix).
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5.5.4.1.2. CFU-EPC formation in mobilised samples
Mobilised MNC-s cells
CFU-EPC activity was observed in 7 of 11 mobilised MNC. Except for one patient
sample that generated 12 CFU-EPC/106 cells (no pre G-CSF or donor follow-up
sample was available on this patient) most samples had low level CFU-EPC
formation (overall mean 2.4 CFU-EPC/106 cells, n=ll, mean 1.5 CFU-EPC/106 cells if
sample that generated 12 CFU-EPC/106 is excluded, n=10) (see Appendix).
Mobilised CD 14 enriched MNC
CD14-enriched MNC from 3 patient samples (1 allogeneic PBSC donor and 2
autologous PBSC patients) showed some CFU-EPC activity (mean 2 CFU-EPC/106
cells). Although the level of CFU-EPC activity in CD14-enriched MNC was modest,
the comparative non G-CSF samples also had low CFU-EPC activity (mean 3
CFU-EPC/106 cells) (see Appendix).
There were no apparent links between CD14+ monocyte content, CD66b+
granulocyte content, ratios of CD14+ monocytes to CD66b+ granulocytes or change in
cell proportions from MNC-s to CD14-enriched MNC and the CFU-EPC
development observed in these samples.
Mobilised CD14-depleted MNC
A single sample, from a patient mobilised with G-CSF+AMD3100 generated
CFU-EPC from the CD14-depleted MNC but not the CD14-enriched MNC. MNC-s
generated CFU-EPC at 12 CFU-EPC/106 cells whilst CD14-enriched MNC had 0
CFU-EPC/106 cells and CD14 deleted MNC showed 4 CFU-EPC/106 cells. This was
not be readily explained by the cell contents of MNC. CD14-enriched MNC
contained 18.8% CD66b+ granulocytes and 86.8% CD14+ monocytes and
CD14-depleted MNC contained 17.6% CD66b+ granulocytes and 5.4% CD141
monocytes, which were comparable to other patient samples (see Appendix).
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5.5.4.1.3. CFU-EPC formation in samples from healthy volunteers
MNC-s from 2 healthy volunteers generated CFU-EPC (20 and 8 CFU-EPC/106 cells).
Following MACS separation, CD14-depleted MNC failed to form CFU-EPC (0
CFU-EPC/106 MNC).
There were insufficient cells in the CD14-enriched MNC fraction for these cells to be
plated alone into CFU-Hill assays. Instead, CD14-enriched MNC were mixed with
MNC-s (ratio lxlO6 CD14-enriched MNC + 2xl06 MNC-s) and then plated into
CFU-EPC assays. On day 2, lxlO6 (mixed) cells were transferred into a 24 well
fibronectin coated plate. Both volunteer samples showed prolific CFU-EPC
formation from the MNC-s + CD14-eririched MNC mix (35 and 50 CFU-EPC/106
cells). These colonies showed typical CFU-EPC morphology.
5.5.5. MACS microbead separations for CD3
MACS microbead separations for CD3 were performed on samples from 5 patients.
These were 2 healthy volunteer samples, 2 autologous G-CSF+chemotherapy
mobilised patient samples and 1 autologous patient donor follow-up sample.
Samples undergoing MACS separation for CD3 had additional MACS separations
performed (for CD66b or CD14) (Table 5.24).
5.5.5.1. Influence of CD3-enrichment on CFU-EPC formation
5.5.5.1.1. CFU-EPC formation in non-mobilised samples
The two samples from healthy volunteers generated CFU-EPC from MNC-s (8 and
20 CFU-EPC/106 cells) but the other non G-CSF sample (autologous PBSC patient
follow-up sample) showed no CFU-EPC activity in MNC-s. CFU-EPC activity was
not observed in any of the CD3-enriched MNC or any of the CD3-depleted MNC
(see Appendix).
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CD3-depleted 47.4 22.9 13.6 2.11 (CD3*) —








CD3-depleted 34.9 8.0 10.4 4.8 (CD3") —








CD3-depleted 85.1 0.2 22.2 7.9 (CD3*) —
CD3 Enriched 98.2 0.2 0.7 81.7 (CD3*) —
Table 5.24 Leukocyte subpopulations and erythrocytes in CD3 enriched and depleted MNC.
Samples obtained from non-mobilised PBSC donors, mobilised PBSC donors and healthy
volunteers. Figures are expressed as proportions of all events.
(Lymph - lymphocytes, NA - not available)
5.5.5.1.2. CFU-EPC formation in mobilised samples
Neither of the MNC-s from the 2 mobilised samples formed CFU-EPC. CFU-EPC
activity was not observed in any of the CD3 enriched MNC nor in any of the
CD3-depleted MNC (see Appendix).
5.5.5.1.3. CFU-EPC in mixing experiments; mixing of CD3 enriched or
CD3-depleted MNC with other cells
CD3 enriched MNC were mixed with CD14-enriched MNC and plated into
CFU-Hill assay (1 healthy volunteer sample and 1 autologous PBSC patient
follow-up sample). Neither sample generated CFU-EPC. When CD3-depleted MNC
were mixed with CD14-enriched MNC and plated into CFU-EPC assay (other
healthy volunteer sample), prolific CFU-EPC activity (120 CFU-EPC/106 cells) in
excess of that recorded for either the MNC-s or the mix of MNC-s and
CD14-enriched MNC (see Appendix).
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5.5.6. Conclusions
The generation of colonies from non-mobilised or G-CSF (and G-CSF+AMD3100
and G-CSF+chemotherapy) mobilised samples does not simply reflect the cell
content of the MNC suspension. Use of MACS to manipulate the cell content of
MNC preparations in order to selectively enrich or deplete a cell population was
successful in 'recovering' some CFU-EPC activity following G-CSF administration.
However, increases in CFU-EPC were not consistent. Overall, patients who had
higher frequencies of CFU-EPC in their non-mobilised samples were more likely to
recover CFU-EPC activity on manipulation of a G-CSF mobilised sample.
It appears that neither the CD66b/granulocytic enriched population nor the
CD14/monocyte depleted population generate CFU-EPC, either in the
non-mobilised or G-CSF mobilised setting. The CD66b MACS separation results
were consistent with those results obtained using PMP for cell separations,
demonstrating a lack of CFU-EPC forming activity within the
polymorphonuclear/lower interface layer.
On occasion CFU-EPC have been generated from a 'failed' MACS separation (when
there has been no depletion/enrichment of the desired cell fraction). However,
overall, mobilised samples that showed some recovery of CFU-EPC activity
following MACS CD66b depletion of MNC had lower CD66b/granulocyte levels
than the samples that failed to generate CFU-EPC post MACS separation. MACS
separations for CD14, to date, produced inconsistent results and it appears to be
inferior to CD66b depletion in enhancing CFU-EPC in mobilised samples. MACS
separation for CD14 failed to produce pure positively selected fractions and it was
found that the weak CD14 expression on a proportion of CD66b+ granulocytes led to
the presence of some granulocytes in CD14-enriched MNC.
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5.6. Investigation of the use of thawed MNC as a source of
CFU-EPC
5.6.1. Introduction
MNC obtained from G-CSF mobilised PBSC donors contained significantly greater
proportions of CD66b+ granulocytes (31.3% in allogeneic and 27.7% in autologous
PBSC MNC) and showed marked reductions in CFU-EPC activity compared to
non-mobilised MNC (CD66b+ granulocytes 2.9% and 5.0% in allogeneic and
autologous non-mobilised PBSC samples respectively). It is proposed that G-CSF,
possibly by altering the proportions of leukocyte subpopulations, contributed to the
reduction in CFU-EPC in mobilised blood samples. If the proportions of the
leukocyte subpopulations in mobilised blood MNC could be altered to be similar to
that of non-mobilised MNC then the frequency of CFU-EPC might increase towards
that of non-mobilised MNC. Myeloid cells do not survive cryogenic preservation
well. It was proposed that freezing and thawing MNC would destroy CD66b+
granulocytes and that thawed MNC would therefore contain lower proportions of
CD66b+ granulocytes which would reduce the impact of 'contaminating' CD66b+
granulocytes on CFU-EPC.
A source of cryopreserved samples from patients known to generate endothelial
colonies (CFU-EPC) would also be an extremely useful research tool. Use of thawed
MNC would enable a number of experiments to be completed on a single sample,
providing comparative data for review. Mixing studies, using samples collected at
different time points and MNC/cells obtained from patients receiving different
treatments, would also be possible. Experiments could also be performed on a
number of samples at once, allowing streamlining of experimental activity.
MNC were isolated from diluted whole blood samples by Histopaque density
gradient centrifugation. After enumeration (Coulter cell counter), MNC (fresh
MNC) were plated into CFU-Hill assays with stem cell and leukocyte phenotypes
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determined by flow cytometry. Aliquots of fresh MNC suspended in culture
medium were cryopreserved after the addition of foetal calf serum and DMSO
using rate controlled freezing (section 2.1.2). MNC were frozen at minus 80C until
thawed (thawed MNC) (sections 2.1.4). In these experiments using thawed MNC we
sought to establish;
1. whether thawed MNC (from non-mobilised or mobilised PBSC donors) were
capable of CFU-EPC formation;
2. the degree of attenuation of CFU-EPC activity in thawed MNC, by
comparing CFU-EPC development in fresh and thawed MNC;
3. the differences in the proportions of leukocyte subpopulations and CD235a+
erythrocytes between fresh and thawed MNC; and
4. whether there were any differences in stem cell phenotypes between fresh
MNC and thawed MNC.
5.6.1.1. Patient Samples
Eleven non-mobilised samples were obtained from 8 subjects (5 non-mobilised
autologous PBSC patients and 3 healthy volunteers). G-CSF mobilised samples were
obtained from 4 patients (3 autologous PBSC patients and 1 allogeneic PBSC donor).
Flow cytometry was performed to assess the major cell populations (leukocyte
subpopulations and CD235a+ erythrocytes) and putative EPC phenotypes contained
in 10 of 11 non-mobilised and all 4 mobilised samples using the same methods and
phenotypic definitions as described sections 5.1.2 and 6.1. MNC were plated into
CFU-EPC assays.
5.6.2. CFU-EPC development in thawed MNC
We have previously determined that plating MNC directly into wells of 24-well
fibronectin coated plates (CFU-Hill(direct)) resulted in the reliable appearance of
CFU-EPC in samples that formed CFU-EPC when plated into a CFU-Hill assay. In
order to have sufficient MNC available for comparative studies using fresh and
thawed MNC, CFU-EPC were assessed in fresh MNC using CFU-Hill(direct) assays,
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using 0.8-1.OxlO6 MNC suspended in l.OmL of CECM. When MNC numbers
permitted, fresh MNC were also plated into CFU-Hill assays (3xl06 fresh MNC
plated into a 12 well fibronectin coated plate). Results were considered in two
groups; non-mobilised (pre G-CSF, donor follow-up samples and volunteer
samples) and G-CSF mobilised patients.
5.6.2.1. CFU-EPC activity in thawed MNC compared to fresh MNC
5.6.2.1.1. Non-mobilised samples
CFU-EPC colonies were generated by all 11 non-mobilised fresh MNC in
CFU-Hill(direct) assays. Colonies displayed typical CFU-EPC morphology. Only 3
of 11 thawed MNC (27.3%) generated CFU-EPC in CFU-Hill(direct) assays.
CFU-EPC frequency in thawed MNC was greatly reduced from that of the
comparable fresh MNC sample. Overall, samples that displayed the greatest
CFU-EPC activity in fresh MNC were more likely to generate CFU-EPC from
thawed MNC. One sample that generated CFU-EPC from an aliquot of thawed
MNC failed to show consistent results as another aliquot of thawed MNC from the











Fresh MNC Thawed MNC
MNC Type
-254 Auto Pre G-CSF
-255 Vol Pre G-CSF
-255 Vol Pre G-CSF
-256 Alio Pre G-CSF
-256 Alio Pre G-CSF
-261 Auto Pre G-CSF
-266 Auto Pre G-CSF
269 Auto Pre G-CSF

















Subject Type Auto Vol Vol Alio Alio Auto Auto Auto Auto Vol Vol







Fresh MNC 2 30 30 19 19 7 1 6 29 8 8
Thawed
MNC
0 0 5 0 0 5 0 3.8 0 0 0
Figure 5.17 Comparison of CFU-EPC in fresh and thawed non-mobilised MNC.
(Vol=volunteer, Auto=autologous PBSC patient, Allo=allogeneic PBSC donor).
5.6.2.1.2. G-CSF Mobilised Samples
No (0 of 4) fresh mobilised MNC generated CFU-EPC when cultured in either
CFU-Hill(direct) or CFU-Hill assays. On thawing, aggregates of non re-suspended
cells/debris were frequently observed. No thawed mobilised MNC generated
CFU-EPC when plated into CFU-EPC assays (CFU-Hill(direct) assay (n=3) or











Sample Fresh Thawed Fresh Thawed
253 — — 0 0
256 19 0 9 0
259 40 — 2 0
266 1 0 0 0
Table 5.25 CFU-EPC activity of fresh and thawed G-CSF mobilised MNC.
We failed to observe any increase in CFU-EPC in G-CSF mobilised thawed MNC
compared to fresh mobilised MNC, suggesting that the degree of reduction in
CD66b+ granulocytic and CD235a+ erythrocyte content of MNC by freeze-thawing
was possibly insufficient to restore CFU-EPC activity. Unlike selection of cells by
MACS, unwanted cells were not removed from the cell culture. Dead cells or
fragmented cells remained as debris within sample and could still affect cell
behaviour (including CFU-EPC activity) of viable cells remaining in culture.
5.6.2.1.3. CFU-EPC morphology non-mobilised samples
Two of three samples that generated CFU-EPC from thawed MNC had sparse, short
spindle cells associated with the CFU-EPC core in the fresh sample. Following
freezing and thawing, CFU-EPC morphology did not change appreciably. One
sample (255) had prominent spindle formation observed in the CFU-EPC assay of
fresh MNC. The thawed MNC sample generated CFU-EPC with reduced spindle
cell number and size compared to fresh MNC. Representative photographs of
CFU-EPC are presented (Figure 5.18).
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Figure 5.18 Images of CFU-EPC generated from fresh and thawed non-mobilised MNC.
Three non-mobilised samples; autologous PBSC patient 261 (left), volunteer 255 (centre
images) and autologous PBSC patient 269 (right); paired data with fresh MNC shown in
upper images and thawed MNC in lower images.
5.6.3. Flow cytometric analysis of leukocyte subpopulations and
CD235a+ erythrocytes
The proportions of leukocytes subpopulations and CD235a+ erythrocytes were
determined in freshly MNC and in thawed MNC. The same definitions for cell
populations were used as were employed in other analyses (see section 5.1.1).
CD66b+ granulocytes were defined as events gating within the live cell gate
co-expressing CD45 and CD66b. CD14+ monocytes were defined as events gating
within the live cell gate co-expressing CD45 and CD14. CD235a+ erythrocytes (red
blood cells) were defined as CD45" events expressing CD235a+ (Glycophorin A) and
falling outside of the live cell gate. Lymphocytes were small (low forward and side
light scatter), CD45+ events gating within the live cell gate and not expressing
CD66b, CD14 or CD235a.
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5.6.3.1. Fresh MNC compared to thawed MNC
Analysis of the proportions of leukocyte subpopulations and CD235a+ erythrocytes
in fresh MNC and thawed MNC from non-mobilised and mobilised autologous
PBSC patients showed significant differences between MNC (Figure 5.19).
5.6.3.1.1. Non-mobilised MNC
In non-mobilised samples, there were no statistically significant changes in the
proportions of leukocyte subpopulations between fresh and thawed MNC (paired
analysis, n=10). There was a significant reduction in the proportion of CD235a+
erythrocytes (18.4% and 14.0% in fresh MNC and thawed MNC respectively, p<0.02)
with a relative increase in the proportion of lymphocytes (37.9% and 50.6%
respectively, p=ns) between fresh and thawed MNC. Less marked changes were
noted in the proportions of CD14+ monocytes (14.4% and 11.1%, p=ns) and CD66b+




































Mobilised MNC Non-mobilised MNC
Fresh Thawed Fresh Thawed
CD66b+ Granulocytes 43.2% 9.9% 1.6% 1.0%
CD14* Monocytes 9.7% 10.9% 14.4% 11.1%
Lymphocytes 11.1% 24.2% 37.9% 50.6%
CD235a+ Erythrocytes 25.3% 8.3% 18.4% 14.0%
Figure 5.19 Leukocyte subpopulations and CD235a+ erythrocytes in fresh or thawed MNC.
Samples obtained from non-mobilised and mobilised PBSC samples. Figures are expressed
as proportions of all events.
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5.6.3.1.2. Mobilised MNC
Overall, comparing the distribution of leukocytes between fresh and thawed G-CSF
mobilised MNC in paired analysis (n=7) showed that there was little change in the
proportion of CD14+ monocytes (9.7% in fresh MNC and 10.9% in thawed MNC,
p=ns). However, freezing resulted in a reductions in the proportions of CD66b+
granulocytes (43.2% and 9.9% respectively, p<0.02) and CD235a+ erythrocytes (25.3%
and 8.3% respectively, p=ns) with a concomitant increase in lymphocytes (11.1% and
24.2%, respectively, p<0.02) (Figure 5.19).
5.6.3.1.3. Non-viable cell populations
When MNC were thawed, reductions in the proportions of viable cells in the
samples were noted. Non-viable cells displayed altered light scatter properties (low
FSC/low SSC) and cells were not contained within the live cell gate. They generally
expressed CD45 together with lineage specific markers, but the intensity of
fluorescence was reduced compared to intact cells. These non-viable cells appeared
to be mainly granulocytic or monocytic in origin, as evidenced by CD66b or CD14
expression on these events, but they were excluded from cell counts.
5.6.3.2. Conclusions
Thawed mobilised MNC contained lower proportions of CD66b+ granulocytes than
fresh MNC; approximately a third of the CD66b+ granulocytes of the comparative
fresh mobilised MNC. There was little change in the proportion of CD14+ monocytes
between fresh and thawed MNC. The lymphocyte populations appeared to be quite
robust. Thawed MNC contained relatively higher proportions of lymphocytes than
fresh MNC largely due to the loss of viable CD235a+ erythrocytes and CD66b+
granulocytes after freezing. Thawed MNC (non-mobilised and mobilised)
contained lower proportions of CD235a+ erythrocytes than fresh MNC.
5.6.4. Flow cytometric analysis of proportions of CD133+ and
CD34+ stem cells
Stem cells were defined as events gating within the live cell gate displaying light
scatter characteristics similar to that of lymphocytes (low FCS and low SSC) and
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expressing CD133 or CD34 (section 6.1). By definition, CD34+ events, using ISHAGE
guidelines, are all CD45+ (191). The analysis of the stem cell phenotypes of
autologous and allogeneic PBSC donors undergoing PBSC mobilisation with
G-CSF+/-chemotherapy presented in chapter 6 showed that there were no
differences between stem cell populations when analysed as proportions of CD45+
stem cells gating within the live cell gate (Stems CD45+R1) or as proportions of stem
cells gating within the live cell gate (and not considering CD45 expression) (Stems
Rl). To include any CD45 /34+ or CD45" stem cells present within mobilised samples,
stem cells were analysed and the data presented in this section either as proportions
of all events or proportions of Stems Rl (Figure 6.1).
5.6.4.1. Proportions of stem cells
Analysis of the proportions of stem cells in mobilised samples showed that thawed
MNC contained significantly greater stem cells (as proportions of all events) than
fresh MNC (3.2% and 0.8% respectively, p<0.01). Thawed MNC contained greater
proportions of CD34+ (2.3%) and CD133+ cells (3.0%) than fresh MNC (CD34 0.7%,
p<0.01 and CD133 0.7%, p<0.02). Populations of KDR+ stem cells were not detected
in either patient group. Non-mobilised thawed MNC contained greater proportions
of CD34+ cells (0.31% and 0.15% in thawed and fresh MNC respectively), CD133+
cells (0.28% and 0.21% respectively) and stem cells (0.48% and 0.23% respectively)
than fresh MNC but these differences were not statistically significant (p=ns).
5.6.4.2. Distribution of stem cell phenotypes
Analysis of stem cell phenotypes in mobilised fresh MNC and mobilised thawed
MNC confirmed that there were no significant differences in the proportions of
CD133+/34", CD133+/34+ and CD133/34+ stem cells between fresh and thawed
mobilised MNC (p=ns for all comparisons). Fresh MNC contained on average 4.8%
CD133'/34-, 78.8% CD133+/34+ and 16.4% CD133/34+ stem cells whilst thawed MNC
contained 9.6% CD133V34-. 70.6% CD133+/34+ and 20.2% CD133/34+ stem cells
(Figure 5.20). The stem cell phenotypes in this experiment were very similar to
mean values presented for all G-CSF mobilised autologous PBSC samples (section
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6.1.8.2.2 and Table 6.6). There were no significant differences in stem cell
phenotypes between fresh and thawed non-mobilised MNC. Fresh MNC contained
38.4% CD133V34-, 44.1% CD133'/34* and 18.5% CD133/34* stem cells whilst thawed
MNC contained 25.9% CD133+/34\ 45.8% CD133+/34+ and 29.0% CD133V34+ stem
































proportions of stem cells)
MNC CD133734 CD133734+ CD133734+
Fresh MNC 4.9% 78.8% 16.4%
Thawed MNC 9.5% 70.5% 20.0%
Autologous mobilised MNC* 6.1% 72.4% 21.8%
Figure 5.20 Stem cell phenotypes in fresh and thawed mobilised MNC.
Distribution of CD133734+, CD133+/34+ and CD133/34+ stem cells shown.
Figures are expressed as mean proportions of stem cells.
* Comparative data from all G-CSF moblised autologous PBSC patients (table 6.6)
5.6.5. Conclusions
It was found that CFU-EPC could not be consistently generated from thawed MNC
even when the comparative fresh MNC sample displayed moderate CFU-EPC
activity. In samples that generated CFU-EPC from both fresh and thawed MNC,
marked reductions in CFU-EPC frequency occurred in thawed MNC. On this basis
the use of thawed MNC for CFU-EPC assessment was not pursued further.
The proportions of leukocyte subpopulations and CD235a+ erythrocytes in thawed
MNC differed substantially from fresh MNC. Significant reductions in the
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proportions of CD66b+ granulocytes and increases in lymphocyte proportions were
noted after thawing mobilised patient samples. Substantial reductions in the
proportions of CD235a+ erythrocytes were observed, statistically significant in
non-mobilised samples, with no changes in the proportions of CD14+ monocytes
occurring. There were no differences between fresh MNC and thawed MNC in the
distribution of CD34 and CD133 on stem cells. Thawed MNC contained
significantly greater proportions of stem cells, CD34+ cells and CD133+ cells than
fresh MNC, likely a reflection of losses of other less robust cell populations during
freezing.
5.7. Addition of autologous plasma to CFU-EPC colony
assays can influence colony forming activity
Results of co-plating experiments using Thinsert inserts™ suggested that soluble
factors and cellular factors could influence CFU-EPC. The contribution of
secreted/soluble factors released into the plasma by cells (mainly neutrophils)
stimulated by G-CSF was assessed by the addition of plasma, obtained from
non-mobilised and mobilised patients to CFU-EPC cell cultures. Non-mobilised
plasma was added to CFU-EPC culture to explore whether any effects on CFU-EPC
were specifically related to G-CSF stimulation.
5.7.1. Method
Venous blood samples were collected into lithium heparin anticoagulated blood
collection tubes. Following centrifugation of the sample, the plasma was collected
and reserved. Autologous patient plasma (autologous referring to plasma and MNC
being obtained from the donor) was added in various concentrations (2-10%) to
wells containing MNC, plated into either the CFU-Hill or the CFU-FIill(direct) assay.
When MNC numbers were limited, CFU-EPC was assessed using CFU-Hill(direct)
assays only. In CFU-Hill assays plasma was added to CECM in the specified
concentrations on day 0 when freshly isolated MNC were plated into 6 or 12 well
fibronectin-coated plates and also when re-plating non-adherent MNC on day 2.
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5.7.2. CFU-EPC formation
5.7.2.1. CFU-EPC in non-mobilised samples
Autologous non-mobilised patient plasma was added to 3 non-mobilised MNC
samples (patients 276, 278, 280). Patients who formed CFU-EPC using standard
culture methods (2 of 3 patients) displayed enhanced CFU-EPC formation following
the addition of 2% autologous patient plasma to the CECM in the culture wells.
Patient 280- MNC were plated into CFU-FIill and CFU-FIill(direct) assays. In the
direct plated assay peak CFU-EPC was recorded with the addition of 2% plasma
whilst in the CFU-Hill assay peak CFU-EPC occurred with the addition of 5%
autologous plasma. Flowever, some CFU-EPC activity was retained within the day 2
adherent MNC suggesting that the CFU-EPC activity with 2% plasma might have
been curtailed on account of this (Table 5.26).




CFU-Hill(direct) 1 15 5 5
CFU-Hill day 2 non-adherent MNC 0 10 15 —
CFU-Hill day 2 adherent MNC 0 2 1 —
Table 5.26 CFU-EPC on addition of non-mobilised plasma to non-mobilised MNC.
(Patient 280).
Patient 278- CFU-EPC were not formed from baseline (0% plasma) culture or on the
addition of autologous plasma.
Patient 276- CFU-EPC (CFU-Hill(direct) assay) increased following the addition of
1% or 2% autologous plasma; 4 CFU-EPC/106 MNC with 0% plasma, increasing to
19 CFU-EPC/106 MNC with 2% plasma. Escalation of plasma concentrations above
2% (5% and 10%) did not result in CFU-EPC. In this case, CFU-EPC activity in the
CFU-Hill(direct) assay containing 2% autologous pre G-CSF plasma exceeded the
CFU-EPC activity of MNC plated into the CFU-FIill assay (15 CFU-EPC/106 MNC,
0% plasma) (Table 5.27).
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CFU-EPC assay CFU-Hill(direct) CFU- Hill
% Autologous plasma 0% 1% 2% 5% 10% 0%
CFU-EPC (per 106 MNC) 4 14 19 0 0 15
Table 5.27 CFU-EPC on addition of non-mobilised plasma to non-mobilised MNC.
(Patient 276).
5.7.2.2. CFU-EPC in G-CSF mobilised samples
Inconsistent changes in CFU-EPC activity were found on the addition of autologous
(mobilised) plasma (n=2). CFU-EPC numbers were marginally increased following
the addition of autologous mobilised plasma to mobilised MNC in 1 case (patient
273) whilst in the other addition of autologous mobilised plasma to mobilised MNC
failed to change (increase) CFU-EPC activity (patient 279).
Patient 273 - Mobilised MNC plated into CFU-Hill(direct) assays recorded no
CFU-EPC with 0% autologous mobilised plasma (0 CFU-EPC/106 MNC) but 1
CFU-EPC/106 MNC with 2% autologous mobilised plasma. In this case co-plating of
mobilised MNC with autologous non-mobilised plasma (at a concentration of 2%
plasma) enhanced CFU-EPC activity to 6 CFU-EPC/106 MNC but CFU-EPC
remained well below that of the paired non-mobilised MNC sample (29
CFU-EPC/106 MNC). Other levels of plasma content were not assessed. Of interest,
increased spindle formation, whereby increasing proportions of individual cells
adopted a spindle-shaped morphology, was noted in the co-plated well containing
autologous non-mobilised plasma and mobilised MNC. This is in contrast to the
appearance of wells containing autologous mobilised plasma and mobilised MNC
which did not display significant spindle formation.
Patient 279- Addition of autologous mobilised plasma to mobilised MNC failed to
increase CFU-EPC. Mobilised MNC plated into the CFU-FIill assay produced 2
CFU-EPC/106 MNC but cells in the CFU-Hill(direct) assay failed to generate any
colonies Addition of autologous mobilised plasma (2% and 5% concentrations)
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failed to increase CFU-EPC. Non-mobilised autologous plasma was not added to
mobilised MNC in this case.
5.7.3. Conclusions
These experiments indicate that autologous non-mobilised plasma has some effect
on CFU-EPC formation. Autologous plasma produced enhancement of CFU-EPC
activity in non-mobilised samples. Interestingly, the addition of non-mobilised
plasma to mobilised MNC had greater effect on CFU-EPC activity than the addition
of mobilised plasma to mobilised MNC, though the level of colony formation was
still below that observed in the paired non-mobilised sample.
These findings could be interpreted as providing supportive evidence for the
importance of soluble/secreted factors to CFU-EPC development. It is speculative as
to whether non-mobilised patient plasma could enhance CFU-EPC formation by
neutralising or antagonising some factor present in mobilised MNC cell culture.
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5.8. Discussion
The proportions of leukocyte subpopulations in whole blood and MNC (day 0 and
day 2) differ significantly between non-mobilised and mobilised PBSC donor
samples. Significant differences were also present in the proportions of CD235a+
erythrocytes present in both MNC obtained from non-mobilised and mobilised
PBSC donors and samples obtained from autologous PBSC patients which also
contained greater proportions of CD235a+ erythrocytes than samples from
allogeneic PBSC donors. Although a number of groups (including our own) have
explored and commented on the importance of monocytes to the development of
CFU-EPC (93, 130-132, 136, 139, 141) our data showed that the reduction in
CFU-EPC following G-CSF administration was not attributable to reductions in
MNC CD14+ monocyte content. Day 0 and day 2 MNC obtained from mobilised
patient samples contained greater proportions of CD14+ monocytes than
comparative non-mobilised day 0 and day 2 MNC. Mobilised peripheral blood and
MNC contained lower proportions of lymphocytes, T cells and CD3+/31+/CXCl<4+
'angiogenic' T cells than non-mobilised samples. A number of studies have
described interactions between T cells and monocytes in initiation of colony
formation (135, 137, 142) which might be relevant to the decline in CFU-EPC
following G-CSF.
The lack of CFU-EPC formation in non-mobilised MNC following MACS
immunomagnetic bead separation for CD14 could possibly be a reflection of the
relatively high purity of CD14' cells in these cultures, has been suggested by van
Been et al (135) to result in loss of CFU-EPC formation. This is not supported by
earlier work using non-mobilised blood in our laboratory (136) or by enhanced
CFU-EPC when non mobilised MNC from healthy volunteers were co-cultured with
CD14-enriched MNC.
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It appeared that the most significant difference between non-mobilised and
mobilised samples was the CD66b+ granulocyte content of mobilised samples. Using
PMP density gradient centrifugation, MACS immunomagnetic MNC separations
and cryopreservation of MNC the affects of alterations to the CD66b+ content of
non-mobilised and mobilised MNC on CFU-EPC formation were assessed. CD66b+
granulocyte enriched MNC fractions failed to show any CFU-EPC development.
The series of co-plating experiments (using CD66b+ granulocyte enriched cells
obtained from PMP separation of whole blood or CD66b MACS immunomagnetic
separations of MNC) showed that the addition of non-mobilised or mobilised
CD66b+ granulocytes to CFU-EIill or CFU-Hill(direct) assays affected colony
formation. Interestingly, mixing CD66b+ granulocytes in direct contact with MNC
reduced CFU-EPC whilst addition of these cells in a ThinCert™ insert either
enhanced CFU-EPC (non-mobilised CD66b+ granulocytes) or reduced CFU-EPC
(mobilised CD66b+ granulocytes). Similarly, MACS immunomagnetic separations
plating CD66b+ enriched or depleted MNC into CFU-EPC assays in isolation or
mixed with MNC showed that CD66b+ granulocyte depletion can increase CFU-EPC
in samples obtained from mobilised patients. Cryopreservation of mobilised MNC
reduced the CD66b+ granulocyte and CD235a+ erythrocyte content of MNC. Thawed
mobilised MNC failed to form CFU-EPC but CFU-EPC were seen in some thawed
non-mobilised MNC. It might be that the initiator of CFU-EPC is sensitive to
freeze/thaw or that the responder cells (or both) are affected by this process.
There is evidence that the effects of CD66b+ granulocytes of CFU-EPC extend
beyond their physical presence in the culture well and that factors released from
these cells influences CFU-EPC. Preliminary studies investigating the effects of
autologous plasma from non-mobilised and G-CSF patients showed effects of 2%
non-mobilised plasma in enhancing CFU-EPC of non-mobilised and mobilised
MNC.
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The stimulation of granulocytes by G-CSF results in the release of enzymes which
have important roles in the mobilisation of HSC and HPC from the BM into the
circulation. G-CSF stimulated granulocytes will continue to be metabolically active
in culture and secreted factors will affect the behaviour of MNC. G-CSF induces
alterations in cell adhesion molecules including L-selectin, VCAM-1 expressed on
CD34+ cells which contribute to their mobilisation from the BM. G-CSF might also
alter the monocyte expression of these cells and through this affect the ability of
MNC (including monocytes) to adhere to fibronectin, a key factor in the
development of CFU-EPC. The influence of G-CSF on the expression of adhesion
molecules by leukocytes is now being investigated. It is suggested that G-CSF could
either affect CFU-EPC responder or initiator cells directly (e.g. the down regulated
expression of receptors on CD14' monocytes) or indirectly, through its effects on
myeloid cells that secondarily influence other leukocytes including CD14+
monocytes. Evidently there is an interaction between the plated cells and the
fibronectin coating the culture plates required in order for the CFU-EPC assay to
generate colonies. If this stimulus cannot take place colonies will then not form.
Fibronectin receptor down-regulation might therefore affect the ability to make
CFU-EPC and investigation of G-CSF-induced changes in molecules involved in
fibronectin adhesion is now being undertaken within the laboratory.
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6. Flow cytometric analysis of putative EPC
phenotypes in patients undergoing G-CSF PBSC
mobilisation
6.1. Analysis of non-mobilised and mobilised PBSC samples
6.1.1. Introduction
The flow cytometric characterisation of samples obtained from autologous and
allogeneic donors undergoing PBSC mobilisation for the presence of cells exhibiting
putative endothelial cell phenotypes is presented in section 6.1. Similar to previous
chapters, samples were collected from patients on three occasions; at donor review
prior to PBSC mobilisation (non-mobilised or pre G-CSF sample), at day 1 PBSCH
(mobilised or post G-CSF sample) and at donor follow-up 4-6 weeks following
PBSCH (donor follow-up sample). In section 6.1 at least 100,000 events gating in the
live cell gate were acquired from each tube. Whole blood samples and MNC were
examined for the presence of cells exhibiting putative endothelial cell phenotypes
with day 0 and day 2 MNC assessed as described in section 5.1. In this chapter, day
2 MNC refers specifically to MNC that remained non-adherent to fibronectin after 2
days of incubation.
6.1.1.1. Defining haematopoietic CD34+ cells and stem cells
Haematopoietic CD34+ cells
The International Society of Hematotherapy and Graft Engineering (ISHAGE)
guidelines were established for enumerating CD34+ events to determine the number
of HSC and HPC within patient samples. A combination of side light scatter (SSC),
forward light scatter (FSC), CD45 antigen expression and CD34 antigen expression
is used to identify all low SSC CD45+/34+ events and to exclude other nucleated cells,
erythrocytes, platelets and debris from the calculation of CD34+ events (191). CD34
enumeration can be carried out as a single or dual platform analysis (193), with the
dual platform method using the patient's peripheral blood leukocyte count to
convert a proportional CD34 count into an absolute value. The immunophenotypes
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of HPC and other precursor cells are well documented and this knowledge is used
clinically to identify normal and abnormal cell populations.
Stem cells
'Stem cells' were defined as events gating within the live cell gate displaying light
scatter characteristics similar to that of lymphocytes and expressing CD133 and/or
CD34, and therefore not restricted to CD45+ events as identified using ISHAGE
guidelines. The term 'stem cells' does not specifically relate to haematopoietic stem
cells though the vast majority of cells identified by flow cytometric analysis were
haematopoietic according to their expression of CD45.
6.1.1.2. Stem cell populations
There were no difficulties in identifying discrete CD34+ and/or CD133+ 'stem' cell
populations in samples from mobilised patients (Figure 6.1). Stem cells were rare
events in normal (non-mobilised) samples. In some cases, even with acquisition of
>150,000 events during flow cytometry, insufficient cells were identified as stem






Pre G-CSF Mobilised Follow-up
Whole
blood
Allogeneic donor 10 (9) 9(9) 8(7)
Autologous donor 35 (29) 29 (29) 7(7)
All PBSC patients 45 (38) 38 (38) 15 (14)
Day 0
MNC
Allogeneic donor 15 (15) 12 (12) 12 (12)
Autologous donor 38 (30) 30 (30) 7(7)
All PBSC patients 53 (45) 42 (42) 19 (19)
Day 2
MNC
Allogeneic donor 9(5) 7(7) 6(3)
Autologous donor 28 (16) 24 (24) 4(2)
All PBSC patients 37 (21) 31 (31) 10(5)
Table 6.1 Allogeneic and autologous PBSC donor samples analysed in section 6.1.
Numbers of whole blood, day 0 MNC and day 2 MNC samples, with numbers of evaluable
samples in parentheses.
-244-
6.1.2. Stem cell gating strategies
6.1.2.1. Stems CD45+R1 versus Stems R1 gates
When only haematopoietic progenitor cells (HPC) are being assessed, CD45
expression should be included in an antibody panel used to define HPC by flow
cytometry. However, the data presented in this section is not restricted to
examination of HPC and considers any non-haematopoietic stem cells. If gating
strategies that included CD45 expression as part of the obligatory set of antigens for
the assignment of CD34+ or stem cell status to identify the stem cell populations,
CD45" stem cells expressing CD133 and/or CD34 would be missed.
Figure 6.1 Representative flow cytometry dot plots from a G-CSF mobilised PB sample.
Figure 6.1a FSC v SSC of all events (Fig 6.1a) with live cell gate indicated (in red outline).
Figure 6.1b FSC v SSC of R1 gated events in figure 6.1a.
Figure 6.1c FSC v SSC of Stems R1 cells identified in figures 6.1 f and 6.1g (Stems R1 gate).
Figure 6.1d CD45-APC expression of stem cells (red), figure gated on CD45.
Figures 6.1e, 6.1f, 6.1g and 6.1h - KDR-FITC, CD133-PE, CD34-PerCP and CD45-APC
expression of events gating in R1 (figure 6.1b).
Polygonal stem cell gates were used to restrict the analysis/area of interest to events of
similar size to lymphocytes (which includes stem cells) within the live cell gate (Stems R1).
Stem cells are CD34+ and/or CD133+ events gating in the Stems R1 region.
Stem cells (shown in red) are CD45' but KDR~.
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6.1.2.1.1. Data presentation
To ensure that any CD45/34+ cells, CD45/133' cells or CD45 stem cells present
within a sample were not overlooked, these cells were defined using light scatter
characteristics and CD34 and/or CD133 antigen expression, to define low SSC events
within the live cell gate (Stems R1 gate) expressing CD34 and/or CD133 (Figure 6.1
and Figure 6.2). CD34+ events and stem cells were also identified using the
parameters established in the ISIIAGE guidelines.
Figure 6.2 Representative flow cytometry dot plots from day 0 G-CSF mobilised MNC.
Mobilised MNC sample contains proportions of CD66b+ granulocytes and CD45"
erythrocytes.
Figure 6.2a FSC v SSC of all events (Fig 6.1a) with live cell gate indicated (in black outline).
Figure 6.2b FSC v SSC of R1 gated events in figure 6.2a.
Figure 6.2c FSC v SSC of Stems R1 identified in figures 6.2f and 6.2g (Stems R1 gate).
Figure 6.2d CD45-APC expression of stem cells (red), figure gated on CD45.
Figures 6.2e, 6.2f, 6.2g and 6.2h - KDR-FITC, CD133-PE, CD34-PerCP and CD45-APC
expression of events gating in R1 region (figure 6.2b).
Polygonal stem cell gates were used to restrict the analysis/ area of interest to events of
similar size to lymphocytes (which includes stem cells) within the live cell gate (Stems R1
gate). Stem cells, identified by their expression of CD133 and/or CD34 (shown in red) are
CD45+ but KDR . KDR+ events (figure 6.2e) were neither CD133+ nor CD34+.
-246-
6.1.3. Proportions of CD34+ stem cells
Analysis of the proportions of CD34+ cells in non-mobilised and mobilised PBSC
patient samples showed that the proportions of CD34' cells increased in whole
blood (0.07% versus 0.60%), day 0 MNC (0.12% versus 0.92%) and day 2 MNC
(0.05% versus 0.20%) following the administration of G-CSF+/-chemotherapy
(p<0.0001, p<0.0001 and p<0.01 for CD34 for whole blood day 0 and day 2 MNC
respectively) (Stems R1 gate). The changes in the proportions of CD34+ cells
following G-CSF remained significant at the 3 time points when allogeneic and
autologous PBSC patients were considered separately. The populations of CD34+
cells mobilised by the administration of G-CSF were clearly evident (Figure 6.1 g and
Figure 6.2g). There were no differences in the proportions of CD34+ cells identified
using Stems R1 or a Stems CD45+R1 gates (Table 6.2 and Table 6.3). There were no
significant differences between the numbers of CD34' cells identified in pre G-CSF
and donor follow-up samples (p=ns). There were no differences in the proportions
of CD34+ cells in non-mobilised samples from allogeneic and autologous PBSC
patients in whole blood (0.06% and 0.08%), day 0 MNC (0.12% and 0.13%) and day 2
MNC (0.02% and 0.06%) (p=ns for the 3 time points).
Mobilised whole blood samples from autologous PBSC patients contained
significantly greater proportions of CD34+ cells (0.74%) than samples from
allogeneic PBSC donors (0.09%, p<0.005). Although greater in MNC from mobilised
autologous PBSC patients, there were no differences between patient groups in the
proportions of CD34+ cells in day 0 MNC (0.57% and 1.12% for allogeneic and
autologous PBSC donors respectively, p=ns) or day 2 MNC (0.30% and 0.17%
respectively, p=ns).
6.1.4. Proportions of CD133+ stem cells
Analysis of the proportions of CD133+ cells in non-mobilised and mobilised PBSC
patient samples showed that the proportions of CD133+ cells increased in whole
blood (0.05% versus 0.50%), day 0 MNC (0.13% versus 0.74%) and day 2 MNC
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(0.08% versus 0.48%) following the administration of G-CSF+/-chemotherapy
(p<0.0001, p<0.0001, pO.OOOl for CD133 for whole blood day 0 and day 2 MNC
respectively) (Stems R1 gate). The changes in the proportions of CD133+ following
G-CSF remained significant at the 3 time points when allogeneic and autologous
PBSC patients were considered separately. The populations of CD133+ cells
mobilised by G-CSF administration were clearly evident (Figure 6.1f and Figure
6.2f). There were no differences in the proportions of CD133+ cells identified using
Stems R1 gates (Table 6.2) or Stems CD45+R1 gates (Table 6.3). There were no
significant differences between the numbers of CD133+ cells identified in pre G-CSF










CD34 CD133 CD34 CD133 CD34 CD133
Pre
G-CSF
Whole blood 0.07% 0.05% 0.06% 0.04% 0.08% 0.06%
Day 0 MNC 0.12% 0.13% 0.12% 0.12% 0.13% 0.13%
Day 2 MNC 0.05% 0.08% 0.02% 0.04% 0.06% 0.10%
G-CSF
mobilised
Whole blood 0.60% 0.50% 0.09% 0.09% 0.74% 0.61%
Day 0 MNC 0.92% 0.74% 0.57% 0.44% 1.12% 0.92%
Day 2 MNC 0.20% 0.48% 0.30% 0.43% 0.17% 0.49%
Donor
Follow-up
Whole blood 0.04% 0.03% 0.04% 0.03% 0.04% 0.03%
Day 0 MNC 0.08% 0.08% 0.10% 0.10% 0.05% 0.04%
Day 2 MNC 0.06% 0.06% 0.03% 0.03% 0.10% 0.09%
Table 6.2 Proportions of CD34+ and CD133+ cells in PBSC donor samples.










CD34 CD133 CD34 CD133 CD34 CD133
Pre
G-CSF
Whole blood 0.07% 0.05% 0.05% 0.04% 0.07% 0.03%
Day 0 MNC 0.12% 0.12% 0.09% 0.11% 0.13% 0.13%
Day 2 MNC 0.03% 0.08% 0.02% 0.03% 0.04% 0.07%
G-CSF
mobilised
Whole blood 0.60% 0.5% 0.10% 0.09% 0.72% 0.60%
Day 0 MNC 0.90% 0.71% 0.52% 0.43% 1.06% 0.91%
Day 2 MNC 0.17% 0.44% 0.24% 0.40% 0.15% 0.44%
Donor
Follow-up
Whole blood 0.04% 0.03% 0.04% 0.03% 0.01% 0.02%
Day 0 MNC 0.05% 0.07% 0.06% 0.08% 0.04% 0.04%
Day 2 MNC 0.02% 0.03% 0.06% 0.07% 0.06% 0.07%
Table 6.3 Proportions of CD34+ and CD133+ cells in PBSC donor samples.
Figures are expressed as proportions of all events (Stems CD45+R1 gate).
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There were no differences in the proportions of CD133+ cells in non-mobilised
samples from allogeneic and autologous PBSC patients in whole blood (0.04% and
0.06%), day 0 MNC (0.12% and 0.13%) and day 2 MNC (0.04% and 0.10%) (p=ns for
the 3 time points). Mobilised whole blood samples from autologous PBSC patients
contained significantly greater proportions of CD133+ cells (0.61%) than samples
from allogeneic PBSC donors (0.09%, p<0.05). However, there were no differences
between patient groups in the proportions of CD133+ cells in day 0 or 2 MNC (day 0
MNC 0.44% and 0.92% for allogeneic and autologous PBSC donors respectively,
p=ns, and day 2 MNC 0.43% and 0.49%, p=ns).
6.1.5. Proportions of KDR+ stem cells
A population of stem cells expressing KDR was not identified by flow cytometric
analysis in this cohort of non-mobilised and mobilised PBSC patient samples. Using
'fluorescence minus 1' gating we failed to detect KDR expression above the levels
contained in control tubes. Given the scarcity of stem cells in non-mobilised samples
we did not anticipate being able to identify KDR+ stem cells in these samples. The
majority of mobilised samples had 100,000-200,000 events acquired for FACS
analysis which were insufficient to detect KDR+ stem cells.
6.1.5.1. KDR gating strategies
The expression of CD133 and CD34 antigens were restricted to stem cells, producing
discrete cell populations that displayed similar FSC and SSC characteristics as
lymphocytes (Figure 6.1). The expression of KDR, however, was not restricted to
stem cells and was frequently detected on leukocytes, particularly CD66b+
granulocytes and CD14+ monocytes. This was particularly apparent in mobilised
samples and was observed to be more pronounced on day 0 MNC than on whole
blood samples, suggesting possible activation of KDR expression on leukocytes
during cell handling. To ensure that a population of KDR+ stem cells was not being
overlooked, the proportions of stem cells expressing KDR were determined using
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two gating strategies. In addition to detection of KDR expression using a 'stem cell'
gate, set using negative controls and a 'fluorescence minus one' staining strategy
(Figure 2.3) to define the positive region with light scatter characteristics similar to
lymphocytes (KDR), a wider gate, which was set using unstained cells and CD45
expression (KDRwide) was employed (Figure 6.3).
Large populations of leukocytes expressing KDR were detected when the KDRwipf.
gate was used. However, the expression of KDR by stem cells, defined by the
expression of CD133 and/or CD34, was not altered by using this alternate KDRwide
gating and no increase in cells co-expressing CD133, CD34 and KDR was detected
using KDRwide gates (Figure 6.3). Unless otherwise stated, KDR expression was
calculated (section 6.2) using polygonal stem cell gates, though for most samples
KDRwidf. gates were also examined. On account of the lack of a definable KDR+ stem
cell population (section 6.1.5) the latter half of section 6.1 examines the distribution
of CD! 33 and CD34 (but not KDR) antigen expression by stem cells.
Figure 6.3 Flow cytometry dot plots of KDR expression in a G-CSF mobilised PB sample.
Upper figures show the expression of KDR-FITC (KDRWC>E gates in yellow and KDR stem
cell gates in blue), CD133-PE and CD34-PerCP by events gating in the live cell gate (red).
The stem cell population, indicated in green, is clearly KDR".
Lower tigures display FL1, FL2 and FL3 dot plots for unstained cells.
FL3-Height
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expression of KDR by UCB CD34+ cells compared to mobilised PB CD34+ cells.
Differences in the expression of some myeloid antigens by CD34+ cells were also
noted with significantly lower expression of CD13 and CD33 identified on UCB
CD34+ cells.
Section 6.3 focussed on the identification of a novel population of CD34+ cells
(CD34BMGHT cells) in UCB samples. In contrast to G-CSF mobilised samples, flow
cytometry of UCB samples demonstrated CD34+ cells with a differential of
fluorescence intensity and CD34+ cells were divided into CD34REG and CD34BRIGHT
populations. When UCB samples and G-CSF mobilised peripheral blood samples
were compared, it was found that CD34+ cells in G-CSF mobilised blood formed a
tight cell population with relatively low intensity CD34 expression, comparable to
the CD34REG population seen in UCB samples. UCB CD34REG and UCB CD34BRIGHT
cells differed significantly in the co-expression of stem cell related and other
antigens. UCB CD34BRIGHT cell populations contained higher proportions of CD45"
and CD133" cells, were more likely to express KDR but less likely to express CD38
than UCB CD34REG cells.
On the basis of higher proportions of CD45" and CD133" cells in UCB CD34BMGHT cell
populations it was investigated whether these cells could be circulating endothelial
cells. Small numbers, but significantly greater proportions of cells were found with
phenotypes consistent with CEC in UCB CD34BRIGHT cells compared to UCB CD34REG
cells, suggesting consideration should be given as to whether EOC formation from
CD34+/133" cells could be attributed to the presence of CEC.
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7. Discussion
The material presented in this thesis relate to the study of the effects of G-CSF on
EPC, assessed using flow cytometric analysis and culture based colony assays,
mainly CFU-Hill but also EOC. Recent opinion is that two broad types of EPC exist,
as defined by cell culture and although these share some features (including lectin
binding, ac-LDL uptake, CD31 expression) the cell types differ in their proliferative
capacity, morphology and functional characteristics (93, 108, 131, 133, 134);
summarised in Figure 7.1
Cells identified as EOC derived from the adherent fraction of MNC plated onto
collagen are now believed to represent true EPC (115). Cells identified in short term
culture on fibronectin coated plates are believed to be myelomonocytic cells of
haematopoietic origin that may facilitate angiogenesis and vascularisation through
their secretion of pro-angiogenic factors and paracrine activity (96, 131, 132, 142). A
role for other inflammatory cells in vascular repair, particularly T cells and their
interactions with monocytes has also been raised (135, 137, 142). Consequently, it is
difficult to relate the results of earlier publications to our current framework of
understanding of EPC and to compare the phenotypic and culture-based detection
of EPC which do not appear to correlate with each other (169, 199).
At present, the term 'EPC' is still used to describe the haematopoietic cells identified
in short term culture of MNC on fibronectin that contribute to neovessel formation
through secretion of pro-angiogenic factors and paracrine activity. The use of
'progenitor' implies that these cells can differentiate into endothelial cells whereas it
is becoming clear that some EPC (e.g. CD14+ monocytes) cannot, but they may be














































Characteristic Early EPC (CFU-Hill) Endothelial Outgrowth
Cell
Cell of Origin Haematopoietic (myelomonocytic) Non-Haematopoietic
Essential Phenotype CD45+/CD14+ CD457 CD34+/ CD133"
Formation CFU-Hill Yes No
Outgrowth Colony Formation No Yes
Incorporation into vessels No Yes
Paracrine effects Yes No
Figure 7.1 Suggested relationship between Endothelial Outgrowth Cells and early 'EPC'.
This body of work follows on from observations made by O Tura that CFU-EPC
numbers declined following administration of G-CSF to patients mobilised with
G-CSFV-chemotherapy for PBSC collection (136). After first reviewing the
characteristics of patients referred to our stem cell collection facility for PBSC
mobilisation (Chapter 3) peripheral blood samples obtained from allogeneic and
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autologous PBSC patients were studied and the initial observations were confirmed
(Chapter 4). CFU-EPC frequency, assessed using a commercially available CFU-EPC
assay (CFU-EPC, Stem Cell Technologies) according to manufacturer instructions,
varied considerably in normal healthy subjects (allogeneic PBSC donors) and in
haematology patients referred for consideration of autologous PBSC collection. A
proportion of healthy donor and non-mobilised patient samples failed to generate
CFU-EPC in the absence of G-CSF or chemotherapy exposure. The administration of
G-CSF for PBSC mobilisation (given alone, sequentially with chemotherapy or with
AMD3100) profoundly reduced CFU-EPC. The effect of G-CSF was consistently
demonstrated for both allogeneic and autologous PBSC donors, regardless of PBSC
mobilisation regimen used. The decline in CFU-EPC following G-CSF was
reversible, as follow-up samples obtained 4-6 weeks after PBSC mobilisation
showed recovery of CFU-EPC frequency to pre mobilisation levels. Whilst G-CSF
produced a significant leukocytosis in allogeneic PBSC donors, peripheral blood
leukocyte counts remained within the normal range following PBSC mobilisation in
autologous PBSC patients, indicating that the reduction of CFU-EPC in mobilised
MNC was not merely due to the dilution of colony-forming cells within an
increasingly cellular peripheral blood.
These findings were consistent with and extend the previous results presented by
our group(136) but are contrary to a number of studies, published in the setting of
G-CSF mobilisation of EPC in patients with cardiovascular disease (163, 165, 167),
patients undergoing PBSC mobilisation (162, 170) or healthy volunteers (167, 189).
These studies assessed early EPC in fibronectin adherent (165, 189) or non-adherent
MNC fractions (162, 163, 167, 170). All introduced modifications from the methods
published by Hill et al(110) and the commercially available assay kit (CFU-EPC,
Stem Cell Technologies) or identified EPC in fibronectin adherent MNC, so it is
difficult to make direct comparisons between these studies and to compare directly
with the work presented here. No other study has described the reduction in
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CFU-EPC following G-CSF administration for HPC mobilisation that we have
consistently observed.
The assay published by Hill et al, designed to assess spontaneous rather than
stimulated colony formation, plated freshly isolated MNC onto fibronectin coated
plates in Medium 199 supplemented with 20% foetal calf serum (FCS) and
streptomycin without additional growth factors, and day 2 fibronectin non-adherent
MNC were transferred to fresh fibronectin plates(HO). The availability of a
commercial CFU-EPC assay (Stem Cell Technologies, UK) that, when followed
according to manufacturer instructions, would produce reproducible and
comparable results between different laboratories, and overcome variations in
results due to differences in FCS, produced a large number of reports from different
laboratories in changes in CFU-EPC in a variety of clinical conditions (110, 111, 135,
137, 199, 200). This assay was chosen for this study on this basis.
Variations in CFU-EPC assays, particularly in time (approaching EOC timescale)
and with the addition of cytokines that possibly counteract the G-CSF effect but
certainly abrogate the spontaneous colony formation that Hill stresses is the basis
for the assay, mean that results cannot be compared to other reports or interpreted
readily. Three studies (162, 163, 167) used Medium 199 supplemented with 20% FCS
but differed in the timing of CFU-EPC assessment, MNC replating and changing of
the media. Three other studies of the effects of G-CSF on EPC failed to assess
spontaneous colony formation as growth factors, particularly VEGF, were added to
cultures (165, 170, 189). The study by Allen et al supplemented RPMI not only with
20% FCS and heparin but with endothelial cell growth factor (170). Flonold et al
assessed EPC in fibronectin adherent MNC using Medium 199 supplemented with
FCS and atorvastatin, an agent reported to increase CFU-EPC (201) for the initial 3
days of primary culture with adherent day 3 MNC then cultured in methylcellulose
in the presence of VEGF for a further 2 weeks (165).
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A single healthy volunteer study (Shepherd et al) that reported increased PB EPC
numbers following either AMD3100 or G-CSF failed to assess spontaneous colony
formation as the authors used VEGF supplemented cultured medium to assess EPC
in fibronectin adherent MNC (189). In this study EPC frequency was presented per
mL blood rather than per 106 cells plated, making it difficult to establish the role of
G-CSF or AMD3100 in increasing the proportions of CFU-EPC forming cells
independently of any cytokine induced leukocytosis (which would occur in healthy
volunteers) altering CFU-EPC per unit volume of peripheral blood. A murine study
(190), found that pre-treatment with VEGF increased AMD3100 mobilisation of EPC
and suggested that HPC and EPC were differentially mobilised. However, like the
previous study, the CFU-EPC assay used by Pitchford et al plated MNC onto
fibronectin in supplemented EGM2 media to which additional VEGF was added
and, although cultured on fibronectin, the cells cultured represented late outgrowth
colonies (190). An earlier study, again using a murine model, assessed clinical
outcomes without phenotypic or culture based EPC assessments (202). However,
the G-CSF and AMD3100 doses administered (190, 202) were not comparable those
used in human studies (189). Also, since 'EPC' remain poorly and inconsistently
defined, it is not certain that mouse and human studies are equivalent.
The CFU-EPC assay as described by Hill et al (110) relies on colony morphology
rather than phenotype for measurement of colony frequency. Although the results
for CFU-EPC presented in this thesis reflected the observations of an individual, the
change in CFU-EPC following G-CSF administration has been observed
independently by a number of group members. Photographs of CFU-EPC cultures
have been reviewed by other group members to reach similar conclusions as how to
'score' cell aggregates. The recommendations by Hill and accompanying the
commercial reagents were used and these criteria have been stringently applied in
our assessments. Concerns remain that representative published images of
CFU-EPC from G-CSF mobilised MNC (163) are not consistent with the colony
morphology reported for CFU-EPC (110). In scoring cells as colonies the primary
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decision to make is whether cell morphology is consistent with CFU-EPC and
secondarily to demonstrate 'endothelial features'. It may be that other research
groups are relying too heavily on immunostaining (CD31, CD105, CD144 etc.), cell
uptake of ac-LDL or Ulex Lectin binding, all non specific characteristics that do not
identify a unique population of endothelial or haematopoietic cells (93, 131-134), to
score a cell cluster as CFU-EPC rather than to first examine 'colony' morphology to
ascertain whether it meets CFU-EPC definitions. Uptake of ac-LDL and Ulex Lectin
binding and the expression of endothelial genes and proteins are properties shared
with peripheral blood monocytes (139).
The lack of CFU-EPC in G-CSF mobilised samples could not be attributed to a
number of technical issues that were explored in chapter 4 and the results show that
the effect of G-CSF in reducing or abolishing CFU-EPC is real and not an artefact.
Delays in MNC separation, which might have led to underestimation of the
differences in CFU-EPC between non-mobilised and mobilised samples, were
shown not to be causative. The lack of CFU-EPC in mobilised samples was shown
not to be due to loss of 'colony forming' cells from the CFU-Hill assay as colony
forming cells were not retained within the day 2 fibronectin adherent MNC at the
expense of CFU-EPC formation in the day 2 non-adherent MNC. When the sum of
CFU-Hill and colonies within day 2 adherent MNC was considered as 'total
CFU-EPC' or CFU-Hill(direct) colonies were examined, similar substantial
reductions in CFU-EPC following G-CSF were found. The frequency of CFU-EPC in
G-CSF mobilised samples was not altered by modifying the concentrations of cells
plated into the cells or by changing the culture medium during the culture period.
Previous work by our group (136) and others (129, 132, 140) have explored the
importance of CD14+ monocytes for early EPC formation (generated from
fibronectin non-adherent or adherent MNC). Based on the increase in PB monocyte
counts following G-CSF (42, 43) it would be reasonable to suppose that CD14-
dependent CFU-EPC might also increase in mobilised samples. However, results of
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previous studies demonstrating increased CFU-EPC following CD14+ monocyte
enrichment of normal blood MNC were not replicated when G-CSF mobilised MNC
were used. Two-hour plastic adherence of G-CSF mobilised MNC failed to increase
CFU-EPC (136).
The proportions of leukocyte subpopulations and CD235a+ erythrocytes in
peripheral blood and MNC plated into CFU-EPC culture were investigated and the
changes that occurred following G-CSF administration to allogeneic and autologous
PBSC patients noted. The effect of alterations in the proportions of CD14+ monocytes
and other leukocyte subpopulations on CFU-EPC in mobilised MNC was assessed
by phenotypic analysis of whole blood, day 0 MNC and day 2 MNC. Significant
changes in the cells that floated on the Histopaque medium following G-CSF
compared to non mobilised samples were observed. MNC recovered from buoyant
Histopaque density gradient centrifugation of mobilised peripheral blood contained
significantly greater proportions of CD66b+ granulocytes and CD235a+ erythrocytes
than non-mobilised samples and whilst the proportions of CD14+ monocytes were
preserved, the proportions of lymphocytes were reduced. Similar to non-mobilised
samples, there were some losses of CD14+ monocytes from the non-adherent cells
between day 0 MNC and day 2 MNC as a result of retention of 2 day fibronectin
adherent MNC within the original well, leading to reductions in the proportion of
CD14+ monocytes in day 2 MNC. However, there was no significant difference
between the proportions of CD14+ monocytes in day 2 mobilised MNC and day 2
non-mobilised MNC for any patient group. The reduction in CFU-EPC in mobilised
samples could not be attributed to reductions in the proportions of (day 0 or day 2)
MNC monocytes following the administration of G-CSF (alone or sequentially with
either chemotherapy or AMD3100). The effect, if any, of CD66b+ granulocytes on
CFU-EPC, the cell population most changed in MNC following G-CSF was therefore
investigated.
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G-CSF mobilised day 0 and day 2 MNC from both allogeneic and autologous PBSC
donors contained significantly greater proportions of CD66b+ granulocytes than
non-mobilised samples (greater than 5-fold increase), a cell population that is not
isolated in buoyant density separation of normal blood. G-CSF induced stimulation
of proliferation and differentiation of HPC is mediated via myeloid G-CSF receptors
(35, 36). G-CSF also stimulates the proliferation of myeloid cells and activation of
mature neutrophils, inducing the release of their cytoplasmic granules and the
contents of secretory vesicles (27, 37, 38). Elastases, proteases and
metalloproteinases (MMP) released from G-CSF stimulated neutrophils facilitate the
release of FIPC from the BM (37). The reduction in CFU-EPC frequency observed in
G-CSF mobilised MNC could simply have been due to dilution of the cell
populations (other than CD14+ monocytes) involved in the generation of CFU-EPC
or it might be that the enzymes and factors released by stimulated neutrophils
present in mobilised MNC and therefore plated into CFU-Hill assays affect
CFU-EPC forming cells.
We presented novel data that illustrated the effects of CD66b+ granulocytic
populations on CFU-EPC (Chapter 5). Assessing the relative proportions of CD66b+
granulocytes in G-CSF mobilised samples showed no differences between day 0
MNC and day 2 fibronectin non-adherent MNC. 'Contaminating' myeloid cell
proportions were equivalent at both time points. Co-plating studies, where purified
CD66b+ granulocyte populations from non-mobilised and mobilised MNC were
cultured in direct contact and separated in transwell inserts, showed that both
sources of CD66b+ granulocytes modulated CFU-EPC. CFU-EPC frequency of
G-CSF mobilised MNC could be modified by immunomagnetic separation to reduce
MNC CD66b+ granulocytic content. Depletion of CD66b+ granulocytes from G-CSF
mobilised MNC was partially successful in increasing CFU-EPC towards that of
non-mobilised MNC. CD66b+ granulocyte enriched cell fractions (PMN-p cells or
CD66b-depleted MNC) did not generate CFU-EPC when plated alone into cell
culture. Contaminating myeloid cells exert a negative influence on CFU-EPC to
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inhibit colony formation but the mechanism of their actions is yet to be elucidated.
The effects of manipulating the CD66b+ granulocytic content on CFU-EPC were not
consistent but there was enough evidence to suggest a strong contributory effect of
myeloid elements on CFU-EPC within mobilised blood samples but it is clearly not
the whole story. It is likely that additional factors are involved in the reduction of
CFU-EPC in mobilised samples, whether this is mediated through granulocytes and
other myeloid cells or a direct action of G-CSF to affect cells involved in CFU-EPC
(e.g. CD14+ monocytes or lymphocytes).
The proportions of PB CD3+ T cells were found to decline in direct proportion to the
reduction in total lymphocytes following G-CSF+/-chemotherapy or
G-CSF+AMD3100 PBSC mobilisation. CD3+/31+/CXCR4+ 'angiogenic' T cells, a T cell
subpopulation reported by Flur et al to be of significance to CFU-EPC (generated in
fibronectin adherent MNC) was assessed in a subset of non-mobilised and
mobilised PBSC patients (142). In G-CSF+/-chemotherapy mobilised peripheral
blood, the proportions of CD3+/31+/CXCR4+ angiogenic T cells decreased as a
consequence of reduced proportions of total lymphocytes in mobilised samples
rather than due to specific alterations in T cell subpopulations. The reduction in
angiogenic T cells following G-CSF+AMD3100 PBSC mobilisation differed from that
observed in G-CSF+chemotherapy mobilised PBSC patients. T cell numbers were
reduced in proportion to the decline in lymphocytes in G-CSF+AMD3100 mobilised
peripheral blood but angiogenic T cells were disproportionately lowered,
attributable to the reduction in the co-expression of CXCR4 by CD3+ T cells, either a
direct result of AMD3100 or its combination with G-CSF. The potential
contributions of G-CSF mobilised CD66b+ granulocytes to CFU-EPC have been
highlighted but it is possible that the decline in lymphocytes following G-CSF had
some effect on the initiation of CFU-EPC, whether independently or through
interactions with CD14+ monocytes, an area that should be further explored.
Previous work by our group, using plastic adherence and immunomagnetic
separation to enrich normal blood and UCB for CD14+ monocytes, demonstrated
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that CFU-EPC were contained within CD14-enriched fractions and whilst CD4+,
CD8+ and CD19+ cells could be identified in CFU-EPC from unselected MNC, these
cells were not demonstrated in CFU-EPC arising from CD14-enriched fractions
(136). Based on these results it is unlikely that alterations in T cell frequency would
affect CFU-EPC frequency. It may be that a very small numbers of T cells are
required for CFU-EPC but so far our data has not shown this.
There is a lack of information on the expected proportions of leukocyte
subpopulations and erythrocytes in MNC recovered from mobilised peripheral
blood samples after buoyant density gradient centrifugation which makes it difficult
to critically appraise our results compared to published studies. Although there was
evidence published on the haematopoietic (CD14+ monocyte) origin of CFU-EPC
generated by short term culture on fibronectin plates at the time, other studies of the
effects of G-CSF on CFU-EPC (early EPC) formation did not present phenotypic
data on constitution of MNC actually plated into cell culture (162, 163, 165, 167, 170,
189). Despite evidence that short term culture of MNC on fibronectin results in
colonies arising from myelomonocytic cells, it is the CD34+ peripheral blood cells
that the authors' identify and correlate with CFU-EPC. Work within our group (136)
using subtractive analysis demonstrated that CFU-EPC were independent of CD34+
or CD133+ cells. The initial publication by Korbling et al that described collection of
HPC from the circulation reported 10% granulocytes in the leukapheresis product
(15). One murine study (202) using G-CSF+AMD3100 to enhance blood flow in a
hindlimb ischaemia model (202), is notable for its examination of G-CSF+AMD3100
mobilised MNC prepared from density gradient centrifugation of whole blood and
the contributions of different cell fractions to recovery of limb perfusion. MACS
immunomagnetic bead separation was used to separate the CDllb+ cells from
MNC, which comprised 36% of isolated 'MNC' and consisted mainly of neutrophils.
Following further separation of CDllb+ cells (FACS sort) into neutrophils,
monocytes, and NK cells the authors demonstrated clinical benefits of CDllb+ MNC
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and CDllb+ monocytes but not of CDllb+ neutrophils but cell fractions were not
plated into CFU-EPC assays (202).
Expression of adhesion molecules including VLA-4 (CD49d) and L-selectin by
CD34+ cells is reduced (55, 56) and soluble factors including sL-selectin, sE-selectin
and sCD44 are increased following G-CSF administration (43, 54). It is reasonable to
suppose that G-CSF stimulated myeloid cells contained in CFU-EPC culture might
affect cell expression of adhesion markers by other cell populations apart from
CD34+ cells including CD14+ monocytes. The effects of G-CSF administration in vivo
on the expression of adhesion molecules by leukocytes is currently being assessed.
Differences in the expression of adhesion molecules between non-mobilised and
mobilised patient samples and differences between UCB and samples from adult
PBSC donors have been observed. Preliminary studies have shown alterations in the
monocytic expression of CD29, CD49d, CD49e and CD49c with differences noted
between UCB, non-mobilised peripheral blood and mobilised peripheral blood.
Alterations in adhesion markers, through the effects of this on the adherence of
potential of colony forming cells to fibronectin, might prove significant in colony
based EPC assessments. Additionally, interruption of signalling through fibronectin
receptors as a result of G-CSF might alter cell activation and cell function.
EPC, variously defined according to their expression of CD34, KDR and CD133
antigens, with expression of these antigens alone or in combination being used to
define them, have been correlated with disease states (110, 111). There is little debate
about the existence of endothelial and haematopoietic progenitors within the CD34+
fraction of BM, UCB and PB MNC. KDR (VEGFR2) and CD133, both used to define
EPC, are also expressed by HSC/HPC (93, 112, 113). CD34+/133+/VEGFR2+ cells
identified by Piechev and others (112, 122, 125, 128) and present in extremely low
numbers (0.0084%+/-0.0052% in whole blood and 2.07%+/-0.15% in mobilised PB
CD34+ cells according to Case et al are haematopoietic (112). The direct contribution
of CD34+/133+/KDR+ cells to vasculogenesis has not been reported (113) so the earlier
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phenotypic definitions of EPC, based on the hypothesis by Asahara et al, may be
incorrect.
The phenotypic identification of EPC using CD34 in combination with CD133
and/or KDR has been often presented together with results of short term culture of
MNC on fibronectin to identify EPC, including those studies examining effects of
G-CSF on EPC (162, 163, 165, 167, 170). In these studies EPC were identified using a
number of different phenotypes; CD34+ (162, 170), CD34+/133+/KDR+ (162, 163),
CD34+/133+ (167), CD133+/KDR+ (167) with some comparing their flow cytometry
results to CFU-EPC and finding no correlation between frequency of putative EPC
phenotypes and culture based EPC assessments (162, 169, 170). However,
phenotypically identified CD34+ EPC, are now believed to have key roles in EOC
formation rather than in early EPC formation (129, 132, 139) leading us to question
the relevance of these putative EPC phenotypes to EPC identified in short term
culture on fibronectin.
Our data demonstrated that in the non-mobilised state, progenitor cells
(haematopoietic or endothelial) are present at very low levels in peripheral blood
and MNC. Similar to others, when defined phenotypically as CD34+/KDR+ or
CD34+/133+/KDR+ cells, EPC were not identifiable by flow cytometry in the
non-mobilised state (128). A stem cell gate (Stems Rl), defined on the basis of light
scatter characteristics and the expression of CD133 and/or CD34 antigens was used
to capture all events expressing CD133 or CD34 and all haematopoietic and non-
haematopoietic progenitor cells (Chapter 6). In non-mobilised samples there was a
relatively even distribution of stem cell phenotypes between CD133+/34" (36.8%),
CD133+/34+ (32.3%) and CD133 /34+ cells (30.8%) in freshly isolated MNC , with no
differences noted between normal donors (allogeneic PBSC donors) and non-
mobilised autologous PBSC patients, confirming earlier reports (123, 136). Virtually
all CD34+ and/or CD133' cells were CD45* and no populations of CD45 cells could
reliably be identified. Analysis of the proportions of stem cells contained in G-CSF
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mobilised peripheral blood arid MNC showed significant differences in stem cell
numbers and phenotypes compared to non-mobilised samples. G-CSF mobilised
CD133+ stem cells and CD34+ stem cells to similar extents, though the proportions of
CD34+ stem cells always exceeded those of CD133+ stem cells.
Consistent with other studies reporting on the effects of G-CSF on EPC, G-CSF
increased the numbers of CD34' (162-164), CD34+/133+(164, 167, 168) and CD34+/133"
/KDR+ cells (162, 163, 166). Increases in CD133+/34~ and CD34+/133 stem cells were
also noted following G-CSF. G-CSF mobilised stem cell populations contained large
proportions of CD133+/34+ dual positive stem cells (3.9% CD133+/34~, 75.9%
CD133+/34+ and 20.1% CD34+/133" in mobilised whole blood and 6.1% CD133+/34",
72.2% CD133+/34+ and 22.0% CD34V133" in mobilised day 0 MNC), figures
comparable to that reported by O Tura and de Wynter et al (123, 136). No differences
were seen in stem cell phenotypes between allogeneic and autologous PBSC donors.
Increases in the proportions of CD133+/34+ cells occurred principally at the expense
of CD133/34+ cells which were present in reduced proportions in mobilised
compared to non-mobilised samples. Similar to non-mobilised samples, almost all
stem cells were CD45+ with only very small populations of CD45" stem cells (CD34+
and/or CD133+ cells, Stems R1 gate) identified in a proportion of samples. When
present, CD45" stem cells appeared to contain greater proportions of CD133+/34" cells
compared to CD45+ stem cells. Preliminary data from the analysis of a small group
of patients undergoing PBSC mobilisation with G-CSF and AMD3100 (without
chemotherapy) showed similar changes in stem cell phenotypes of mobilised
samples with a predominance of CD133+/34+ stem cells in mobilised samples.
Examination of putative EPC phenotypes found in G-CSF mobilised peripheral
blood and UCB samples confirmed that virtually all CD34+ progenitor cells
mobilised by G-CSF were haematopoietic and expressed CD45 whilst CD34+/45"
cells were identified in UCB. Although UCB stem cells were enriched in CD133+/34+
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cells (62% of stem cells), figures comparable to that reported by other studies (123,
169), this differed significantly from G-CSF mobilised peripheral blood. Despite
being rich in CD34+ cells, preliminary studies failed to identify EOC within
unselected G-CSF mobilised MNC. However, UCB MNC, another CD34-rich source,
reliably generated EOC. There are a lack of reports relating to EOC formation in
G-CSF mobilised MNC. A single human study (Shepherd et al) reported increased
EOC (per mL blood) following the administration of G-CSF and also following
AMD3100 when MNC (collected by leukapheresis) were cultured in EGM2
supplemented with FCS together with VEGF (189). A murine study, similarly used
supplemented EGM2 with additional VEGF to assess late outgrowth cells appearing
on fibronectin (190). In our laboratory, selection of MNC according to their
expression of CD34 and CD133 has demonstrated enhanced EOC within CD34+/133"
UCB MNC (O Tura, personal communication) which is in agreement with reports
by other groups (112, 134, 150). A unique population of CD34+ cells (CD34BRIGHT),
defined by their bright CD34 expression, was identified in UCB CD34+ but not in G-
CSF mobilised peripheral blood CD34+ or non-mobilised PB CD34+ cells. UCB
CD34BRIGHT cells were more likely to be CD133" and CD38 and to express KDR
compared to UCB CD34REG, mobilised PB CD34+ cells (all CD34REG) and
non-mobilised PB CD34' cells (all CD34REG). EOC were enriched in UCB CD34+/133"
MNC fractions. However, G-CSF mobilised MNC, which is also enriched in CD34+
cells, and have CD34+/133" cells accounting for just over 20% of (CD34+ and/or
CD133+) stem cells, are yet to be shown to produce EOC. We propose that these
UCB CD34BR1GHT cells might be critical for EOC formation and could contain the
EOC progenitors.
The source of EOC within a subset of CD34+/133" cells, possibly from this CD34BRIGHT
fraction, would be consistent with conclusions published by three groups
investigating the phenotype of cells contributing to EOC, that EOC arose from
CD45/34+ cells that did not express CD133. (112, 134, 150). The belief that EPC
could be defined phenotypically by cell expression of three antigens, CD34, CD133
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and KDR, has been refuted. Untergasser et al reported that EOC arose in peripheral
blood and UCB CD34+/133" but not CD34+/133+ cells (150). Case et al reported that
BM and UCB CD34+/45" cells formed EOC but failed to generate CFU-EPC or
haematopoietic activity whilst CD34+/45+ cells were enriched for haematopoietic
colony forming activity (112). Timmermans et al reported that UCB and BM MNC
derived EOC arise from CD34+/45~ cells and identified CD34+/133 /KDR+ cells as the
source of EOC (134). CD34+/133+/KDR+ cells from UCB and mobilised PB CD34+ cells
were CD45+ (>99%) and failed to generate CFU-EPC or EOC but produced low and
high proliferative potential HPC in haematopoietic assays (112). Our own work
showing increased EOC in CD34+/133" UCB cells is consistent with their conclusions
(O Tura).
UCB CD34REG and CD34BR,GHT cells were examined for CEC phenotypes using the
antibody combinations CD34+/31+/45~, CD34+/45/146+ and CD34+/45/146+/31+
reported by others (116, 194-196) to identify CEC. Although there was no difference
in CD31 expression between UCB CD34REG and CD34BRIGHT cells, UCB CD34BRIGHT
cells contained greater proportions of CD34+/31+/45" (36.1%), CD34+/45/146+ (5.4%)
and CD34+/45 /146+/31+ (5.0%) than UCB CD34REG cells (8.0% (p<0.0.01), 1.0% and
0.8% respectively). We should therefore question whether the CD34+/133" cells (112,
134, 150) or CD34+/133 /KDR+cells (112), thought to be critical to EOC formation, do
in fact arise from circulating cells that are endothelial-committed and may be quite
mature, and not a primitive progenitor as implied in some interpretations (96, 153).
CD34+ cells expressing CD31 and CD146 have been reported by another group as
identifying EOC (189). In this study of EPC phenotype by Shepherd et al, EPC were
identified in G-CSF mobilised peripheral blood and in day 14-28 cultured EOC, as
CD34+/31V144+/146V105+ cells that did not express CD45 or CD14 with cell numbers
increasing (per mL peripheral blood) following G-CSF. Insufficient EOC
(CD34731 '/I 44h/1 4671 0574571 4 cells) were obtained for transplantation into a
murine hindlimb ischaemia model and cells did not survive cryopreservation. Cells
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were only passaged three times and no reference to continued cell proliferation was
made by the authors (189). A study examining KDR+ cell populations (Vroling et al)
identified increased numbers of CD45/34+/KDR+ cells in the peripheral blood of
patients with cancer compared to healthy controls(203). These cells expressed CD31,
CD146 and CD105 but were CD133" and CD13"(203). Vroling et al considered these
cells to be distinct from phenotypically defined CD146+ circulating endothelial cells,
largely on the basis of their light scatter characteristics. Further phenotypic and
culture based assessments of CD34+ subsets within UCB and mobilised peripheral
blood are now being performed within our group.
It would appear that in most areas, the co-administration of sequential G-CSF and
AMD3100 prevented any AMD3100-specific effects being noted. It was found that
G-CSF+AMD3100 produced similar changes in CFU-EPC formation, leukocyte
subpopulations, and stem cell phenotypes as observed following
G-CSF+/-chemotherapy PBSC mobilisation. The only clear difference between G-CSF
and G-CSF+AMD3100 mobilised patient samples was reductions of 'angiogenic' T
cells observed, as a result of the reduction in co-expression of CXCR4 by CD3+ T
cells in the latter group. AMD3100, a reversible CXCR4 antagonist, does not cleave
the CXCR4 receptor. It is possible that the epitope targeted by the particular
anti-CXCR4 antibody used in flow cytometry analysis was still affected by
AMD3100 at the time of sampling. Sequential administration of AMD3100 with
G-CSF might have had additive effects on the CXCR4 receptor or perhaps more
likely the timing of the 5lh dose of G-CSF, administered 1-2 hours prior to collection
of mobilised samples led to the profound reduction in CXCR4 expression by CD3+ T
cells. Recently published microarray data using an animal (macaque) model,
suggests the differential mobilisation of progenitors by G-CSF and AMD3100 (204).
In this study, 3 gene expression clusters were identified, with sequential G-CSF
+AMD3100 up-regulating genes distinct from mobilisation with either G-CSF or
AMD3100 alone. There is no immediate prospect of using AMD310U alone for PBSC
mobilisation in the local clinical setting, restricting our ability to investigate this
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agent separately but animal studies suggest that this agent does mobilise different
progenitors to G-CSF and could therefore be useful clinically in the setting of
vascular repair (190, 204).
The clinical outcomes of a number of studies using G-CSF to mobilised cells for
vascular repair, mostly in patients following myocardial infarction has been
reported. The use of G-CSF mobilised progenitor cells for cardiovascular
regeneration stalled once adverse findings of increased incidence of instent stenosis
in following intracoronary implantation of autologous G-CSF mobilised MNC were
reported (171). Subsequent to this, a small uncontrolled trial reported improved
cardiac function following intracoronary infusion of autologous G-CSF mobilised
MNC (172). A number of studies demonstrated no clinical benefit of using G-CSF
alone, without the collection and local implantation of autologous mobilised cells, as
an adjunct to standard medical care following myocardial infarction (166, 168, 173-
175). Two studies reporting clinical improvements following G-CSF (176, 177) have
been criticised and a meta-analysis on the use of G-CSF in patients with acute MI
concluded that G-CSF administration failed to demonstrate any overall benefits
compared with conventional treatment (178).
Whilst a handful of studies have reported enhanced CFU-EPC following G-CSF, this
work confirmed our previous findings of reductions in CFU-EPC following G-CSF
administration. There are difficulties in interpreting phenotypic and culture based
assessments of EPC, due to differences in methodologies used and also because our
understanding of the cells encompassed by the term 'endothelial progenitor cells'
has changed. Whilst some studies identified increased proportions of
phenotypically defined EPC following G-CSF, and some studies identify increased
numbers of CFU-EPC, it is difficult to relate these results to studies that have failed
to demonstrate clinical benefits (on revascularisation and cardiac function for
example) of G-CSF. In such studies the clinical effects of G-CSF were assessed by a
range of standard tests of cardiac function. The role of G-CSF in mobilising EOC is
yet to be explored to any great extent. Using phenotypic analysis to compare UCB
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and mobilised MNC differences between these sample groups were identified
which when related to results of recent publications investigating EOC (112, 134,
150) and to results of our EOC cultures led to further investigation of CD34+
subpopulations.
The cells contributing to the repair of damaged tissue are not well defined. It may be
that BM derived endothelial cells (91, 107, 205) and vascular wall derived
endothelial precursors (113) are important but there is likely a large , possibly
indirect, contribution made by BM-derived cells of haematopoietic origin. A number
of recent studies suggest that transplanted G-CSF mobilised CD34+ or CD133+ cells
may provide a microenvironment supportive of tissue regeneration and vascular
repair through autocrine and paracrine actions (183, 202). A phase I/IIa trial of
locally implanted autologous G-CSF mobilised CD34+ cells in patients with critical
limb ischaemia reported clinical benefits in the ischaemic limb (188). Two recent
studies also reported clinical benefits of locally implanted human G-CSF mobilised
CD34+ or CD133+ cells in animal models of injury (185, 187) and suggested that
implanted cells enhanced angiogenesis of recipient cells by creating a favourable
microenvironment for tissue regeneration and by producing pro-angiogenic
cytokines.
With recognition that pro-angiogenic effects of cell therapy extend beyond
incorporation of transplanted cells into the vessel wall, the affect of cytokines
(VEGF, IL-8) and proteases, including matrix metalloproteinases (MMP) released by
EPC as well as other functions of EPC, identified in short term culture on
fibronectin, on vessel formation has being investigated (130-132). The role G-CSF in
stimulating the release of enzymes including MMP from neutrophils (53) may also
be relevant to vascular repair. The Moldovan group has reported on the influence of
monocytes and macrophages, through formation of cord-like structures and release
of factors including macrophage specific metalloelastase 12 (MMP-12) which
degrade the extracellular matrix, in facilitating the co-localisation and spatial
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arrangement cells involved in neovessel formation (143, 144, 206). If G-CSF reduces
the ability of CD14+ monocytes to participate in CFU-EPC, it may also down-
regulate other angiogenesis-related 'monocyte' activities. With the recognition of the
contributions of mature haematopoietic cells and haematopoietic progenitors to
vascular repair and the roles of the microenvironment, cytokines and other cellular
elements to this process, current in vitro models and assays may be inadequate. The
contribution of different processes and cells to a global measure of vascular repair
will not easily be resolved.
Whilst it would be of great benefit to be able to prospectively identify and quantify
EPC it may not be possible to assess 'vasculogenic potential' in a single test, whether
this be culture based, phenotypic or another form of assessment. The ability to study
bone marrow, which was not explored during the course of this work, would be
beneficial in providing comparative data for mobilised samples, something that is
now being actively pursued as it may be that the changes that occur in progenitor
cells within the bone marrow and the bone marrow stroma leading to progenitor
cell mobilisation have significant effects on our assessments of putative EPC. Recent
publications reporting clinical benefits of mobilised CD34+ and CD133+ cells leads us
to speculate that the cells delivering the therapeutic effect may be true
haematopoietic progenitor cells rather than major contributions by EPC.
The rationale behind use of GCSF mobilised blood in vascular repair is that it
contains a high level of putative EPC to address the reduced level of EPC found in
patients with vascular disease and cardiovascular disease. This study has confirmed
earlier findings in our research group that contradict what has previously been
understood. GCSF administered for the mobilisation of FIPC does not lead to a high
level of EPC, as assessed by CFU-EPC (or EOC) assays. If our findings of reduced
CFU-EPC in G-CSF mobilised blood are translated from the laboratory and into the
clinic, any clinical benefits reported from the administration of G-CSF or the
implantation of G-CSF-mobilised cells in the setting of myocardial or vascular
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damage may not have been delivered by EPC but by HPC and other haematopoietic
cells. This would suggest that the clinical basis for use of GCSF mobilised blood may
need to be reconsidered. Once the different components of angio/vasculogenesis are
better defined and their functions understood it may then be possible to design
therapeutic regimens that can answer these questions and move cell-based therapy
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Figure 1 CFU-EPC in non mobilised MNC-s cells (A and D), CFU-EPC and cell clusters
in G-CSF mobilised MNC-s cells (B and E) and CFU-EPC in G-CSF mobilised
CD66b-depleted MNC (C and F); allogeneic PBSC patient (patient 27G).
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Figure 2 CFU-EPC in non mobilised MNC-s cells (A and D), well appearance of
CD66b-enriched MNC (B), CFU-EPC in G-CSF+AMD3100 mobilised MNC-s cells (E)
and CFU-EPC in G-CSF+AMD3100 mobilised CD66b-depleted MNC (C and F);














299 G+A No 4 0 0 ND
299 G+A No 0 0 0 ND
314 G+C No 0 0 0 ND
300 G No 1 0 0 ND
304 G+C No 2 0 0 ND
305 G+C No 2 0 0 ND
311 G+C No 2 0 0 ND
HV01 Nil No 20 0 ND 30 (14+MNC-s)
HV02 Nil No 8 0 ND 50 (14+MNC-s)
299 G+A Yes 1 0 0 ND
293 G Yes 0 0 0 ND
294 G Yes 1 0 0 ND
314 G+C Yes 0 0 1 ND
309 G+C Yes 0 0 4 ND
300 G Yes 1 0 0 ND
302 G+C Yes 3 0 0 ND
305 G+C Yes 1 0 0 ND
315 G+C Yes 0 0 ND 0 (14+MNC-s)
316 G+A Yes 12 4 0 2 (14+MNC-s)


















Mixed culture Mixed culture
314 G+C 0 2 ND ND 1 0 (MNC-S+14*) 0 (3 +14+)
315 G+C 0 0 0 0 0 0 (MNC-s+14*) 0 (MNC-S+3*)
HV02 nil 8 10 0 0 ND 50 (MNC-S+14*) 100 (3+14*)
HV01 nil 20 0 ND 0 ND 30 (MNC-s+14*) 0 (3 +14*)
314 nil 0 0 0 0 (MNC-s+14*) 0 (3 +14*)
Table CFU-EPC results for CD3 MACS immunomagnetic separation experiments.
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Appendix
Tube FL-1 FL-2 FI-3 FI-4
1 — — — —
2 — — — Anti 45-APC
3 — Anti 133-PE Anti 34-PerCP Anti 45-APC
4 Anti KDR-FITC Anti 133-PE Anti 34-PerCP Anti 45-APC
5 Anti 38-FITC Anti 133-PE Anti 34-PerCP Anti 45-APC
6 Anti KDR-FITC Anti CXCR4-PE Anti 34-PerCP Anti 45-APC
7 Anti 31-FITC Anti CXCR4-PE Anti 3-PerCP Anti 45-APC
8 Anti 31-FITC Anti CXCR4-PE Anti 19-PerCP Anti 45-APC
9 — — — —
10 Anti 38-FITC Anti 15-PE Anti 34-PerCP Anti 13-APC
11 Anti 33-FITC Anti 14-PE Anti 34-PerCP Anti 13-APC
12 Anti 64-FITC Anti 14-PE Anti 34-PerCP Anti 45-APC
13 Anti 66B-FITC Anti 15-PE Anti 34-PerCP Anti 45-APC
14 Anti 66B-FITC Anti 235a-PE Anti 14-PerCP Anti 45-APC
Stem cell subset analysis - antibody panel
Tube FL-1 FL-2 FI-3 FI-4
1 — — — —
2 — — — Anti 45-APC
3 — Anti 133-PE Anti 34-PerCP Anti 45-APC
4 Anti KDR-FITC Anti 133-PE Anti 34-PerCP Anti 45-APC
5 Anti 38-FITC Anti 133-PE Anti 34-PerCP Anti 45-APC
6 Anti KDR-FITC Anti CXCR4-PE Anti 34-PerCP Anti 45-APC
7 Anti 31-FITC Anti 146PE Anti 34-PerCP Anti 45-APC
8 Anti 31-FITC Anti CXCR4-PE Anti 3-PerCP Anti 45-APC
9 Anti 66B-FITC Anti 235a-PE Anti 14-PerCP Anti 45-APC
Stem cell subset analysis - abbreviated antibody panel
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CSF administration depresses both endothelial cell angiogenesis
and monocyte proangiogenic activity, and we suggest that any
angiogenic benefit observed following implantation of cells
mobilized by G-CSF may come only from a paracrine effect
from FlPCs.
Summary. Background: The most common source of hemato¬
poietic progenitor cells (FlPCs) for hematopoietic reconstitution
comprises granulocyte colony-stimulating factor (G-CSF)-
mobilized peripheral blood stem cells (PBSCs). It has been
proposed that endothelial progenitor cells (EPCs) share
precursors with HPCs, and that EPC release may accompany
F1PC mobilization to the circulation following G-CSF admin¬
istration. Objective: To investigate EPC activity following HPC
mobilization, and the direct effects of exogenous G-CSF
administration on human umbilical vein endothelial cells
(HUVECs) and endothelial outgrowth cells (EOCs), using
in vitro and in vivo correlates of angiogenesis. Patients/
Methods: Heparinized venous blood samples were collected
from healthy volunteers and from cord blood at parturition.
G-CSF-mobilized samples were collected before administra¬
tion, at apheresis harvest, and at follow-up. PBSCs were
phenotyped by flow cytometry, and cultured in standard
colony-forming unit (CFU)-EPC and EOC assays. The effect of
exogenous G-CSF was investigated by addition of it to
HUVECs and EOCs in standard tubule formation and aortic
ring assays, and in an in vivo sponge implantation model.
Results: Our data show that G-CSF mobilization of PBSCs
produces a profound, reversible depression ofcirculating CFU-
EPCs. Furthermore, G-CSF administration did not mobilize
CD34 + CD133- cells, which include precursors of EOCs. No
EOCs were cultured from any mobilized PBSCs studied.
Exogenous G-CSF inhibited CFU-EPC generation, HUVEC
and EOC tubule formation, microvessel outgrowth, and
implanted sponge vascularization in mice. Conclusions: G-
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Introduction
The recent discovery that endothelial progenitor cells (EPCs),
which play a role in de novo vascularization (vasculogenesis),
circulate in adult blood and reside in the bone marrow [1,2]
prompted a range of studies based on localized implantation of
autologous cells, aimed at vascularizing ischemic tissue,
particularly in myocardial and critical limb ischemias. EPCs
have not yet been definitively characterized, but have been
linked with hematopoietic progenitor cells (HPCs). EPCs and
HPCs share a common ancestor, the hemangioblast, in the
developing fetus that may be retained in adult life [3], HPCs
derived from bone marrow [bone marrow stem cells (BMSCs)]
or peripheral blood (PB) [peripheral blood stem cells (PBSCs)]
following granulocyte colony-stimulating factor (G-CSF)
administration have been utilized as sources of EPCs for
regenerative vascularization. A recent meta-analysis showed
that BMSC treatment generally improves short-term measure¬
ments of cardiac function after myocardial infarction.
However, there is, as yet, little evidence with which to assess
the long-term clinical effects of this treatment [4], Although
most studies so far reported have used BMSCs for therapeutic
angiogenesis, those in which G-CSF-mobilized PBSCs were
used gave comparable, mild improvements in cardiovascular
lesions [5], and both sources are generally regarded as adequate
for therapeutic angiogenesis, just as they are for hematopoiesis.
To date, some studies have shown that EPCs, as well as HPCs,
are demonstrably mobilized by G-CSF [6-8], However, this
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depends on how EPCs are defined and interpreted: we can
measure increases or decreases in EPC numbers following G-
CSF administration, depending on how EPCs are defined [9],
The current characterizations of EPCs have been based on
phenotype and on colony assays. HPCs are routinely defined
for clinical use by their expression of CD34 or CD133 [ 10]. A
link between CD34/CD133 expression and the EPC phenotype
was proposed almost from the initial discovery of circulating
EPCs [II. 12], but recent studies have indicated that cells
expressing CD 133 and their progeny remain hematopoietic,
and only CD34 + CD133- cells are true EPCs [13.14], True
EPCs are defined as cells that, in culture over 3 4 weeks on
collagen, can give rise to endothelial outgrowth cells (EOCs)
[14-16], whereas cells that give rise over 5-6 days to colonies on
fibronectin (colony-forming unit endothelial progenitor cells)
(CFU-EPCs), formerly proposed to be EPCs [17], are now
recognized to be generated by monocytes [16,18,19], CFU-
EPCs stain for many endothelial markers [20,21] but also retain
CD 14 expression [22], Monocytes can themselves mimic
endothelial cells (ECs) by upregulating expression of many
markers held to be endothelial, and have probably been
mistaken for ECs in many investigations [22,23], Although it is
implicit in many studies that the observed clinical benefit is
delivered by EPCs, which are ultimately incorporated as ECs
into new vasculature, it is becoming apparent that neovascu¬
larization can also be promoted indirectly by cells that release
paracrine factors that promote angiogenesis without being
incorporated as ECs [24], Although such cells may not be true
EPCs. their proangiogenic effect may be important, and this
may be why so many different cell phenotypes have been
proposed to be EPCs [25,26],
To date. G-CSF PBSC mobilization has been generally
regarded as a practical and feasible source of cells for
therapeutic angiogenesis [27-29], However, a recent meta¬
analysis reported that G-CSF infusion alone had no significant
clinical benefit in myocardial infarction [30], and it was
reported that G-CSF-mobilizcd PBSCs were less effective in
inducing ulcer healing than were BMSCs [31], The mechanism
by which G-CSF may mobilize EPCs and/or enhance angio¬
genesis is still unknown. Similarly, the effects of G-CSF on ECs
and the vasculature have not been extensively studied [32], In
this study, we have investigated circulating EPC activity
following HPC mobilization by G-CSF administration, and




Male C57B6J mice aged 10-12 weeks were purchased from
Charles River Laboratories (Tranent, UK) or Harlan Olac Ltd
(Loughborough, UK). Experimental procedures were
approved by the University of Edinburgh ethics committee,
and were authorized by the Home Office under the Animals
(Scientific Procedures) Act 1986.
Cell sources and sampling
Peripheral venous blood samples from healthy adults (normal
PB) were collected into heparin and from cord blood (CB)
following elective caesarean section. For sequential studies,
healthy PBSC donors (mobilized PB donors) and PBSC
transplant patients (mobilized PB patients) donated 10 mL of
venous PB before G-CSF mobilization (pre-G-CSF); at
apheresis harvest (post-G-CSF), and 1-2 months after harvest
(follow-up). The G-CSF protocol used in this work was the
standard local clinical mobilization regimen. The G-CSF
(lenograstim) dose for healthy donors was 10 pg kg-1 d~',
given for four consecutive days before collection of post-
G-CSF cells (at apheresis) on day 5. Patient samples were
subjected to chemotherapy — salvage chemotherapy (lym¬
phoma patients) or cyclophosphamide (multiple myeloma
patients) — followed by G-CSF (lenograstim), starting at least
24 h following the last dose of chemotherapy — 5 pg kg-1 d~'
(lymphoma patients) or 10 pg kg-1 d_1 (multiple myeloma
patients) — and given for 6-7 days before collection of post-
G-CSF cells when CD34+ counts exceeded 10 x 106 L_l. Pre-
G-CSF treatment cells were collected 10-30 days prior to
G-CSF administration. Healthy adult donors (for allogeneic
transplant) are the primary study subjects, and results for
patients are included for comparison. Further clinical, hema¬
tologic and laboratory data are reviewed elsewhere (J. Craw¬
ford, MD thesis, University of Edinburgh, submitted).
Appropriate ethical informed consent was obtained from
subjects in all cases. Mononuclear cells (MNCs) were isolated
by buoyant density centrifugation over Ficoll-Paque Plus (GE
Healthcare, Uppsala, Sweden).
Isolation of short-term (2 h) plastic-adherent MNCs
MNCs (30 x 106) in 5 mL of IMDM (Invitrogen, Paisley, UK)
containing 10% fetal bovine serum (Sigma, Dorset, UK) were
plated in 25-cm2 Corning tissue culture flasks (Fisher Scientific,
Loughborough, UK) and incubated at 37 °C. After 2 h,
adherent cells were detached using 1 mL of trypsin-EDTA in
saline (Sigma). Harvested cells were resuspended in IMDM and
characterized by flow cytometry for use in further experiments.
Flow cytometry analysis and sorting
Cells were directly stained and analyzed on a FACS Calibur
flow cytometer (Becton Dickinson, Oxford. UK), using
CellQuest Pro software for phenotypic expression of surface
markers, and analyzed using FCS Express (DeNovo Software,
Los Angeles, CA, USA), as described previously [9], Cells were
sorted using a FACS Aria flow cytometer (Becton Dickinson),
using Diva software. Sorted populations were recovered and
characterized by further analysis. The anti-human monoclonal
antibodies used for flow cytometry included anti-CD34-fluo¬
rescein isothiocyanate, anti-CD 14-phycocrythrin, anti-CD45-
PerCP (Becton Dickinson), and anti-CD 133-allophycocyanin
(Myltenyi Biotec, Bisley, UK).
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CFU-EPCs
This assay, based on the method of Hill et al. [17], was
performed using a commercial kit according to the manufac¬
turer's recommendations (Stem Cell Technologies, Grenoble,
France). As previously described [9,20,21], 5 x 106 unmodified
MNCs were resuspended in EndoCult Liquid Medium (Stem
Cell Technologies) and plated on fibronectin-coated six-well
plates (Becton Dickinson) for 2 days. The non-adherent cells
were recovered, resuspended in fresh medium, and transferred
to a fibronectin-coated 24-well plate (Becton Dickinson) at
1 x 106 per well in the presence or absence of G-CSF
(100 ng mL~') for a further 3 days; the colonies per well were
then counted, and the EPC frequency was calculated. The
concentration of G-CSF used in this and other in vitro assays
described below was based on a previously determined
optimal dose for CD34+ PBSC expansion/differentiation to
neutrophils [33],
Culture of EOCs
EOC culture was performed as described by Ingram et al. [34].
Briefly, 30 x 106 MNCs from normal PB or 10 x 106 MNCs
from CB were resuspended in endothelial growth medium
(EBM-2; Lonza, Slough, UK) and plated onto type 1 rat tail
collagen-coated six-well tissue culture plates (Becton Dickin¬
son). The cells were incubated at 37 °C with 5% C02 for
3^1 weeks. The medium was changed every 2 days for 7 days,
and then twice a week until first passage. Colonies were counted
when they became evident but before they became confluent.
In vitro vascular tubule formation assay
Matrigel matrix (Becton Dickinson) solution was thawed
overnight at 4 °C, and all plasticware was precooled. Human
umbilical vein endothelial cells (HUVECs) (Lonza) and EOCs
were resuspended at 1 x 105 mL"' in EBM-2 in the presence or
absence of G-CSF (100 ng ~'niL). Five hundred microliters of
cells were added to duplicate wells precoated with 250 pL of
Matrigel that had been allowed to solidify for 1 h at 37 °C.
Capillary structures and EC networks were examined by phase
contrast microscopy (x 40 lens), using an inverted microscope
(Nikon Eclipse TS100-F, Nikon Instruments, Kingston Upon
Thames. UK). Pictures were taken at 4 h and at 22 h. The EC
network was quantified from the image fields by scoring the
number of cell-cell connections.
In vitro angiogenesls: aortic ring assay
C57BI6 mice were killed by asphyxiation in CCK The thoracic
aorta was removed, washed in serum-free MCDB 131 medium
(Invitrogen), cleaned of periadventitial tissue, and divided into
1-mm rings. Aortic rings were embedded in 200 pL of Matrigel
(Becton Dickinson) and incubated at 37 °C in serum-lree
MCDB 131, with heparin, ascorbic acid and GA1000 (Cambrex
Biosciences, Wokingham, UK) in the presence or absence of
G-CSF (100 ng mL-1). The medium was changed every 48 h.
All assays were performed in triplicate. The growth of new
vessels was counted at day 4 and day 8 by light microscopy.
Subcutaneous sponge implantation assay for in vivo
vascularization
Mice were anesthetized with halothane, and a sterilized sponge
cylinder (0.5 cm diameter, 1 cm long) (Caligen Foam, Acc-
rington, UK) was implanted subcutaneously on each flank.
Each animal had an intervention-impregnated sponge [growth-
factor-reduccd (GFR)-Matrigcl + G-CSF] on one side and a
control, vehicle-impregnated sponge (GFR-Matrigel alone) on
the other side. Twenty days after implantation, mice were
killed, and sponges were excised. Sponges were fixed in 4%
formalin and embedded in paraffin wax. Sections (5 pm) were
stained with hematoxylin-eosin for identification of blood
vessels, as previously described [35]. Vessel density within
sponges was determined using the mean of triplicate Chalkley
counts on each of two sections per sponge [36].
Statistical analysis
Unless otherwise stated, continuous variables are reported as
mean ± standard error of the mean. Statistical analyses were
performed with GraphPad Prism 4 (Graph Pad Software, La
Jolla. CA, USA), using two-tailed Student's r-test, Mann-
Whitney (7-test or Wilcoxon paired tests where appropriate. A
P-value of < 0.05 was considered to indicate statistical
significance.
Results
The effects of in vivo administration of a PBSC-mobilizing
G-CSF regimen on indicators of angiogenesis
The induced depression of CFU-EPC capacity in PB MNCs
following G-CSF administration is profound but transient
When individual healthy subjects (PBSC donors) were followed
sequentially, G-CSF administration caused a profound decline
in CFU-EPC activity from normal levels, which recovered with
time (Fig. I A). The CFU-EPC activity was virtually abolished
after G-CSF administration as compared with the pre-G-CSF
sample (P < 0.001, paired r-test, n = 21). CFU-EPC activity
returned to almost basal levels in follow-up samples after
1-2 months following completion of G-CSF treatment
(P < 0.01, paired r-test, n = 13). Similar depression and
recovery of CFU-EPC activity following G-CSF mobilization
of PBSCs (for autologous transplantation) was seen in a large
series of hematology patients (data not shown).
G-CSF-mobilized PB MNCs are unable to generate CFU-
EPCs and these are not recovered by monocyte
enrichment Confirming what we have previously reported
[9], CFU-EPCs were most prevalent in normal PB MNCs and
were virtually absent from G-CSF-mobilized PB MNCs,
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Fig. I. Influence of administration of granulocyte colony-stimulating factor (G-CSF) for hematopoietic progenitor cell (HPC) mobilization (Mob) on
colony-forming unit endothelial progenitor cells (CFU-EPCs) in peripheral blood (PB) mononuclear cells (MNCs). (A) There was a fall in CFU-EPCs
following G-CSF administration to healthy adult HPC donors and a subsequent rise in CFU-EPCs at l-2-month follow-up after mobilization. (B) CFU-
EPCs in normal PB MNCs and in HPC-rich MNC sources. (C) CFU-EPCs in MNCs (black) and following monocyte (CD 14) enrichment by plastic
adherence (grey). A P-valuc of < 0.05 was considered to indicate statistical significance (*P < 0.05; **P < 0.01; ***p < 0.001). Pre, prc-G-CSF
administration; Post, post-G-CSF administration.
whether from patient or healthy donor sources (Fig. 1B). We
found that CFU-EPCs were slightly increased (e.g. from 21 to
25 per 106 MNCs, n = 6) when normalPB MNCs were
enriched for monocytes (to around 80% CD 14 + ) by 2 h of
adherence on uncoated culture plates. Further enrichment of
monocytes (to 98%) by CDI4+ selection by FACS further
increased CFU-EPCs (e.g. from 25 to 41 per 106 MNCs,
n = 6) and completely removed CFU-EPCs from the CD 14-
depleted adherent cells. CFU-EPCs were not found in CD34-
enriched (> 90%) or CD133-enriched (> 90%) MNCs from
different HPC-rich sources (Table 1).
In a larger series studied by plastic adherence enrichment
alone, normalPB MNCs generated a mean of 37 CFU-EPCs
per 106 cells plated. CB MNCs generated fewer than five CFU-
EPCs per I06 cells plated, and G-CSF-mobilized PB MNCs
were virtually unable to form any CFU-EPCs (0.6 CFU-EPCs
per 106 cells plated (Fig. IC). Whereas enrichment of CD 14 +
cells by plastic adherence increased the number of CFU-EPCs
slightly in normal PB MNCs and significally in CB MNCs, no
CFU-EPCs were seen when CD14-enriched cells from G-CSF-
mobilized MNCs were cultured.
Mobilization of PB HPCs with G-CSF alters the phenotype
proportions of CD34+ cell subpopulations G-CSF-
mobilized PB samples had a more than 10-fold higher
proportion of CD34+ cells than normal PB samples
(Fig. 2A). In agreement with our earlier studies [9], G-CSF-
mobilized PB samples had markedly higher coexpression of
CD 133 by CD34+ cells (81.4% ± 10.5%) than normal PB
samples (23.1% ± 18.2%). This was true for both healthy
donors (P < 0.001, Mann Whitney [/-test, n = 9) and for
Tabic 1 Effect of subpopulation enrichment/depletion on colony-forming







2-h adherent cells (> 80% CD14 + )* 25
2-h non-adhcrcnt cells* 2
CD14-cnrichcd (> 98%)* 41
CDI4-depleted* 0
CD34-cnriched (> 90%)+ 0
CD34-dcplctcdf 3
CD133-enrichcd (> 90%)f 0
CD133-dcplctcdf 8
CFU-EPCs arc slightly increased when normal peripheral blood
MNCs arc enriched for monocytes (to about 80% CD14 + ) by 2 h of
adherence on uncoated culture plates. Further enrichment of mono¬
cytes (to 98%) by CD14+ selection by fluorescence-activated cell
sorting further increased CFU-EPCs and completely removed CFU-
EPCs from the CD14-dcplctcd plastic-adherent cells. CFU-EPCs were
not found in CD34-cnrichcd (> 90%) or CD133-cnrichcd (> 90%)
MNCs from different HPC-rich cell sources. Their depleted column
cluatcs tend to show reduced CFU-EPC activity as compared with the
unfractioned starting MNCs, which may imply some loss of CFU-EPC
activity by retention on columns by adhesion, implying these cells arc
adherent. *Paircd normal peripheral blood samples (n = 6). tUn-
paired HPC-rich samples (bone marrow, cord blood, mobilized blood).
autologous patients (Fig. 2B). Furthermore, in contrast to
normal PB, in which a mean of 37% of CD34+ cells were
CD45low, G-CSF-mobilizcd PB samples contained very low
proportions of CD34 + CD45low cells (mean G-CSF-mobilized
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CD34+ as a proportion of
leukocytes


























Mean (SD) Normal PB Mob PB donors Mob PB patients
Sample size (n) 11 9 11
CD34+ (106 L"1) 0.421 (0.110) 41.14 (37.27) 13.64(10.91)
CD34+ CDISS+OOSL-1) 0.097 (0.020) 33.49 (03.91) 10.87 (01.60)
CD34+ CD45low (106 L"1) 0.156 (0.088) 0.671 (0.559) 0.224 (0.274)
Fig. 2. Influence of administration of granulocyte colony-stimulating factor (G-CSF) on hematopoietic progenitor cell (HPC) mobilization on CD34 +
cclls and CD34+ subpopulations in peripheral blood (PB) leukocytes. (A) CD34+ cells as a proportion of total leukocytes in normal PB and in G-CSF-
mobilizcd PB from healthy donors and from hematologic malignancy patients in remission (mPB). (B) The proportion of CD34+ cells coexprcssing
CD133 in normal PB and in G-CSF-mobilizcd PB from healthy donors and from hematologic malignancy patients in remission. (C) The proportion of
CD34 + cells with low to negligible CD45 expression in normal PB and in G-CSF-mobilizcd PB from healthy donors and from hematologic malignancy
patients in remission. (D) Absolute numbers of circulating HPC subpopulations per liter of PB: all CD34+ cells; CD34 + cells coexprcssing CD133; and
CD34+ cells low in CD45 expression. The results arc calculated from research laboratory determination of total leukocyte counts and proportional
subpopulations, expressed as mean ± standard deviation (SD). A P-value of < 0.05 was considered to indicate statistical significance (*P < 0.05;
**P < 0.01; ***p < 0.001). Mob, mobilized; WBC, white blood cell.
PB autologous, 1.64%; mean G-CSF-mobilized PB allogeneic,
1.63%) (P < 0.001, Mann-Whitney {/-test, n = 9) (Fig. 2C),
and their absolute numbers were little increased in G-CSF-
mobilized PB as compared with normal PB, in contrast to total
CD34+ numbers (Fig. 2D).
G-CSF-mobilized PB MNCs are unable to generate
EOCs CB MNCs (n = 15) reliably generated EOC colonies
when 10 x 106 MNCs were plated. For normal PB MNCs
(n = 12), at least 30 x 106 MNCs had to be plated. G-CSF-
mobilized blood MNCs were unable to form any EOC colonies
for up to 30 x 1 f/' MNCs plated (n = 7), either for healthy
donors or for patients (Table 2).
EOC potential is associated with CD34 + CD133- cells
Enrichment of the CD34+ fraction of CB MNCs by magnetic
bead cell sorting (> 90% purity) showed that this fraction was
the source of all EOC colonies. No colonies were found in
CD34-depleted MNCs (Table 2). Conversely, the CD133-
enriched fraction from CB MNCs (> 90% purity) gave no
EOC colonies, and all of the EOC colonies were generated
from the CD 133-depleted fraction. When the CD 133- fraction
was further sorted into CD34+ and CD34- fractions, only the
CD34+ (CD133-) fraction gave EOC colonies. The number
of cells required to produce EOC colonies fell dramatically with
Tabic 2 Attainment of endothelial outgrowth cell (EOC) colonics from
different mononuclear cell (MNC) sources and subpopulations
EOC Number of MNCs
colonics plated for one
Source (cord blood MNCs) found EOC colony
Unfractioncd MNCs Yes 3 x 106
CDl33-cnrichcd (> 90%) No (> 1.3 x 106)
CDl33-dcplctcd Yes 0.5 x 106
CD34-cnrichcd (> 90%) Yes 1.7 x 106
CD34-dcplctcd No (> 3 x 106)
CD34 + CD 133 + (> 90%) No (> 1.65 x 106)
CD34 + CD 133-dcplcted Yes 0.002 x 106
EOCs can be routinely cultured from cord blood MNCs plated at 5-
10 x 106 per well on collagen. For normal adult peripheral blood
MNCs, 30 x 106 MNCs per well arc required to give approximately
one EOC colony. From cord blood MNCs separated by magnetic
beads, CD34-enrichcd cells form EOCs, but their CD34-dcplctcd
cluatcs do not. CD133-cnrichcd cells do not form EOCs, but their
CD133-dcplelcd cluatcs do: if the CD133-dcplctcd cells are further
fractionated according to CD34 expression, the CD34-cnrichcd
(CD34 + CD133-) cells form EOCs but the CD34- cluatcs do not.
enrichment of CD34 + CD 133- cells. Enrichment for the
CD34 + CD133- cell population increased the frequency of
EOC generation from CB MNCs, but not when G-CSF-
mobilized blood MNCs were used.
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The effect of direct addition of exogenous G-CSF on in vitro
indicators of angiogenesis
The number of CFU-EPCs is reduced by addition of G-CSF
to colony cultures The addition of G-CSF to normal PB
MNCs in vitro significantly reduced the CFU-EPC frequency
as compared with controls without G-CSF (P < 0.01, paired
/-test, n = 8) (Fig. 3). The addition of 100 ng mF1 vascular
endothelial growth factor (VEGF) or stromal cell-derived
factor-1 (SDF-I) to the wells to which G-CSF had been added
did not rescue colony formation (data not shown).
Tubule formation by IIUVECs and EOCs is reduced by G-
CSF Vascular tubule formation by HGVECs in Matrigel
showed a significant reduction at 22 h in the presence of G-
CSF as compared with controls (P < 0.01, paired /-test,
n = 5) (Fig. 4C); a paired example is shown in Fig. 4A,B. The
addition of 100 ng mL"1 VEGF or SDF-I to the wells with G-
CSF did not rescue tube formation (data not shown). EOCs
grown on collagen behave like HUVECs in many ways, and
form tubules in Matrigel. As with HUVECs, tubule fonnation
by EOCs in Matrigel was inhibited by G-CSF (n = 5)
(Fig. 4D-F).
A (i) No G-CSF (ii) With G-CSF
Fig. 3. Influence of exogenous granulocyte colony-stimulating factor
(G-CSF) in vitro on colony-forming unit endothelial progenitor cells
(CFU-EPCs). (A) Representative microscopy images of CFU-EPC
formation (i) by normal peripheral blood mononuclear cells (MNCs) and
(ii) in the presence of exogenous G-CSF (100 ng mL"1). There was a
significant reduction in MNC CFU-EPCs in the presence of G-CSF as
compared with paired samples without G-CSF. A P-valuc of < 0.05 was
considered to indicate statistical significance (*P < 0.05; **P < 0.01;
***P < 0.001).
Angiogenesis from mouse aortic rings in vitro is reduced by
G-CSF The numbers of vessels formed from murine aortic-
rings cultured in vitro and scored after 4 and 8 days were
reduced in the presence of G-CSF as compared with controls at
both time points (P < 0.05, paired /-test, n = 4, means of
triplicates). Results scored at 8 days are shown in Fig. 5C. A
paired example is shown in Fig. 5A.B.
In vivo spontaneous angiogenesis in subcutaneous sponge
implants in mice is inhibited by G-CSF Control vehicle-
impregnated sponges (GFR-Matrigel only) and G-CSF-
impregnated sponges (G-CSF in GRF-Matrigel) excised after
20 days following implantation both appeared red on gross
inspection, with lace-like coverings of blood vessels. They also
both showed infiltration of organized matrix and an abundance
of blood vessels. On histologic examination, all sponges
exhibited vascularization, but G-CSF-impregnated sponges
had significantly fewer blood vessels than controls when scored
by Chalkley counts (P < 0.001, Mann-Whitney C-test,
n = 4) (Fig. 6). A group of mice (n = 4) implanted with
untreated sponges (no GFR-Matrigel vehicle) on both flanks
exhibited a similar level of vasculogenesis as that seen in
vehicle-impregnated sponges (GFR-Matrigel), demonstrating
that GFR-Matrigel as vehicle has no intrinsic effect on
vascularization (not shown).
Discussion
It is well established that G-CSF administration successfully
mobilizes progenitor cells to PB, and these cells are able to
reconstitute the hematopoietic system; therefore, it is thought
that G-CSF mobilization might also increase the number of
circulating EPCs. In this study, we used PBSCs from subjects
receiving G-CSF for HPC mobilization, to examine the
possibility that EPCs are mobilized into the circulation concur¬
rently. We were unable to detect EPCs in G-CSF-mobilized
PBSCs, using several of the published EPC phenotypes. G-CSF
administration for HPC mobilization not only failed to mobilize
EPCs, but also inhibited angiogenesis in vitro and in vivo.
Neither G-CSF-mobilized PB MNCs nor enriched monocytes
are able to generate CFU-EPCs
Initial observations showed that, following administration of
G-CSF to healthy allogeneic PBSC donors, there was a
profound depression of CFU-EPC generation [9]. This
reduction in endothelial colony potential has been consis¬
tently shown by independent observers in our group and in
over 70 different samples studied. Longitudinal analysis of
sequential PB samples from healthy donors undergoing
PBSC mobilization showed that CFU-EPC numbers were
severely reduced immediately after G-CSF administration,
but returned to almost pretreatment levels within 2 months
(Fig. I A). Similar results have been obtained in hematologic
malignancy patients undergoing PBSC mobilization for
autologous transplantation, and may indicate that preceding
© 2010 International Society on Thrombosis and Hacmostasis
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Fig. 4. Influence of exogenous granulocyte colony-stimulating factor (G-CSF) in vitro on tubule formation. (A. B) Representative microscopy images of
(A) normal tubule formation by human umbilical vein endothelial cells (HUVECs) and (B) tubule formation by HUVECs in a paired culture with
exogenous G-CSF added. (C) There was a significant reduction in H UVEC tubule connections in the presence of G-CSF as compared with paired samples
without G-CSF. (D, E) Representative microscopy images of (D) normal tubule formation by endothelial outgrowth cells (EOCs) and (E) tubule formation
by EOCs in a paired culture with exogenous G-CSF added. (F) There was a significant reduction in EOC tubule connections in the presence of G-CSF as
compared to paired samples without G-CSF. A f-valuc of < 0.05 was considered to indicate statistical significance (*P < 0.05; **P < 0.01;
***P < 0.001).
chemotherapy does not markedly affect many putative
laboratory measures of PBSC or endothelial function.
Although CFU-EPCs were originally proposed by Hill
et al. [17] as a correlate of EPC frequency, it is now
established that they represent an expression of the activity
of CD14+ monocytes [37], which possibly constitute a key
proangiogenic monocyte subpopulation, not related to any
HPC population. Monocyte enrichment by plastic adherence
increased the frequency of CFU-EPC generation from
umbilical cord MNCs but did not increase the frequency
of CFU-EPC generation from G-CSF-mobilized blood
MNCs (Fig. 1C), which, in contrast to CB monocytes,
appear to be unresponsive in this assay.
A recognized, strong, inverse correlation between CFU-EPC
frequency and cardiovascular risk has been reported exten¬
sively (reviewed in [20,21]). This accumulation of reports is not
trivial, and indicates that CFU-EPC measurement can assess
some aspects of angiogenic capacity. Thus, although CFU-
EPC measurement seems not to be an indicator of EPC
frequency, as originally proposed, depressed CFU-EPC activ¬
ity in G-CSF-mobilized samples probably reflects reduced
monocyte proangiogenic capacity.
C-CSF-mobilized PB MNCs are unable to generate EOCs
There are a number of claims that G-CSF mobilizes EPCs [6-
8], but these depend on how EPCs are defined and interpreted.
A very few studies are based on a reported increase in CFU-
EPC frequency [7], and nearly all are based on putative
phenotype characterization of EPCs. Although the proposed
phenotypes for EPC have been dominated by variants based on
coexpression of CD34 and CD 133, the definitive phenotype of
an EPC remains elusive. Recently, it has been reported that
true circulating EPCs (EOCs) are CD34-positive but CD 133-
negative and CD45-negative, whereas cells expressing CD 133
and CD45 remain hematopoietic and do not give rise to true
ECs [13,14,38]. Previous observations showed that the HPCs in
G-CSF-mobilized blood are predominantly CD34 + CD133 +
[9,39], so by phenotype alone there is no evidence of mobili¬
zation of EOCs (contained in the CD34 + CD133- subpopula¬
tion) by G-CSF (Fig. 2B), and nor is there evidence that
CD34 + cells with low or negligible expression of the pan-
leukocyte marker CD45 are selectively mobilized by G-CSF
(Fig. 2C). Indeed, no EOCs could be cultured from G-CSF-
mobilized blood MNCs (30 x 106) from either autologous
patients or allogeneic donors, whereas, in most cases, at least
one EOC colony can be found in comparable normal PB
MNCs, so there is no evidence that EOCs are mobilized by G-
CSF. As there is little or no selective mobilization of
CD34 + CD133-CD45- cells by G-CSF, this may account
for the failure to find EOCs in these samples. Furthermore,
enrichment for the proposed EOC precursor population
(CD34 + CD133-) by magnetic beads increased the frequency
of EOC generation from umbilical cord MNCs, but not from
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Normal aortic ring assay Aortic ring assay with G-CSF
Effect of G-CSF in vitro on blood vessel outgrowth
No G-CSF with G-CSF
Fig. 5. Influence of exogenous granulocyte colony-stimulating factor
(G-CSF) in vitro on microvesscl outgrowth from mouse aortic rings.
Representative microscopy images of (A) normal microvcssel outgrowth
from mouse aortic ring and (B) microvcsscl outgrowth from a paired
aortic ring sample from the same mouse in the presence of added
exogenous G-CSF. (C) There was a significant reduction in microvesscl
outgrowth from mouse aortic rings in the presence of G-CSF as compared

















Fig. 6. Inhibition of angiogcncsis in vivo by granulocyte colony-
stimulating factor (G-CSF). There was a reduction of spontaneous
vascularization of subcutancously implanted sponges containing G-CSF
in growth-factor-rcduccd Matrigcl as compared with contralateral sponges
in the same animal containing growth-factor-rcduccd Matrigcl alone. A
P-valuc of < 0.05 was considered to indicate statistical significance
(*P < 0.05; **P < 0.01; ***P < 0.001).
G-CSF-mobilized blood MNCs. We have no evidence to judge
whether EOCs are prsent at low frequency/absent or inactive in
G-CSF-mobilized MNCs.
G-CSF has a direct inhibitory effect on angiogenesis
Although some of the effects of G-CSF on CFU-EPCs in vivo
might result from alteration of the balance of different cell
types in the circulation and dilution of some MNC subpop-
ulations by others, it can be shown that G-CSF has a direct
effect in vitro on CFU-EPCs. In paired MNC samples, the
addition of G-CSF resulted in a decrease in CFU-EPC
frequency (Fig. 3). Furthermore, the addition of known
angiogenesis-pronroting cytokines such as VEGF or SDF-1
to the G-CSF-treated MNCs did not rescue colony formation.
Similarly, it can be shown that G-CSF depresses the expression
in vitro of accepted endothelial cell functions, such as the
formation of cell-cell links in human EC (HUVEC and EOC)
tubule formation in Matrigel (Fig. 4) and in microvessel
outgrowth from mouse aortic rings (Fig. 5).
The direct effect of G-CSF on angiogenesis was ultimately
confirmed with the use of an in vivo mouse model of
angiogenesis (subcutaneous sponge implantation). Localized
G-CSF substantially inhibited spontaneous vascularization of
sponges in vivo (Fig. 6), in direct contrast to what was seen in
paired sponges lacking G-CSF in the same animals. Honold
el at. [8] showed that EPCs in G-CSF-mobilized samples were
transiently dysfunctional, owing to the cleavage of the chemo-
kine receptor CXCR4, which is directly involved in stem cell
homing. Thus, the observed reduction of endogenous blood
vessel formation in the G-CSF-treated sponge may reflect a
localized decline in the ability to recruit potential murine
angiogenic cells. Preliminary evidence from our current work
suggests that G-CSF may downregulate the expression of
certain cell surface receptors and adherence molecules, which
may impair the ability of cells to function in certain environ¬
ments; this could explain the observed CFU-EPC depression
and might be important in endothelial function and/or
angiogenesis. This is currently under investigation.
In agreement with our findings, a recent meta-analysis
reported that G-CSF infusion alone has no significant clinical
benefit in myocardial infarction [30], and G-CSF-mobilized
PBSCs were reported to be less effective in inducing ulcer
healing than BMSCs [31], However, a significant number of
reports to date have shown that cellular therapies employing
G-CSF-mobilized cells have some clinical benefit [27-29]. Thus,
although G-CSF may not selectively mobilize true EPCs as
defined by EOCs, and although it may inhibit monocyte
proangiogenic activity and EC angiogenic activity, G-CSF
does induce an increase in the number of circulating HPCs,
which might home to ischemic lesions [27] and could therefore
provide a paracrine effect without any incorporation into new
vessels. These may be equivalent to the cells provided from
bone marrow, and if that is the principal effect required in some
aspects of therapeutic vascularization, then mobilized PBSCs
may be as beneficial as BMSCs in clinical use.
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In summary, this study has shown that there is a profound
reduction in the number of CFU-EPCs following G-CSF
administration, which recovers with time. To the best of our
knowledge, we are the first to show that there is no evidence of
circulating EOCs following G-CSF administration for mobi¬
lization of HPCs. G-CSF-mobilized PBSC were predominantly
CD34 + CD133+ cells, which are almost certainly hematopoi¬
etic cells. The presence in vitro of exogenous G-CSF had a
direct antiangiogenic effect that was not abrogated by the
addition of proangiogenic factors.
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